






















851


















Examples B-2150 through B-2173 are prepared from Scaffold C-32

Example#	R^2	R^j			
B-2150					
B-2151					
B-2152					
B-2153					
B-2154					
B-2155					
B-2156					

852





















Example#	R ²	R ¹			
B-2157					
B-2158					
B-2159					
B-2160					
B-2161					
B-2162					
B-2163					
B-2164					
B-2165					
B-2166					















Example#	R ²	R ¹			
B-2167					
B-2168					
B-2169					
B-2170					
B-2171					
B-2172					
B-2173					




Examples 2174 through B-2197 are prepared from Scaffold C-64

Example#	R^2	R^J			
B-2174					
B-2175					
B-2176					
B-2177					
B-2178					
B-2179					
B-2180					





















Example#	R ²	R ¹			
B-2181					
B-2182					
B-2183					
B-2184					
B-2185					
B-2186					
B-2187					
B-2188					
B-2189					
B-2190					















Example#	R ²	R ¹			
B-2191					
B-2192					
B-2193					
B-2194					
B-2195					
B-2196					
B-2197					




Examples B-2198 through B-2221 re prepared from Scaffold C-22

Example#	R ²	R ^J			
B-2198					
B-2199					
B-2200					
B-2201					
B-2202					
B-2203					
B-2204					

Example#	R ²	R ^J			
B-2205					
B-2206					
B-2207					
B-2208					
B-2209					
B-2210					
B-2211					
B-2212					
B-2213					
B-2214					

Example#	R ²	R ¹			
B-2215					
B-2216					
B-2217					
B-2218					
B-2219					
B-2220					
B-2221					

860





















Examples B-2222 through B-2245 are prepared from Scaffold C-29

Example#

 R^2 R^J

B-2222					
B-2223					
B-2224					
B-2225					
B-2226					
B-2227					
B-2228					

















861

Example#	R ²	R ¹			
B-2229					
B-2230					
B-2231					
B-2232					
B-2233					
B-2234					
B-2235					
B-2236					
B-2237					


862

Example#

 R^2 R^1





















B-2238					
B-2239					
B-2240					
B-2241					
B-2242					
B-2243					
B-2244					
B-2245					















863



Examples B-2246 through B-2269 are prepared from Scaffold C-35

Example#	R^2	R^J			
B-2246					
B-2247					
B-2248					
B-2249					
B-2250					
B-2251					
B-2252					

Example#	R ²	R ¹			
B-2253					
B-2254					
B-2255					
B-2256					
B-2257					
B-2258					
B-2259					
B-2260					
B-2261					
B-2262					

Example#	R ²	R ¹			
B-2263					
B-2264					
B-2265					
B-2266					
B-2267					
B-2268					
B-2269					

5

10

Examples B-2270 through B-2317

15

In a parallel array reaction block containing 48 fritted vessels, each reaction vessel was charged with 250 mg of polymer bound carbodiimide **B48** (1.0 mmol/g resin) and a solution of the acid-containing scaffold **C-**
20 **49** in dimethylformamide (0.1 M, 500 uL). To each slurry was added a solution of pyridine in dichloromethane (0.2 M, 1000 uL) followed by a solution of a unique amine **B47** (0.2 M, 375 uL) in dimethylformamide. The reaction mixtures were agitated on a Labline benchtop orbital
25 shaker at 250 RPM for 16-20 h at ambient temperature. The reaction mixtures were filtered into conical vials and the polymer was washed with 1.5 mL of dimethylformamide and 2.0 mL of dichloromethane. The filtrates were evaporated to dryness in a Savant
30 apparatus and dimethylformamide (350 uL) was added to each conical vial to dissolve the residue. A solution of tetrafluorophthalic anhydride (1.0 M, 150 uL) in

867



dimethylformamide was added to the reconstituted conical vials and the mixture incubated for 2 hours at ambient temperature. Polyamine polymer B33 (4.0 meq N/g resin, 250 mg) and 1.0 mL dichloromethane was then added to the
5 reaction mixture in each conical vial. After agitating the reaction mixtures for 16 h at 250 RPM on an orbital shaker at ambient temperature, the mixtures were filtered through a polypropylene syringe tube fitted with a porous frit. The polymers were washed twice with
10 dimethylformamide (1.0 mL each) and the filtrates and washings collected in conical vials. The filtrates were evaporated to dryness and weighed to afford the desired amide products B-2270 through B-2317 as oils or solids. The analytical data and yields for the products prepared
15 in this manner are listed below.

20

25






















30

868
























B-2270			12	352	353
B-2271			39	432	433
B-2272			26	400	-
B-2273			14	396	397
B-2274			30	434	435
B-2275			43	443	-
B-2276			35	364	365






















869






















	R^2		Yield	Calcd. Mass Spec.	Observed Mass Spec M+H
B-2277			33	490	-
B-2278			53	460	461
B-2279			10	420	-
B-2280			7	435	436
B-2281			18	401	402
B-2282			22	390	413 ^a *M+Na
B-2283			10	394	417 ^a *M+Na
B-2284			7	423	-
B-2285			23	450	-
B-2286			4	506	-

870




	R^2		Yield	Calcd. Mass Spec.	Observed Mass Spec M+H
B-2287			5	437	438
B-2288			8	435	436
B-2289			4	450	451
B-2290			9	456	457
B-2291			9	415	416
B-2292			5	368	369
B-2293			5	366	367
B-2294			5	381	382
B-2295			16	410	411
B-2296			4	483	-

871

	R^2		Yield	Calcd. Mass Spec.	Observed Mass Spec M+H
B-2297			7	490	-
B-2298			4	537	-
B-2299			4	507	508
B-2300			7	442	-
B-2301			20	396	397
B-2302			30	459	-
B-2303			6	482	-
B-2304			5	395	396
B-2305			10	460	-
B-2306			11	466	467

	R^2		Yield	Calcd. Mass Spec.	Observed Mass Spec M+H
B-2307			5	421	422
B-2308			26	470	-
B-2309			24	424	425
B-2310			9	348	-
B-2311			21	338	339
B-2312			28	398	399
B-2313			6	410	-
B-2314			15	363	364
B-2315			11	444	-
B-2316			11	418	-

873

R^2			Yield	Calcd. Mass Spec.	Observed Mass Spec M+H
B-2317			36	428	-

874

5

10

By analogy to the procedure identified above for the preparation of Examples B-2270 through B-2317, the following examples B-2318 through B-2461 were prepared.


15

20

25




















30




















875






















	R ²		Yield	Calcd. Mass Spec.	Observed Mass Spec M+H
B-2318			23	426	427
B-2319			23	394	-
B-2320			50	490	491
B-2321			49	426	427
B-2322			40	366	367
B-2323			68	410	411
B-2324			57	456	457




















876

	R^2		Yield	Calcd. Mass Spec.	Observed Mass Spec M+H
B-2325			41	382	383
B-2326			71	440	441
B-2327			36	464	465
B-2328			32	467	468
B-2329			34	465	466
B-2330			26	364	365
B-2331			38	464	465
B-2332			33	483	484
B-2333			36	378	379












	R^2		Yield	Calcd. Mass Spec.	Observed Mass Spec M+H
B-2334			44	428	429
B-2335			27	406	407
B-2336			41	428	429
B-2337			27	423	424
B-2338			33	469	470
B-2339			52	518	519
B-2340			64	442	443
B-2341			41	350	351
B-2342			34	414	415

878



	R^2		Yield	Calcd. Mass Spec.	Observed Mass Spec M+H
B-2343			29	424	425
B-2344			33	492	493
B-2345			30	420	421
B-2346			35	474	475
B-2347			34	392	393
B-2348			51	458	459
B-2349			73	517	518
B-2350			22	448	449
B-2351			64	486	487

	R^2		Yield	Calcd. Mass Spec.	Observed Mass Spec M+H
B-2352			41	482	483
B-2353			57	438	439
B-2354			63	484	485
B-2355			28	536	537
B-2356			29	408	409
B-2357			41	436	437
B-2358			41	451	452
B-2359			57	502	503
B-2360			46	496	497

880

	R^2		Yield	Calcd. Mass Spec.	Observed Mass Spec M+H
B-2361			13	476	477
B-2362			46	493	494
B-2363			57	396	397
B-2364			61	438	439
B-2365			72	424	425

881




















R²

Yield




















Calcd. Mass
Spec.Observed
Mass Spec
M+H

B-2366			34	380	381
B-2367			52	480	481
B-2368			35	407	407
B-2369			31	435	436
B-2370			33	414	415
B-2371			28	366	367
B-2372			37	422	423




















882

	R^2		Yield	Calcd. Mass Spec.	Observed Mass Spec M+H
B-2373			50	432	433
B-2374			29	382	383
B-2375			35	395	396
B-2376			36	428	429
B-2377			68	438	439
B-2378			55	446	447
B-2379			33	364	365
B-2380			51	421	422
B-2381			52	429	430




















883

	R^2		Yield	Calcd. Mass Spec.	Observed Mass Spec M+H
B-2382			48	407	408
B-2383			53	382	383
B-2384			38	447	448
B-2385			59	498	450
B-2386			45	429	430
B-2387			74	558	-
B-2388			53	475	-
B-2389			33	493	494
B-2390			53	487	488












884

	R^2		Yield	Calcd. Mass Spec.	Observed Mass Spec M+H
B-2391			30	435	436
B-2392			57	464	465
B-2393			50	418	419
B-2394			65	488	489
B-2395			59	437	438
B-2396			34	534	535
B-2397			32	516	517
B-2398			81	533	534
B-2399			55	502	-


885

	R^2		Yield	Calcd. Mass Spec.	Observed Mass Spec M+H
B-2400			34	381	382
B-2401			32	378	379
B-2402			71	519	520
B-2403			68	527	528
B-2404			62	447	448
B-2405			71	536	537
B-2406			47	394	395
B-2407			65	508	509
B-2408			34	495	496

886




















	R^2		Yield	Calcd. Mass Spec.	Observed Mass Spec M+H
B-2409			47	448	449
B-2410			73	542	543
B-2411			81	489	490
B-2412			54	409	410
B-2413			37	493	494

887









































	R ²		Yield	Calcd. Mass Spec.	Observed Mass Spec · M+H
B-2414			14	473	474
B-2415			19	421	422
B-2416			13	386	387
B-2417			29	414	415
B-2418			6	420	421
B-2419			10	454	-
B-2420			5	442	443

888




















	R^2		Yield	Calcd. Mass Spec.	Observed Mass Spec M+H
B-2421			28	454	455
B-2422			47	420	421
B-2423			53	400	401
B-2424			15	400	401
B-2425			18	522	523
B-2426			38	464	465
B-2427			26	468	469
B-2428			22	432	433
B-2429			41	404	405












889

	R^2		Yield	Calcd. Mass Spec.	Observed Mass Spec M+H
B-2430			15	476	477
B-2431			6	446	447
B-2432			37	404	405
B-2433			8	428	429
B-2434			13	476	477
B-2435			23	442	443
B-2436			5	486	487
B-2437			4	492	493
B-2438			58	422	423

	R^2		Yield	Calcd. Mass Spec.	Observed Mass Spec M+H
B-2439			12	454	455
B-2440			8	521	522
B-2441			6	443	444
B-2442			37	514	515
B-2443			15	518	-
B-2444			52	520	-
B-2445			33	517	518
B-2446			70	500	501
B-2447			56	488	489

891

	R^2		Yield	Calcd. Mass Spec.	Observed Mass Spec M+H
B-2448			51	522	523
B-2449			19	512	513
B-2450			16	538	539
B-2451			71	511	512
B-2452			71	500	501
B-2453			61	470	-
B-2454			15	472	473
B-2455			39	520	-
B-2456			51	533	534

	R^2		Yield	Calcd. Mass Spec.	Observed Mass Spec M+H
B-2457			55	540	-
B-2458			22	488	489
B-2459			8	486	487
B-2460			13	534	535
B-2461			13	542	-


5

10

Example C-1

15

5-AMINOMETHYL-4-(4-PYRIDYL)-3-(4-FLUOROPHENYL) PYRAZOLE



20 1-(4-fluorophenyl)-2-(4-pyridyl)-1-ethanone. 4-
picoline (40 g, 0.43 mol) was added to a LiHMDS solution
(0.45 mol, 450 mL of a 1.0 M solution in THF) over 30
minutes at room temperature (a slight exotherm was
observed) The resulting solution was stirred for 1 h.
25 This solution was added to ethyl 4-fluorobenzoate (75.8
g, 0.45 mol, neat) over 1 h. The mixture was stirred
overnight (16 h). Water (200 mL) was added and the
mixture was extracted with EtOAc (2x200 mL). The organic
layer was washed with brine (1x200 mL) and dried over

Na_2SO_4 . The organic layer was filtered and the solvent was removed to leave oily solid. Hexane was added to the oil and the resulting solid was filtered and washed with hexane (cold). A yellow solid was isolated (50 g, 54%):
5 ^1H NMR (CDCl_3) δ 8.58 (d, J = 5.7 Hz, 2H), 8.02 (dd, J = 5.5, 8.0, 2H), 7.12-7.21 (m, 4H), 4.23 (s, 2H); ^{19}F NMR (CDCl_3) δ -104.38 (m); LC/MS, t_r = 2.14 minutes (5 to 95% acetonitrile/water over 15 minutes at 1 mL/min, at 254 nm at 50°C), $M+H$ = 216; High Resolution MS Calcd for
10 $\text{C}_{23}\text{H}_{20}\text{N}_4\text{O}_2\text{F}$ ($M+H$): 216.0825. Found: 216.0830 (Δ mmu = 0.5).

N-benzyloxycarbonyl-5-aminomethyl-4-(4-pyridyl)-3-(4-fluorophenyl) pyrazole. A 3L round bottom flask
15 fitted with a mechanical stirrer, N_2 inlet and an addition funnel was charged with 557 mL (0.56 mol) of 1 M t -BuOK in THF and 53 mL (0.56 mol) of t -BuOH. The ketone, 1 (60 g, 0.28 mol) was dissolved in 600 mL of THF and added to the stirred mixture at room temperature. A yellow
20 precipitate formed and the mixture was stirred for 1 h. N-benzyloxycarbonyl-glycinyll N-hydroxysuccinimide (128.6 g, 0.42 mol) was dissolved in 600 mL of THF and added dropwise at r.t. over 1h. The mixture was stirred for another 5 minutes and 150 mL of water was added. the pH
25 was adjusted to 6.7 with 70 mL of AcOH. Hydrazine monohydrate (41 mL in 100 mL of water) was added via an addition funnel. The mixture was stirred for 1 h and was diluted with 500 mL of water and 500 mL of ethyl acetate. The biphasic mixture was transferred to a sep funnel and
30 the layers were separated. The aqueous layer was extracted with EtOAc (3x300 mL). The organic layer was

dried (Na_2SO_4), filtered and evaporated to leave 157 g of a crude reddish oil.

The oil was suspended in CH_2Cl_2 and filtered to remove any insoluble material (DCU, hydrazone of the monoketone). The solution was split into two portions and each portion was chromatographed (Biotage 75L, 3% EtOH/ CH_2Cl_2 then 6% EtOH/ CH_2Cl_2). The appropriate fractions were concentrated (some contamination from the monoketone and the hydrazone) from each portion to leave a yellow solid. The solid was suspended in ethyl acetate and heated to boiling for 10 minutes. The solution was allowed to cool to R.T. overnight. The precipitate was filtered to give 30 g of a white solid (27% yield of 2): ^1H NMR (DMF-d_7) δ 13.36 (s, 1H), 8.57 (d, J = 5.8 Hz, 2H), 7.16-7.52 (m, 11H), 5.11 (s, 2H), 4.48 (d, J = 5.4 Hz, 2H); ^{19}F NMR (DMF-d_7) δ -114.9 (m), -116.8 (m) (split fluorine signal is due to the pyrazole tautomers); LC/MS, t_r = 3.52 minutes (5 to 95% acetonitrile/water over 15 minutes at 1 mL/min, at 254 nm at 50°C), $M+H$ = 403; High Resolution MS Calcd for $\text{C}_{23}\text{H}_{20}\text{N}_4\text{O}_2\text{F}$ ($M+H$): 403.1570. Found: 403.1581 (Δ mmu = 1.1).

5-aminomethyl-4-(4-pyridyl)-3-(4-fluorophenyl) pyrazole. To a 1L Parr bottle was added 7 g (17.4 mmol) of 2 and 180 mL of MeOH and 90 mL of THF to give a clear solution. The bottle was purged with nitrogen and 1.5 g of 10% Pd/C (wet Degussa type E101) was added. The Parr bottle was pressured to 40 psi (H_2) and was agitated. Hydrogen uptake was 5 psi after 5 h. The bottle was repressured to 42 psi and was agitated overnight. The bottle was purged with N_2 and was filtered through Celite. The Celite was washed with MeOH (3x50 mL) and

896


the filtrate was concentrated to give 4.5 g of an off-white solid (94%). ^1H NMR (DMSO- d_6) δ 8.52 (d, J = 4.63 Hz, 2H), 7.36 (dd, J = 5.64, 8.1 Hz, 2H), 7.16-7.30 (m, 4H), 3.79 (s, 2H); ^{19}F NMR (DMSO- d_6) δ -114.56 (m); LC/MS, t_r = 1.21 minutes (5 to 95% acetonitrile/water over 15 minutes at 1 mL/min, at 254 nm at 50°C), $M+H$ = 269 m/z ; High Resolution MS Calcd for $\text{C}_{15}\text{H}_{14}\text{N}_4\text{F}$ ($M+H$): 269.1202. Found: 269.1229 (Δ mmu = 2.7).







10






The following pyridylpyrazoles (C-2 through C-21, Table C-1) were prepared according to the experimental procedure described above for example C-1.







15

Table C-1.

Example No.	Structure	MW, $M + H$ Calculated Found	^1H NMR (solvent), ppm
C-2		323.1672 323.1670	(DMF- d_7): 8.77 (t, J = 4.4 Hz, 2H), 7.60 (m, 2H), 7.44 (t, J = 4.4 Hz, 2H), 7.35 (m, 2H), 3.22 (bd, 2H), 3.01 (septet, J = 5.3 Hz, 1H), 2.74 (m, 2H), 1.95 (m, 4H)

C-3		282.127 (M) 282.1245 (M, EI)	(DMF-d ₇): 8.77 (br s, 2H), 7.64-7.62 (m, 2H), 7.50 (br s, 2H), 7.38-7.34 (m, 2H), 4.40-4.37 (m, 1H), 1.56 (br s, 3H)
C-4		282.127 (M) 282.1147 (M, EI)	(DMF-d ₇): 8.77 (br s, 2H), 7.64-7.62 (m, 2H), 7.50 (br s, 2H), 7.38-7.35 (m, 2H), 4.40-4.37 (m, 1H), 1.57 (br s, 3H)
C-5		323.1672 323.1687	(DMSO-d ₆): 8.56 (br, 2H), 7.32 (m, 2H), 7.18 (m, 4H), 2.91 (m, 2H), 2.71 (m, 2H) 1.88 (m, 1H), 1.65 (m, 2H), 1.40 (m, 2H)
C-6		359 359	(DMSO-d ₆): 8.46 (d, J = 4.6 Hz, 2H), 7.32-7.13 (m, 7H), 6.98-6.96 (m, 4H), 4.06 (t, J = 7.0 Hz, 1H), 2.98-2.95 (m, 2H)
C-7		359 359	(DMSO-d ₆): 8.46 (d, J = 5.4 Hz, 2H), 7.32-7.28 (m, 2H), 7.20-7.12 (m, 5H), 6.98-6.96 (m, 4H), 4.06 (t, J = 7.0 Hz, 1H), 2.98-2.94 (m, 2H)
C-8		313.1465 313.1492	(DMSO-d ₆): 13.83 (bs, 1H), 8.61 (d, J = 5.7 Hz, 2H), 8.33 (bs, 1H), 7.33 (m, 6H), 4.44 (m, 1H), 3.63 (m, 2H), 3.27 (s, 3H)

C-9		313.1465 313.1457	(DMSO-d ₆): 8.55 (dd, J = 1.5, 4.4 Hz, 2H), 7.37-7.32 (m, 2H), 7.26 (dd, J = 1.6, 4.4 Hz, 2H), 7.22-7.16 (m, 2H), 4.06 (t, J = 6.5 Hz, 1H), 3.49 (d, J = 6.6 Hz, 2H), 3.20 (s, 3H)
C-10		354 354	(DMSO-d ₆): 13.03 (bs, 1H), 8.50 (dd, J=1.6, 2.7 Hz, 2H), 7.58 (bq, J=4.3 Hz, 1H), 7.3 (m, 2H), 7.12-7.21 (m, 4H), 3.77 (t, J= 6.3 Hz, 1H), 2.45 (d, J=4.5 Hz, 3H), 1.97 (t, J= 7.4 Hz, 2H), 1.85 (dt, J=7.3, 7.1 Hz, 2H)
C-11		354 354	(DMSO-d ₆): 13.03 (bs, 1H), 8.50 (dd, J=1.6, 2.7 Hz, 2H), 7.58 (bq, J=4.3 Hz, 1H), 7.3 (m, 2H), 7.12-7.21 (m, 4H), 3.77 (t, J= 6.3 Hz, 1H), 2.45 (d, J=4.5 Hz, 3H), 1.97 (t, J= 7.4 Hz, 2H), 1.85 (dt, J=7.3, 7.1 Hz, 2H)
C-12		283.1359 283.1363	(DMSO-d ₆): 8.53 (d, J = 5.0 Hz, 2H), 7.37-7.32 (m, 2H), 7.21-7.17 (m, 4H), 2.83 (d, J = 6.0 Hz, 2H), 2.77 (d, J = 6.0 Hz, 2H)
C-13		297.1515 297.1515	(DMSO-d ₆): 8.53 (d, J = 5.4 Hz, 2H), 7.34 (dd, J = 5.8, 8.2 Hz, 2H), 7.18

			(dd, $J = 5.8, 9.8$ Hz, 4H), 2.68 (t, $J = 7.3$ Hz, 2H), 2.52 (m, 2H), 1.64 (m, 2H)
C-14		284.0829 284.0806	(CD ₃ OD): 8.74 (br, 2H), 7.77 (br, 2H), 7.45-7.58 (m, 3H), 7.30-7.40 (m, 1H), 4.43 (s, 2H)
C-15		285 285	(DMSO-d ₆): 8.53 (br, 2H), 7.56 (br, 2H), 7.26 (m, 4H), 3.75 (br, 2H)
C-16		329, 331 329, 331	(DMSO-d ₆): 8.53 (d, $J =$ 4.4 Hz, 2H), 7.42 (d, $J =$ 7.9 Hz, 2H), 7.34 (d, $J =$ 8.5 Hz, 2H), 7.24 (d, $J =$ 4.6 Hz, 2H), 3.76 (bs, 2H)
C-17		339 339	(DMSO-d ₆): 8.53 (t, $J =$ 4.3 Hz, 2H), 7.33 (m, 3H), 7.19 (t, $J = 4.6$ Hz, 2H), 7.14 (d, $J = 7.3$ Hz, 1H), 3.23 (m, 2H), 2.88, (m, 3H), 1.92, (m, 3H), 1.70 (m, 1H)
C-18		339 339	(DMSO-d ₆): 8.57 (d, $J =$ 4.6 Hz, 2H), 7.41 (d, $J =$ 8.3 Hz, 2H), 7.29 (d, $J =$ 8.5 Hz, 2H), 7.20 (d, $J =$ 4.8 Hz, 2H), 3.18 (bd, 2H), 2.88 (m, 1H), 2.76 (m, 2H), 1.82 (br, 4H)
C-19		383, 385 383, 385	(DMSO-d ₆): 8.56 (br, 2H), 7.52 (br, 2H), 7.14-7.29 (m, 4H), 2.99 (br, 2H),

900




			2.71 (br, 1H), 2.51 (br, 2H), 1.68 (br, 4H)
--	--	--	---

5










10












The following pyridylpyrazoles (C-22 through C-40, Table C-2) are prepared utilizing the general schemes C-1 and C-2 and the experimental procedure described for example C-1 above.





Table C-2

Cmpd. No.	Structure
C-22	
C-23	
C-24	

901

C-25	 <chem>NCC1=CN=C(C2=CC=CC=C2Br)C(=N1)C3=CC=CC=N3</chem>
C-26	 <chem>NCC1=CN=C(C2=CC=C(C)C=C2)C(=N1)C3=CC=CC=N3</chem>
C-27	 <chem>C1CCNCC1C2=CN=C(C3=CC=CC=C3Br)C(=N2)C4=CC=CC=N4</chem>
C-28	 <chem>C1CCNCC1C2=CN=C(C3=CC=C(C)C=C3)C(=N2)C4=CC=CC=N4</chem>
C-29	 <chem>NCC1=CN=C(C2=CC=CC=C2S)C(=N1)C3=CC=CC=N3</chem>
C-30	 <chem>C1CCNCC1C2=CN=C(C3=CC=CC=C3S)C(=N2)C4=CC=CC=N4</chem>
C-31	 <chem>C1CCNCC1C2=CN=C(C3=CC=C(C(F)(F)F)C=C3)C(=N2)C4=CC=CC=N4</chem>
C-32	 <chem>NCC1=CN=C(C2=CC=C(F)C=C2)C(=N1)C3=CC=CC=N3</chem>
C-33	 <chem>C1CCNCC1C2=CN=C(C3=CC=C(F)C=C3)C(=N2)C4=CC=CC=N4</chem>


C-34	
C-35	
C-36	
C-37	
C-38	
C-39	
C-40	
C-41	
C-42	
C-43	
C-44	

C-45	
C-46	
C-47	
C-48	

5

Example C-49

10



15

Step A

The pyrazole (2.60 g, 10.3 mmol) from **example C-4** was suspended in 52 mL of dichloroethane and 52 mL of 2.5 M

904

NaOH. Tetrabutylammonium hydroxide (0.5 mL of a 1 M aqueous solution) was added to the stirred mixture. To this mixture was added t-butyl bromoacetate (2.10 g, 10.8 mmol). The reaction mixture was stirred at room
5 temperature for 4 h. The mixture was poured onto 200 mL of CH_2Cl_2 and 200 mL of H_2O . The phases were separated and the organic phase was washed with water (1x100 mL) and brine (1x100 mL). The organic layer was dried over Na_2SO_4 and was filtered. The solvent was removed to leave
10 an off-white solid. This solid was triturated with hexane and the resulting solid isolated by filtration. The solid was washed with hexane to leave 3.4 g of a white solid (90%).

15


Step B

20 The alkylated pyrazole (3.7 g, 10.1 mmol) from Step A was treated with 57 mL of 4 N HCL in dioxane. The solution was stirred at room temperature for 4 h. The solvent was removed under reduced pressure and the residue was dissolved in THF. The solution was treated
25 with propylene oxide (10.3 mmol) and was stirred for 1h at room temperature. The solvent was removed to leave an oil. The residual solvent was chased with several portions of EtOH. The resulting solid was triturated with Et_2O and the title compound Example C-49 was
30 isolated by filtration to afford 3.0 g of an off-white solid (95%). Mass spec: M+H calcd: 312; found 312. ^1H NMR (DMSO-d_6): 8.81 (d, J = 6.4 Hz, 2H), 7.73 (d, J =

905


5.8 Hz, 2H), 7.40 (m, 2H), 7.23 (t, J = 8.5 Hz, 1H), 5.16 (s, 2H), 2.40 (s, 3H).

5

Example C-50

According to the procedure described above in Example C-49, Example C-50 was also prepared starting from 4-[3-(4-fluorophenyl)-1H-pyrazole-4-yl]pyridine. Mass spec: M+H calcd: 298; found 298. ¹H NMR (DMSO-d₆): 8.75 (d, J = 6.4 Hz, 2H), 8.68 (s, 1H), 7.78 (d, J = 6.6 Hz, 2H), 7.52 (dd, J = 5.4, 8.5 Hz, 2H), 7.31 (t, J = 8.9 Hz, 2H), 5.16 (s, 2H).


20

Example C-51

Starting with the N-Boc-piperidinyl analog of Example C-2, Example C-51 is also prepared according to the methods described in Scheme C-1.


Example C-52

5




Step A: Picoline is treated with a base chosen from but not limited to n-BuLi, LDA, LiHMDS, tBuOK, or NaH in an organic solvent such as THF, ether, t-BuOH or dioxane from -78 °C to 50 °C for a period of time from 10 minutes to 3 hours. The picoline solution is then added to a solution of N-Cbz-(L)-phenylalaninyl N-hydroxysuccinimide. The reaction is allowed to stir from 30 minutes to 48 hours during which time the temperature may range from -20 °C to 120 °C. The mixture is then poured into water and extracted with an organic solvent. After drying and removal of solvent the pyridyl monoketone is isolated as a crude solid which could be purified by crystallization and/or chromatography.

20




Step B: A solution of the pyridyl monoketone in ether, THF, tBuOH, or dioxane is added to a base chosen from but

not limited to n-BuLi, LDA, LiHMDS, tBuOK, or NaH contained in hexane, THF, ether, dioxane, or tBuOH from -78 °C to 50 °C for a period of time from 10 minutes to 3 hours. Formyl acetic anhydride is then added as a solution in THF, ether, or dioxane to the monoketone anion while the temperature is maintained between -50 °C and 50 °C. The resulting mixture is allowed to stir at the specified temperature for a period of time from 5 minutes to several hours. The resulting pyridyl diketone intermediate is utilized without purification in Step C.




Step C: The solution containing the pyridyl diketone is quenched with water and the pH is adjusted to between 4 and 8 utilizing an inorganic or organic acid chosen from HOAc, H₂SO₄, HCl, or HNO₃. The temperature during this step is maintained between -20 °C and room temperature. Hydrazine or hydrazine hydrate is then added to the mixture while maintaining the temperature between -20 °C and 40 °C for a period of 30 minutes to several hours. The mixture is then poured into water and extracted with an organic solvent. The N-Cbz-protected pyridyl pyrazole is obtained as a crude solid which is purified by chromatography or crystallization.

908



5 Step: D

The CBZ protecting group is cleaved using hydrogen gas under pressure and Pd-C in an alcohol solvent, affording scaffold C-52 after filtration and concentration.









10

- 15 The following compounds C-53 through C-59 in Table C-3 are prepared according to the general procedure described above for the preparation of C-52.

Table C-3

Example No.	Structure
C-53	 <chem>N[C@@H](Cc1ccccc1)C2=CN=C(C2C3=CC=CC=C3)N4=CC=CC=N4</chem>


C-54	
C-55	
C-56	
C-57	
C-58	
C-59	

Example C-60**5 Step A:**

A Boc protected pyridylpyrazole is treated with benzaldehyde in methylene chloride at room temperature in

the presence of a drying agent for a period of time ranging from 1-24 h. Solvent is then evaporated and the resulting imine is used in step B without further purification.

5




Step B:


The pyridylpyrazole imine is dissolved in THF and stirred
10 under nitrogen at temperatures ranging from -78 to -20 $^{\circ}\text{C}$.
A base such as LDA, $n\text{-BuLi}$, or LiHMDS is added dropwise
to the mixture which is then stirred for an additional 10
minutes to 3 h. Two equivalents of a methyl iodide are
then added to the mixture and stirring is continued for
15 several hours. The mixture is then quenched with acid
and allowed to warm to room temperature and stirred
several hours until cleavage of the Boc and the imine
functions is complete. The pH is adjusted to 12 and then
the mixture is extracted with an organic solvent, which
20 is dried and evaporated. The crude pyridylpyrazole is
then crystallized and/or chromatographed to give purified
C-60.

911

Step B




1) Base
2) MeI
3) Acid, H₂O



C-60

5

Example C-61




10 Example C-61 is prepared according to the method described in example C-60, substituting 1,4-dibromobutane for methyl iodide.

15

20

Example C-62




Example C-62 is prepared according to the method described in example C-60, substituting 1,3-dibromoethane for methyl iodide.

5


Example C-63

The synthesis of compound C-63 starts with the
10 condensation reaction of bromomaleic anhydride B77 with
2, 4-dimethoxybenzylamine in acetic acid and acetic
anhydride. The maleimide B78 is then treated with 4'-
fluoroacetophenone in the presence of catalytic amount
Pd₂(dba)₃ and sodium t-butoxide to form the
15 fluoroacetophenone substituted maleimide B79. B79 is
then treated with tert-butoxybis(dimethylamino)methane to
yield the α-ketoenamine B80. The α-ketoenamine B80 is
condensed with hydrazine to form the N-protected
maleimide pyrazole B81. The 2,4-dimethoxybenzyl group is
20 cleaved with ceric ammonium nitrate (CAN) to give the
title compound C-63.

913


**Example C-64**

5



Using the method described in Schemes C-6 and C-7,
10 Example 64 is prepared.


914

Example C-65

5

Using the method described in Schemes C-6 and C-7,
Example 65 is prepared.

10

Example C-66


15

Using the method described in Schemes C-6 and C-7,
Example C-66 is synthesized, substituting N-2,4-
20 dimethoxybenzyl-4-bromopyridone for B78.

25

Example C-67


5



Using the method described in Schemes C-6 and C-7, Example C-67 is synthesized, substituting N-2,4-dimethoxybenzyl-4-bromopyridone for B78, and substituting
10 N-Boc-glycyl N-hydroxysuccinimide for B82.

Example C-68


15



Using the method described in Schemes C-6 and C-7, Example C-68 is synthesized, substituting N-2,4-dimethoxybenzyl-4-bromopyridone for B78.
20

25


916

Example C-69

5

Using the method described in Schemes C-6 and C-7, Example 69 is prepared, substituting N-Boc-nipecotyl N-hydroxysuccinimide for B83.


10

Example C-70

15 Using the method described in Schemes C-6 and C-7, Example 70 is prepared, substituting N-Boc-nipecotyl N-hydroxysuccinimide for B83.

Example C-71


20



917


Using the method described in Schemes C-6 and C-7, Example 71 is prepared, substituting N-methyl-3-bromomaleimide for B78.

5

Example C-72

10 Using the method described in Schemes C-6 and C-7, Example 72 is prepared, substituting N-methyl-3-bromomaleimide for B78, and substituting N-Boc-nipecotyl N-hydroxysuccinimide for B83.

15


Example C-73

20 Using the method described in Schemes C-6 and C-7, Example 73 is prepared, substituting N-methyl-3-bromomaleimide for B78 and substituting N-Boc-nipecotyl N-hydroxysuccinimide for B83.

25

General Synthetic Procedures


Scheme C-8 illustrates a general method that can be used for the introduction of various groups on an unsubstituted nitrogen atom that is present as part of pyrazole (Cviii) with appropriately substituted aldehydes ($R_{302}CHO$) or ketones ($R_{302}COR_{303}$) in the presence of a reducing agent such as sodium cyanoborohydride or sodium triacetoxyborohydride affords the desired products (Cix). Typical conditions for the reductive alkylation include the use of an alcoholic solvent at temperatures ranging from 20 °C to 80 °C. In Scheme C-8, R_{302} and R_{303} are selected from but not limited to alkyl, benzyl, substituted benzyl, arylalkyl, heteroarylalkyl.



Scheme C-9 illustrates another method for introduction of substituents on the unsubstituted nitrogen atom present as part of the C-3 position of the pyrazole (Cviii). Treatment of the pyrazole (Cviii) with

a suitable alkylating agent ($R_{304}X$) such as an alkyl chloride, alkyl bromide, alkyl iodide or with an alkyl methanesulfonate or alkyl p-toluenesulfonate in the presence of a suitable base affords the desired alkylated pyrazoles (**Cx**). Examples of suitable bases include diisopropylethylamine, triethylamine, N-methylmorpholine, potassium carbonate and potassium bicarbonate.

Scheme C-9




Typical conditions for the alkylation include reaction with the suitable base in a polar aprotic solvent such as acetonitrile, dimethylformamide, dimethylacetamide or dimethyl sulfoxide at temperatures ranging from 20 °C to 150 °C. Typical R_{304} substituents are selected from but are not limited to alkyl, substituted benzyl, heteroaromatic, substituted heteroalkyl and substituted heteroarylalkyl groups.

Compounds containing acyl, sulfonyl or ureidyl groups at the nitrogen atom can be prepared as shown in Scheme C-10. Treatment of the pyrazole **Cviii** with a suitable acylating agent in the presence of a base such as N-methylmorpholine, triethylamine, diisopropylethylamine or dimethylamino pyridine in an

organic solvent such as dichloromethane, dichloroethane or dimethylformamide at temperatures ranging from 20 °C to 120 °C affords the desired acylated pyrazoles (**Cxi**). Suitable acylating agents include acid halides, activated esters of acids such as the N-hydroxysuccinimide esters, p-nitrophenyl esters, pentafluorophenyl esters, sulfonyl halides, isocyanates, and isothiocyanates.

Scheme C-10



A general synthesis of 2-substituted pyrimidinylpyrazole compounds of type **Cxv** is shown in Scheme C-11.

Step A:

4-Methyl-2-methylmercaptopyrimidine is treated with a base selected from but not limited to n-BuLi, LDA, LiHMDS, t-BuOK, NaH in an organic solvent such as THF, ether, t-BuOH, dioxane from -78 °C to 50 °C for a period of time from 30 minutes to 5 hours. The resulting 4-methyl anion is then added to a solution of an appropriate ester **B88**. The reaction is allowed to stir from 30 minutes to 48 hours during which time the

temperature may range from 0 °C to 100 °C. The reaction mixture is then poured into water and extracted with an organic solvent. After drying and removal of solvent the desired monoketone **B89** is isolated as a crude solid which can be recrystallized or purified by chromatography.

Step B:

Monoketone **B89** is treated with a base selected from but not limited to n-BuLi, LDA, LiHMDS, t-BuOK, NaH, K₂CO₃, or Cs₂CO₃ in an organic solvent such as THF, ether, t-BuOH, dioxane, toluene or DMF from -78 °C to 50 °C for a period of time from 30 minutes to 5 hours. A solution of an appropriately activated ester of a carboxylic acid $\text{CbzNR}^n-(\text{CH}_2)_n\text{CR}^f(\text{R}^g)-\text{COOH}$ or $\text{BocNR}^n-(\text{CH}_2)_n\text{CR}^f(\text{R}^g)-\text{COOH}$, preferably but not limited to the N-hydroxysuccinimide ester **B90** is then added to the monoketone anion while maintaining the temperature between 0 °C to 100 °C. The reaction is allowed to stir at the specified temperature for a period of time ranging from 30 minutes to 48 hours. The resulting pyrimidine diketone intermediate **B91** is utilized without further purification in Step C.

Step C:

The solution or suspension containing the diketone intermediate **B91** is quenched with water and the pH adjusted to between 4 and 8 using an acid chosen from AcOH, H₂SO₄, HCl or HNO₃, while maintaining the temperature between 0 °C to 40 °C. Hydrazine or hydrazine monohydrate is then added to the mixture while maintaining the temperature between 0 °C to 40 °C. The mixture is stirred

for a period of 30 minutes to 16 hours maintaining the temperature between 20 °C to 50 °C, poured into water and extracted with an organic solvent. The pyrimidinyl pyrazole **CxiiBoc** or **CxiiCbz** is obtained as crude solid which is purified by chromatography or crystallization.

Step D:

The 2-methylmercapto group in the pyrimidinyl pyrazole (**CxiiBoc** or **CxiiCbz**) is oxidized to the 2-methylsulfone (where $n = 2$) or the 2-methylsulfoxide (where $n = 1$) using either Oxone or m-chloroperbenzoic acid as an oxidizing agent in a suitable solvent at temperatures ranging from 25 °C to 100 °C. Solvents of choice for the oxidation include dichloromethane, acetonitrile, tetrahydrofuran or hydroalcoholic mixtures. The 2-methylsulfone ($n = 2$) or the 2-methylsulfoxide ($n = 1$) (**CxiiiBoc** or **CxiiiCbz**) is purified by crystallization or chromatography.

Step E:


The 2-methylsulfone/2-methylsulfoxide group in **CxiiiBoc** or **CxiiiCbz** is conveniently displaced with various amines or alkoxides at temperatures ranging from 20 °C to 200 °C in solvents that include but are not limited to dimethylformamide, acetonitrile, tetrahydrofuran and dioxane. The alkoxides can be generated from their alcohols by treatment with a base selected from but not limited to sodium hydride, lithium hexamethyldisilazide, potassium tertiary-butoxide in solvents such as tetrahydrofuran, dimethylformamide and

dioxane at temperatures ranging from 0 °C to 100 °C. The resulting 2-amino or 2-oxo derivatives (**CxivBoc** or **CxivCbz**) are purified by either chromatography or crystallization.

Step F:

The carbamate protecting groups from **CxivBoc** or **CxivCbz** are removed to afford the desired compounds **Cxv** containing either a free primary amine (R'' is hydrogen) or a free secondary amine (R'' is not equal to hydrogen). The Boc protecting groups are cleaved utilizing either trifluoroacetic acid in methylene chloride or hydrochloric acid in dioxane at room temperature for several hours. The Cbz protecting groups are cleaved using hydrogen gas at atmospheric or higher pressures and a catalyst (palladium on charcoal) in an alcoholic solvent. The resulting amines **Cxv** are then crystallized or purified by chromatography.


SCHEME C-11



The following examples contain detailed descriptions of the methods of preparation of compounds that form part of the invention. These descriptions are presented for illustrative purposes only and are not intended as a restriction on the scope of the invention. All compounds showed NMR spectra consistent with their assigned structures.

Example C-74

5-(4-PIPERIDYL)-4-(4-PYRIDYL)-3-(4-CHLOROPHENYL) PYRAZOLE




By following the method of Example C-1 and substituting methyl-4-chlorobenzoate for ethyl-4-fluorobenzoate and *N*-*t*-butoxycarbonyl-isonipecotyl *N*-hydroxysuccinimide for *N*-benyloxycarbonyl-glycinyll *N*-hydroxysuccinimide the title compound was prepared as the *N*-*t*-butoxycarbonyl protected compound. The deprotection of the *N*-*t*-butoxycarbonyl intermediate was accomplished with 4 N HCl in dioxane to afford the title compound as the hydrochloride salt: ¹HNMR (d₆-DMSO) δ 8.57 (d, *J* = 4.83 Hz, 2 H), 7.41 (d, *J* = 8.26 Hz, 2 H), 7.29 (d, *J* = 8.26 Hz, 2 H), 7.20 (d, *J* = 4.63 Hz, 2 H), 3.18 (bd, *J* =

926

12.08 Hz, 2 H), 2.88 (m, 1 H), 2.76 (m, 2 H), 1.82 (bs, 4 H). MS (M+H): 339 (base peak).


Example C-75

**5-(N-METHYL-4-PIPERIDYL)-4-(4-PYRIDYL)-3-(4-CHLOROPHENYL)
PYRAZOLE**



To a solution of 5-(4-piperidyl)-4-(4-pyridyl)-3-(4-chlorophenyl) pyrazole hydrochloride (Example C-74) (25 g, 61 mmol) in 140 mL of formic acid (96%) was added 50 g of formaldehyde (37%). The solution was stirred at 75 °C for 48 h and was cooled to room temperature. The excess formic acid was removed under reduced pressure and the residue was dissolved in 100 mL of water. The solution was added to concentrated $\text{NH}_4\text{OH}/\text{H}_2\text{O}$ and the mixture was extracted with ethyl acetate (3 x 200 mL). The combined organic layers were washed with brine (1 x 250 mL) and was dried over Na_2SO_4 . The solution was filtered and concentrated to leave a white solid. The solid was triturated with ether and was filtered to afford the title compound: MS (M+H): 353 (base peak).

Example C-76


5-(N-ACETYL-4-PIPERIDYL)-4-(4-PYRIDYL)-3-(4-CHLOROPHENYL)
PYRAZOLE

To a stirred suspension of 5-(4-piperidyl)-4-(4-pyridyl)-3-(4-chlorophenyl) pyrazole hydrochloride (Example C-74) (1 g, 2.4 mmol) in 24 mL of CH_2Cl_2 , was added 4-dimethylamino pyridine (0.88 g, 7.2 mmol) and acetyl chloride (0.21 g, 2.6 mmol). The solution was stirred for 3 h and the solvent was removed under reduced pressure. The residue was treated with saturated NH_4OH (20 mL) and the suspension was extracted with ethyl acetate (3 x 30 mL). The combined extracts were washed with brine (1 x 50 mL), dried over MgSO_4 , filtered and concentrated to leave a solid. The solid was triturated with ether and was filtered to leave the title compound: MS (M+H): 381 (base peak).

928

Example C-77


5-(N-METHOXYACETYL-4-PIPERIDYL)-4-(4-PYRIDYL)-3-(4-CHLOROPHENYL) PYRAZOLE



By following the method of Example C-76 and substituting methoxy acetyl chloride for acetyl chloride the title compound was prepared: ^1H NMR ($\text{DMSO}-d_6$) δ 8.75 (d, $J = 6.72$ Hz, 2 H), 7.70 (d, $J = 6.72$ Hz, 2 H), 7.38 (d, $J = 8.60$ Hz, 2 H), 7.29 (dd, $J = 6.72, 1.88$ Hz, 2 H), 4.40 (d, $J = 11.8$ Hz, 1 H), 4.05 (m, 2 H), 3.70 (d, $J = 12.70$ Hz, 1 H), 3.25 (s, 3 H), 3.0 (m, 2 H), 2.55 (m, 1 H), 1.7 (m, 4 H). MS ($M+H$): 411 (base peak).

Example C-78

5-(N-METHYLSULFONYL-4-PIPERIDYL)-4-(4-PYRIDYL)-3-(4-CHLOROPHENYL) PYRAZOLE




929

By following the method of Example C-76 and substituting methylsulfonyl chloride (2.0 equivalents) for acetyl chloride the title compound was prepared: ¹HNMR (DMSO-d₆) δ 8.70 (d, J = 6.72 Hz, 2 H), 7.72 (d, J = 6.72 Hz, 2 H), 7.38 (d, J = 7.66 Hz, 2 H), 7.30 (dd, J = 6.72, 1.88 Hz, 2 H), 3.58 (bd, J = 11.8 Hz, 2 H), 2.87 (m, 1 H), 2.82 (s, 3 H), 2.72 (m, 2 H), 1.85 (m, 4 H). MS (M+H): 417 (base peak).

Example C-79


5-[N-METHOXYETHYL-4-PIPERIDYL]-4-(4-PYRIDYL)-3-(4-CHLOROPHENYL) PYRAZOLE




To a stirred suspension of 5-(4-piperidyl)-4-(4-pyridyl)-3-(4-chlorophenyl) pyrazole hydrochloride (Example C-74) (500 mg, 1.2 mmol) in 12 mL of DMF was added Hunig's base (790 mg, 6.1 mmol) and 2-bromoethyl methyl ether (850 mg, 6.1 mmol). The solution was stirred at room temperature for 5 days. The solution was poured onto 2.5 N NaOH and was extracted with ethyl acetate (3 x 100 mL). The combined extracts were washed with water (3 x 100 mL) and brine (1 x 100 mL). The organic phase was dried over Na₂SO₄ and was filtered. The

930


solvent was removed under reduced pressure to leave a solid. The solid was triturated and filtered to leave the title compound: ¹HNMR (CDCl₃) δ 8.63 (d, *J* = 4.23 Hz, 2 H), 7.28 (m, 4 H), 7.14 (d, *J* = 4.43 Hz, 2 H), 3.57 (t, *J* = 5.24 Hz, 2 H), 3.38 (s, 3 H), 3.14 (bd, *J* = 10.1 Hz, 2 H), 2.79 (m, 1 H), 2.68 (t, *J* = 5.04, 2 H), 2.08 (m, 4 H), 1.92 (m, 2 H). MS (M+H): 397 (base peak).

Example C-80**5-(N-ALLYL-4-PIPERIDYL)-4-(4-PYRIDYL)-3-(4-CHLOROPHENYL)
PYRAZOLE**

By following the method of example C-79 and substituting allyl bromide for 2-bromoethyl methyl ether the title compound was prepared: MS (M+H): 379 (base peak)

Example C-81**5-(N-PROPARGYL-4-PIPERIDYL)-4-(4-PYRIDYL)-3-(4-CHLOROPHENYL) PYRAZOLE**

By following the method of example C-79 and substituting propargyl bromide for 2-bromoethyl methyl ether the title compound was prepared: MS (M+H): 377 (base peak)


Example C-82**5-[N-(2-METHYLTHIAZOLYL)-4-PIPERIDYL]-4-(4-PYRIDYL)-3-(4-CHLOROPHENYL) PYRAZOLE**

To a suspension of 5-(4-piperidyl)-4-(4-pyridyl)-3-(4-chlorophenyl) pyrazole hydrochloride (Example C-74) in 12 mL of MeOH was added trimethyl orthoformate (2.6 g,

24.4 mmol) and 2-thiazolecarboxaldehyde (1.4 g, 12.2 mmol). The suspension was stirred at room temperature for 2 h. To this mixture was added NaCNBH₃ (1.5 g, 24.4 mmol) and the resulting suspension was stirred at room temperature for 7 days. The mixture was poured onto 2.5 N NaOH and was extracted with ethyl acetate (2 x 100 mL). The combined extracts were washed with brine (1 x 100 mL), dried over Na₂SO₄, filtered and concentrated to leave a solid. This solid was triturated with ether and filtered to afford the title compound: MS (M+H): 436 (base peak).

Example C-83

5-(4-PIPERIDYL)-4-(4-PYRIDYL)-3-[4-(TRIFLUOROMETHYL)PHENYL] PYRAZOLE




By following the method of Example C-1 and substituting methyl-4-(trifluoromethyl)benzoate for ethyl-4-fluorobenzoate and *N*-*t*-butoxycarbonyl-isonipecotyl *N*-hydroxysuccinimide for *N*-benyloxycarbonyl-glycinyl *N*-hydroxysuccinimide the title compound was prepared as the *N*-*t*-butoxycarbonyl protected compound. The deprotection of the *N*-*t*-butoxycarbonyl intermediate

933

was accomplished with 4 N HCl in dioxane to afford the title compound as its hydrochloride salt: MS (M+H): 373 (base peak).

Example C-84


5-(N-METHYL-4-PIPERIDYL)-4-(4-PYRIDYL)-3-[4-(TRIFLUOROMETHYL)PHENYL] PYRAZOLE



By following the method of Example C-75 and substituting 5-(4-piperidyl)-4-(4-pyridyl)-3-[4-(trifluoromethyl)phenyl] pyrazole hydrochloride (Example C-83) for 5-(4-piperidyl)-4-(4-pyridyl)-3-(4-chlorophenyl) pyrazole hydrochloride (Example C-74) the title compound was prepared: MS (M+H): 387 (base peak).

Example C-85


5-[N-(2-PROPYL)-4-PIPERIDYL]-4-(4-PYRIDYL)-3-[4-(TRIFLUOROMETHYL)PHENYL] PYRAZOLE



To a solution of 5-(4-piperidyl)-4-(4-pyridyl)-3-[4-(trifluoromethyl)phenyl] pyrazole (Example C-83) (300 mg, 0.7 mmol) in 50 mL of acetone was added 1 mL of AcOH and NaBH(OAc)₃ (15 g, 70.8 mmol). The mixture was warmed to reflux and was stirred for 5 days. The reaction mixture was poured onto 100 mL of 2.5 N NaOH and was extracted with ethyl acetate (2 x 100 mL). The extracts were combined and washed with brine (1 x 100 mL). The organic phase was dried over Na₂SO₄, filtered, and concentrated to afford the title compound: MS (M+H): 415 (base peak).

Example C-86

5-(4-PIPERIDYL)-4-(4-PYRIDYL)-3-[3-(TRIFLUOROMETHYL)PHENYL] PYRAZOLE




By following the method of Example C-1 and substituting methyl-3-(trifluoromethyl)benzoate for ethyl-4-fluorobenzoate and N-t-butoxycarbonyl-isonipecotyl N-hydroxysuccinimide for N-benzyloxycarbonyl-glycinyll N-hydroxysuccinimide the title compound was prepared as the N-t-butoxycarbonyl protected compound. The deprotection of the N-t-butoxycarbonyl intermediate was accomplished with 4 N HCl in dioxane to afford the

935


title compound as its hydrochloride salt: MS (M+H): 373 (base peak).the pyrazole C-3 substituent (Cviii). Treatment of the

Example C-87


5-(N-METHYL-4-PIPERIDYL)-4-(4-PYRIDYL)-3-[3-(TRIFLUOROMETHYL)PHENYL] PYRAZOLE



By following the method of Example C-75 and substituting 5-(4-piperidyl)-4-(4-pyridyl)-3-[3-(trifluoromethyl)phenyl] pyrazole hydrochloride (Example C-86) for 5-(4-piperidyl)-4-(4-pyridyl)-3-(4-chlorophenyl) pyrazole hydrochloride (Example C-74) the title compound was prepared: MS (M+H): 387 (base peak).

Example C-88**5-(4-PIPERIDYL)-4-(4-PYRIDYL)-3-(3-CHLOROPHENYL) PYRAZOLE**

By following the method of Example C-1 and substituting methyl-3-chlorobenzoate for ethyl-4-fluorobenzoate and *N*-*t*-butoxycarbonyl-isonipecotyl *N*-hydroxysuccinimide for *N*-benyloxycarbonyl-glyciny *N*-hydroxysuccinimide the title compound was prepared as the *N*-*t*-butoxycarbonyl protected compound. The deprotection of the *N*-*t*-butoxycarbonyl intermediate was accomplished with 4 *N* HCl in dioxane to afford the title compound: MS (*M*+*H*): 339 (base peak).


Example C-89**5-(*N*-METHYL-4-PIPERIDYL)-4-(4-PYRIDYL)-3-(3-CHLOROPHENYL)
PYRAZOLE**

937

By following the method of Example C-75 and substituting 5-(4-piperidyl)-4-(4-pyridyl)-3-(3-chlorophenyl) pyrazole hydrochloride (Example C-88) for 5-(4-piperidyl)-4-(4-pyridyl)-3-(4-chlorophenyl) pyrazole hydrochloride (Example C-74) the title compound was prepared: MS (M+H): 353 (base peak).


Example C-90

5-(3-PIPERIDYL)-4-(4-PYRIDYL)-3-(4-FLUOROPHENYL) PYRAZOLE




By following the method of Example C-1 and substituting N-t-butoxycarbonyl-nipecotyl N-hydroxysuccinimide for N-benzyloxycarbonyl-glyciny N-hydroxysuccinimide the title compound was prepared as the N-t-butoxycarbonyl protected compound. The deprotection of the N-t-butoxycarbonyl intermediate was accomplished with 4 N HCl in dioxane to afford the title compound as its hydrochloride salt: MS (M+H): 323 (base peak).

938

Example C-91**5-(*N*-METHYL-3-PIPERIDYL)-4-(4-PYRIDYL)-3-(4-FLUOROPHENYL)
PYRAZOLE**

By following the method of Example C-75 and substituting 5-(3-piperidyl)-4-(4-pyridyl)-3-(4-fluorophenyl) pyrazole hydrochloride (Example C-90) for 5-(4-piperidyl)-4-(4-pyridyl)-3-(4-chlorophenyl) pyrazole hydrochloride (Example C-74) the title compound was prepared: MS (M+H): 337 (base peak).


Example C-92**5-*cis*-(4-AMINOCYCLOHEXYL)-4-(4-PYRIDYL)-3-(4-
CHLOROPHENYL) PYRAZOLE**

By following the method of Example C-1 and substituting methyl-4-chlorobenzoate for ethyl-4-

fluorobenzoate and *N*-*t*-butoxycarbonyl-*cis*-4-aminocyclohexanoyl *N*-hydroxysuccinimide for *N*-benyloxycarbonyl-glycinyll *N*-hydroxysuccinimide the title compound was prepared as the *N*-*t*-butoxycarbonyl protected compound. The deprotection of the *N*-*t*-butoxycarbonyl intermediate was accomplished with 4 N HCl in dioxane to afford the title compound: ¹HNMR (d₆-DMSO) δ 8.56 (d, *J* = 6.04 Hz, 2 H), 7.39 (d, *J* = 8.66 Hz, 2 H), 7.31 (d, *J* = 8.46 Hz, 2 H), 7.17 (d, *J* = 5.84 Hz, 2 H), 3.05 (m, 1 H), 2.62 (m, 1 H), 1.99 (m, 2 H), 1.53 (m, 6 H). MS (M+H): 353 (base peak).


Example C-93

5-*cis*-(4-*N,N*-DIMETYLAMINOCYCLOHEXYL)-4-(4-PYRIDYL)-3-(4-CHLOROPHENYL) PYRAZOLE



By following the method of Example C-75 and substituting 5-*cis*-(4-aminocyclohexyl)-4-(4-pyridyl)-3-(4-chlorophenyl) pyrazole (Example C-92) for 5-(4-piperidyl)-4-(4-pyridyl)-3-(4-chlorophenyl) pyrazole hydrochloride (Example C-74) the title compound was prepared: MS (M+H): 381 (base peak).


Example C-94

5-[*cis*-4-*N*-(2-PROPYL)AMINOCYCLOHEXYL]-4-(4-PYRIDYL)-3-(4-CHLOROPHENYL) PYRAZOLE

To a slurry of 5-*cis*-(4-aminocyclohexyl)-4-(4-pyridyl)-3-(4-chlorophenyl) pyrazole (Example C-92) (1.0 g, 2.8 mmol, 1.0 eq) in methylene chloride (28 mL) was added acetone (0.5 mL), acetic acid (0.5 mL) and solid sodium triacetoxyborohydride. The slurry was stirred for 5 h and the volatiles were removed. The residue was partitioned between 2.5 M NaOH (25 mL) and ethyl acetate (25 mL) and the aqueous layer was extracted with ethyl acetate (3 x 25 mL). The combined organic layer was washed with brine (50 mL), dried over MgSO₄ and evaporated. The residue was triturated with ether to yield the title compound as a white powder: ¹HNMR (d₆-DMSO) δ 8.56 (d, *J* = 5.84 Hz, 2H), 7.40 (d, *J* = 8.26 Hz, 2H), 7.30 (d, *J* = 8.66 Hz, 2H), 7.18 (d, *J* = 5.64 Hz, 2H), 2.95 (m, 2H), 2.72 (m, 1H), 1.90 (m, 2H), 1.73 (m, 2H), 1.55 (m, 4H), 1.07 (d, *J* = 5.64 Hz, 6H). MS (M+H): 395 (base peak).

Example C-95


5-*cis*-[4-*N*-(ACETYL)AMINOCYCLOHEXYL]-4-(4-PYRIDYL)-3-(4-CHLOROPHENYL) PYRAZOLE



By following the method of Example C-76 and substituting 5-*cis*-(4-aminocyclohexyl)-4-(4-pyridyl)-3-(4-chlorophenyl) pyrazole (Example C-92) for 5-(4-piperidyl)-4-(4-pyridyl)-3-(4-chlorophenyl) pyrazole hydrochloride (Example C-74) the title compound was prepared: MS (M+H): 395 (base peak).

Example C-96

5-*cis*-[4-*N*-(METHOXYACETYL)AMINOCYCLOHEXYL]-4-(4-PYRIDYL)-3-(4-CHLOROPHENYL) PYRAZOLE




By following the method of Example C-76 and substituting 5-*cis*-(4-aminocyclohexyl)-4-(4-pyridyl)-3-

942

(4-chlorophenyl) pyrazole (Example C-92) for 5-(4-piperidyl)-4-(4-pyridyl)-3-(4-chlorophenyl) pyrazole hydrochloride (Example C-74) and methoxy acetyl chloride for acetyl chloride the title compound was prepared: MS (M+H): 425 (base peak).

Example C-97


5-*cis*-[4-N-(METHYLSULFONYL)AMINOCYCLOHEXYL]-4-(4-PYRIDYL)-3-(4-CHLOROPHENYL) PYRAZOLE



By following the method of Example C-76 and substituting 5-*cis*-(4-aminocyclohexyl)-4-(4-pyridyl)-3-(4-chlorophenyl) pyrazole (Example C-92) for 5-(4-piperidyl)-4-(4-pyridyl)-3-(4-chlorophenyl) pyrazole hydrochloride (Example C-74) and methylsulfonyl chloride for acetyl chloride the title compound was prepared: MS (M+H): 431 (base peak).

Example C-98


5-*cis*-(4-AMINOCYCLOHEXYL)-4-(4-PYRIDYL)-3-(4-FLUOROPHENYL) PYRAZOLE



By following the method of Example C-1 and substituting *N*-*t*-butoxycarbonyl-*cis*-4-aminocyclohexanoyl *N*-hydroxysuccinimide for *N*-benyloxycarbonyl-glyciny l *N*-hydroxysuccinimide the title compound was prepared as the *N*-*t*-butoxycarbonyl protected compound. The deprotection of the *N*-*t*-butoxycarbonyl intermediate was accomplished with 4 N HCl in dioxane to afford the title compound: MS (M+H): 337 (base peak).

Example C-99


5-(*cis*-4-*N,N*-DIMETHYLAMINOCYCLOHEXYL)-4-(4-PYRIDYL)-3-(4-FLUOROPHENYL) PYRAZOLE



By following the method of Example C-75 and substituting 5-*cis*-(4-aminocyclohexyl)-4-(4-pyridyl)-3-(4-fluorophenyl) pyrazole (Example C-98) for 5-(4-piperidyl)-4-(4-pyridyl)-3-(4-chlorophenyl) pyrazole hydrochloride (Example C-74) the title compound was prepared: MS (M+H): 365 (base peak).

Example C-100


5-*cis*-[4-N-(2-PROPYL)AMINOCYCLOHEXYL]-4-(4-PYRIDYL)-3-(4-FLUOROPHENYL) PYRAZOLE



By following the method of Example C-94 and substituting *cis*-5-(4-aminocyclohexyl)-4-(4-pyridyl)-3-(4-fluorophenyl) pyrazole (Example C-98) for 5-(*cis*-4-n-(2-propyl)aminocyclohexyl)-4-(4-pyridyl)-3-(4-chlorophenyl) pyrazole (Example C-92) the title compound was prepared: MS (M+H): 379 (base peak).

Example C-101


5-*cis*-(4-AMINOCYCLOHEXYL)-4-(4-PYRIDYL)-3-[4-(TRIFLUOROMETHYL)PHENYL] PYRAZOLE



By following the method of Example C-1 and substituting methyl-4-(trifluoromethyl)benzoate for ethyl-4-fluorobenzoate and *N*-*t*-butoxycarbonyl-*cis*-4-aminocyclohexanoyl *N*-hydroxysuccinimide for *N*-benyloxycarbonyl-glycinyll *N*-hydroxysuccinimide the title compound was prepared as the *N*-*t*-butoxycarbonyl protected compound. The deprotection of the *N*-*t*-butoxycarbonyl intermediate was accomplished with 4 N HCl in dioxane to afford the title compound: MS (M+H): 387 (base peak).

Example C-102


5-*cis*-(4-*N,N*-DIMETHYLAMINOCYCLOHEXYL)-4-(4-PYRIDYL)-3-[4-(TRIFLUOROMETHYL)PHENYL] PYRAZOLE



By following the method of Example C-75 and substituting 5-*cis*-(4-aminocyclohexyl)-4-(4-pyridyl)-3-[4-(trifluoromethyl)phenyl] pyrazole (Example C-101) for 5-(4-piperidyl)-4-(4-pyridyl)-3-(4-chlorophenyl) pyrazole hydrochloride (Example C-74) the title compound was prepared: MS (M+H): 415 (base peak).

Example C-103


5-*cis*-(4-AMINOCYCLOHEXYL)-4-(4-PYRIDYL)-3-[3-(TRIFLUOROMETHYL)PHENYL] PYRAZOLE



By following the method of Example C-1 and substituting methyl-3-(trifluoromethyl)benzoate for ethyl-4-fluorobenzoate and *N*-*t*-butoxycarbonyl-*cis*-4-aminocyclohexanoyl *N*-hydroxysuccinimide for *N*-benyloxycarbonyl-glycinyll *N*-hydroxysuccinimide the title compound was prepared as the *N*-*t*-butoxycarbonyl protected compound. The deprotection of the *N*-*t*-butoxycarbonyl intermediate was accomplished with 4 N HCl in dioxane to afford the title compound: MS (M+H): 387 (base peak).

Example C-104


5-*cis*-(4-*N,N*-DIMETHYLAMINOCYCLOHEXYL)-4-(4-PYRIDYL)-3-[3-(TRIFLUOROMETHYL)PHENYL] PYRAZOLE



By following the method of Example C-75 and substituting 5-*cis*-(4-aminocyclohexyl)-4-(4-pyridyl)-3-(3-(trifluoromethyl)phenyl) pyrazole (Example C-103) for 5-(4-piperidyl)-4-(4-pyridyl)-3-(4-chlorophenyl) pyrazole hydrochloride (Example C-74) the title compound was prepared: MS (M+H): 415 (base peak).

Example C-105

5-*cis*-(4-AMINOCYCLOHEXYL)-4-(4-PYRIDYL)-3-(3-CHLOROPHENYL) PYRAZOLE




By following the method of Example C-1 and substituting methyl-3-chlorobenzoate for ethyl-4-


fluorobenzoate and *N*-*t*-butoxycarbonyl-*cis*-4-aminocyclohexanoyl *N*-hydroxysuccinimide for *N*-benyloxycarbonyl-glycinyll *N*-hydroxysuccinimide the title compound was prepared as the *N*-*t*-butoxycarbonyl protected compound. The deprotection of the *N*-*t*-butoxycarbonyl intermediate was accomplished with 4 N HCl in dioxane to afford the title compound: MS (M+H): 353 (base peak).

Example C-106


5-*cis*-(4-*N,N*-DIMETHYLAMINOCYCLOHEXYL)-4-(4-PYRIDYL)-3-(3-CHLOROPHENYL) PYRAZOLE



By following the method of Example C-75 and substituting 5-*cis*-(4-aminocyclohexyl)-4-(4-pyridyl)-3-(3-chlorophenyl) pyrazole hydrochloride (Example C-105) for 5-(4-piperidyl)-4-(4-pyridyl)-3-(4-chlorophenyl) pyrazole hydrochloride (Example C-74) the title compound was prepared: MS (M+H): 381 (base peak).

Example C-107**5-(*N*-ACETIMIDO-4-PIPERIDYL)-4-(4-PYRIDYL)-3-(4-FLUOROPHENYL) PYRAZOLE**

To a suspension of 5-(4-piperidyl)-4-(4-pyridyl)-3-(4-fluorophenyl) pyrazole (Example C-2) (0.11 g, 0.35 mmol) in 2 mL EtOH was added ethyl acetamidate hydrochloride (0.065 g, 0.53 mmol) and the mixture was refluxed for 30 minutes. The solution was left at 5-10 °C for 16 h and filtered to obtain the title compound as a white solid: MS (M+H): 364 (base peak).

Example C-108**5-(*N*-CARBOXAMIDINO-4-PIPERIDYL)-4-(4-PYRIDYL)-3-(4-FLUOROPHENYL) PYRAZOLE**


To a stirred suspension of 5-(4-piperidyl)-4-(4-pyridyl)-3-(4-fluorophenyl) pyrazole (C-2) (1.5 g, 4.7

950

mmol) in 47 mL of DMF was added Hunig's base (0.60 g, 4.7 mmol) and pyrazole carboxamide hydrochloride (0.68 g, 4.7 mmol). The slurry was allowed to stir at room temperature for 4 days. The reaction mixture was poured onto 300 mL of ether. The resulting precipitate was filtered to leave the title compound as the hydrochloride salt: MS (M+H): 365 (base peak).

Example C-109


5-(N-CYCLOPROPANOYL-4-PIPERIDYL)-4-(4-PYRIDYL)-3-(4-CHLOROPHENYL) PYRAZOLE



By following the method of Example C-76 and substituting cyclopropanoyl chloride for acetyl chloride the title compound was prepared: MS (M+H): 407 (base peak).

Example C-110


5-[N-(2-FLUORO)BENZOYL-4-PIPERIDYL]-4-(4-PYRIDYL)-3-(4-CHLOROPHENYL) PYRAZOLE



By following the method of Example C-76 and substituting 2-fluorobenzoyl chloride for acetyl chloride the title compound was prepared: MS (M+H): 461 (base peak).

Example C-111

5-(N-METHYLSULFONYL-4-PIPERIDYL)-4-(4-PYRIDYL)-3-(4-FLUOROPHENYL) PYRAZOLE




By following the method of Example C-76 and substituting 5-(4-piperidyl)-4-(4-pyridyl)-3-(4-fluorophenyl) pyrazole (Example C-2) for 5-(4-piperidyl)-4-(4-pyridyl)-3-(4-chlorophenyl) pyrazole (Example C-74)

and methylsulfonyl chloride for acetyl chloride the title compound was prepared: MS (M+H): 401 (base peak).

Example C-112


5-(N-METHOXYACETYL-4-PIPERIDYL)-4-(4-PYRIDYL)-3-(4-FLUOROPHENYL) PYRAZOLE



By following the method of Example C-76 and substituting 5-(4-piperidyl)-4-(4-pyridyl)-3-(4-fluorophenyl) pyrazole (Example C-2) for 5-(4-piperidyl)-4-(4-pyridyl)-3-(4-chlorophenyl) pyrazole (Example C-74) and methoxy acetyl chloride for acetyl chloride the title compound was prepared: MS (M+H): 395 (base peak).

Example C-113


5-(N-ACETYL-4-PIPERIDYL)-4-(4-PYRIDYL)-3-(4-FLUOROPHENYL) PYRAZOLE




By following the method of Example C-76 and substituting 5-(4-piperidyl)-4-(4-pyridyl)-3-(4-fluorophenyl) pyrazole Example (C-2) for 5-(4-piperidyl)-4-(4-pyridyl)-3-(4-chlorophenyl) pyrazole Example (C-74) the title compound was prepared: MS (M+H): 365 (base peak).

Example C-114


5-[2-(1,1-DIMETHYL)AMINOETHYL]-4-(4-PYRIDYL)-3-(4-FLUOROPHENYL) PYRAZOLE



By following the method of Example C-1 and substituting *N*-*t*-butoxycarbonyl-2-amino-2,2-dimethylpropanoyl *N*-hydroxysuccinimide for *N*-benzyloxycarbonyl-glycinyll *N*-hydroxysuccinimide the title compound was prepared as the *N*-*t*-butoxycarbonyl protected compound. The deprotection of the *N*-*t*-butoxycarbonyl intermediate was accomplished with 4 N HCl in dioxane to afford the title compound as the hydrochloride salt: MS (M+H): 327 (base peak).

Example C-115**5-(METHOXYMETHYL)-4-(4-PYRIDYL)-3-(4-CHLOROPHENYL)
PYRAZOLE**

By following the method of Example C-1 and substituting methyl-4-chlorobenzoate for ethyl-4-fluorobenzoate and 2-methoxyacetyl *N*-hydroxysuccinimide for *N*-benyloxycarbonyl-glycinyll *N*-hydroxysuccinimide the title compound was prepared: MS (M+H): 300 (base peak).


Example C-116**5-(4-AMINOBENZYL)-4-(4-PYRIDYL)-3-(4-CHLOROPHENYL)
PYRAZOLE**

By following the method of Example C-1 and substituting methyl-4-chlorobenzoate for ethyl-4-fluorobenzoate and *N*-*t*-butoxycarbonyl-4-aminophenyl

acetyl *N*-hydroxysuccinimide for *N*-benzyloxycarbonyl-glyciny *N*-hydroxysuccinimide the title compound was prepared as the *N*-*t*-butoxycarbonyl protected compound. The deprotection of the *N*-*t*-butoxycarbonyl intermediate was accomplished with 4 N HCl in dioxane to afford the title compound as the hydrochloride salt: MS (M+H): 361 (base peak).

Example C-117


5-[4-(*N,N*-DIMETHYL)AMINOBENZYL]-4-(4-PYRIDYL)-3-(4-CHLOROPHENYL) PYRAZOLE



By following the method of Example C-75 and substituting 5-(4-aminobenzyl)-4-(4-pyridyl)-3-(4-chlorophenyl) pyrazole (Example C-116) for 5-(4-piperidyl)-4-(4-pyridyl)-3-(4-chlorophenyl) pyrazole hydrochloride (Example C-74) the title compound was prepared: MS (M+H): 389 (base peak).

Example C-118


**5-[4-(*N*-ACETYL)AMINO BENZYL]-4-(4-PYRIDYL)-3-(4-
CHLOROPHENYL) PYRAZOLE**



By following the method of Example C-76 and substituting 5-(4-aminobenzyl)-4-(4-pyridyl)-3-(4-chlorophenyl) pyrazole (Example C-116) for 5-(4-piperidyl)-4-(4-pyridyl)-3-(4-chlorophenyl) pyrazole hydrochloride (Example C-74) the title compound was prepared: MS (M+H): 403 (base peak).

Example C-119

**5-(*N*-METHYLAMINOMETHYL)-4-(4-PYRIDYL)-3-(4-FLUOROPHENYL)
PYRAZOLE**




5-(*N*-formylaminomethyl)-4-(4-pyridyl)-3-(4-fluorophenyl) pyrazole. To a suspension of 5-aminomethyl-

4-(4-pyridyl)-3-(4-fluorophenyl) pyrazole (Example C-1) (8.04 g, 30 mmol) in 120 mL dichloromethane was added p-nitrophenylformate (6.01 g, 36 mmol) as a solid. The suspension was stirred for 24 h at room temperature and the solvents removed under reduced pressure. The residue was triturated with ether and filtered to obtain the desired 5-(*N*-formylaminomethyl)-4-(4-pyridyl)-3-(4-fluorophenyl) pyrazole derivative as a white solid: MS (M+H): 297 (base peak).

5-(*N*-methylaminomethyl)-4-(4-pyridyl)-3-(4-fluorophenyl) pyrazole. To a suspension of 5-(*N*-formylaminomethyl)-4-(4-pyridyl)-3-(4-fluorophenyl) pyrazole (8.74 g, 29.5 mmol) in 90 mL anhydrous tetrahydrofuran was added a 1.0 M solution of borane in tetrahydrofuran (90 mL, 90 mmol) and the mixture was stirred at room temperature for 24 h. 1 N aqueous hydrochloric acid (100 mL) was then added to this mixture and the solution was refluxed for 5 hours and cooled to room temperature. The solution was extracted with ether (2 x 250 mL) and the pH of the aqueous layer adjusted to 9 by addition of concentrated ammonium hydroxide. The aqueous layers (pH ~ 9) were then extracted with ethyl acetate (4 x 150 mL). The organic extracts were dried over sodium sulfate, filtered and evaporated to dryness under reduced pressure. The residue was triturated with acetonitrile and filtered to obtain the title compound as a white solid: MS (M+H): 283 (base peak).

Example C-120

5-[N-(2-AMINO-2,2-DIMETHYLACETYL)AMINOMETHYL]-4-(4-PYRIDYL)-3-(4-FLUOROPHENYL) PYRAZOLE




5-(N-*t*-butoxycarbonylaminomethyl)-4-(4-pyridyl)-3-(4-fluorophenyl) pyrazole. To a solution of 5-aminomethyl-4-(4-pyridyl)-3-(4-fluorophenyl) pyrazole (Example C-1) (0.27 g, 1 mmol) in anhydrous dimethylformamide (4 mL) was added *N*-tert-butoxycarbonyl aminoisobutyric acid *N*-hydroxysuccinimide ester (0.33 g, 1.1 mmol) and the mixture stirred at 40 °C for 24 h. The resulting solution was evaporated to dryness under reduced pressure. The residue was dissolved in dichloromethane (30 mL) and washed with a saturated solution of sodium bicarbonate (2 x 20 mL) and brine (20 mL). The organic layers were dried over sodium sulfate, filtered and evaporated under reduced pressure to dryness to afford 5-(N-*t*-butoxycarbonylaminomethyl)-4-(4-pyridyl)-3-(4-fluorophenyl) pyrazole as a white solid.

5-(N-(2-amino-2,2-dimethylacetyl)aminomethyl)-4-(4-pyridyl)-3-(4-fluorophenyl) pyrazole. To a solution of the above compound in acetonitrile (2 mL) was added 1 mL of a 4.0 M solution of hydrochloric acid in dioxane. The

reaction mixture was stirred at room temperature for 6 hours. The suspension was evaporated to dryness under reduced pressure. The resulting residue was stirred in acetonitrile (5 mL), filtered and dried in a vacuum dessicator to afford the title compound as a hydrochloride salt: MS (M+H): 354 (base peak).

Example C-121


5-[N-(2-AMINO-2,2-DIMETHYLACETYL)AMINOMETHYL]-4-(4-PYRIDYL)-3-(4-CHLOROPHENYL) PYRAZOLE



By following the method of Example C-120 and substituting 5-aminomethyl-4-(4-pyridyl)-3-(4-chlorophenyl) pyrazole (Example C-15) for 5-aminomethyl-4-(4-pyridyl)-3-(4-fluorophenyl) pyrazole (Example C-1) the title compound was prepared: MS (M+H): 370 (base peak).

Example C-122

5-[4-N-(2-DIMETHYLAMINOACETYL)PIPERIDYL]-4-(4-PYRIDYL)-3-(4-CHLOROPHENYL) PYRAZOLE




To a solution of N,N-dimethylglycine hydrochloride (0.28 g, 2 mmol) in dimethylformamide (4 mL) was added hydroxybenzotriazole (0.27 g, 2 mmol), N,N-diisopropylethyl amine (0.7 mL, 4 mmol) and polymer supported ethyl carbodimide (Example B-49) (1 g, 2.39 mmol). To this solution after 30 minutes at room temperature was added 5-(4-piperidyl)-4-(4-pyridyl)-3-(4-chlorophenyl) pyrazole hydrochloride (Example C-74), 0.41 g, 1 mmol). The suspension was agitated on a labtop orbital shaker for 24 h. The suspension was filtered, washed with dimethylformamide (2 x 5 mL) and the filtrates evaporated under high pressure. The residue was dissolved in dichloromethane (30 mL), washed with a saturated solution of sodium bicarbonate (50 mL) and brine (50 mL). The organic layers were dried over sodium sulfate, filtered and evaporated under high vacuum to afford the title compound as a white solid: MS (M+H): 424 (base peak).

961

Example C-123


**(S)-5-(2-PYROLIDINYL)-4-(4-PYRIDYL)-3-(4-FLUOROPHENYL)
PYRAZOLE**



By following the method of Example C-1 and substituting (S)-N-t-butoxycarbonyl-prolinyl N-hydroxysuccinimide for N-benzyloxycarbonyl-glyciny N-hydroxysuccinimide the title compound was prepared as the N-t-butoxycarbonyl protected compound. The deprotection of the N-t-butoxycarbonyl intermediate was accomplished with 4 N HCl in dioxane to afford the title compound: MS (M+H): 309 (base peak).

Example C-124


**(S)-5-(N-METHYL-2-PYROLIDINYL)-4-(4-PYRIDYL)-3-(4-
FLUOROPHENYL) PYRAZOLE**



By following the method of Example C-75 and substituting (S)-5-(2-pyrrolidinyl)-4-(4-pyridyl)-3-(4-fluorophenyl) pyrazole (Example C-123) for 5-(4-piperidyl)-4-(4-pyridyl)-3-(4-chlorophenyl) pyrazole hydrochloride (Example C-74) the title compound was prepared: MS (M+H): 323 (base peak).

Example C-125


(R)-5-(2-PYROLIDINYL)-4-(4-PYRIDYL)-3-(4-FLUOROPHENYL) PYRAZOLE



By following the method of Example C-1 and substituting (R)-N-t-butoxycarbonyl-prolinyl N-hydroxysuccinimide for N-benzyloxycarbonyl-glyciny N-hydroxysuccinimide the title compound was prepared as the N-t-butoxycarbonyl protected compound. The deprotection of the N-t-butoxycarbonyl intermediate was accomplished with 4 N HCl in dioxane to afford the title compound: MS (M+H): 309 (base peak).

Example C-126


(R)-5-(N-METHYL-2-PYROLIDINYL)-4-(4-PYRIDYL)-3-(4-FLUOROPHENYL) PYRAZOLE



By following the method of Example C-75 and substituting (R)-5-(2-pyrrolidinyl)-4-(4-pyridyl)-3-(4-fluorophenyl) pyrazole (Example C-125) for 5-(4-piperidyl)-4-(4-pyridyl)-3-(4-chlorophenyl) pyrazole hydrochloride (Example C-74) the title compound was prepared: MS (M+H): 323 (base peak).

Example C-127

(R)-5-(3-PIPERIDYL)-4-(4-PYRIDYL)-3-(4-FLUOROPHENYL) PYRAZOLE




By following the method of Example C-1 and substituting (R)-N-t-butoxycarbonyl-nipecotyl N-hydroxysuccinimide for N-benzyloxycarbonyl-glyciny N-

964

hydroxysuccinimide the title compound was prepared as the *N*-*t*-butoxycarbonyl protected compound. The deprotection of the *N*-*t*-butoxycarbonyl intermediate was accomplished with 4 N HCl in dioxane to afford the title compound: MS (M+H): 323 (base peak).

Example C-128

(*R*)-5-(*N*-METHYL-3-PIPERIDYL)-4-(4-PYRIDYL)-3-(4-FLUOROPHENYL) PYRAZOLE




By following the method of Example C-75 and substituting (*R*)-5-(3-piperidyl)-4-(4-pyridyl)-3-(4-fluorophenyl) pyrazole (Example C-125) for 5-(4-piperidyl)-4-(4-pyridyl)-3-(4-chlorophenyl) pyrazole hydrochloride (Example C-74) the title compound was prepared: MS (M+H): 337 (base peak).

965

Example C-129


2,2-DIMETHYL-4-[4-(4-PYRIDYL)-3-(4-CHLOROPHENYL)

PYRAZOLYL] BUTYRIC ACID



By following the method of Example C-1 and substituting methyl-4-chlorobenzoate for ethyl-4-fluorobenzoate and 2,2-dimethyl glutaric anhydride for *N*-benzyloxycarbonyl-glycinyll *N*-hydroxysuccinimide the title compound was prepared: MS (M+H): 370 (base peak).


Example C-130

4-[4-(4-PYRIDYL)-3-(4-FLUOROPHENYL) PYRAZOLYL] BUTYRIC
ACID

By following the method of Example C-1 and substituting glutaric anhydride for *N*-benzyloxycarbonyl-glycinyll *N*-hydroxysuccinimide the title compound was prepared: MS (M+H): 326 (base peak).

Example C-131

4-[4-(4-PYRIDYL)-3-(4-FLUOROPHENYL) PYRAZOLYL] BUTYRAMIDE



Methyl 4-(4-(4-pyridyl)-3-(4-fluorophenyl) pyrazolyl) butyrate. To a solution of 4-(4-(4-pyridyl)-3-(4-fluorophenyl) pyrazolyl) butyric acid (Example C-130) (40 g, 123 mmol) in 650 mL of MeOH was added 20 mL of concentrated H_2SO_4 . The solution was stirred overnight at room temperature. The solution was concentrated and diluted with 200 mL of water. The solution was cooled with an ice/water bath and to the solution was added 150 mL of saturated NaHCO_3 . The solution was neutralized further with 50% NaOH to pH 7. The resulting slurry was extracted with CH_2Cl_2 (3 x 250 mL). The combined extracts were washed with water (1 x 300 mL) and saturated NaHCO_3 (1 x 500 mL). The organic phase was dried over Na_2SO_4 , filtered and concentrated to afford methyl 4-(4-(4-pyridyl)-3-(4-fluorophenyl) pyrazolyl) butyrate: MS (M+H): 340 (base peak).


4-(4-(4-pyridyl)-3-(4-fluorophenyl) pyrazolyl) butyramide. A solution of methyl 4-(4-(4-pyridyl)-3-(4-fluorophenyl) pyrazolyl) butyrate (39 g, 120 mmol) in 600 mL of MeOH was saturated with NH_3 . The solution was

967

periodically treated with additional NH_3 over a 24 h period. The solution was degassed with a stream of nitrogen and the solution was concentrated to leave a yellow solid. The solid was slurried in ether and filtered to leave the title compound: MS (M+H): 325 (base peak).

Example C-132

5-[4-(1-HYDROXY)BUTYL]-4-(4-PYRIDYL)-3-(4-FLUOROPHENYL) PYRAZOLE




A stirred suspension of 4-(4-(4-pyridyl)-3-(4-fluorophenyl)pyrazolyl) butyric acid (Example C-130) (2 g, 6.15 mmol) in 100 ml of anhydrous ether was cooled to 0 °C under nitrogen. Lithium aluminum hydride (467 mg, 12.3 mmol) was added to this suspension slowly. After the addition was complete, the mixture was warmed to room temperature and stirred for additional 2 h. The reaction was quenched slowly with 1N KHSO_4 (80 ml). The mixture was transferred to a separatory funnel and the aqueous layer was removed. The aqueous layer was then made basic with K_2CO_3 (pH 8). The aqueous solution was extracted with ethyl acetate (2 x 100 mL). The combined ethyl acetate extracts were washed with water (1 x 100

mL), dried over MgSO_4 , filtered and concentrated to give the title compound: MS (M+H): 312 (base peak).

Example C-133


5-[4-(1,1-DIMETHYL-1-HYDROXY)BUTYL]-4-(4-PYRIDYL)-3-(4-FLUOROPHENYL) PYRAZOLE




A solution of 4-(4-(4-pyridyl)-3-(4-fluorophenyl)pyrazolyl) butyric acid (Example C-130) (200 mg, 0.615 mmol) in 50 ml of MeOH was treated with 10 ml of 4 N HCl/dioxane. The reaction mixture was stirred for 5 hours and evaporated to dryness. To this residue was added 15 ml of 1N methyl magnesium bromide in butyl ether and 5 ml of anhydrous THF. The reaction was heated to reflux under nitrogen for 64 h.

The reaction was quenched with 20 ml of saturated ammonium chloride. This mixture was transferred to a separatory funnel and was extracted with 100 ml ethyl acetate (2 x 100 mL). The combined ethyl acetate extracts were washed with water (1 x 100 mL), dried over MgSO_4 , filtered and concentrated to afford a crude oil. The crude oil was subjected to column chromatography by using 3.5 % MeOH/ CH_2Cl_2 , followed by 6 % MeOH/ CH_2Cl_2 , to give the title compound: MS (M+H): 340 (base peak).


Example C-134

5-(4-(1-AMINO)BUTYL)-4-(4-PYRIDYL)-3-(4-FLUOROPHENYL)
PYRAZOLE

To a suspension of 4-(4-(4-pyridyl)-3-(4-fluorophenyl) pyrazolyl) butyramide (Example C-131) (2 g, 6.2 mmol) in 100 mL of anhydrous ether was added lithium aluminum hydride (467 mg, 12.3 mmol). After the addition was complete, the mixture was warmed to room temperature and stirred for additional 2 h. The reaction was quenched with 20 mL of ethyl acetate and was poured onto 100 mL of 2.5 N NaOH. The mixture was extracted with ethyl acetate (3 x 50 mL). The combined extracts were washed with brine (1 x 100 mL), dried over Na₂SO₄, filtered and concentrated to afford the title compound: MS (M+H): 311 (base peak).

Example C-135**4-(4-(4-PYRIDYL)-3-(4-FLUOROPHENYL) PYRAZOLYL) PROPIONIC
ACID**

By following the method of Example C-1 and substituting succinic anhydride for *N*-benzyloxycarbonyl-glycinyll *N*-hydroxysuccinimide the title compound was prepared: MS (M+H): 312 (base peak).

Example C-136**5-(4-PIPERIDYL)-4-(4-PYRIMIDYL)-3-(4-CHLOROPHENYL)
PYRAZOLE**


By following the method of Example C-1 and substituting methyl-4-chlorobenzoate for ethyl-4-fluorobenzoate, *N*-*t*-butoxycarbonyl-isonipecotyl *N*-hydroxysuccinimide for *N*-benzyloxycarbonyl-glycinyll *N*-hydroxysuccinimide and 4-methylpyrimidine for 4-picoline

971

the title compound was prepared as the *N*-*t*-butoxycarbonyl protected compound. The deprotection of the *N*-*t*-butoxycarbonyl intermediate was accomplished with 4 N HCl in dioxane to afford the title compound as the hydrochloride salt: ^1H NMR (CDCl_3) δ 9.2 (s, 1 H), 8.48 (d, J = 5.19 Hz, 1 H), 7.31 (m, 4 H), 6.94 (d, J = 4.79 Hz, 1 H), 3.69 (m, 3 H), 3.12 (m, 2 H), 2.3 (m, 3 H), 1.24 (m, 2 H). MS ($M+H$): 340 (base peak).

Example C-137


5-(*N*-METHYL-4-PIPERIDYL)-4-(4-PYRIMIDYL)-3-(4-CHLOROPHENYL) PYRAZOLE



By following the method of Example C-75 and substituting 5-(4-piperidyl)-4-(4-pyrimidyl)-3-(4-chlorophenyl) pyrazole (Example C-136) for 5-(4-piperidyl)-4-(4-pyridyl)-3-(4-chlorophenyl) pyrazole hydrochloride (Example C-74) the title compound was prepared: ^1H NMR (CDCl_3) δ 9.2 (d, J = 1.2 Hz, 1 H), 8.48 (d, J = 5.59 Hz, 1 H), 7.31 (m, 4 H), 6.95 (dd, J = 1.2, 5.6 Hz, 1 H), 3.39 (m, 1 H), 3.03 (d, J = 11.6 Hz, 2 H), 2.38 (s, 3 H), 2.06 (m, 4 H), 1.24 (m, 2 H). MS ($M+H$): 354 (base peak).

Example C-138


**5-(N-ACETYL-3-PIPERIDYL)-4-(4-PYRIDYL)-3-(4-FLUOROPHENYL)
PYRAZOLE**



By following the method of Example C-76 and substituting 5-(3-piperidyl)-4-(4-pyridyl)-3-(4-fluorophenyl) pyrazole (C-90) for 5-(4-piperidyl)-4-(4-pyridyl)-3-(4-chlorophenyl) pyrazole (C-74) the title compound was prepared: MS (M+H): 365 (base peak).

Example C-139

**5-(N-METHOXYACETYL-3-PIPERIDYL)-4-(4-PYRIDYL)-3-(4-
FLUOROPHENYL) PYRAZOLE**



By following the method of Example C-76 and substituting 5-(3-piperidyl)-4-(4-pyridyl)-3-(4-fluorophenyl) pyrazole (C-90) for 5-(4-piperidyl)-4-(4-pyridyl)-3-(4-chlorophenyl) pyrazole (C-74) and methoxy


973

acetyl chloride for acetyl chloride the title compound was prepared: MS (M+H): 395 (base peak).

Additional compounds of the present invention which could be prepared using one or more of the reaction schemes set forth in this application include, but are not limited to, the following:


Example C-140

5-(4-N-t-butoxycarbonylpiperidinyl)-4-[4-(2-thiomethyl)pyrimidinyl]-3-(4-chlorophenyl)pyrazole




Example C-141

5-(4-piperidinyl)-4-[4-(2-thiomethyl)pyrimidinyl]-3-(4-chlorophenyl)pyrazole




Example C-142

5-(4-*N*-methylpiperidinyl)-4-[4-(2-thiomethyl)pyrimidinyl]-3-(4-chlorophenyl)pyrazole




Example C-143

5-(4-*N*-*t*-butoxycarbonylpiperidinyl)-4-[4-(2-methanesulfonyl)pyrimidinyl]-3-(4-chlorophenyl)pyrazole



Example C-144


5-(4-piperidinyl)-4-[4-(2-methanesulfonyl)pyrimidinyl]-3-(4-chlorophenyl)pyrazole



975


Example C-145

5-(4-*N*-methylpiperidinyl)-4-[4-(2-methanesulfonyl)pyrimidinyl]-3-(4-chlorophenyl)pyrazole




Example C-146

5-(4-*N*-*t*-butoxycarbonylpiperidinyl)-4-[4-(2-amino)pyrimidinyl]-3-(4-chlorophenyl)pyrazole




Example C-147

5-(4-piperidinyl)-4-[4-(2-amino)pyrimidinyl]-3-(4-chlorophenyl)pyrazole




Example C-148


5-(4-N-methylpiperidinyl)-4-[4-(2-amino)pyrimidinyl]-3-(4-chlorophenyl)pyrazole

**Example C-149**

5-(4-N-t-butoxycarbonylpiperidinyl)-4-[4-(2-methylamino)pyrimidinyl]-3-(4-chlorophenyl)pyrazole

**Example C-150**


5-(4-piperidinyl)-4-[4-(2-methylamino)pyrimidinyl]-3-(4-chlorophenyl)pyrazole



977


Example C-151

5-(4-N-methylpiperidinyl)-4-[4-(2-methylamino)pyrimidinyl]-3-(4-chlorophenyl)pyrazole




Example C-152

5-(4-N-t-butoxycarbonylpiperidinyl)-4-[4-(2-isopropylamino)pyrimidinyl]-3-(4-chlorophenyl)pyrazole




Example C-153

5-(4-piperidinyl)-4-[4-(2-isopropylamino)pyrimidinyl]-3-(4-chlorophenyl)pyrazole




Example C-154

5-(4-*N*-methylpiperidinyl)-4-[4-(2-isopropylamino)pyrimidinyl]-3-(4-chlorophenyl)pyrazole




Example C-155

5-(4-*N*-*t*-butoxycarbonylpiperidinyl)-4-[4-(2-(2-methoxyethylamino))pyrimidinyl]-3-(4-chlorophenyl)pyrazole




Example C-156

5-(4-piperidinyl)-4-[4-(2-(2-methoxyethylamino))pyrimidinyl]-3-(4-chlorophenyl)pyrazole




Example C-157

5-(4-*N*-methylpiperidinyl)-4-[4-(2-(2-methoxyethylamino))pyrimidinyl]-3-(4-chlorophenyl)pyrazole




Example C-158

5-(4-*N*-*t*-butoxycarbonylpiperidinyl)-4-[4-(2-methoxy)pyrimidinyl]-3-(4-chlorophenyl)pyrazole



Example C-159


5-(4-piperidinyl)-4-[4-(2-methoxy)pyrimidinyl]-3-(4-chlorophenyl)pyrazole




980

Example C-160


5-(4-*N*-methylpiperidinyl)-4-[4-(2-methoxy)pyrimidinyl]-3-(4-chlorophenyl)pyrazole

**Example C-161**

5-(4-*N*-*t*-butoxycarbonylpiperidinyl)-4-[4-(2-isopropoxy)pyrimidinyl]-3-(4-chlorophenyl)pyrazole


**Example C-162**

5-(4-piperidinyl)-4-[4-(2-isopropoxy)pyrimidinyl]-3-(4-chlorophenyl)pyrazole




Example C-163

5-(4-*N*-methylpiperidinyl)-4-[4-(2-isopropoxy)pyrimidinyl]-3-(4-chlorophenyl)pyrazole




Example C-164

5-(4-*N*-*t*-butoxycarbonylpiperidinyl)-4-[4-(2-(2-*N,N*-dimethylamino)ethoxy)pyrimidinyl]-3-(4-chlorophenyl)pyrazole




Example C-165

5-(4-piperidinyl)-4-[4-(2-(2-*N,N*-dimethylamino)ethoxy)pyrimidinyl]-3-(4-chlorophenyl)pyrazole




Example C-166


5-(4-*N*-methylpiperidinyl)-4-[4-(2-(2-*N,N*-dimethylamino)ethoxy)pyrimidinyl]-3-(4-chlorophenyl)pyrazole

**Example C-167**

5-(*N*-acetylhydroxylimido-4-piperidyl)-4-(4-pyridyl)-3-(4-chlorophenyl)pyrazole


**Example C-168**

5-(*N*-benzylhydroxylimido-4-piperidyl)-4-(4-pyridyl)-3-(4-chlorophenyl)pyrazole




Example C-169


**5-(*N*-phenylacethydroxylimido-4-piperidyl)-4-(4-pyridyl)-
3-(4-chlorophenyl)pyrazole**

**Example C-170**

**5-[*N*-methyl-4-(3,4-dehydro)piperidyl]-4-(4-pyridyl)-3-(4-
chlorophenyl)pyrazole**


**Example C-171**

**5-[*N*-isopropyl-4-(3,4-dehydro)piperidyl]-4-(4-pyridyl)-3-(4-
chlorophenyl)pyrazole**




Example C-172


5-[*N*-benzyl-4-(3,4-dehydro)piperidyl]-4-(4-pyridyl)-3-(4-chlorophenyl)pyrazole

**Example C-173**

5-[*N*-methyl-4-(4-fluoro)piperidyl]-4-(4-pyridyl)-3-(4-chlorophenyl)pyrazole


**Example C-174**

5-[*N*-methyl-4-(4-hydroxy)piperidyl]-4-(4-pyridyl)-3-(4-chlorophenyl)pyrazole




Example C-175

5-[*N*-methyl-4-(4-methoxy)piperidyl]-4-(4-pyridyl)-3-(4-chlorophenyl)pyrazole




Example C-176

5-[*N*-methyl-4-(2,5-tetramethyl-4-fluoro)piperidyl]-4-(4-pyridyl)-3-(4-chlorophenyl)pyrazole



Example C-177


5-[*N*-methyl-4-(2,5-tetramethyl-4-hydroxy)piperidyl]-4-(4-pyridyl)-3-(4-chlorophenyl)pyrazole




986

Example C-178


5-[*N*-methyl-4-(2,5-tetramethyl-4-methoxy)piperidyl]-4-(4-pyridyl)-3-(4-chlorophenyl)pyrazole

**Example C-179**

5-[4-(3-fluoro)piperidyl]-4-(4-pyridyl)-3-(4-chlorophenyl)pyrazole

**Example C-180**


5-[4-(*N*-methyl-3-fluoro)piperidyl]-4-(4-pyridyl)-3-(4-chlorophenyl)pyrazole




987

Example C-181


5-[4-(*N*-isopropyl-3-fluoro)piperidyl]-4-(4-pyridyl)-3-(4-chlorophenyl)pyrazole

**Example C-182**

5-[4-(*N*-benzyl-3-fluoro)piperidyl]-4-(4-pyridyl)-3-(4-chlorophenyl)pyrazole


**Example C-183**

5-[4-(*N*-acetyl-3-fluoro)piperidyl]-4-(4-pyridyl)-3-(4-chlorophenyl)pyrazole




Example C-184

5-[4-(2-oxo)piperidyl]-4-(4-pyridyl)-3-(4-chlorophenyl)pyrazole

**Example C-185**


5-[4-(N-methyl-2-oxo)piperidyl]-4-(4-pyridyl)-3-(4-chlorophenyl)pyrazole




989

Example C-186


5-[4-(*N*-isopropyl-2-oxo)piperidyl]-4-(4-pyridyl)-3-(4-chlorophenyl)pyrazole

**Example C-187**

5-[4-(*N*-benzyl-2-oxo)piperidyl]-4-(4-pyridyl)-3-(4-chlorophenyl)pyrazole


**Example C-188**

5-[4-(*N*-acetyl-2-oxo)piperidyl]-4-(4-pyridyl)-3-(4-chlorophenyl)pyrazole




Example C-189


5-[5-(2-oxo)piperidyl]-4-(4-pyridyl)-3-(4-chlorophenyl)pyrazole

**Example C-190**

5-[5-(*N*-methyl-2-oxo)piperidyl]-4-(4-pyridyl)-3-(4-chlorophenyl)pyrazole


**Example C-191**

5-[5-(*N*-isopropyl-2-oxo)piperidyl]-4-(4-pyridyl)-3-(4-chlorophenyl)pyrazole




Example C-192


5-[5-(*N*-benzyl-2-oxo)piperidyl]-4-(4-pyridyl)-3-(4-chlorophenyl)pyrazole

**Example C-193**

5-[5-(*N*-acetyl-2-oxo)piperidyl]-4-(4-pyridyl)-3-(4-chlorophenyl)pyrazole


**Example C-194**

5-(*N*-acethydroxylimido-3-piperidyl)-4-(4-pyridyl)-3-(4-chlorophenyl)pyrazole




Example C-195


5-(*N*-benzhydroxylimido-3-piperidyl)-4-(4-pyridyl)-3-(4-chlorophenyl)pyrazole

**Example C-196**

5-(*N*-phenacethydroxylimido-3-piperidyl)-4-(4-pyridyl)-3-(4-chlorophenyl)pyrazole


**Example C-197**

5-(2-morpholinyl)-4-(4-pyridyl)-3-(4-chlorophenyl)pyrazole




Example C-198


5-(*N*-methyl-2-morpholinyl)-4-(4-pyridyl)-3-(4-chlorophenyl)pyrazole

**Example C-199**

5-(*N*-isopropyl-2-morpholinyl)-4-(4-pyridyl)-3-(4-chlorophenyl)pyrazole


**Example C-200**

5-(*N*-benzyl-2-morpholinyl)-4-(4-pyridyl)-3-(4-chlorophenyl)pyrazole




Example C-201


5-(*N*-acetyl-2-morpholinyl)-4-(4-pyridyl)-3-(4-chlorophenyl)pyrazole

**Example C-202**

5-[*trans*-4-(*N*-*t*-butoxycarbonylamino)methylcyclohexyl]-4-(4-pyridyl)-3-(4-chlorophenyl)pyrazole

**Example C-203**


5-(*trans*-4-aminomethylcyclohexyl)-4-(4-pyridyl)-3-(4-chlorophenyl)pyrazole




995

Example C-204


5-[trans-4-(*N*-isopropylamino)methylcyclohexyl]-4-(4-pyridyl)-3-(4-chlorophenyl)pyrazole

**Example C-205**

5-[trans-4-(*N,N*-dimethylamino)methylcyclohexyl]-4-(4-pyridyl)-3-(4-chlorophenyl)pyrazole


**Example C-206**

5-[trans-4-(*N*-acetylamino)methylcyclohexyl]-4-(4-pyridyl)-3-(4-chlorophenyl)pyrazole




Example C-207


5-[*trans*-4-(*N*-*t*-butoxycarbonylamino)cyclohexyl]-4-(4-pyridyl)-3-(4-chlorophenyl)pyrazole

**Example C-208**

5-(*trans*-4-aminocyclohexyl)-4-(4-pyridyl)-3-(4-chlorophenyl)pyrazole


**Example C-209**

5-[*trans*-4-(*N,N*-dimethylamino)cyclohexyl]-4-(4-pyridyl)-3-(4-chlorophenyl)pyrazole




Example C-210


5-[trans-4-(N-isopropylamino)cyclohexyl]-4-(4-pyridyl)-3-(4-chlorophenyl)pyrazole

**Example C-211**

5-[trans-4-(N-acetylamino)cyclohexyl]-4-(4-pyridyl)-3-(4-chlorophenyl)pyrazole


**Example C-212**

5-[cis-4-(N-t-butoxycarbonyl)methylaminocyclohexyl]-4-(4-pyridyl)-3-(4-chlorophenyl)pyrazole




Example C-213

5-(*cis*-4-methylaminocyclohexyl)-4-(4-pyridyl)-3-(4-chlorophenyl)pyrazole




Example C-214

5-[*cis*-4-(*N,N*-dimethyl)methylaminocyclohexyl)]-4-(4-pyridyl)-3-(4-chlorophenyl)pyrazole




Example C-215

5-[*cis*-4-(*N*-isopropyl)methylaminocyclohexyl)]-4-(4-pyridyl)-3-(4-chlorophenyl)pyrazole




Example C-216

5-[*cis*-4-(*N*-acetyl)methylaminocyclohexyl)]-4-(4-pyridyl)-
3-(4-chlorophenyl)pyrazole




Example C-217

5-[3-(1,1-dimethyl-1-(*N*-*t*-butoxycarbonylamino)propyl)-4-(4-pyridyl)-3-(4-chlorophenyl)pyrazole



Example C-218


5-[3-(1,1-dimethyl-1-amino)propyl)-4-(4-pyridyl)-3-(4-chlorophenyl)pyrazole




1000

Example C-219


5-[3-(1,1-dimethyl-1-(*N,N*-dimethylamino)propyl-4-(4-pyridyl)-3-(4-chlorophenyl)pyrazole

**Example C-220**

5-[3-(1,1-dimethyl-1-(*N*-isopropylamino)propyl-4-(4-pyridyl)-3-(4-chlorophenyl)pyrazole

**Example C-221**


5-[3-(1,1-dimethyl-1-(*N*-acetylamino)propyl-4-(4-pyridyl)-3-(4-chlorophenyl)pyrazole




1001

Example C-222


5-[4-(1-carboxamidino)benzyl-4-(4-pyridyl)-3-(4-chlorophenyl)pyrazole

**Example C-223**

5-[4-(1-N-methylcarboxamidino)benzyl-4-(4-pyridyl)-3-(4-chlorophenyl)pyrazole

**Example C-224**


5-[4-(1-N-benzylcarboxamidino)benzyl-4-(4-pyridyl)-3-(4-chlorophenyl)pyrazole




1002

Example C-225


5-[3-(1-carboxamidino)benzyl-4-(4-pyridyl)-3-(4-chlorophenyl)pyrazole

**Example C-226**

5-[3-(1-N-methylcarboxamidino)benzyl-4-(4-pyridyl)-3-(4-chlorophenyl)pyrazole

**Example C-227**


5-[3-(1-N-benzylcarboxamidino)benzyl-4-(4-pyridyl)-3-(4-chlorophenyl)pyrazole




1003

Example C-228


5-[3-(*N*-*t*-butoxycarbonyl)aminobenzyl]-4-(4-pyridyl)-3-(4-chlorophenyl)pyrazole

**Example C-229**

5-(3-aminobenzyl)-4-(4-pyridyl)-3-(4-chlorophenyl)pyrazole

**Example C-230**


5-[3-(*N,N*-dimethylamino)benzyl]-4-(4-pyridyl)-3-(4-chlorophenyl)pyrazole




1004

Example C-231

5-[3-(*N*-isopropylamino)benzyl]-4-(4-pyridyl)-3-(4-chlorophenyl)pyrazole

**Example C-232**


5-[3-(*N*-benzylamino)benzyl]-4-(4-pyridyl)-3-(4-chlorophenyl)pyrazole




1005

Example C-233


5-[3-(*N*-acetylamino)benzyl]-4-(4-pyridyl)-3-(4-chlorophenyl)pyrazole

**Example C-234**

5-[4-(2-amino)methylimidazolyl]-4-(4-pyridyl)-3-(4-chlorophenyl)pyrazole

**Example C-235**


5-[4-(2-*N,N*-dimethylamino)methylimidazolyl]-4-(4-pyridyl)-3-(4-chlorophenyl)pyrazole




1006

Example C-236


**5-[4-(2-*N*-isopropylamino)methylimidazolyl]-4-(4-pyridyl)-
3-(4-chlorophenyl)pyrazole**

**Example C-237**

**5-[4-(2-*N*-benzylamino)methylimidazolyl]-4-(4-pyridyl)-3-
(4-chlorophenyl)pyrazole**

**Example C-238**


**5-[4-(2-*N*-acetylamino)methylimidazolyl]-4-(4-pyridyl)-3-
(4-chlorophenyl)pyrazole**



1007


Example C-239

5-[4-(2-amino)methyloxazolyl]-4-(4-pyridyl)-3-(4-chlorophenyl)pyrazole




Example C-240

5-[4-(2-*N,N*-dimethylamino)methyloxazolyl]-4-(4-pyridyl)-3-(4-chlorophenyl)pyrazole



Example C-241


5-[4-(2-*N*-isopropylamino)methyloxazolyl]-4-(4-pyridyl)-3-(4-chlorophenyl)pyrazole




1008

Example C-242


5-[4-(2-*N*-benzylamino)methyloxazolyl]-4-(4-pyridyl)-3-(4-chlorophenyl)pyrazole

**Example C-243**

5-[4-(2-*N*-acetylamino)methyloxazolyl]-4-(4-pyridyl)-3-(4-chlorophenyl)pyrazole


**Example C-244**

5-[4-(2-amino)methylthiazolyl]-4-(4-pyridyl)-3-(4-chlorophenyl)pyrazole




Example C-245

5-[4-(2-*N,N*-dimethylamino)methylthiazolyl]-4-(4-pyridyl)-
3-(4-chlorophenyl)pyrazole

**Example C-246**


5-[4-(2-*N*-isopropylamino)methylthiazolyl]-4-(4-pyridyl)-
3-(4-chlorophenyl)pyrazole




1010

Example C-247

5-[4-(2-*N*-benzylamino)methylthiazolyl]-4-(4-pyridyl)-3-(4-chlorophenyl)pyrazole

**Example C-248**

5-[4-(2-*N*-acetylamino)methylthiazolyl]-4-(4-pyridyl)-3-(4-chlorophenyl)pyrazole



Biological data from compounds of Examples B-0001 through B-1573 and of Examples B-2270 through B-2462 are shown in the following tables.

In vitro P38-alpha kinase inhibitory data are shown in the column identified as:

"P38 alpha kinase IC₅₀, uM or % inhib @ conc. (uM)"

10

In vitro whole cell assay for measuring the ability of the compounds to inhibit TNF production in human U937 cells stimulated with LPS are shown in the column identified as:

"U937 Cell IC₅₀, uM or % inhib @ conc., (uM)"

In vivo assessment of the ability of the compounds to inhibit LPS-stimulated TNF release in the mouse is shown in the column identified as:

"Mouse LPS Model, % TNF inhib @ dose @ predose time"
wherein in the dose is milligram per kilogram (mpk) administered by oral gavage and the predose time indicates the number of hours before LPS challenge when the compound is administered.

In vivo assessment of the ability of the compounds to inhibit LPS-stimulated TNF release in the rat is shown in the column identified as:

"Rat LPS Model, % TNF inhib @ dose @ predose time"
wherein in the dose is milligram per kilogram (mpk) administered by oral gavage and the predose time

1012

indicates the number of hours before LPS challenge when the compound is administered.

Example#	P38 alpha kinase IC50,uM or % inhib@conc. (uM)	U937 Cell IC50,uM or % inhib@conc. (uM)	Mouse LPS Model % TNF inhib @ dose @predose time	Rat LPS Model % inhib @dose @predose time
B-0001	53.0%@1.0uM	40.0% @1.0uM		
B-0002	71.0%@1.0uM	28.0%@10.0uM		
B-0003	70.0%@1.0uM	76.0% 10.0uM		
B-0004	80.0%@1.0uM	4.61uM		
B-0005	95.0%@1.0uM	2.97uM		
B-0006	82.0%@1.0uM	80%@10.0uM		
B-0007	74.0%@1.0uM	85.0%@10.0uM		
B-0008	42.0%@1.0uM	65.0%@10.0uM		
B-0009	0.04 uM	0.72uM		
B-0010	0.52 uM	0.65uM		
B-0011	0.03 uM	4.47uM		
B-0012	30.0%@1.0uM	44.0% @1.0uM		
B-0013	70.0%@1.0uM	84.0%@10.0uM		
B-0014	79.0%@1.0uM	80.0%@10.0uM		
B-0015	82.0%@1.0uM	80.0%@10.0uM		
B-0016	94.0%@1.0uM	3.98uM		
B-0017	56.0%@1.0uM	79.0%@10.0uM		
B-0018	60.0%@1.0uM	59.0%@10.0uM		
B-0019	84.0%@1.0uM	100.0%@10.0uM		
B-0020	73.0%@1.0uM	81.0%@10.0uM		
B-0021	68.0%@1.0uM	76.0%@10.0uM		
B-0022	69.0%@1.0uM	44.0@1.0uM		
B-0023	90.0%@1.0uM	77.0%@10.0uM		
B-0024	94.0%@1.0uM	52.0%@1.0uM		
B-0025	89.0%@1.0uM	79.0%@10.0uM		
B-0026	96.0%@1.0uM	3.27uM		
B-0027	94.0%@1.0uM	11.0uM		
B-0028	69.0%@1.0uM	45.0%@10.0uM		
B-0029	91.0%@1.0uM	58.0%@10.0uM		
B-0030	92.0%@1.0uM	75.0%@10.0uM		
B-0031	94.0%@1.0uM	100.0%@10.0uM		
B-0032	94.0%@1.0uM	78.0%@10.0uM		
B-0033	97.0%@1.0uM	10.0uM		
B-0034	95.0%@1.0uM	10.0uM		
B-0035	94.0%@1.0uM	10.0uM		
B-0036	92.0%@1.0uM	8.24uM		
B-0037	91.0%@1.0uM	86.0%@10.0uM		
B-0038	71.0%@1.0uM	84.0%@10.0uM		
B-0039	89.0%@1.0uM	72.0%@10.0uM		
B-0040	93.0%@1.0uM	2.3uM		
B-0041	65.0%@1.0uM	66.0%@10.0uM		
B-0042	94.0%@1.0uM	2.76uM		

Example#	P38 alpha kinase IC50,uM or % inhib@conc. (uM)	U937 Cell IC50,uM or % inhib@conc. (uM)	Mouse LPS Model % TNF inhib @ dose @predose time	Rat LPS Model % inhib @dose @predose time
B-0043	0.22 uM	0.54uM		
B-0044	0.14 uM	0.19uM		
B-0045	94.0%@1.0uM	1.01uM		
B-0046	96.0%@1.0uM	54.0%@1.0uM		
B-0047	94.0%@1.0uM	74.0%@10.0uM		
B-0048	94.0%@1.0uM	76.0%@10.0uM		
B-0049	88%@1.0uM	33.0%@1.0uM		
B-0050	73%@1.0uM	34.0%@1.0uM		
B-0051	3.3uM	2.15uM	47%@100mpk@-6h	79%@3mpk@-4h
B-0052	92%@1.0uM	15.0%@1.0uM		
B-0053	95%@1.0uM	34.0%@1.0uM		
B-0054	90%@1.0uM	30.0%@1.0uM		
B-0055	93%@1.0uM	>1.0uM		
B-0056	96%@1.0uM	21.0%@1.0uM		
B-0057	96%@1.0uM	29.0%@1.0uM		
B-0058	79%@1.0uM	18.0%@1.0uM		
B-0059	83%@1.0uM	35.0%@1.0uM		
B-0060	73%@1.0uM	22.0%@1.0uM		
B-0061	62%@1.0uM	27.0%@1.0uM		
B-0062	94%@1.0uM	36.0%@1.0uM		
B-0063	96%@1.0uM	40.0%@1.0uM		
B-0064	90%@1.0uM	4.0%@1.0uM		
B-0065	83%@1.0uM	21.0%@1.0uM		
B-0066	94%@1.0uM	28.0%@1.0uM		
B-0067	91%@1.0uM	1.0%@1.0uM		
B-0068	72%@1.0uM	22.0%@1.0uM		
B-0069	96%@1.0uM	37.0%@1.0uM		
B-0070	92%@1.0uM	30.0%@1.0uM		
B-0071	86%@1.0uM	31.0%@1.0uM		
B-0072	77%@1.0uM	32.0%@1.0uM		
B-0073	91%@1.0uM	24.0%@1.0uM		
B-0074	92%@1.0uM	42.0%@1.0uM		
B-0075	91%@1.0uM	35.0%@1.0uM		
B-0076	58%@1.0uM	21.0%@1.0uM		
B-0077	0.8uM	10.0uM		
B-0078	80%@1.0uM	20.0%@1.0uM		
B-0079	93%@1.0uM	13.0%@1.0uM		
B-0080	73%@1.0uM	73.0%@1.0uM		
B-0081	92%@1.0uM	13.0%@1.0uM		
B-0082	47%@1.0uM	27.0%@1.0uM		
B-0083	0.22uM	6.51uM		
B-0084	56%@1.0uM	30.0%@1.0uM		

Example#	P38 alpha kinase IC50,uM or % inhib@conc. (uM)	U937 Cell IC50,uM or % inhib@conc. (uM)	Mouse LPS Model % TNF Inhib @ dose @predose time	Rat LPS Model % inhib @dose @predose time
B-0085	83%@1.0uM	21.0%@1.0uM		
B-0086	91%@1.0uM	37.0%@1.0uM		
B-0087	0.55uM	2.26uM	38%@30mpk@-6h	
B-0088	96%@1.0uM	9.0%@1.0uM		
B-0089	0.04uM	3.33uM		
B-0090	98%@1.0uM	52.0%@1.0uM		
B-0091	96%@1.0uM	40.0%@1.0uM		
B-0092	97%@1.0uM	34.0%@1.0uM		
B-0093	3.18 uM	1.25uM	30%@30mpk@-6h	
B-0094	96%@1.0uM	52.0%@1.0uM		
B-0095	98%@1.0uM	38.0%@1.0uM		
B-0096	91%@1.0uM	22.0%@1.0uM		
B-0097	72.0%@10.0uM	38.0%@1.0uM		
B-0098	66.0%@10.0uM	12.0%@1.0uM		
B-0099	43.0% @1.0uM	>1.0uM		
B-0100	75.0% @1.0uM	5.0uM		
B-0101	71.0% @1.0uM	2.11uM		
B-0102	81.0%@1.0uM	15.0%@1.0uM		
B-0103	71.0%@1.0uM	6.0%@1.0uM		
B-0104	56.0% @1.0uM	2.78uM		
B-0105	78.0%@1.0uM	5.0uM		
B-0106	62.0%@1.0uM	5.0uM		
B-0107	0.27uM	5.0uM		
B-0108	61.0%@1.0uM	4.85uM		
B-0109	45.0%@1.0uM	19.0%@1.0uM		
B-0110	66.0%@1.0uM	13.0%@1.0uM		
B-0111	57.0%@1.0uM	>1.0uM		
B-0112	97.0%@1.0uM	1.12uM		
B-0113	75.0%@1.0uM	43.0%@1.0uM		
B-0114	45.0%@1.0uM	3.92uM		
B-0115	47.0%@1.0uM	2.0%@1.0uM		
B-0116	73.0%@1.0uM	35.0%@1.0uM		
B-0117	0.46 uM	1.78 uM	30%@30mpk@-6h	
B-0118	1.18 uM	1.29 uM		
B-0119	89.0%@10.0uM	2.78uM		
B-0120	0.008 uM	0.21 uM	77%@100mpk@-6h	70%@3mpk@-4h
B-0121	79.0%@1.0uM	1.22uM		
B-0122	79.0%@10.0uM	2.0%@1.0uM		
B-0123	59.0%@1.0uM	>1.0uM		
B-0124	73.0%@1.0uM	15.0%@1.0uM		
B-0125	70.0%@10.0uM	17.0%@1.0uM		
B-0126	66.0%@1.0uM	1.57uM		

1016

Example#	P38 alpha kinase IC50,uM or % inhib@conc. (uM)	U937 Cell IC50,uM or % inhib@conc. (uM)	Mouse LPS Model % TNF inhib @ dose @predose time	Rat LPS Model % inhib @dose @predose time
B-0127	82.0%@1.0uM	0.96uM		
B-0128	78.0%@1.0uM	1.81uM		
B-0129	51.0%@1.0uM	31.0%@1.0uM		
B-0130	69.0%@1.0uM	58.0%@1.0uM		
B-0131	43.0%@1.0uM	46.0%@1.0uM		
B-0132	76.0%@1.0uM	8.0%@1.0uM		
B-0133	51.0%@1.0uM	42.0%@1.0uM		
B-0134	60.0%@1.0uM	2.17uM		
B-0135	78.0%@1.0uM	58.0%@1.0uM		
B-0136	77.0%@1.0uM	44.0%@1.0uM		
B-0137	41.0%@1.0uM	37.0%@1.0uM		
B-0138	50.0%@1.0uM	32.0%@1.0uM		
B-0139	54.0%@10.0uM	17.0%@1.0uM		
B-0140	67%@10.0uM	9.0%@1.0uM		
B-0141	78.0%@1.0uM	10.0%@1.0uM		
B-0142	86.0%@1.0uM	12.0%@1.0uM		
B-0143	42.0% @1.0uM	3.63uM		
B-0144	86.0% @1.0uM	43.0%@1.0uM		
B-0145	54.0% @10.0uM	12.0% @1.0uM		
B-0146	77.0% @10.0uM	28.0% @1.0uM		
B-0147	44.0% @1.0uM	22.0% @1.0uM		
B-0148	51.0% @1.0uM	>1.0uM		
B-0149	1.15 uM	10.0 uM		
B-0150	27.0% @10.0uM	35.0% @1.0uM		
B-0151	43.0% @1.0uM	30.0% @1.0uM		
B-0152	51.0% @1.0uM	24.0% @1.0uM		
B-0153	57.0% @1.0uM	21.0% @1.0uM		
B-0154	65.0% @10.0uM	14.0% @1.0uM		
B-0155	40.0% @10.0uM	26.0% @1.0uM		
B-0156	42.0% @10.0uM	13.0% @1.0uM		
B-0157	48.0% @10.0uM	9.0% @1.0uM		
B-0158	58.0% @10.0uM	39.0% @1.0uM		
B-0159	54.0% @10.0uM	5.0% @1.0uM		
B-0160	59.0% @10.0uM	26.0% @1.0uM		
B-0161	72.0% @10.0uM	13.0% @1.0uM		
B-0162	23%@1.0uM	2.05 uM		
B-0163	20.0% @10.0uM	10.0% @1.0uM		
B-0164	37.0% @10.0uM	20.0% @1.0uM		
B-0165	70.0% @10.0uM	19.0% @1.0uM		
B-0166	45.0% @10.0uM	37.0% @1.0uM		
B-0167	40.0% @1.0uM	37.0% @1.0uM		
B-0168	44%@1.0uM	2.36 uM		

Example#	P38 alpha kinase IC50,uM or % inhib@conc. (uM)	U937 Cell IC50,uM or % inhib@conc. (uM)	Mouse LPS Model % TNF inhib @ dose @predose time	Rat LPS Model % inhib @dose @predose time
B-0169	43.0% @1.0uM	21.0% @1.0uM		
B-0170	43.0% @1.0uM	30.0% @1.0uM		
B-0171	61.0% @10.0uM	21.0% @1.0uM		
B-0172	16.0% @10.0uM	11.0% @1.0uM		
B-0173	33.0% @10.0uM	48.0% @1.0uM		
B-0174	54.0% @10.0uM	43.0% @1.0uM		
B-0175	41.0% @10.0uM	31.0% @1.0uM		
B-0176	50.0% @1.0uM	30.0% @1.0uM		
B-0177	70.0% @10.0uM	27.0% @1.0uM		
B-0178	12.0% @10.0uM	35.0% @1.0uM		
B-0179	27.0% @10.0uM	37.0% @1.0uM		
B-0180	34.0% @10.0uM	23.0% @1.0uM		
B-0181	5.0% @1.0uM	2.0% @1.0uM		
B-0182	39.0% @10.0uM	40.0% @1.0uM		
B-0183	12.0% @10.0uM	34.0% @1.0uM		
B-0184	66.0% @10.0uM	17.0% @1.0uM		
B-0185	65.0% @10.0uM	25.0% @1.0uM		
B-0186	40.0% @1.0uM	25.0% @1.0uM		
B-0187	4.0% @10.0uM	14.0% @1.0uM		
B-0188	70.0% @10.0uM	35.0% @1.0uM		
B-0189	42.0% @10.0uM	9.0% @1.0uM		
B-0190	59.0% @10.0uM	31.0% @1.0uM		
B-0191	40.0% @1.0uM	29.0% @1.0uM		
B-0192	12.0% @10.0uM	47.0% @1.0uM		
B-0193	0.54 uM	6% @1.0uM		
B-0194	1.31 uM	22% @1.0uM		
B-0195	1.03 uM	55% @1.0uM		
B-0196	2.24 uM	>1.0uM		
B-0197	2.0 uM	14% @1.0uM		
B-0198	1.2 uM	2% @1.0uM		
B-0199	1.34 uM	3% @1.0uM		
B-0200	1.31 uM	16% @1.0uM		
B-0201	0.29 uM	59% @1.0uM		
B-0202	0.55 uM	2.26 uM		
B-0203	0.16 uM	65% @1.0uM		
B-0204	0.21 uM	48% @1.0uM		
B-0205	0.096 uM	54% @1.0uM		
B-0206	5.76 uM	14% @1.0uM		
B-0207	0.12 uM	52% @1.0uM		
B-0208	0.067 uM	>1.0uM		
B-0209	0.29 uM	8% @1.0uM		
B-0210	0.057 uM	67% @1.0uM		

Example#	P38 alpha kinase IC50,uM or % inhib@conc. (uM)	U937 Cell IC50,uM or % inhib@conc. (uM)	Mouse LPS Model % TNF inhib @ dose @predose time	Rat LPS Model % inhib @dose @predose time
B-0211	0.25 uM	30%@1.0uM		
B-0212	0.12 uM	28%@1.0uM		
B-0213	0.31 uM	39%@1.0uM		
B-0214	0.16 uM	50%@1.0uM		
B-0215	0.11 uM	51%@1.0uM		
B-0216	0.56 uM	>1.0uM		
B-0217	0.55 uM	>1.0uM		
B-0218	0.53 uM	18%@1.0uM		
B-0219	0.91 uM	18%@1.0uM		
B-0220	0.13 uM	40%@1.0uM		
B-0221	2.4 uM	>1.0uM		
B-0222	0.4uM	29.0%@1.0uM		
B-0223	0.2uM	1.0%@1.0uM		
B-0224	<0.1uM	93.0%@1.0uM		
B-0225	0.047uM	37.0%@1.0uM		
B-0226	0.074uM	20.0%@1.0uM		
B-0227	0.045uM	1.0%@1.0uM		
B-0228	0.15uM	44.0%@1.0uM		
B-0229	<0.1uM	61.0%@1.0uM		
B-0230	0.041uM	30.0%@1.0uM		
B-0231	0.055uM	40.0%1.0uM		
B-0232	0.048uM	24.0%@1.0uM		
B-0233	0.095uM	43.0%@1.0uM		
B-0234	0.11uM	68.0%@1.0uM		
B-0235	1.31uM	90.0%@1.0uM		
B-0236	0.077uM	46.0%@1.0uM		
B-0237	0.13uM	60.0%@1.0uM		
B-0238	0.47uM	82.0%@1.0uM		
B-0239	5.73uM	84.0%@1.0uM		
B-0240	0.2uM	70.0%@1.0uM		
B-0241	0.1uM	45.0%@1.0uM		
B-0242	<0.1uM	78.0%@1.0uM		
B-0243	0.039uM	53.0%@1.0uM		
B-0244	0.02uM	57.0%@1.0uM		
B-0245	0.13uM	24.0%@1.0uM		
B-0246	<0.1uM	>1.0uM		
B-0247	0.082uM	75.0%@1.0uM		
B-0248	<0.1uM	11.0%@1.0uM		
B-0249	<0.1uM	75.0%@1.0uM		
B-0250	0.28uM	36.0%@1.0uM		
B-0251	0.31uM	1.0%@1.0uM		
B-0252	0.041uM	54.0%@1.0uM		

Example#	P38 alpha kinase IC50,uM or % inhib@conc. (uM)	U937 Cell IC50,uM or % inhib@conc. (uM)	Mouse LPS Model % TNF inhib @ dose @predose time	Rat LPS Model % inhib @dose @predose time
B-0253	0.061uM	74.0%@1.0uM		
B-0254	0.12uM	59.0%@1.0uM		
B-0255	0.32uM	68.0%@1.0uM		
B-0256	<0.1uM	88.0%@1.0uM		
B-0257	1.71uM	11.0%@1.0uM		
B-0258	0.37uM	63.0%@1.0uM		
B-0259	0.35uM	58.0%@1.0uM		
B-0260	0.56uM	23.0%@1.0uM		
B-0261	0.49uM	23.0%@1.0uM		
B-0262	0.41uM	89.0%@1.0uM		
B-0263	0.62uM	64.0%@1.0uM		
B-0264	0.14uM	18.0%@1.0uM		
B-0265	0.92uM	24.0%@1.0uM		
B-0266	0.25uM	24.0%@1.0uM		
B-0267	0.48uM	11.0%@1.0uM		
B-0268	3.39uM	19.0%@1.0uM		
B-0269	9.81uM	19.0%@1.0uM		
B-0270	5.79uM	13.0%@1.0uM		
B-0271	7.55uM	12.0%@1.0uM		
B-0272	1.81uM	48.0%@1.0uM		
B-0273	5.03uM	13.0%@1.0uM		
B-0274	2.68uM	25.0%@1.0uM		
B-0275	2.67uM	33.0%@1.0uM		
B-0276	1.25uM	26.0%@1.0uM		
B-0277	0.68uM	34.0%@1.0uM		
B-0278	1.26uM	36.0%@1.0uM		
B-0279	1.39uM	33.0%@1.0uM		
B-0280	0.86uM	18.0%@1.0uM		
B-0281	7.37uM	24.0%@1.0uM		
B-0282	0.75uM	38.0%@1.0uM		
B-0283	6.66uM	29.0%@1.0uM		
B-0284	0.083uM	65.0%@1.0uM		
B-0285	4.57uM	29.0%@1.0uM		
B-0286	0.33uM	50.0%@1.0uM		
B-0287	4.0uM	22.0%@1.0uM		
B-0288	4.46uM	26.0%@1.0uM		
B-0289	0.15uM	55.0%@1.0uM		
B-0290	0.66uM	44.0%@1.0uM		
B-0291	1.33uM	20.0%@1.0uM		
B-0292	0.22uM	28.0%@1.0uM		
B-0293	0.66uM	53.0%@1.0uM		
B-0294	0.68uM	45.0%@1.0uM		

Example#	P38 alpha kinase IC50,uM or % inhib@conc. (uM)	U937 Cell IC50,uM or % inhib@conc. (uM)	Mouse LPS Model % TNF Inhib @ dose @predose time	Rat LPS Model % Inhib @dose @predose time
B-0295	0.82uM	45.0%@1.0uM		
B-0296	8.03uM	36.0%@1.0uM		
B-0297	0.78uM	30.0%@1.0uM		
B-0298	0.58uM	48.0%@1.0uM		
B-0299	0.87uM	54.0%@1.0uM		
B-0300	0.78uM	32.0%@1.0uM		
B-0301	0.19uM	50.0%@1.0uM		
B-0302	4.02uM	24.0%@1.0uM		
B-0303	0.22uM	10.0%@1.0uM		
B-0304	0.56uM	28.0%@1.0uM		
B-0305				
B-0306				
B-0307				
B-0308				
B-0309				
B-0310				
B-0311				
B-0312				
B-0313				
B-0314				
B-0315				
B-0316				
B-0317				
B-0318				
B-0319				
B-0320				
B-0321				
B-0322				
B-0323				
B-0324				
B-0325				
B-0326				
B-0327				
B-0328				
B-0329				
B-0330				
B-0331				
B-0332				
B-0333				
B-0334				
B-0335				
B-0336				

Example#	P38 alpha kinase IC50,uM or % inhib@conc. (uM)	U937 Cell IC50,uM or % inhib@conc. (uM)	Mouse LPS Model % TNF inhib @ dose @predose time	Rat LPS Model % inhib @dose @predose time
B-0337				
B-0338				
B-0339				
B-0340				
B-0341				
B-0342				
B-0343				
B-0344				
B-0345				
B-0346				
B-0347				
B-0348				
B-0349				
B-0350				
B-0351				
B-0352				
B-0353	1.37uM	55%@1.0uM		
B-0354	1.0uM	0.66uM	51%@30mpk@-6h	54%@3mpk@-4h
B-0355	0.75uM	40.0%@1.0uM		
B-0356	0.66uM	24.0%@1.0uM		
B-0357	1.46uM	0.66uM		
B-0358	0.37uM	17.0%@1.0uM		
B-0359	0.45uM	47.0%@1.0uM		
B-0360	1.6uM	19.0%@1.0uM		
B-0361	0.33uM	46.0%@1.0uM		
B-0362	0.52uM	27.0%@1.0uM		
B-0363	4.67uM	25.0%@1.0uM		
B-0364	1.44uM	27.0%@1.0uM		
B-0365	0.96uM	27.0%@1.0uM		
B-0366	0.7uM	46.0%@1.0uM		
B-0367	1.0uM	23.0%@1.0uM		
B-0368	1.0uM	0.64uM	37%@30mpk@-6h	
B-0369	0.16uM	57.0%@1.0uM		
B-0370	0.65uM	28.0%@1.0uM		
B-0371	0.49uM	28.0%@1.0uM		
B-0372	0.35uM	29.0%@1.0uM		
B-0373	0.45uM	18.0%@1.0uM		
B-0374	1.38uM	12.0%@1.0uM		
B-0375	1.0uM	19.0%@1.0uM		
B-0376	2.99uM	12.0%@1.0uM		
B-0377	1.29uM	36.0%@1.0uM		
B-0378	1.1uM	36.0%@1.0uM		

Example#	P38 alpha kinase IC50,uM or % inhib@conc. (uM)	U937 Cell IC50,uM or % inhib@conc. (uM)	Mouse LPS Model % TNF inhib @ dose @predose time	Rat LPS Model % inhib @dose @predose time
B-0379	0.53uM	24.0%@1.0uM		
B-0380	1.41uM	32.0%@1.0uM		
B-0381	0.22uM	47.0%@1.0uM		
B-0382	0.41uM	32.0%@1.0uM		
B-0383	1.43uM	10.0%@1.0uM		
B-0384	4.02uM	16.0%@1.0uM		
B-0385	0.057uM	0.9uM	30%@30mpk@-6h	0%@3mpk@-4h
B-0386	0.13uM	54.0%@1.0uM		
B-0387	0.41uM	52.0%@1.0uM		
B-0388	<0.1uM	36.0%@1.0uM		
B-0389	0.01uM	0.05uM		62%@3mpk@-4h
B-0390	0.089uM	55.0%@1.0uM		
B-0391	0.86uM	18.0%@1.0uM		
B-0392	0.13uM	57.0%@1.0uM		
B-0393	0.043uM	66.0%@1.0uM		
B-0394	0.13uM	45.0%@1.0uM		
B-0395	0.087uM	48.0%@1.0uM		
B-0396	0.097uM	0.44uM		
B-0397	0.17uM	41.0%@1.0uM		
B-0398	0.054uM	66.0%@1.0uM		
B-0399	0.14uM	39.0%@1.0uM		
B-0400	0.16uM	25.0%@1.0uM		
B-0401	0.46uM	52.0%@1.0uM		
B-0402	0.14uM	1.51uM		
B-0403	1.77uM	2.42uM		
B-0404	0.31uM	48.0%@1.0uM		
B-0405	0.79uM	30.0%@1.0uM		
B-0406	0.54uM	35.0%@1.0uM		
B-0407	0.76uM	27.0%@1.0uM		
B-0408	0.5uM	50.0%@1.0uM		
B-0409	0.53uM	30.0%@1.0uM		
B-0410	0.38uM	44.0%@1.0uM		
B-0411	0.62uM	50.0%@1.0uM		
B-0412	0.24uM	48.0%@1.0uM		
B-0413	0.18uM	55.0%@1.0uM		
B-0414	2.54uM	25.0%@1.0uM		
B-0415	0.42uM	43.0%@1.0uM		
B-0416	0.32uM	34.0%@1.0uM		
B-0417	0.91uM	28.0%@1.0uM		
B-0418	0.22uM	27.0%@1.0uM		
B-0419	0.85uM	41.0%21.0uM		
B-0420	0.83uM	49.0%@1.0uM		

Example#	P38 alpha kinase IC50,uM or % inhib@conc. (uM)	U937 Cell IC50,uM or % inhib@conc. (uM)	Mouse LPS Model % TNF inhib @ dose @predose time	Rat LPS Model % inhib @dose @predose time
B-0421	0.46uM	57.0%@1.0uM		
B-0422	<0.1uM	40.0%@1.0uM		
B-0423	0.18uM	33.0%@1.0uM		
B-0424	0.083uM	32.0%@1.0uM		
B-0425	0.26uM	54.0%@1.0uM		
B-0426	0.055uM	0.74uM		41%@3mpk@-4h
B-0427	0.63uM	39.0%@1.0uM		
B-0428	0.99uM	27.0%@1.0uM		
B-0429	0.27uM	45.0%@1.0uM		
B-0430	0.29uM	75.0%@1.0uM		
B-0431	0.21uM	64.0%@1.0uM		
B-0432	<0.1uM	89.0%@1.0uM		
B-0433	<0.1uM	92.0%@1.0uM		
B-0434	0.12uM	65.0%@1.0uM		
B-0435	0.3uM	61.0%@1.0uM		
B-0436	1.11uM	71.0%@1.0uM		
B-0437	0.58uM	59.0%@1.0uM		
B-0438	<0.1uM	91.0%@1.0uM		
B-0439	2.12uM	65.0%@1.0uM		
B-0440	0.66uM	63.0%@1.0uM		
B-0441	0.8uM	58.0%@1.0uM		
B-0442	<0.1uM	91.0%@1.0uM		
B-0443	2.01uM	71.0%@1.0uM		
B-0444	1.01uM	51.0%@1.0uM		
B-0445	<0.1uM	83.0%@1.0uM		
B-0446	0.78uM	80.0%@1.0uM		
B-0447	0.19uM	71.0%@1.0uM		
B-0448	0.4uM	79.0%@1.0uM		
B-0449	0.83uM	81.0%@1.0uM		
B-0450	0.26uM	81.0%@1.0uM		
B-0451	0.071uM	83.0%@1.0uM	42%@30mpk@-6h	
B-0452	0.7uM	75.0%@1.0uM		
B-0453	0.47uM	75.0%@1.0uM		
B-0454	0.11uM	80.0%@1.0uM		
B-0455	<0.1uM	95.0%@1.0uM		36%@3mpk%-4h
B-0456	1.81uM	67.0%@1.0uM		
B-0457	0.089uM	81.0%@1.0uM		
B-0458	0.033uM	70.0%@1.0uM		
B-0459	0.099uM	76.0%@1.0uM		
B-0460	0.061uM	92.0%@1.0uM		
B-0461	0.025uM	96.0%@1.0uM		
B-0462	<0.1uM	97.0%@1.0uM		

Example#	P38 alpha kinase IC50,uM or % inhib@conc. (uM)	U937 Cell IC50,uM or % inhib@conc. (uM)	Mouse LPS Model % TNF inhib @ dose @predose time	Rat LPS Model % inhib @dose @predose time
B-0463	0.052uM	95.0%@1.0uM		
B-0464	<0.1uM	91.0%@1.0uM		
B-0465	0.084uM	98.0%@1.0uM		
B-0466	<0.1uM	98.0%@1.0uM		0%@3mpk@-4h
B-0467	<0.1uM	77.0%@1.0uM		
B-0468	0.031uM	93.0%@1.0uM		
B-0469	0.056uM	92.0%@1.0uM		
B-0470	0.063uM	92.0%@1.0uM		
B-0471	0.027uM	97.0%@1.0uM		
B-0472	0.19uM	54.0%@1.0uM		
B-0473	0.004uM	95.0%@1.0uM		
B-0474	0.024uM	86.0%@1.0uM		
B-0475	0.21uM	74.0%@1.0uM		
B-0476	0.56uM	69.0%@1.0uM		
B-0477	1.48uM	96.0%@1.0uM		
B-0478	0.034uM	87.0%@1.0uM		
B-0479	0.031uM	90.0%@1.0uM		15%@3mpk@-4h
B-0480	0.12uM	88.0%@1.0uM		
B-0481	0.014uM	95.0%@1.0uM		56%@3mpk@-4h
B-0482	0.97uM	68.0%@1.0uM		
B-0483	0.57uM	68.0%@1.0uM		
B-0484	0.28uM	62.0%@1.0uM		
B-0485	0.04uM	95.0%@1.0uM		
B-0486	0.24uM	80.0%@1.0uM		
B-0487	0.11uM	89.0%@1.0uM		54%@3mpk@-4h
B-0488	0.62uM	88.0%@1.0uM		
B-0489	0.3uM	80.0%@1.0uM		
B-0490	0.91uM	74.0%@1.0uM		
B-0491	0.43uM	66.0%@1.0uM		
B-0492	0.069uM	42.0%@1.0uM		
B-0493	0.3uM	36.0%@1.0uM		
B-0494	0.13uM	30.0%@1.0uM		
B-0495	0.12uM	25.0%@1.0uM		
B-0496	0.83uM	16.0%@1.0uM		
B-0497	0.44uM	31.0%@1.0uM		
B-0498	0.33uM	11.0%@1.0uM		
B-0499	0.39uM	37.0%@1.0uM		
B-0500	0.26uM	41.0%@1.0uM		
B-0501	0.049uM	52.0%@1.0uM		
B-0502	0.065uM	48.0%@1.0uM		
B-0503	0.16uM	73.0%@1.0uM		
B-0504	0.4uM	43.0%@1.0uM		

Example#	P38 alpha kinase IC50,uM or % inhib@conc. (uM)	U937 Cell IC50,uM or % inhib@conc. (uM)	Mouse LPS Model % TNF inhib @ dose @predose time	Rat LPS Model % inhib @dose @predose time
B-0505	0.28uM	44.0%@1.0uM		
B-0506	0.94uM	43.0%@1.0uM		
B-0507	0.18uM	75.0%@1.0uM		
B-0508	2.0uM	48.0%@1.0uM		
B-0509	0.1uM	86.0%@1.0uM		
B-0510	0.69uM	61.0%@1.0uM		
B-0511	0.007uM	90.0%@1.0uM		
B-0512	1.0uM	53.0%@1.0uM		
B-0513	0.72uM	52.0%@1.0uM		
B-0514	0.14uM	87.0%@1.0uM		
B-0515	0.42uM	61.0%@1.0uM		
B-0516	0.37uM	84.0%@1.0uM		
B-0517	0.094uM	52.0%@1.0uM		
B-0518	0.11uM	64.0%@1.0uM		
B-0519	0.043uM	87.0%@1.0uM		
B-0520	0.4uM	67.0%@1.0uM		
B-0521	1.37uM	52.0%@1.0uM		
B-0522	0.15uM	75.0%@1.0uM		
B-0523	0.19uM	83.0%@1.0uM		
B-0524	0.4uM	77.0%@1.0uM		
B-0525	0.16uM	76.0%@1.0uM		
B-0526	0.031uM	87.0%@1.0uM		
B-0527	1.09uM	63.0%@1.0uM		
B-0528	0.14uM	70.0%@1.0uM		
B-0529	0.11uM	73.0%@1.0uM		
B-0530	5.53uM	45.0%@1.0uM		
B-0531	0.5uM	48.0%@1.0uM		
B-0532	0.45uM	1.01uM	41%@30mpk@-6h	
B-0533	1.23uM	47.0%@1.0uM		
B-0534	0.41uM	54.0%@1.0uM		
B-0535	0.44uM	0.87uM		
B-0536	0.46uM	0.15uM		
B-0537	3.44uM	51.0%@1.0uM		
B-0538	1.13uM	45.0%@1.0uM		
B-0539	2.84uM	21.0%@1.0uM		
B-0540	3.62uM	54.0%@1.0uM		
B-0541	3.24uM	28.0%@1.0uM		
B-0542	1.55uM	50.0%@1.0uM		
B-0543	1.56uM	43.0%@1.0uM		
B-0544	1.12uM	27.0%@1.0uM		
B-0545	1.06uM	41.0%@1.0uM		
B-0546	1.04uM	18.0%@1.0uM		
B-0547	1.24uM	21.0%@1.0uM		
B-0548	1.77uM	28.0%@1.0uM		
B-0549	2.22uM	22.0%@1.0uM		

Example#	P38 alpha kinase IC50,uM or % inhib@conc. (uM)	U937 Cell IC50,uM or % inhib@conc. (uM)	Mouse LPS Model % TNF Inhib @ dose @predose time	Rat LPS Model % inhib @dose @predose time
B-0550	2.41uM	14.0%@1.0uM		
B-0551	1.08uM	56.0%@1.0uM		
B-0552	0.13uM	46.0%@1.0uM		
B-0553	1.44uM	47.0%@1.0uM		
B-0554	2.58uM	20.0%@1.0uM		
B-0555	1.87uM	34.0%@1.0uM		
B-0556	0.49uM	39.0%@1.0uM		
B-0557	1.37uM	32.0%@1.0uM		
B-0558	0.85uM	33.0%@1.0uM		
B-0559	0.53uM	49.0%@1.0uM		
B-0560	2.57uM	31.0%@1.0uM		
B-0561	2.07uM	40.0%@1.0uM		
B-0562	0.22uM	0.3uM		5%@3mpk@-4h
B-0563	0.18uM	0.13uM		
B-0564	0.82uM	58%@1.0uM		
B-0565	0.23uM	0.59uM		
B-0566	<0.1uM	0.17uM		0%@3mpk@-4h
B-0567	0.14uM	0.28uM		
B-0568	1.22uM	46.0%@1.0uM		
B-0569	0.15uM	0.26uM		
B-0570	0.27uM	46.0%@1.0uM		
B-0571	0.38uM	44.0%@1.0uM		
B-0572	0.27uM	41.0%@1.0uM		
B-0573	0.36uM	1.7uM		
B-0574	0.13uM	0.66uM		37%@3mpk@-4h
B-0575	0.032uM	0.17uM		
B-0576	0.068uM	0.39uM		65%@3mpk@-4h
B-0577	0.091uM	66.0%@1.0uM		
B-0578	1.88uM	47.0%@1.0uM		
B-0579	0.11uM	79.0%@1.0uM		
B-0580	2.23uM	0.84uM		
B-0581	0.26uM	2.17uM		
B-0582	1.03uM	37.0%@1.0uM		
B-0583	3.93uM	26.0%@1.0uM		
B-0584	0.66uM	54.0%@1.0uM		
B-0585	0.83uM	79.0%@1.0uM	50%@30mpk@-6h	
B-0586	0.81uM	51.0%@1.0uM		
B-0587	6.84uM	38%@1.0uM		
B-0588	12.8uM	42%@1.0uM		
B-0589	1.71uM	42%@1.0uM		
B-0590	1.57uM	38.0uM		
B-0591	3.59uM	29.0%@1.0uM		
B-0592	1.62uM	45.0%@1.0uM		
B-0593	1.22uM	36.0%@1.0uM		
B-0594	-	41.0%@1.0uM		
B-0595	2.42uM	22.0%@1.0uM		
B-0596	20.0uM	41.0%@1.0uM		
B-0597	1.68uM	63.0%@1.0uM		
B-0598	2.12uM	50.0%@1.0uM		

Example#	P38 alpha kinase IC50,uM or % inhib@conc. (uM)	U937 Cell IC50,uM or % inhib@conc. (uM)	Mouse LPS Model % TNF inhib @ dose @predose time	Rat LPS Model % inhib @dose @predose time
B-0599	4.16uM	21.0% @ 1.0uM		
B-0600	0.002uM	28.0% @ 1.0uM		
B-0601	0.089uM	1.31uM		43% @ 3mpk % -4h
B-0602	0.97uM	61.0% @ 1.0uM		
B-0603	0.09uM	51.0% @ 1.0uM		
B-0604	0.3uM	20.0% @ 1.0uM		
B-0605	0.18uM	47.0% @ 1.0uM		
B-0606	0.17uM	53.0% @ 1.0uM		
B-0607	2.79uM	70.0% @ 1.0uM		
B-0608	0.059uM	73.0% @ 1.0uM		
B-0609	<0.1uM	87.0% @ 1.0uM		
B-0610	<0.1uM	88.0% @ 1.0uM		
B-0611	0.65uM	60.0% @ 1.0uM		
B-0612	0.16uM	60.0% @ 1.0uM		
B-0613	0.17uM	76.0% @ 1.0uM		
B-0614	0.76uM	70.0% @ 1.0uM		0% @ 3mpk @ -4h
B-0615	0.08uM	83.0% @ 1.0uM		
B-0616	0.38uM	87.0% @ 1.0uM		
B-0617	0.045uM	92.0% @ 1.0uM		
B-0618	0.37uM	80.0% @ 1.0uM		
B-0619	<0.1uM	88.0% @ 1.0uM		
B-0620	1.59uM	58.0% @ 1.0uM		
B-0621	0.36uM	68.0% @ 1.0uM		
B-0622	0.076uM	78.0% @ 1.0uM		
B-0623	0.12uM	76.0% @ 1.0uM		
B-0624	0.085uM	54.0% @ 1.0uM		
B-0625	0.023uM	88.0% @ 1.0uM		
B-0626	<0.1uM	85.0% @ 1.0uM		
B-0627	0.25uM	69.0% @ 1.0uM		
B-0628	0.023uM	72.0% @ 1.0uM		
B-0629	0.2uM	79.0% @ 1.0uM		
B-0630	0.06uM	77.0% @ 1.0uM		
B-0631	0.065uM	81.0% @ 1.0uM		
B-0632	<0.1uM	79.0% @ 1.0uM		
B-0633	0.6uM	80.0% @ 1.0uM		
B-0634	0.6uM	40.0% @ 1.0uM		
B-0635	0.15uM	55.0% @ 1.0uM		
B-0636	<0.1uM	86.0% @ 1.0uM		
B-0637	0.11uM	92.0% @ 1.0uM		
B-0638	0.25uM	89.0% @ 1.0uM		
B-0639	0.051uM	93.0% @ 1.0uM		50% @ 3mpk @ -4h
B-0640	0.36uM	94.0% @ 1.0uM		
B-0641	0.58uM	65.0% @ 1.0uM		
B-0642	0.49uM	90.0% @ 1.0uM		
B-0643	0.069uM	85.0% @ 1.0uM		0% @ 3mpk @ -4h
B-0644	0.058uM	89.0% @ 1.0uM		
B-0645	0.58uM	80.0% @ 1.0uM		
B-0646	0.26uM	94.0% @ 1.0uM		
B-0647	1.61uM	76.0% @ 1.0uM		

Example#	P38 alpha kinase IC50,uM or % inhib@conc. (uM)	U937 Cell IC50,uM or % inhib@conc. (uM)	Mouse LPS Model % TNF inhib @ dose @predose time	Rat LPS Model % inhib @dose @predose time
B-0648	<0.1uM	83.0%@1.0uM		
B-0649	0.83uM	39.0%@1.0uM		
B-0650	0.006uM	95.0%@1.0uM		8%@3mpk@-4h
B-0651	1.78uM	81.0%@1.0uM		
B-0652	0.19uM	83.0%@1.0uM		
B-0653	2.01uM	74.0%@1.0uM		
B-0654	5.97uM	78.0%@1.0uM		
B-0655	1.25uM	76.0%@1.0uM		
B-0656	0.007uM	95.0%@1.0uM		28%@3mpk@-4h
B-0657	0.17uM	83.0%@1.0uM		
B-0658	1.14uM	91.0%@1.0uM		
B-0659	2.64uM	87.0%@1.0uM		
B-0660	0.088uM	92.0%@1.0uM		
B-0661	<0.1uM	90.0%@1.0uM		
B-0662	<0.1uM	95.0%@1.0uM		
B-0663	0.88uM	74.0%@1.0uM		
B-0664	0.39uM	80.0%@1.0uM		
B-0665	0.47uM	72.0%@1.0uM		
B-0666	0.17uM	73.0%@1.0uM		
B-0667	0.83uM	75.0%@1.0uM		
B-0668	0.27uM	78.0%@1.0uM		
B-0669	0.89uM	34.0%@1.0uM		
B-0670	3.15uM	32.0%@1.0uM		
B-0671	6.38uM	36.0%@1.0uM		
B-0672	6.59uM	32.0%@1.0uM		
B-0673	8.54uM	48.0%@1.0uM		
B-0674	2.81uM	42.0%@1.0uM		
B-0675	5.42uM	3.0%@1.0uM		
B-0676	2.09uM	22.0%@1.0uM		
B-0677	1.63uM	25.0%@1.0uM		
B-0678	0.38uM	52.0%@1.0uM		
B-0679	0.062uM	45.0%@1.0uM		
B-0680	0.42uM	67.0%@1.0uM		
B-0681	1.96uM	17.0%@1.0uM		
B-0682	0.76uM	39.0%@1.0uM		
B-0683	13.0uM	32.0%@1.0uM		
B-0684	0.54uM	68.0%@1.0uM		
B-0685	15.4uM	33.0%@1.0uM		
B-0686	0.42uM	59.0%@1.0uM		
B-0687	10.1uM	15.0%@1.0uM		
B-0688	0.66uM	58.0%@1.0uM		
B-0689	14.6uM	27.0%@1.0uM		
B-0690	27.1uM	36.0%@1.0uM		
B-0691	0.16uM	48.0%@1.0uM		
B-0692	0.38uM	29.0%@1.0uM		
B-0693	0.39uM	28.0%@1.0uM		
B-0694	0.62uM	21.0%@1.0uM		
B-0695	0.23uM	32.0%@1.0uM		
B-0696	0.085uM	35.0%@1.0uM		

Example#	P38 alpha kinase IC50,uM or % inhib@conc. (uM)	U937 Cell IC50,uM or % inhib@conc. (uM)	Mouse LPS Model % TNF inhib @ dose @predose time	Rat LPS Model % inhib @dose @predose time
B-0697	0.45uM	44.0%@1.0uM		
B-0698	2.33uM	43.0%@1.0uM		
B-0699	0.34uM	31.0%@1.0uM		
B-0700	0.24uM	56.0%@1.0uM		
B-0701	0.39uM	45.0%@1.0uM		
B-0702	0.036uM	39.0%@1.0uM		
B-0703	0.12uM	39.0%@1.0uM		
B-0704	2.19uM	29.0%@1.0uM		
B-0705	0.44uM	21.0%@1.0uM		
B-0706	0.44uM	32.0%@1.0uM		
B-0707	1.7uM			
B-0708	2.1uM			
B-0709	0.84uM			
B-0710	1.99uM			
B-0711	1.99uM			
B-0712	2.9uM			
B-0713	4.3uM			
B-0714	3.7uM			
B-0715	3.2uM			
B-0716	4.6uM			
B-0717	4.3uM			
B-0718	1.4uM			
B-0719	3.4uM			
B-0720	1.3uM			
B-0721	3.8uM			
B-0722	0.07uM	>1.0uM		
B-0723	0.47uM			
B-0724	0.06uM	17.0%@1.0uM		
B-0725	9.7uM			
B-0726	1.4uM			
B-0727	0.51uM			
B-0728	20.0uM			
B-0729	0.87uM			
B-0730	0.25uM	11.0%@1.0uM		
B-0731	0.87uM	>1.0uM		
B-0732	14.0uM			
B-0733	32.0uM			
B-0734	0.92uM			
B-0735	1.0uM			
B-0736	26.0uM			
B-0737	2.6uM			
B-0738	2.7uM			
B-0739	4.1uM			
B-0740	4.4uM			
B-0741	26.0uM			
B-0742	2.2uM			
B-0743	1.2uM			
B-0744	23.0uM			
B-0745	6.0uM			

1030

Example#	P38 alpha kinase IC50,uM or % inhib@conc. (uM)	U937 Cell IC50,uM or % inhib@conc. (uM)	Mouse LPS Model % TNF inhib @ dose @predose time	Rat LPS Model % inhib @dose @predose time
B-0746	0.01uM	22.0%@1.0uM		
B-0747	1.1uM			
B-0748	1.2uM			
B-0749	4.4uM			
B-0750	0.92uM			
B-0751	1.6uM			
B-0752	0.33uM			
B-0753	0.37uM			
B-0754	0.55uM			
B-0755	2.3uM			
B-0756	0.94uM			
B-0757	0.54uM	16.0%@1.0uM		
B-0758	1.5uM			
B-0759	0.3uM			
B-0760	0.01uM	13.0%@1.0uM		
B-0761	<0.1uM			
B-0762	0.13uM	5.0%@1.0uM		
B-0763	0.015uM	17.0%@1.0uM		
B-0764	0.67uM	26.0%@1.0uM		
B-0765	0.3uM	29.0%@1.0uM		
B-0766	0.95uM			
B-0767	0.08uM			
B-0768	1.4uM			
B-0769	12.7uM			
B-0770	2.3uM			
B-0771	0.5uM			
B-0772	0.8uM			
B-0773	14.0uM			
B-0774	1.5uM			
B-0775	0.6uM	>1.0uM		
B-0776	0.9uM	>1.0uM		
B-0777	21.0uM			
B-0778	51.0uM			
B-0779	0.5uM			
B-0780	1.1uM			
B-0781	48.0uM			
B-0782	22.0uM			
B-0783	8.0uM			
B-0784	7.0uM			
B-0785	23.0uM			
B-0786	24.0uM			
B-0787	1.5uM			
B-0788	1.2uM			
B-0789	33.0uM			
B-0790	1.0uM	4.0%@1.0uM		
B-0791	0.3uM	>1.0uM		
B-0792	1.1uM			
B-0793	0.3uM			
B-0794	2.9uM	2.0%@1.0uM		

Example#	P38 alpha kinase IC50,uM or % inhib@conc. (uM)	U937 Cell IC50,uM or % inhib@conc. (uM)	Mouse LPS Model % TNF inhib @ dose @predose time	Rat LPS Model % Inhib @dose @predose time
B-0795	1.9uM	11.0%@1.0uM		
B-0796	1.4uM			
B-0797	1.04uM	-		
B-0798	1.73uM	-		
B-0799	-	>1.0uM		
B-0800	1.01uM	>1.0uM		
B-0801	0.67uM	>1.0uM		
B-0802	-	>1.0uM		
B-0803	0.057uM	53.0%@1.0uM		
B-0804	0.3uM	32.0%@1.0uM		
B-0805	0.71uM	>1.0uM		
B-0806	3.28uM	>1.0uM		
B-0807	10.8uM	-		
B-0808	3.09uM	>1.0uM		
B-0809	1.22uM	7.0%@1.0uM		
B-0810	1.11uM	>1.0uM		
B-0811	2.79uM	2.0%@1.0uM		
B-0812	2.12uM	>1.0uM		
B-0813	3.02uM	>1.0uM		
B-0814	-	>1.0uM		
B-0815	2.11uM	>1.0uM		
B-0816	3.46uM	>1.0uM		
B-0817	3.07uM	33.0%@1.0uM		
B-0818	4.97uM	>1.0uM		
B-0819	1.08uM	>1.0uM		
B-0820	1.64uM	3.0%@1.0uM		
B-0821	1.44uM	-		
B-0822	1.33uM	-		
B-0823	2.39uM	>1.0uM		
B-0824	3.41uM	-		
B-0825	-	-		
B-0826	1.74uM	-		
B-0827	15.6uM	-		
B-0828	7.9uM	-		
B-0829	0.61uM	65.0%@1.0uM		
B-0830	0.54uM	34.0%@1.0uM		
B-0831	0.9uM	>1.0uM		
B-0832	1.49uM	-		
B-0833	0.95uM	23.0%@1.0uM		
B-0834	1.25uM	-		
B-0835	-	-		
B-0836	1.24uM	-		
B-0837	1.96uM	>1.0uM		
B-0838	3.1uM	-		
B-0839	4.3uM	-		
B-0840	0.63uM	47.0%@1.0uM		
B-0841	0.32uM	36.0%@1.0uM		
B-0842	0.74uM	63.0%@1.0uM		
B-0843	0.61uM	>1.0uM		

Example#	P38 alpha kinase IC50,uM or % inhib@conc. (uM)	U937 Cell IC50,uM or % inhib@conc. (uM)	Mouse LPS Model % TNF inhib @ dose @predose time	Rat LPS Model % inhib @dose @predose time
B-0844	0.4uM	25.0%@1.0uM		
B-0845	1.78uM	-		
B-0846	1.8uM	-		
B-0847	0.73uM	21.0%@1.0uM		
B-0848	1.56uM	-		
B-0849	1.25uM	-		
B-0850	1.81uM	-		
B-0851	0.91uM	39.0%@1.0uM		
B-0852	1.02uM	-		
B-0853	-	38.0%@1.0uM		
B-0854	-	25.0%@1.0uM		
B-0855	-	8.0%@1.0uM		
B-0856	-	38.0%@1.0uM		
B-0857	6.25uM	-		
B-0858	2.1uM	48.0%@1.0uM		
B-0859	39.5uM	-		
B-0860	38.1uM	-		
B-0861	1.32uM	12.0%@1.0uM		
B-0862	2.15uM	4.0%@1.0uM		
B-0863	0.81uM	25.0%@1.0uM		
B-0864	0.39uM	40.0%@1.0uM		
B-0865	0.66uM	46.0%@1.0uM		
B-0866	1.38uM	28.0%@1.0uM		
B-0867	0.62uM	>1.0uM		
B-0868	3.28uM	8.0%@1.0uM		
B-0869	4.19uM	>1.0uM		
B-0870	3.13uM	>1.0uM		
B-0871	1.9uM	>1.0uM		
B-0872	3.13uM	3.0%@1.0uM		
B-0873	6.92uM	>1.0uM		
B-0874	1.92uM	>1.0uM		
B-0875	2.13uM	8%@1.0uM		
B-0876	0.89uM	>1.0uM		
B-0877	1.17uM	13.0%@1.0uM		
B-0878	0.65uM	19.0%@1.0uM		
B-0879	0.87uM	1.0%@1.0uM		
B-0880	0.15uM	40.0%@1.0uM		
B-0881	1.36uM	>1.0uM		
B-0882	1.48uM	9%@1.0uM		
B-0883	1.06uM	>1.0uM		
B-0884	1.89uM	-		
B-0885				
B-0886				
B-0887				
B-0888				
B-0889				
B-0890				
B-0891				
B-0892				

Example#	P38 alpha kinase IC50,uM or % inhib@conc. (uM)	U937 Cell IC50,uM or % inhib@conc. (uM)	Mouse LPS Model % TNF inhib @ dose @predose time	Rat LPS Model % inhib @dose @predose time
B-0893				
B-0894				
B-0895				
B-0896				
B-0897				
B-0898				
B-0899				
B-0900				
B-0901				
B-0902				
B-0903				
B-0904				
B-0905				
B-0906				
B-0907				
B-0908				
B-0909				
B-0910				
B-0911				
B-0912				
B-0913				
B-0914				
B-0915				
B-0916				
B-0917				
B-0918				
B-0919				
B-0920				
B-0921				
B-0922				
B-0923				
B-0924				
B-0925				
B-0926				
B-0927				
B-0928				
B-0929				
B-0930				
B-0931				
B-0932				
B-0933	47.0%@1.0uM	37.0%@1.0uM		
B-0934	67.0%@1.0uM	36.0%@1.0uM		
B-0935	69.0%@1.0uM	54.0%@1.0uM		
B-0936	69.0%@1.0uM	>1.0uM		
B-0937	64.0%@1.0uM	1.74uM		
B-0938	51.0%@1.0uM	29.0%@1.0uM		
B-0939	78.0%@1.0uM	14.0%@1.0uM		
B-0940	56.0%@1.0uM	22.0%@1.0uM		
B-0941	81.0%@1.0uM	25.0%@1.0uM		

Example#	P38 alpha kinase IC50,uM or % inhib@conc. (uM)	U937 Cell IC50,uM or % inhib@conc. (uM)	Mouse LPS Model % TNF inhib @ dose @predose time	Rat LPS Model % inhib @dose @predose time
B-0942	82.0% @1.0uM	2.0% @1.0uM		
B-0943	63.0% @10.0uM	24.0% @1.0uM		
B-0944	45.0% @1.0uM	27.0% @1.0uM		
B-0945	96.0% @1.0uM	0.93uM		
B-0946	76.0% @1.0uM	31.0% @1.0uM		
B-0947	69.0% @1.0uM	34.0% @1.0uM		
B-0948	68.0% @1.0uM	1.81uM		
B-0949	90.0% @1.0uM	17.0% @1.0uM		
B-0950	81.0% @1.0uM	0.58uM		
B-0951	82.0% @1.0uM	20.0% @1.0uM		
B-0952	44.0% @1.0uM	21.0% @1.0uM		
B-0953	63.0% @1.0uM	25.0% @1.0uM		
B-0954	62.0% @1.0uM	0.52uM		
B-0955	49.0% @1.0uM	0.54uM		
B-0956	56.0% @1.0uM	1.33uM		
B-0957	79.0% @1.0uM	22.0% @1.0uM		
B-0958	74.0% @1.0uM	0.38uM		
B-0959	83.0% @1.0uM	39.0% @1.0uM		
B-0960	48.0% @1.0uM	4.0% @1.0uM		
B-0961	79.0% @1.0uM	23.0% @1.0uM		
B-0962	85.0% @1.0uM	2.71uM		
B-0963	76.0% @1.0uM	39.0% @1.0uM		
B-0964	94.0% @1.0uM	5.0uM		
B-0965	74.0% @1.0uM	1.1uM		
B-0966	50.0% @1.0uM	5.0% @1.0uM		
B-0967	80.0% @1.0uM	29.0% @1.0uM		
B-0968	35.0% @1.0uM	26.0% @1.0uM		
B-0969	63.0% @1.0uM	35.0% @1.0uM		
B-0970	76.0% @10.0uM	0.88uM		
B-0971	61.0% @1.0uM	39.0% @1.0uM		
B-0972	85.0% @1.0uM	2.0% @1.0uM		
B-0973	66.0% @10.0uM	48.0% @1.0uM		
B-0974	57.0% @1.0uM	47.0% @1.0uM		
B-0975	82.0% @1.0uM	32.0% @1.0uM		
B-0976	79.0% @1.0uM	36.0% @1.0uM		
B-0977	60.0% @1.0uM	26.0% @1.0uM		
B-0978	59.0% @1.0uM	36.0% @1.0uM		
B-0979	56.0% @10.0uM	23.0% @1.0uM		
B-0980	68.0% @1.0uM	31.0% @1.0uM		
B-0981	62.0% @1.0uM	57.0% @1.0uM		
B-0982	65.0% @1.0uM	23.0% @1.0uM		
B-0983	75.0% @1.0uM	0.8uM		
B-0984	60.0% @1.0uM	51.0% @1.0uM		
B-0985	86.0% @1.0uM	0.75uM		
B-0986	70.0% @1.0uM	71.0% @1.0uM		
B-0987	78.0% @1.0uM	79.0% @1.0uM		
B-0988	72.0% @1.0uM	65.0% @1.0uM		
B-0989	85.0% @1.0uM	0.85uM		
B-0990	-	26.0% @1.0uM		

Example#	P38 alpha kinase IC50,uM or % inhib@conc. (uM)	U937 Cell IC50,uM or % inhib@conc. (uM)	Mouse LPS Model % TNF inhib @ dose @predose time	Rat LPS Model % Inhib @dose @predose time
B-0991	58.0%@1.0uM	33.0%@1.0uM		
B-0992	77.0%@1.0uM	45.0%@1.0uM		
B-0993	57.0%@1.0uM	73.0%@1.0uM		
B-0994	55.0%@1.0uM	43.0%@1.0uM		
B-0995	53.0%@1.0uM	14.0%@1.0uM		
B-0996	54.0%@1.0uM	27.0%@1.0uM		
B-0997	69.0%@1.0uM	22.0%@1.0uM		
B-0998	67.0%@1.0uM	25.0%@1.0uM		
B-0999	61.0%@1.0uM	24.0%@1.0uM		
B-1000	55.0%@1.0uM	42.0%@1.0uM		
B-1001	63.0%@1.0uM	31.0%@1.0uM		
B-1002	70.0%@1.0uM	41.0%@1.0uM		
B-1003	74.0%@1.0uM	29.0%@1.0uM		
B-1004	79.0%@1.0uM	45.0%@1.0uM		
B-1005	58.0%@1.0uM	23.0%@1.0uM		
B-1006	69.0%@1.0uM	38.0%@1.0uM		
B-1007	52.0%@1.0uM	34.0%@1.0uM		
B-1008	54.0%@1.0uM	23.0%@1.0uM		
B-1009	80.0%@1.0uM	55.0%@1.0uM		
B-1010	75.0%@1.0uM	1.0uM		
B-1011	72.0%21.0uM	17.0%@1.0uM		
B-1012	-	20.0%@1.0uM		
B-1013	85.0%@1.0uM	7.0%@1.0uM		
B-1014	88.0%@1.0uM	20.0%@1.0uM		
B-1015	77.0%@1.0uM	34.0%@1.0uM		
B-1016	58.0%@1.0uM	10.0%@1.0uM		
B-1017	96.0%@1.0uM	58.0%@1.0uM		
B-1018	88.0%@1.0uM	34.0%@1.0uM		
B-1019	82.0%@1.0uM	66.0%@1.0uM		
B-1020	87.0%@1.0uM	36.0%@1.0uM		
B-1021	82.0%@1.0uM	35.0%@1.0uM		
B-1022	84.0%@1.0uM	53.0%@1.0uM		
B-1023	93.0%@1.0uM	70.0%@1.0uM		
B-1024	89.0%@1.0uM	57.0%@1.0uM		
B-1025	61.0%@1.0uM	23.0%@1.0uM		
B-1026	87.0%@1.0uM	53.0%@1.0uM		
B-1027	58.0%@1.0uM	18.0%@1.0uM		
B-1028	70.0%@1.0uM	17.0%@1.0uM		
B-1029	69.0%@1.0uM	54.0%@1.0uM		
B-1030	76.0%@1.0uM	60.0%@1.0uM		
B-1031	69.0%@1.0uM	42.0%@1.0uM		
B-1032	76.0%@1.0uM	37.0%@1.0uM		
B-1033	86.0%@1.0uM	34.0%@1.0uM		
B-1034	66.0%@1.0uM	39.0%@1.0uM		
B-1035	75.0%@1.0uM	52.0%@1.0uM		
B-1036	68.0%@1.0uM	68.0%@1.0uM		
B-1037	-	41.0%@1.0uM		
B-1038	57.0%@1.0uM	0.57uM		
B-1039	-	1.33uM		

Example#	P38 alpha kinase IC50,uM or % inhib@conc. (uM)	U937 Cell IC50,uM or % inhib@conc. (uM)	Mouse LPS Model % TNF inhib @ dose @predose time	Rat LPS Model % inhib @dose @predose time
B-1040	72.0%@1.0uM	0.38uM		
B-1041	70.0%@1.0uM	73.0%@1.0uM		
B-1042	79.0%@1.0uM	12.0%@1.0uM		
B-1043	64.0%@1.0uM	53.0%@1.0uM		
B-1044	94.0%@1.0uM	0.93uM		
B-1045	78.0%@1.0uM	25.0%@1.0uM		
B-1046	72.0%@1.0uM	66.0%@1.0uM		
B-1047	72.0%@1.0uM	58.0%@1.0uM		
B-1048	67.0%@1.0uM	19.0%@1.0uM		
B-1049	67.0%@1.0uM	65.0%@1.0uM		
B-1050	-	0.54uM		
B-1051	68.0%@1.0uM	41%@1.0uM		
B-1052	69.0%@1.0uM	66%@1.0uM		
B-1053	78.0%@1.0uM	0.4uM		
B-1054	79.0%@1.0uM	55.0%@1.0uM		
B-1055	89.0%@1.0uM	63.0%@1.0uM		
B-1056	89.0%@1.0uM	0.76uM		
B-1057	85.0%@1.0uM	0.72uM		
B-1058	0.66uM	43.0%@1.0uM		
B-1059	0.18uM	24.0%@1.0uM		
B-1060	0.11uM	32.0%@1.0uM		
B-1061	0.03uM	19.0%@1.0uM		
B-1062	<0.1uM	26.0%@1.0uM		
B-1063	0.16uM	44.0%@1.0uM		
B-1064	0.39uM	50.0%@1.0uM		
B-1065	0.56uM	40.0%@1.0uM		
B-1066	<0.1uM	39.0%@1.0uM		
B-1067	1.6uM	32.0%@1.0uM		
B-1068	0.48uM	24.0%@1.0uM		
B-1069	0.22uM	27.0%@1.0uM		
B-1070	<0.1uM	44.0%@1.0uM		
B-1071	<0.1uM	48.0%@1.0uM		
B-1072	0.38uM	28.0%@1.0uM		
B-1073	<0.1uM	21.0%@1.0uM		
B-1074	0.23uM	33.0%@1.0uM		
B-1075	0.03uM	29.0%@1.0uM		
B-1076	0.08uM	31.0%@1.0uM		
B-1077	<0.1uM	38.0%@1.0uM		
B-1078	0.26uM	48.0%@1.0uM		
B-1079	<0.1uM	40.0%@1.0uM		
B-1080	0.19uM	28.0%@1.0uM		
B-1081	<0.1uM	37.0%@1.0uM		
B-1082	<0.1uM	54.0%@1.0uM		
B-1083	<0.1uM	23.0%@1.0uM		
B-1084	0.43uM	29.0%@1.0uM		
B-1085	<0.1uM	29.0%@1.0uM		
B-1086	<0.1uM	42.0%@1.0uM		
B-1087	0.05uM	32.0%@1.0uM		
B-1088	0.73uM	49.0%@1.0uM		

Example#	P38 alpha kinase IC50,uM or % inhib@conc. (uM)	U937 Cell IC50,uM or % inhib@conc. (uM)	Mouse LPS Model % TNF Inhib @ dose @predose time	Rat LPS Model % inhib @dose @predose time
B-1089	<0.1uM	39.0%@1.0uM		
B-1090	<0.1uM	90.0%@1.0uM		
B-1091	<0.1uM	73.0%@1.0uM		
B-1092	0.27uM	85.0%@1.0uM		
B-1093	0.33uM	36.0%@1.0uM		
B-1094	0.013uM	69.0%@1.0uM		
B-1095	<0.1uM	70.0%@1.0uM		
B-1096	<0.1uM	32.0%@1.0uM		
B-1097	<0.1uM	44.0%@1.07uM		
B-1098	<0.1uM	82.0%@1.0uM		
B-1099	0.26uM	74.0%@1.0uM		
B-1100	0.22uM	56.0%@1.0uM		
B-1101	0.026uM	82.0%@1.0uM		
B-1102	0.035uM	83.0%@1.0uM		
B-1103	0.094uM	90.0%@1.0uM		
B-1104	0.12uM	69.0%@1.0uM		
B-1105	<0.1uM	84.0%@1.0uM		
B-1106	<0.1uM	86.0%@1.0uM		
B-1107	0.057uM	84.0%@1.0uM		
B-1108	0.22uM	81.0%@1.0uM		
B-1109	0.054uM	80.0%@1.0uM		
B-1110	0.47uM	64.0%@1.0uM		
B-1111	0.19uM	64.0%@1.0uM		
B-1112	0.58uM	43.0%@1.0uM		
B-1113	<0.1uM	72.0%@1.0uM		
B-1114	0.069uM	51.0%@1.0uM		
B-1115	0.024uM	89.0%@1.0uM		
B-1116	0.41uM	81.0%@1.0uM		
B-1117	0.13uM	73.0%@1.0uM		
B-1118	0.33uM	91.0%@1.0uM		
B-1119	0.35uM	80.0%@1.0uM		
B-1120	0.47uM	9.0%@1.0uM		
B-1121	3.58uM	29.0%@1.0uM		
B-1122	1.84uM	32.0%@1.0uM		
B-1123	2.93uM	27.0%@1.0uM		
B-1124	1.49uM	52.0%@1.0uM		
B-1125	0.56uM	41.0%@1.0uM		
B-1126	1.5uM	>1.0uM		
B-1127	0.71uM	7.0%@1.0uM		
B-1128	2.55uM	26.0%@1.0uM		
B-1129	1.07uM	46.0%@1.0uM		
B-1130	0.5uM	29.0%@1.0uM		
B-1131	0.076uM	34.0%@1.0uM		
B-1132	0.72uM	11.0%@1.0uM		
B-1133	0.38uM	33.0%@1.0uM		
B-1134	1.71uM	33.0%@1.0uM		
B-1135	0.23uM	38.0%@1.0uM		
B-1136	1.17uM	40.0%@1.0uM		
B-1137	0.038uM	35.0%@1.0uM		

Example#	P38 alpha kinase IC50,uM or % inhib@conc. (uM)	U937 Cell IC50,uM or % inhib@conc. (uM)	Mouse LPS Model % TNF inhib @ dose @predose time	Rat LPS Model % Inhib @dose @predose time
B-1138	1.82uM	>1.0uM		
B-1139	0.041uM	29.0%@1.0uM		
B-1140	1.68uM	39.0%@1.0uM		
B-1141	2.47uM	32.0%@1.0uM		
B-1142	0.11uM	37.0%@1.0uM		
B-1143	0.17uM	40.0%@1.0uM		
B-1144	0.44uM	72.0%@1.0uM		
B-1145	1.07uM	71.0%@1.0uM		
B-1146	0.47uM	61.0%@1.0uM		
B-1147	0.095uM	53.0%@1.0uM		
B-1148	0.43uM	61.0%@1.0uM		
B-1149	1.55uM	48.0%@1.0uM		
B-1150	0.47uM	75.0%@1.0uM		
B-1151	0.32uM	72.0%@1.0uM		
B-1152	0.73uM	53.0%@1.0uM		
B-1153	2.22uM	52.0%@1.0uM		
B-1154	0.085uM	46.0%@1.0uM		
B-1155	3.22uM	30.0%@1.0uM		
B-1156	0.27uM	78.0%@1.0uM		
B-1157	0.26uM	66.0%@1.0uM		
B-1158	74.0%@1.0uM	0.68uM	53.0% @30mpk @-6h	
B-1159	66.0%@1.0uM	1.03uM	60.0% @30mpk @-6h	
B-1160	79.0%@1.0uM	0.38uM		
B-1161	64.0%21.0uM	0.93uM	40.0% @30mpk @-6h	45.0% @3mpk @-4h
B-1162	79.0%@1.0uM	0.59uM	40.0% @30mpk @-6h	
B-1163	74.0%@1.0uM	0.37uM		
B-1164	-	0.35uM		
B-1165	66.0%@1.0uM	0.99uM		
B-1166	77.0%@1.0uM	0.39uM	50.0% @30mpk @-6h	50.0% @3mpk @-4h
B-1167	70.0%@1.0uM	1.06uM		
B-1168	66.0%@1.0uM	0.63uM		
B-1169	80.0%@1.0uM	0.11uM		
B-1170	82.0%@1.0uM	0.57uM		
B-1171	78.0%@1.0uM	0.23uM		
B-1172	68.0%@1.0uM	1.95uM		
B-1173	65.0%@1.0uM	62.0% @1.0uM		
B-1174	80.0%@1.0uM	0.86uM		
B-1175	72.0%@1.0uM	1.83uM		
B-1176	67.0%@1.0uM	67.0% @1.0uM		
B-1177	70.0%@1.0uM	1.16uM		
B-1178	92.0%@1.0uM	1.61uM		
B-1179	86.0%@1.0uM	0.41uM		
B-1180	78.0%@1.0uM	0.53uM		
B-1181	79.0%@1.0uM	66.0% @1.0uM		
B-1182	72.0%@1.0uM	0.65uM		
B-1183	77.0%@1.0uM	0.2uM		
B-1184	69.0%@1.0uM	0.63uM		
B-1185	71.0%@1.0uM	0.79uM		
B-1186	83.0%@1.0uM	60.0% @1.0uM		

Example#	P38 alpha kinase IC50,uM or % inhib@conc. (uM)	U937 Cell IC50,uM or % inhib@conc. (uM)	Mouse LPS Model % TNF inhib @ dose @predose time	Rat LPS Model % inhib @dose @predose time
B-1187	76.0%@1.0uM	1.89uM		
B-1188	-	36.0%@1.0uM		
B-1189	68.0%@1.0uM	0.83uM		
B-1190	78.0%@1.0uM	62.0%@1.0uM		
B-1191	74.0%@1.0uM	57.0%@1.0uM		
B-1192	84.0%@1.0uM	0.47uM		
B-1193	69.0%@1.0uM	65.0%@1.0uM		
B-1194	87.0%@1.0uM	0.58uM		
B-1195	52.0%@1.0uM	60.0%@1.0uM		
B-1196	74.0%@1.0uM	68.0%@1.0uM		
B-1197	77.0%@1.0uM	45.0%@1.0uM		
B-1198	92.0%@1.0uM	0.46uM		
B-1199	87.0%@1.0uM	49.0%@1.0uM		
B-1200	95.0%@1.0uM	0.64uM		
B-1201	84.0%@1.0uM	0.51uM		
B-1202	71.0%@1.0uM	58.0%@1.0uM		
B-1203	84.0%@1.0uM	58.0%@1.0uM		
B-1204	68.0%@1.0uM	59.0%@1.0uM		
B-1205	74.0%@1.0uM	46.0%@1.0uM		
B-1206	81.0%@1.0uM	0.34uM		
B-1207	90.0%@1.0uM	58.0%@1.0uM		
B-1208	82.0%@1.0uM	51.0%@1.0uM		
B-1209	86.0%@1.0uM	55.0%@1.0uM		
B-1210	82.0%@1.0uM	57.0%@1.0uM		
B-1211	88.0%@1.0uM	59.0%@1.0uM		
B-1212	90.0%@1.0uM	57.0%@1.0uM		
B-1213	84.0%@1.0uM	0.62uM		
B-1214	76.0%@1.0uM	58.0%@1.0uM		
B-1215	86.0%@1.0uM	0.23uM		
B-1216	88.0%@1.0uM	0.18uM		
B-1217	87.0%@1.0uM	0.46uM		
B-1218	88.0%@1.0uM	76.0%@1.0uM		
B-1219	85.0%@1.0uM	37.0%@1.0uM		
B-1220	81.0%@1.0uM	53.0%@1.0uM		
B-1221	82.0%@1.0uM	44.0%@1.0uM		
B-1222	65.0%@1.0uM	9.0%@1.0uM		
B-1223	80.0%@1.0uM	61.0%@1.0uM		
B-1224	82.0%@1.0uM	74.0%@1.0uM		
B-1225	89.0%@1.0uM	73.0%@1.0uM		
B-1226	89.0%@1.0uM	0.18uM		
B-1227	83.0%@1.0uM	0.22uM		
B-1228	90.0%@1.0uM	0.72uM		
B-1229	87.0%@1.0uM	0.65uM		
B-1230	90.0%@1.0uM	0.25uM		
B-1231	94.0%@1.0uM	0.56uM		
B-1232	81.0%@1.0uM	54.0%@1.0uM		
B-1233	85.0%@1.0uM	0.36uM		
B-1234	89.0%@1.0uM	0.49uM		
B-1235	0.04uM	76.0%@1.0uM		

Example#	P38 alpha kinase IC50,uM or % inhib@conc. (uM)	U937 Cell IC50,uM or % inhib@conc. (uM)	Mouse LPS Model % TNF inhib @ dose @predose time	Rat LPS Model % inhib @dose @predose time
B-1236	0.1uM	53.0%@1.0uM		
B-1237	0.22uM	39.0%@1.0uM		
B-1238	0.14uM	16.0%@1.0uM		
B-1239	<0.1uM	38.0%@1.0uM		
B-1240	<0.1uM	59.0%@1.0uM		
B-1241	0.04uM	81.0%@1.0uM		
B-1242	0.08uM	83.0%@1.0uM		
B-1243	0.04uM	47.0%@1.0uM		
B-1244	0.26uM	44.0%@1.0uM		
B-1245	0.49uM	42.0%@1.0uM		
B-1246	0.27uM	40.0%@1.0uM		
B-1247	<0.1uM	58.0%@1.0uM		
B-1248	<0.1uM	68.0%@1.0uM		
B-1249	0.24uM	60.0%@1.0uM		
B-1250	0.14uM	18.0%@1.0uM		
B-1251	0.41uM	38.0%@1.0uM		
B-1252	0.17uM	46.0%@1.0uM		
B-1253	0.15uM	57.0%@1.0uM		
B-1254	0.16uM	68.0%@1.0uM		
B-1255	12.9uM	75.0%@1.0uM		
B-1256	0.12uM	41.0%@1.0uM		
B-1257	1.48uM	40.0%@1.0uM		
B-1258	0.07uM	56.0%@1.0uM		
B-1259	<0.1uM	0.48uM		
B-1260	0.11uM	48.0%@1.0uM		
B-1261	0.74uM	44.0%@1.0uM		
B-1262	<0.1uM	63.0%@1.0uM		
B-1263	1.05uM	57.0%@1.0uM		
B-1264	0.32uM	47.0%@1.0uM		
B-1265	0.43uM	51.0%@1.0uM		
B-1266	<0.1uM	58.0%@1.0uM		
B-1267	<0.1uM	73.0%@1.0uM		
B-1268	<0.1uM	79.0%@1.0uM		
B-1269	0.46uM	84.0%@1.0uM		
B-1270	0.47uM	83.0%@1.0uM		
B-1271	0.13uM	74.0%@1.0uM		
B-1272	0.014uM	38.0%@1.0uM		
B-1273	<0.1uM	36.0%@1.0uM		
B-1274	<0.1uM	41.0%@1.0uM		
B-1275	<0.1uM	50.0%@1.0uM		
B-1276	0.062uM	11.0%@1.0uM		
B-1277	<0.1uM	47.0%@1.0uM		
B-1278	0.12uM	85.0%@1.0uM		
B-1279	<0.1uM	79.0%@1.0uM		
B-1280	0.039uM	83.0%@1.0uM		
B-1281	<0.1uM	85.0%@1.0uM		
B-1282	<0.1uM	75.0%@1.0uM		
B-1283	<0.1uM	64.0%@1.0uM		
B-1284	<0.1uM	75.0%@1.0uM		

Example#	P38 alpha kinase IC50,uM or % inhib@conc. (uM)	U937 Cell IC50,uM or % inhib@conc. (uM)	Mouse LPS Model % TNF inhib @ dose @predose time	Rat LPS Model % inhib @dose @predose time
B-1285	0.057uM	80.0%@1.0uM		
B-1286	0.15uM	78.0% ²¹ .0uM		
B-1287	0.25uM	55.0%@1.0uM		
B-1288	0.15uM	74.0%@1.0uM		
B-1289	0.73uM	35.0%@1.0uM		
B-1290	0.26uM	75.0%@1.0uM		
B-1291	0.097uM	55.0%@1.0uM		
B-1292	0.01uM	74.0%@1.0uM		
B-1293	0.31uM	48.0%@1.0uM		
B-1294	0.013uM	54.0%@1.0uM		
B-1295	0.079uM	74.0%@1.0uM		
B-1296	0.038uM	48.0%@1.0uM		
B-1297	0.02uM	>1.0uM		
B-1298	0.055uM	20.0%@1.0uM		
B-1299	0.091uM	>1.0uM		
B-1300	0.071uM	18.0%@1.0uM		
B-1301	0.12uM	15.0%@1.0uM		
B-1302	0.023uM	11.0%@1.0uM		
B-1303	0.08uM	>1.0uM		
B-1304	0.11uM	10.0%@1.0uM		
B-1305	0.64uM	9.0%@1.0uM		
B-1306	0.11uM	>1.0uM		
B-1307	0.009uM	16.0%@1.0uM		
B-1308	<0.1uM	>1.0uM		
B-1309	0.045uM	>1.0uM		
B-1310	0.12uM	11.0%@1.0uM		
B-1311	0.05uM	57.0%@1.0uM		
B-1312	0.35uM	>1.0uM		
B-1313	0.035uM	37.0%@1.0uM		
B-1314	0.045uM	24.0%@1.0uM		
B-1315	0.055uM	12.0%@1.0uM		
B-1316	0.026uM	36.0%@1.0uM		
B-1317	0.019uM	9.0%@1.0uM		
B-1318	<0.1uM	1.0%@1.0uM		
B-1319	0.24uM	>1.0uM		
B-1320	0.047uM	43.0%@1.0uM		
B-1321	0.47uM	66.0%@1.0uM		
B-1322	0.12uM	87.0%@1.0uM		
B-1323	0.013uM	85.0%@1.0uM		
B-1324	0.16uM	83.0%@1.0uM		
B-1325	0.27uM	95.0%@1.0uM		
B-1326	0.092uM	84.0%@1.0uM		
B-1327	0.13uM	65.0%@1.0uM		
B-1328	0.032uM	86.0%@1.0uM		
B-1329	0.66uM	54.0%@1.0uM		
B-1330	0.053uM	85.0%@1.0uM		
B-1331	0.004uM	85.0%@1.0uM		
B-1332	0.007uM	81.0%@1.0uM		
B-1333	0.45uM	76.0%@1.0uM		

Example#	P38 alpha kinase IC50,uM or % inhib@conc. (uM)	U937 Cell IC50,uM or % inhib@conc. (uM)	Mouse LPS Model % TNF inhib @ dose @predose time	Rat LPS Model % inhib @dose @predose time
B-1334	0.13uM	73.0%@1.0uM		
B-1335	0.097uM	63.0%@1.0uM		
B-1336	0.072uM	83.0%@1.0uM		
B-1337	0.4uM	90.0%@1.0uM		
B-1338	0.18uM	73.0%@1.0uM		
B-1339	0.12uM	67.0%@1.0uM		
B-1340	0.043uM	63.0%@1.0uM		
B-1341	0.42uM	52.0%@1.0uM		
B-1342	0.25uM	59.0%@1.0uM		
B-1343	0.065uM	83.0%@1.0uM		
B-1344	0.014uM	86.0%@1.0uM		
B-1345	0.27uM	73.0%@1.0uM		
B-1346	0.043uM	86.0%@1.0uM		
B-1347	0.021uM	84.0%@1.0uM		
B-1348	0.009uM	69.0%@1.0uM		
B-1349	0.037uM	86.0%@1.0uM		
B-1350	0.019uM	78.0%@1.0uM		
B-1351	0.068uM	78.0%@1.0uM		
B-1352	0.013uM	76.0%@1.0uM		
B-1353	0.062uM	80.0%@1.0uM		
B-1354	0.013uM	83.0%@1.0uM		
B-1355	0.07uM	75.0%@1.0uM		
B-1356	0.059uM	91.0%@1.0uM		
B-1357	0.18uM	84.0%@1.0uM		
B-1358	0.16uM	76.0%@1.0uM		
B-1359	0.005	84.0%@1.0uM		
B-1360	0.11	0.15uM		54%@3mpk@-4h
B-1361	0.03	0.29uM		
B-1362	0.003	0.29uM		
B-1363	0.009	0.28uM	51.0%@30pmk @-6H	53%@3mpk@-4h
B-1364	0.009	0.27uM	53.0%@30mpk@-6.0H	17%@3mpk@-4h
B-1365	0.17	88.0%@1.0uM		
B-1366	0.04	0.27uM		
B-1367	<0.1	0.22uM		
B-1368	0.031	0.33uM	44.0%@30mpk @-	
B-1369	<0.1	0.29uM		
B-1370	<0.1	0.77uM		
B-1371	0.06	83.0%@1.0uM		
B-1372	<0.1	0.41uM	48.0%@30mpk @-	
B-1373	0.016	0.17uM		
B-1374	<0.1	0.28uM		
B-1375	0.01	0.25uM		
B-1376	0.009	0.26uM	3.0%@30mpk @-6H	
B-1377	0.12	5.0uM		
B-1378	0.02	1.04uM		
B-1379	<0.1	0.092uM		
B-1380	<0.1	0.26uM		

Example#	P38 alpha kinase IC50,uM or % inhib@conc. (uM)	U937 Cell IC50,uM or % inhib@conc. (uM)	Mouse LPS Model % TNF inhib @ dose @predose time	Rat LPS Model % inhib @dose @predose time
B-1381	0.055	0.73uM		
B-1382	<0.1	0.44uM		
B-1383	0.0012	0.15uM		
B-1384	0.57	0.37uM		
B-1385	<0.1	0.11uM		
B-1386	<0.1	0.25uM		
B-1387	<0.1	0.1uM		
B-1388	0.57	1.38uM		
B-1389	0.06	0.57uM		
B-1390	<0.1	71.0%@1.0uM		
B-1391	0.016uM	82.0%@1.0uM		
B-1392	0.059uM	82.0%@1.0uM		
B-1393	3.17uM	80.0%@1.0uM		
B-1394	0.32uM	78.0%@1.0uM		
B-1395	1.48	61.0%@1.0uM		
B-1396	1.55	73.0%@1.0uM		
B-1397	0.92	85.0%@1.0uM		
B-1398	0.67	83.0%@1.0uM		
B-1399	0.14	74.0%@1.0uM		
B-1400	0.024	83.0%@1.0uM		
B-1401	0.033	75.0%@1.0uM		
B-1402	0.12	76.0%@1.0uM		
B-1403	4.54	71%@1.0uM		
B-1404	0.6	70%@1.0uM		
B-1405	0.28	70%@1.0uM		
B-1406	1.39	56.0%@1.0uM		
B-1407	0.4	71.0%@1.0uM		
B-1408	0.27	69.0%@1.0uM		
B-1409	<0.1	72.0%@1.0uM		
B-1410	<0.1	69%@1.0uM		
B-1411	<0.1	81.0%@1.0uM		
B-1412	0.097	80.0%@1.0uM		
B-1413	0.016	78.0%@1.0uM		
B-1414	0.025	83.0%@1.0uM		
B-1415	1.41	79.0%@1.0uM		
B-1416	0.14	81.0%@1.0uM		
B-1417	0.069	69.0%@1.0uM		
B-1418	1.01	82.0%@1.0uM		
B-1419	0.3	84.0%@1.0uM		
B-1420	<0.1	82.0%@1.0uM		
B-1421	0.014	75.0%@1.0uM		
B-1422	0.58	68.0%@1.0uM		
B-1423	1.58	84.0%@1.0uM		
B-1424	0.86	76.0%@1.0uM		
B-1425	0.09	83.0%@1.0uM		
B-1426	0.19	80.0%@1.0uM		
B-1427	<0.1	84.0%@1.0uM		
B-1428	<0.1	86.0%@1.0uM		
B-1429	<0.1	87.0%@1.0uM		

Example#	P38 alpha kinase IC50,uM or % inhib@conc. (uM)	U937 Cell IC50,uM or % inhib@conc. (uM)	Mouse LPS Model % TNF inhib @ dose @predose time	Rat LPS Model % inhib @dose @predose time
B-1430	0.75uM	35.0% @1.0uM		
B-1431	0.36uM	58.0% @1.0uM		
B-1432	0.11uM	51.0% @1.0uM		
B-1433	0.26uM	21.0% @1.0uM		
B-1434	0.19uM	28.0% @1.0uM		
B-1435	1.8uM	45.0% @1.0uM		
B-1436	1.0uM	20.0% @1.0uM		
B-1437	0.3uM	23.0% @1.0uM		
B-1438	2.01uM	27.0% @1.0uM		
B-1439	1.7uM	17.0% @1.0uM		
B-1440	0.87uM	3.0% @1.0uM		
B-1441	1.95uM	66.0% @1.0uM		
B-1442	1.54uM	18.0% @1.0uM		
B-1443	0.014uM	83.0% @1.0uM		
B-1444	0.3uM	24.0% @1.0uM		
B-1445	0.43uM	27.0% @1.0uM		
B-1446	0.77uM	36.0% @1.0uM		
B-1447	0.5uM	34.0% @1.0uM		
B-1448	1.43uM	22.0% @1.0uM		
B-1449	1.61uM	50.0% @1.0uM		
B-1450	2.1uM	49.0% @1.0uM		
B-1451	2.88uM	50% @1.0uM		
B-1452	2.41uM	47.0% @1.0uM		
B-1453	2.53uM	49.0% @1.0uM		
B-1454	1.6uM	12.0% @1.0uM		
B-1455	1.21uM	8.0% @1.0uM		
B-1456	1.29uM	>1.0uM		
B-1457	0.43uM	43.0% @1.0uM		
B-1458	0.95uM	65.0% @1.0uM		
B-1459	0.67uM	46.0% @1.0uM		
B-1460	0.96uM	29.0% @1.0uM		
B-1461	0.4uM	39.0% @1.0uM		
B-1462	0.22uM	50.0% @1.0uM		
B-1463	2.34uM	26.0% @1.0uM		
B-1464	1.18uM	27.0% @1.0uM		
B-1465	3.23uM	31.0% @1.0uM		
B-1466	1.69uM	>1.0uM		
B-1467	1.22uM	1.0% @1.0uM		
B-1468	1.61uM	10.0% @1.0uM		
B-1469	0.37uM	14.0% @1.0uM		
B-1470	0.6uM	28.0% @1.0uM		
B-1471	0.85uM	25.0% @1.0uM		
B-1472	0.93uM	12.0% @1.0uM		
B-1473	1.24uM	14.0% @1.0uM		
B-1474	1.23uM	31.0% @1.0uM		
B-1475	2.1uM	24.0% @1.0uM		
B-1476	0.047uM	42.0% @1.0uM		
B-1477	2.5uM	34.0% @1.0uM		
B-1478				

	P38 alpha kinase IC50,uM or % inhib@conc. (uM)	U937 Cell IC50,uM or % inhib@conc. (uM)	Mouse LPS Model % TNF Inhib @ dose @predose time	Rat LPS Model % inhib @dose @predose time
Example#				
B-1479				

Example#	P38 alpha kinase IC50,uM or % inhib@conc. (uM)	U937 Cell IC50,uM or % inhib@conc. (uM)	Mouse LPS Model % TNF inhib @ dose @predose time	Rat LPS Model % inhib @dose @predose time
B-2270	0.72uM	31%@10.0uM		
B-2271	0.93uM	38%@10.0uM		
B-2272	0.26uM	53.0%@10.0uM		
B-2273	1.92uM	39.0%@10.0uM		
B-2274	0.26uM	59.0%@10.0uM		
B-2275	2.16uM	53.0%@10.0uM		
B-2276	11.5uM	37.0%@10.0uM		
B-2277	14.9uM	44.0%@10.0uM		
B-2278	0.8uM	51.0%@10.0uM		
B-2279	0.32uM	36.0%@10.0uM		
B-2280	0.4uM	57.0%@10.0uM		
B-2281	0.81uM	60.0%@10.0uM		
B-2282	0.91uM	41.0%@10.0uM		
B-2283	0.04uM	53.0%@10.0uM		
B-2284	4.61uM	62.0%@10.0uM		
B-2285	2.29uM	49.0%@10.0uM		
B-2286	0.017uM	0.78uM	25%@30mpk@-1h	
B-2287	2.56uM	61.0%@10.0uM		
B-2288	6.51uM	46.0%@10.0uM		
B-2289	3.0uM	30.0%@10.0uM		
B-2290	2.37uM	59.0%@10.0uM		
B-2291	0.019uM	41%@10.0uM		
B-2292	8.82uM	57.0%@10.0uM		
B-2293	2.11uM	56.0%@10.0uM		
B-2294	1.68uM	50.0%@10.0uM		
B-2295	1.79uM	56.0%@10.0uM		
B-2296	17.3uM	63.0%@10.0uM		
B-2297	3.59uM	57.0%@10.0uM		
B-2298	0.29uM	4.22uM		
B-2299	1.97uM	62.0%@10.0uM		
B-2300	0.07uM	43.0%@10.0uM		
B-2301	0.18uM	44.0%@10.0uM		
B-2302	1.0uM	58.0%@1.0uM		
B-2303	0.011uM	54.0%@10.0uM		
B-2304	1.41uM	50.0%@10.0uM		
B-2305	0.54uM	60.0%@10.0uM		
B-2306	5.88uM	39.0%@10.0uM		
B-2307	2.29uM	69.0%@10.0uM		
B-2308	0.66uM	56.0%@10.0uM		
B-2309	0.29uM	47.0%@10.0uM		

Example#	P38 alpha kinase IC50,uM or % inhib@conc. (uM)	U937 Cell IC50,uM or % inhib@conc. (uM)	Mouse LPS Model % TNF inhib @ dose @predose time	Rat LPS Model % inhib @dose @predose time
B-2310	0.12uM	1.2uM	50%@30mpk@-6h	
B-2311	7.18uM	60.0%@10.0uM		
B-2312	2.93uM	43.0%@10.0uM		
B-2313	42.3uM	58.0%@10.0uM		
B-2314	11.0uM	66.0%@10.0uM		
B-2315	0.49uM	36.0%@10.0uM		
B-2316	0.46uM	58.0%@10.0uM		
B-2317	1.0uM	60.0%@10.0uM		
B-2318	73.0%@10.0uM	25.0%@10.0uM		
B-2319	75.0%@10.0uM	40.0%@10.0uM		
B-2320	44.0%@10.0uM	35.0%@10.0uM		
B-2321	69.0%@10.0uM	27.0%@10.0uM		
B-2322	76.0%@10.0uM	38.0%@10.0uM		
B-2323	69.0%@10.0uM	46.0%@10.0uM		
B-2324	58.0%@10.0uM	36.0%@10.0uM		
B-2325	60.0%@10.0uM	51.0%@10.0uM		
B-2326	76.0%@10.0uM	33.0%@10.0uM		
B-2327	76.0%@10.0uM	23.0%@10.0uM		
B-2328	65.0%@10.0uM	28.0%@10.0uM		
B-2329	72.0%@10.0uM	53.0%@10.0uM		
B-2330	81.0%@10.0uM	37.0%@10.0uM		
B-2331	74.0%@10.0uM	44.0%@10.0uM		
B-2332	70.0%@10.0uM	47.0%@10.0uM		
B-2333	58.0%@10.0uM	36.0%@10.0uM		
B-2334	81.0%@10.0uM	45.0%@10.0uM		
B-2335	82.0%@10.0uM	50.0%@10.0uM		
B-2336	48.0%@10.0uM	35.0%@10.0uM		
B-2337	46.0%@10.0uM	59.0%@10.0uM		
B-2338	73.0%@10.0uM	50.0%@10.0uM		
B-2339	84.0%@10.0uM	>10.0uM		
B-2340	35.0%@10.0uM	12.0%@10.0uM		
B-2341	75.0%@10.0uM	50.0%@10.0uM		
B-2342	83.0%@10.0uM	46.0%@10.0uM		
B-2343	43.0%@10.0uM	27.0%@10.0uM		
B-2344	71.0%@10.0uM	50.0%@10.0uM		
B-2345	64.0%@10.0uM	38.0%@10.0uM		
B-2346	45.0%@10.0uM	48.0%@10.0uM		
B-2347	49.0%@10.0uM	50.0%@10.0uM		
B-2348	76.0%@10.0uM	48.0%@10.0uM		
B-2349	75.0%@10.0uM	27.0%@10.0uM		

Example#	P38 alpha kinase IC50,uM or % inhib@conc. (uM)	U937 Cell IC50,uM or % inhib@conc. (uM)	Mouse LPS Model % TNF inhib @ dose @predose time	Rat LPS Model % Inhib @dose @predose time
B-2350	38.0%@10.0uM	56.0%@10.0uM		
B-2351	77.0%@10.0uM	1.0%@10.0uM		
B-2352	37.0%@10.0uM	19.0%@10.0uM		
B-2353	38.0%@10.0uM	33.0%@10.0uM		
B-2354	65.0%@10.0uM	25.0%@10.0uM		
B-2355	84.0%@10.0uM	50.0%@10.0uM		
B-2356	77.0%@10.0uM	45.0%@10.0uM		
B-2357	47.0%@10.0uM	41.0%@10.0uM		
B-2358	17.0%@10.0uM	52.0%@10.0uM		
B-2359	76.0%@10.0uM	35.0%@10.0uM		
B-2360	45.0%@10.0uM	>10.0uM		
B-2361	19.0%@10.0uM	46.0%@10.0uM		
B-2362	60%@100.0uM	39.0%@10.0uM		
B-2363	44.0%@10.0uM	1.0%@10.0uM		
B-2364	47.0%@10.0uM	4.0%@10.0uM		
B-2365	82.0%@10.0uM	43.0%@10.0uM		
B-2366	70.0%@10.0uM	59.0%@10.0uM		
B-2367	46.0%@10.0uM	40.0%@1.0uM		
B-2368	65.0%@10.0uM	55.0%@10.0uM		
B-2369	32.0%@10.0uM	>10.0uM		
B-2370	73%@100.0uM	20.0%@10.0uM		
B-2371	54.0%@10.0uM	36.0%@10.0uM		
B-2372	55.0%@100.0uM	>10.0uM		
B-2373	50.0%@100.0uM	6%@10.0uM		
B-2374	35.0%@10.0uM	20.0%@10.0uM		
B-2375	62.0%@100.0uM	>10.0uM		
B-2376	32.0%@10.0uM	17.0%@10.0uM		
B-2377	34.0%@10.0uM	17.0%@10.0uM		
B-2378	48.0%@10.0uM	61.0%@10.0uM		
B-2379	73.0%@100.0uM	45.0%@1.0uM		
B-2380	81%@100.0uM	53.0%@10.0uM		
B-2381	68%@100.0uM	2.0%@10.0uM		
B-2382	51.0%@10.0uM	24.0%@10.0uM		
B-2383	63.0%@10.0uM	35.0%@10.0uM		
B-2384	49%@100.0uM	10.0%@10.0uM		
B-2385	79.0%@10.0uM	19.0%@10.0uM		
B-2386	38.0%@10.0uM	19.0%@10.0uM		
B-2387	50.0%@100.0uM	>10.0uM		
B-2388	42.0%@10.0uM	24.0%@10.0uM		
B-2389	39.0%@10.0uM	29.0%@10.0uM		

Example#	P38 alpha kinase IC50,uM or % inhib@conc. (uM)	U937 Cell IC50,uM or % inhib@conc. (uM)	Mouse LPS Model % TNF inhib @ dose @predose time	Rat LPS Model % inhib @dose @predose time
B-2390	34.0%@10.0uM	27.0%@1.0uM		
B-2391	40.0%@10.0uM	59.0%@10.0uM		
B-2392	63.0%@10.0uM	46.0%@10.0uM		
B-2393	43.0%@10.0uM	>10.0uM		
B-2394	37.0%@10.0uM	22.0%@10.0uM		
B-2395	32.0%@10.0uM	28.0%@10.0uM		
B-2396	75.0%@10.0uM	>10.0uM		
B-2397	83.0%@10.0uM	22.0%@10.0uM		
B-2398	55%@100.0uM	10.0%@10.0uM		
B-2399	69.0%@10.0uM	18.0%@10.0uM		
B-2400	60.0%@10.0uM	40.0%@10.0uM		
B-2401	78.0%@10.0uM	44.0%@10.0uM		
B-2402	43.0%@10.0uM	52.0%@10.0uM		
B-2403	72%@100.0uM	52.0%@10.0uM		
B-2404	58%@100.0uM	52.0%@10.0uM		
B-2405	47%@100.0uM	>10.0uM		
B-2406	45.0%@10.0uM	24.0%@10.0uM		
B-2407	47%@100.0uM	27.0%@10.0uM		
B-2408	39.0%@10.0uM	10.0%@10.0uM		
B-2409	78.0%@10.0uM	26.0%@10.0uM		
B-2410	33.0%@10.0uM	32.0%@10.0uM		
B-2411	26%@100.0uM	13.0%@10.0uM		
B-2412	40.0%@10.0uM	31.0%@10.0uM		
B-2413	75.0%@10.0uM	37.0%@10.0uM		
B-2414	86.0%@10.0uM	38.0%@10.0uM		
B-2415	94.0%@10.0uM	50.0%@10.0uM		
B-2416	85.0%@10.0uM	43.0%@1.0uM		
B-2417	83.0%@10.0uM	18.0%@10.0uM		
B-2418	88.0%@10.0uM	34.0%@10.0uM		
B-2419	86.0%@10.0uM	66.0%@10.0uM		
B-2420	70.0%@10.0uM	34.0%@10.0uM		
B-2421	89.0%210.0uM	38.0%@10.0uM		
B-2422	90.0%@10.0uM	17.0%@10.0uM		
B-2423	85.0%@10.0uM	>10.0uM		
B-2424	86.0%@10.0uM	43.0%@10.0uM		
B-2425	79.0%@10.0uM	42.0%@10.0uM		
B-2426	88.0%@10.0uM	53.0%@10.0uM		
B-2427	87.0%@10.0uM	59.0%@10.0uM		
B-2428	82.0%@10.0uM	50.0%@10.0uM		
B-2429	92.0%@10.0uM	32.0%@10.0uM		

Example#	P38 alpha kinase IC50,uM or % inhib@conc. (uM)	U937 Cell IC50,uM or % inhib@conc. (uM)	Mouse LPS Model % TNF inhib @ dose @predose time	Rat LPS Model % Inhib @dose @predose time
B-2430	90.0% @ 10.0uM	61.0% @ 10.0uM		
B-2431	85.0% @ 10.0uM	68.0% @ 10.0uM		
B-2432	86.0% @ 10.0uM	40.0% @ 10.0uM		
B-2433	94.0% @ 10.0uM	84.0% @ 10.0uM		
B-2434	92.0% @ 10.0uM	63.0% @ 10.0uM		
B-2435	84.0% @ 10.0uM	4.0% @ 10.0uM		
B-2436	80.0% @ 10.0uM	54.0% @ 10.0uM		
B-2437	82.0% @ 10.0uM	41.0% @ 10.0uM		
B-2438	75.0% @ 10.0uM	40.0% @ 10.0uM		
B-2439	81.0% @ 10.0uM	44.0% @ 10.0uM		
B-2440	77.0% @ 10.0uM	78.0% @ 10.0uM		
B-2441	86.0% @ 10.0uM	46.0% @ 10.0uM		
B-2442	86.0% @ 10.0uM	>10.0uM		
B-2443	84.0% @ 10.0uM	44.0% @ 10.0uM		
B-2444	89.0% @ 10.0uM	7.0% @ 10.0uM		
B-2445	94.0% @ 10.0uM	15.0% @ 10.0uM		
B-2446	90.0% @ 10.0uM	28.0% @ 10.0uM		
B-2447	94.0% @ 10.0uM	>10.0uM		
B-2448	75.0% @ 10.0uM	30.0% @ 10.0uM		
B-2449	86.0% @ 10.0uM	42.0% @ 10.0uM		
B-2450	87.0% @ 10.0uM	46.0% @ 1.0uM		
B-2451	87.0% @ 10.0uM	45.0% @ 10.0uM		
B-2452	89.0% @ 10.0uM	33.0% @ 10.0uM		
B-2453	91.0% @ 10.0uM	>10.0uM		
B-2454	88.0% @ 10.0uM	40.0% @ 10.0uM		
B-2455	87.0% @ 10.0uM	54.0% @ 10.0uM		
B-2456	86.0% @ 10.0uM	53.0% @ 10.0uM		
B-2457	90.0% @ 10.0uM	18.0% @ 10.0uM		
B-2458	83.0% @ 10.0uM	36.0% @ 10.0uM		
B-2459	82.0% @ 10.0uM	81.0% @ 10.0uM		
B-2460	80.0% @ 10.0uM	79.0% @ 10.0uM		
B-2461	67.0% @ 10.0uM	59.0% @ 10.0uM		

Biological data from a number of compounds of Examples C-74 through C-139 are shown in the following tables.

In vitro P38-alpha kinase inhibitory data are shown in the column identified as:

"P38 alpha kinase IC50, μ M"

In vitro human whole blood assay data for measuring the ability of the compounds to inhibit TNF production in human whole blood stimulated with LPS are shown in the column identified as:

"Human Whole Blood IC50, μ M or %Inhib@conc. (μ M)"

In vivo assessment of the ability of the compounds to inhibit LPS-stimulated TNF release in the rat is shown in the column identified as:

"Rat LPS Model % Inhibition@dose@predose time"

wherin the dose is milligram per kilogram (mpk) administered by oral gavage and the predose time indicates the number of hours before LPS challenge when the compound is administered.

Example#	P38 alpha kinase IC50, μ M	Human Whole Blood IC50, μ M or %Inhib@conc. (μ M)	Rat LPS Model % Inhibition@ dose@predose time
C-74	0.037	0.56	54%@5mpk@-4h
C-75	0.045	0.4	71%@5mpk@-4h
C-76	0.07	3.24	66%@5mpk@-4h
C-77	0.071	8.2	92%@5mpk@-4h
C-78	0.068	10.5	87%@5mpk@-4h
C-79	0.045	0.52	83%@5mpk@-4h

1052

Example#	P38 alpha kinase IC50, μM	Human Whole Blood IC50, μM or %Inhib@conc. (μM)	Rat LPS Model % Inhibition@ dose@predose time
C-80	0.008	51% @ 5 μM	
C-81	0.037	40% @ 5 μM	
C-82	0.15	7.31	
C-83	0.24	1.23	25% @ 5mpk @ -4h
C-84	0.048	0.88	22% @ 5mpk @ -4h
C-85	0.57	>25	
C-86	0.007	0.19	66% @ 5mpk @ -4h
C-87	0.027	0.34	
C-88	0.012	0.3	59% @ 5mpk @ -4h
C-89	0.039	0.12	27% @ 5mpk @ -4h
C-90	0.037	0.48	
C-91	0.054	2.31	63% @ 5mpk @ -4h
C-92	0.024	0.28	66% @ 5mpk @ -4h
C-93	0.009	0.38	50% @ 5mpk @ -4h
C-94	0.02	0.27	73% @ 5mpk @ -4h
C-95	0.13	3.91	32% @ 5mpk @ -4h
C-96	0.077	2.1	38% @ 5mpk @ -4h
C-97	0.025	3.83	21% @ 5mpk @ -4h
C-98	0.016	0.64	78% @ 5mpk @ -4h
C-99	0.062	0.38	36% @ 5mpk @ -4h
C-100	0.027	0.27	44% @ 5mpk @ -4h
C-101	0.083	3.71	52% @ 5mpk @ -4h
C-102	0.29	7.56	72% @ 5mpk @ -4h
C-105	0.033	0.13	46% @ 5mpk @ -4h
C-106	0.026	0.44	23% @ 5mpk @ -4h
C-107	0.014	0.38	11% @ 5mpk @ -4h
C-108	0.02	0.73	0% @ 5mpk @ -4h
C-111	0.21	6.05	39% @ 5mpk @ -4h
C-112	0.54	6.36	89% @ 5mpk @ -4h
C-113	0.082	2.72	77% @ 5mpk @ -4h
C-114	0.11	1.73	39% @ 5mpk @ -4h
C-115	0.042	10.2	39% @ 5mpk @ -4h
C-116	0.429	0.50	53% @ 5mpk @ -4h
C-117	3.42	7.26	71% @ 5mpk @ -4h
C-118	0.298	>25	39% @ 5mpk @ -4h
C-120	0.7	18.6	26% @ 5mpk @ -4h
C-121	0.11	15.3	39% @ 5mpk @ -4h
C-122	0.025		55% @ 5mpk @ -4h
C-123	0.67	>25.0	

1053

Example#	P38 alpha kinase IC50, μM	Human Whole Blood IC50, μM or %Inhib@conc. (μM)	Rat LPS Model % Inhibition@ dose@predose time
C-124	0.17	4.56	51%@20mpk@-4h
C-125	7.22	>25.0	
C-126	0.71	>25.0	6%@20mpk@-4h
C-127	0.038	0.27	53%@5mpk@-4h
C-128	0.09	2.22	63%@5mpk@-4h
C-132	0.086	44%@ 5 μM	
C-133	0.16	4.54	55%@5mpk@-4h
C-135	6.0		
C-136	0.032		
C-137	0.051		58%@5mpk@-4h
C-138	0.28	0.68	26%@5mpk@-4h
C-139	0.2	3.66	46%@5mpk@-4h


C-3015/2

1054

Additional compounds of interest can be prepared as set forth above and as described below in Scheme D-1, wherein the R_1 and R_2 substituents are as defined previously.

5

Scheme D-1



The synthesis begins with the treatment of 4-methylpyrimidine 2 with a base such as LiHMDS, LDA or tBuOK in an organic solvent such as THF or ether which is cooled in an ice bath (0-10 °C). To the resulting 4-methylanion is added a solution of a suitably protected (Boc is shown) ethyl ester of isonipecotic acid 1 in THF or ether. The reaction is allowed to warm to room

1055

temperature and stirred for a period of 4 hours to 20 hours at which time the desired ketone 3 is isolated after aqueous work up. Condensation of the ketone 3 with tosylhydrazide in toluene or benzene as a solvent at
5 refluxing temperatures for a period of 1 hour to 5 hours affords the hydrazone 4. The hydrazone 4 is reacted with a suitably substituted benzoyl chloride 5, in the presence of a base such as LiHMDS or LDA or tBuOK or triethylamine at temperatures ranging from 0 °C to 70 °C. The reaction
10 is stirred for a period of 3-6 hours. Acidic hydrolysis of the protecting groups with an aqueous acid such as HCl or H₂SO₄ and subsequent neutralization with an aqueous base such as NaOH or KOH affords the desired pyrazole 6. Treatment of the pyrazole 6 with an acid chloride 7 in the
15 presence of base or with an acid 8 under standard peptide coupling conditions (EDC or DCC or PyBrOP with an additive such as HOBT or HATU and base such as N-methylmorpholine or diisopropylethylamine or triethylamine) affords the desired pyrazole amide 9. In most instance the desired
20 products can be obtained pure by direct trituration with solvents such as methanol, ethyl acetate, acetonitrile or ether and/or recrystallization from suitable solvents.


The following examples contain detailed descriptions of the methods of preparation of these additional
25 compounds that form part of the invention. These detailed descriptions are presented for illustrative purposes only and are not intended as a restriction on the scope of the invention. All compounds showed NMR spectra consistent with their assigned structures.

30


Example D-1

1056

N-(2-Hydroxyacetyl)-5-(4-piperidyl)-4-(4-pyrimidyl)-3-(4-chlorophenyl)pyrazole




5




Step 1: A 5 L 4-necked round bottom flask fitted
 10 with an overhead mechanical stirrer, N₂ inlet and a
 thermocouple was charged with 600 g (2.75 mol) of di-tert-
 butyl-dicarbonate and 1.5 L of CH₂Cl₂. The solution was
 cooled to 0 °C and 428 g (2.73 mol) of ethyl isonipecotate
 was added dropwise via an addition funnel. The addition
 15 took 45 minutes and the temperature rose from 0 °C to 17.4
 °C. The reaction mixture was stirred for an additional 2
 hours at ambient temperature. The solvent was removed *in*
vacuo to afford 725 g of a yellow oil (residual solvent
 remained).

20

1057



Step 2: A 3 L 3-necked round bottom flask fitted with an overhead mechanical stirrer, a N₂ inlet, an addition
 5 funnel and a thermocouple was charged with 1850 mL (1.85 mol) of a 1.0 M solution of LiHMDS in THF. The flask was cooled to 5 °C and 68 mL (0.74 mol) of 4-methylpyrimidine was added (neat) to the stirred solution. To this solution was added 198 g (0.77 mol) of Ethyl-N-t-
 10 butylcarbonyl isonipecotate dissolved in 160 mL of THF. The ice bath was removed and the reaction was allowed to stir for 18 hours. The reaction was quenched with 500 mL of saturated NH₄Cl and was extracted with 500 mL of ethyl acetate. The organic phase was washed with 500 mL of
 15 brine, dried over anhydrous Na₂SO₄, filtered and concentrated *in vacuo* to afford 235 g of a brown oil.




20 Step 3: A 2 L 3-necked round bottom flask fitted with an overhead mechanical stirrer, a Dean-Stark trap and

1058

a thermocouple was charged with 1.5 L of toluene, 226 g (0.742 mol) of N-t-butylcarbonyl-1-(4-piperidyl)-2-(4-pyrimidyl)-1-ethanone and 138.4 g (0.743 mol) of tosyl hydrazide. The mixture was warmed to reflux. The solution was allowed to reflux for 2 hours and was cooled to ambient temperature. The reaction was allowed to stand overnight. A fine precipitate formed and was removed by filtration. The filtrate was concentrated in vacuo to afford a brown solid. The solid was suspended in 500 mL of ethyl acetate and the resulting mixture was placed in a sonication bath for 5 hours. The mixture was cooled in an ice bath and was filtered to afford 310 g of a wet solid. The solid was dried in a vacuum oven (40 °C, 5 mm) overnight to afford 248 g of the desired hydrazone (71%).

¹H NMR (CDCl₃) δ 9.03 (d, *J* = 1.2 Hz, 1H), 8.72 (d, *J* = 5.2 Hz, 2H), 7.89 (d, *J* = 8.3 Hz, 2H), 7.32 (d, *J* = 8.1 Hz, 2H), 7.26 (dd, *J* = 5.2, 1.0 Hz, 1H), 4.03 (d, *J* = 12.1 Hz, 2H), 3.76 (s, 2H), 2.71 (t, *J* = 12.1 Hz, 2H), 2.43 (s, 3H), 2.34 (m, 1H), 1.66 (d, *J* = 13.5 Hz, 2H), 1.47 (s, 9H), 1.38 (m, 2H); MS (M + H): 474 (base peak).

Step 4:




1059

Method A. A 2 L 3-necked round bottom flask fitted with an overhead mechanical stirrer, a N₂ inlet, an addition funnel and a thermocouple was charged with 400 mL (400 mmol) of a 1.0 M solution of LiHMDS in THF. The solution was cooled to -21.9 °C and a solution of 62 g (131 mmol) of N-*t*-butylcarbonyl-1-(4-piperidyl)-2-(4-pyrimidyl)-1-ethanone *p*-toluenesulfonyl hydrazone in 400 mL of THF was added slowly. The temperature never exceeded -11 °C throughout the addition. The solution was re-cooled to -19.6 °C and 23.0 g (131 mmol in 250 mL of THF) of *p*-chlorobenzoylchloride was added slowly. The temperature never exceeded -13 °C throughout the addition. The cooling bath was removed and the reaction was allowed to warm to ambient temperature. After 3 hours the reaction was quenched with 600 mL of 3 N HCl. The reaction was warmed to reflux and was held at reflux for 2 hours. The reaction was allowed to cool to ambient temperature overnight. The reaction mixture was washed with 1.4 L of Et₂O and the aqueous phase was neutralized with 1 L of 2.5 N NaOH. The aqueous phase was extracted with ethyl acetate (2 x 1000 mL). The combined organic phases were washed with brine (1 x 500 mL), dried over anhydrous Na₂SO₄, filtered and concentrated *in vacuo* to afford 21 g of a yellow solid. The solid was suspended in 500 mL of 2:1 Et₂O/hexane. After sonication the solid was isolated by filtration to leave a wet solid. The solid was dried in a vacuum oven to afford 13.8 g of 5-(4-piperidyl)-4-(4-pyrimidyl)-3-(4-chlorophenyl) pyrazole. ¹H NMR (DMSO-*d*₆) 9.18 (s, 1H), 8.65 (d, *J* = 5.2, 1H), 7.44 (d, *J* = 8.5, 2H), 7.37 (d, *J* = 7.7 Hz, 2H), 7.15 (d,

1060

$J = 5.2$ Hz, 1H), 3.16 (m, 1H), 3.00 (d, $J = 11.9$ Hz, 2H), 2.52 (m, 2H), 1.69 (m, 4H); MS (M + H): 340 (base peak).



5


Method B: To a solution of 200 g (423 mmol) of N-t-butylcarbonyl-1-(4-piperidyl)-2-(4-pyrimidyl)-1-ethanone p-toluenesulfonyl hydrazone in 800 mL THF was added 70 mL (500 mmol) of triethylamine in a 3 L three necked flask. The solution was cooled in an ice/salt/water bath to 0-5 °C. To this cold solution was added a solution of 4-chlorobenzoyl chloride (74 g, 423 mmol) in 100 mL THF dropwise, maintaining the temperature below 10 °C. After the addition was complete the ice-bath was removed and replaced with a heating mantle. 4-N, N-dimethylaminopyridine (5 g, 40 mmol) was added and the reaction mixture was heated to 50 °C for 15-30 minutes. The reaction mixture was filtered and the residue washed

20

1061

with THF (100 mL). The combined filtrates were evaporated under reduced pressure to a semisolid.

The semisolid residue was dissolved in 450 mL THF and 180 mL of 12 N HCl was added to this solution rapidly. The reaction mixture was heated to 65 °C for 1.5-2 hours and transferred to a separatory funnel. The organic layer was discarded and the aqueous phase was washed twice with 200 mL of THF. The aqueous phase was transferred back to a 2 L flask and cooled to 0-10 °C in an ice bath. The pH of the solution was adjusted to between ~ 9-10 by dropwise addition of 15 N ammonium hydroxide (~ 180 mL). This mixture was transferred back to a separatory funnel and extracted with warm n-butanol (3 X 150 mL). The combined n-butanol phases were evaporated under reduced pressure to dryness. The residue was then stirred with methanol (200 mL), filtered and dried to obtain 129 g (90%) of the desired 5-(4-piperidyl)-4-(4-pyrimidyl)-3-(4-chlorophenyl) pyrazole as a off-white solid. This material was identical in all respects to the material prepared by Method A.



Step 5: A 1 L round bottom flask was charged with 34.2 g (102 mmol) of 5-(4-piperidyl)-4-(4-pyrimidyl)-3-(4-chlorophenyl) pyrazole, 500 mL of CH₂Cl₂ and 26.6 mL (153 mmol) of Hunig's base. To this suspension was added 16.5

1062

g (122 mmol) of 1-hydroxybenzotriazole and 8.1 g (106 mmol) of glycolic acid. The addition of glycolic acid was followed by the addition of 23.7 g (122 mmol) of 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride.

5 The reaction was allowed to stir at ambient temperature overnight. The reaction was concentrated *in vacuo* to leave an oily residue. The residue was dissolved in 400 mL of methanol and 50 mL of 2.5 N NaOH. The reaction mixture was stirred at ambient temperature for 1 hour.

10 The mixture was acidified to pH 5 with 2 N HCl and was extracted with CH₂Cl₂ (6 x 200 mL). The combined organic phases were filtered through phase paper and the filtrate was concentrated *in vacuo* to leave a yellow residue. The residue was treated with 75 mL of acetonitrile. A


15 precipitate formed. The solid was filtered and washed with additional acetonitrile and Et₂O to afford 31.4 g of N-(2-hydroxyacetyl)-5-(4-piperidyl)-4-(4-pyrimidyl)-3-(4-chlorophenyl) pyrazole. ¹H NMR (DMSO-d₆) 9.20 (s, 1H), 8.67 (d, *J* = 4.8, 1H), 7.40 (m, 4H), 7.17 (d, *J* = 4.0, 1H), 4.53 (m, 2H), 4.13 (s, 2H), 3.77 (m, 1H), 3.05 (t, *J* = 12.7 Hz, 1H), 2.69 (m, 1H), 1.90 (m, 2H), 1.73 (m, 2H); MS (M + H): 398 (base peak).

Example D-2

25

N-(2-Hydroxyacetyl)-5-(4-piperidyl)-4-(4-pyrimidyl)-3-(4-chlorophenyl)pyrazole hydrochloride

1063




A 25 mL round bottom flask was charged with 65 mg
 5 (0.164 mmol) of N-(2-hydroxyacetyl)-5-(4-piperidyl)-4-(4-
 pyrimidyl)-3-(4-chlorophenyl) pyrazole and 2.5 mL of
 dioxane. To this suspension was added 0.082 mL of 4 N HCl
 in dioxane. The mixture was stirred for 2 hours. The
 mixture was diluted with 5 mL of Et₂O and filtered. The
 10 solid was dried over solid CaSO₄ under vacuum for 12 h to
 afford 68 mg of N-(2-hydroxyacetyl)-5-(4-piperidyl)-4-(4-
 pyrimidyl)-3-(4-chlorophenyl) pyrazole hydrochloride. ¹H
 NMR (DMSO-d₆) 9.18(s, 1H), 8.63(d, J=5.37 Hz, 1H),
 7.40(d, J=8.59 Hz, 2H), 7.33(d, J=8.59 Hz, 2H), 7.15(m,
 1H), 4.40(m, 1H), 4.06(m, 2H), 3.72(m, 1H), 3.33(m, 1H),
 15 2.97(m, 1H), 2.62(m, 1H), 1.83(m, 2H), 1.64(m, 2H); MS
 (M+H): 398

Example D-3

20

N-(2-Methoxyacetyl)-5-(4-piperidyl)-4-(4-pyrimidyl)-3-(4-
 chlorophenyl)pyrazole (fumarate salt)

1064




To a suspension of 250 mg (0.74 mmol) of 5-(4-piperidyl)-4-(4-pyrimidyl)-3-(4-chlorophenyl) pyrazole (Example C-1, Step 3) and 180 mg (1.48 mmol) of N,N-dimethylamino pyridine in 20 mL of CH_2Cl_2 , was added 88 mg (0.81 mmol) of 2-methoxyacetyl chloride. The reaction was stirred for 5 hours. The reaction was quenched with 20 mL of saturated NH_4Cl . The mixture was extracted with n-butyl alcohol and the organic layer was washed with brine. The solvent was removed to afford 72 mg of an oil. This oil was dissolved in 1 mL of warm MeOH. This solution was combined with a warm solution of 1 equivalent of fumaric acid in warm MeOH. The solution was cooled to ambient temperature and the reaction was allowed to stir for 1 hour. The solvent was removed *in vacuo* and the residue was triturated with Et_2O . The resulting solid was isolated by filtration to yield 56 mg of an off-white powder. ^1H NMR ($\text{DMSO}-d_6$) 13.23 (bs, 1H), 9.19 (d, J = 1.2 Hz, 1H), 8.65 (d, J = 5.1 Hz, 1H), 7.41 (m, 4H), 7.16 (dd, J = 5.4, 1.2 Hz, 1H), 4.45 (bd, J = 11.1 Hz, 1H), 4.11 (q_{AB} , J = 39.0, 13.8 Hz, 2H), 3.86 (bd, J = 12.9 Hz, 1H), 3.32 (m, 4H), 3.04 (bt, J = 12.3 Hz, 1H), 2.63 (bt, J = 12.0 Hz, 1H), 1.77 (m, 4H); MS ($M + H$): 411 (base peak).

1065

Example D-4

N-(2-Hydroxy-2-methylpropionyl)-5-(4-piperidyl)-4-(4-pyrimidyl)-3-(4-chlorophenyl)pyrazole hydrochloride

5



Step 1: To a suspension of 2.05 g (6.1 mmol) of 5-(4-piperidyl)-4-(4-pyrimidyl)-3-(4-chlorophenyl) pyrazole (Example C-1, Step 3) and 3.7 g (30.5 mmol) of N,N-dimethylamino pyridine in 30 mL of CH_2Cl_2 was added 1.06 mL (7.3 mmol) of 2-acetoxy-2-methylpropionyl chloride. The reaction was allowed to stir overnight at ambient temperature. The reaction was quenched with saturated NH_4Cl and water. The resulting aqueous phase was extracted with CH_2Cl_2 . The combined organic layers were concentrated *in vacuo* to leave an oily solid. The residue was treated with CH_3CN and allowed to stand for 15 minutes. The resulting suspension was diluted with Et_2O and was filtered to afford 2.2 g of a solid. Analysis by LC/MS indicated that the solid was a mixture of the hydroxy derivative and the acetoxy derivative. This solid was carried on to the next step without further purification.


Step 2: A solution of 1 g of the solid from step 1 in 10 mL of MeOH was treated with 500 mg of solid K_2CO_3 . The mixture was allowed to stir overnight at ambient

1066

temperature. The suspension was treated with water and the resulting solution was extracted with ethyl acetate. The organic phase was filtered through phase separation paper (to remove the residual water) and was concentrated
5 in vacuo to leave an oily solid. The solid was dried under vacuum and was treated with CH_3CN . The suspension was filtered to afford 825 mg of an off-white solid. This solid was suspended in 5 mL of dioxane and 0.5 mL of 4 N HCl in dioxane was added. The suspension was stirred for
10 1 hour and the suspension was filtered to leave a solid. The solid was washed with Et_2O and the resulting suspension was filtered to give 900 mg of the title compound. ^1H NMR ($\text{DMSO}-d_6$) 9.23 (s, 1H), 8.69 (s, 1H), 7.45 (m, 4H), 7.19 (s, 1H), 4.8 (br m, 4H), 3.85 (m, 2H),
15 3.38 (m, 1H), 1.89 (m, 2H), 1.72 (m, 2H), 1.37 (s, 6H); MS (M + H): 426 (base peak).

Example D-5

20 (S)-N-(2-Hydroxypropionyl)-5-(4-piperidyl)-4-(4-pyrimidyl)-3-(4-chlorophenyl)pyrazole hydrochloride



25 By following the method of Example C-1 and substituting (S)-lactic acid for glycolic acid the title compound was prepared. ^1H NMR ($\text{DMSO}-d_6$) 13.15 (s, br, 1H), 9.12 (d, $J=1.07$ Hz, 1H), 8.59 (d, $J=5.37$ Hz, 1H),

1067


7.39(d, $J=7.79\text{Hz}$, 2H), 7.31(d, $J=8.33$, 2H), 7.10(dd, $J=1.34$, 5.1Hz, 1H), 4.76(m, 1H), 4.41(m, 2H), 3.99(m, 1H), 2.97(m, 1H), 2.45(m, 1H), 1.83(m, 2H), 1.64(m, 2H), 1.15(m, 3H); MS (M+H): 412 (base peak).

5

Example D-6

(R)-N-(2-Hydroxypropionyl)-5-(4-piperidyl)-4-(4-pyrimidyl)-3-(4-chlorophenyl)pyrazole hydrochloride

10



By following the method of Example C-1 and substituting (R)-lactic acid for glycolic acid the title compound was prepared. ^1H NMR (CDCl_3) 9.24(s, 1H), 8.52(d, $J = 5.0$ Hz, 1H), 7.32-7.36(m, 4H), 6.98(d, $J = 5.3$ Hz, 1H), 4.72(d, $J = 10.5$ Hz, 1H), 4.55(br, 1H), 3.88(d, $J = 13.1$ Hz, 1H), 3.66(br, 1H), 3.19(br, 1H), 2.82(t, $J = 12.4$ Hz, 1H), 2.10(br, 2H), 1.37(d, $J = 6.2$ Hz, 3H), 1.81-1.90(m, 2H); MS (M + H): 412 (base peak).


20

Example D-7

(R)-N-(2-Hydroxy-2-phenylacetyl)-5-(4-piperidyl)-4-(4-pyrimidyl)-3-(4-chlorophenyl)pyrazole

25

1068




By following the method of Example C-1 and substituting (*R*)-phenylacetic acid for glycolic acid the title compound was prepared. ¹H NMR (DMSO-*d*₆) 9.15 (d, *J* = 0.9 Hz, 1H), 8.63 (d, *J* = 5.4 Hz, 1H), 7.40 (m, 9H), 7.13 (t, *J* = 6.6 Hz, 1H), 5.43 (d, *J* = 19.5 Hz, 1H), 4.51 (s, 1H), 4.04 (m, 1H), 3.33 (m, 4H), 2.8 (m, 2H), 1.68 (m, 3H); MS (*M* + *H*): 474 (base peak).

10

Example D-8

N-(2-Hydroxyacetyl)-5-(4-piperidyl)-4-(4-pyrimidyl)-3-(4-fluorophenyl)pyrazole

15



By following the method of Example C-1 and substituting 4-fluorobenzoyl chloride for 4-chlorobenzoyl chloride the title compound was prepared. ¹H NMR (DMF-*d*₇) 13.48 (s, 1H), 9.40 (s, 1H), 8.86 (d, *J* = 5.1 Hz, 1H), 7.71 (br, 2H), 7.42 (bd, *J* = 5.2 Hz, 3H), 4.78 (br, 1H), 4.43 (s, 2H), 4.04 (br, 1H), 3.79 (br, 1H), 3.70 (s, 1H),

20


1069

3.34 (t, $J = 12.2$ Hz, 1H), 3.0 (br, 1H), 2.21 (d, $J = 10.9$ Hz, 2H), 2.08 (br, 1H); MS ($M + H$): 382 (base peak).

Example D-9

5

N-(2-Hydroxyacetyl)-5-(4-piperidyl)-4-(4-pyrimidyl)-3-(4-trifluoromethylphenyl)pyrazole



10

By following the method of Example C-1 and substituting 4-trifluoromethylbenzoyl chloride for 4-chlorobenzoyl chloride the title compound was prepared.


^1H NMR (DMF-d_7) 13.47 (s, 1H), 9.24 (s, 1H), 8.73 (d, $J = 4.0$ Hz, 1H), 7.77 (bd, $J = 13.3$ Hz, 4H), 7.34 (d, $J = 4.3$ Hz, 1H), 4.61 (br, 1H), 4.26 (s, 2H), 3.87 (br, 1H), 3.52 (s, 2H), 3.17 (t, $J = 12.0$ Hz, 1H), 2.8 (br, 1H), 2.02 (br, 2H), 1.91 (br, 1H); MS ($M + H$): 432 (base peak).

20

Example D-10

N-(2-Hydroxyacetyl)-5-(4-piperidyl)-4-(4-pyrimidyl)-3-(4-trifluoromethoxyphenyl)pyrazole


1070



By following the method of Example C-1 and substituting 4-trifluoromethoxybenzoyl chloride for 4-chlorobenzoyl chloride the title compound was prepared. ¹H NMR (DMF-d₇) 13.55(s, 1H), 9.40(s, 1H), 8.88(d, J = 4.6 Hz, 1H), 7.81(d, J = 7.7 Hz, 2H), 7.64(br, 2H), 7.47(d, J = 4.4 Hz, 1H), 4.75(br, 1H), 4.42(s, 2H), 4.04(d, J = 12.5 Hz, 1H), 3.69(br, 2H), 3.34(t, J = 12.0 Hz, 1H), 3.0(br, 1H), 2.20(d, J = 11.7 Hz, 2H), 2.05(br, 1H); MS (M + H): 448 (base peak).

Example D-11

15 N-(2-Hydroxyacetyl)-5-(4-piperidyl)-4-(4-pyrimidyl)-3-(3-chlorophenyl)pyrazole



20 By following the method of Example C-1 and substituting 3-chlorobenzoyl chloride for 4-chlorobenzoyl chloride the title compound was prepared. ¹H NMR (DMF-d₂) 13.41(s, 1H), 9.24(s, 1H), 8.73(d, J = 4.9 Hz, 1H), 7.56(s, 1H), 7.49(br, 2H), 7.41(br, 1H), 7.32(d, J = 4.2

1071


Hz, 1H), 4.60(d, $J = 11.7$ Hz, 1H), 4.25(s, 2H), 3.87(d, $J = 12.7$ Hz, 1H), 3.52(bs, 2H), 3.17(t, $J = 12.1$ Hz, 1H), 2.84(d, $J = 12.5$ Hz, 1H), 2.03(d, $J = 11.9$ Hz, 2H), 1.87(br, 1H); MS ($M + H$): 398 (base peak).

5

Example D-12

N-(2-Hydroxyacetyl)-5-(4-piperidyl)-4-(4-pyrimidyl)-3-(3-fluorophenyl)pyrazole

10



By following the method of Example C-1 and substituting 3-fluorobenzoyl chloride for 4-chlorobenzoyl chloride the title compound was prepared. ^1H NMR (DMF-d_7) 13.38(s, 1H), 9.24(s, 1H), 8.72(d, $J = 5.2$ Hz, 1H), 7.49(dd, $J = 8.0$ and 6.2 Hz, 1H), 7.24-7.32(m, 4H), 4.60(d, $J = 13.1$ Hz, 1H), 4.25(s, 2H), 3.87(d, $J = 13.3$ Hz, 1H), 3.55-3.60(m, 1H), 3.52(s, 1H), 3.17(t, $J = 12.2$ Hz, 1H), 2.82(d, $J = 12.9$ Hz, 1H), 2.03(d, $J = 10.9$ Hz, 2H), 1.83-1.96(m, 1H); MS ($M + H$): 382 (base peak).


20

Example D-13

N-(2-Hydroxyacetyl)-5-(4-piperidyl)-4-(4-pyrimidyl)-3-(3-trifluoromethylphenyl)pyrazole

25

1072




By following the method of Example C-1 and substituting 3-trifluoromethylbenzoyl chloride for 4-chlorobenzoyl chloride the title compound was prepared.

¹H NMR (DMF-d₇) 13.76(s, 1H), 9.41(s, 1H), 8.91(d, *J* = 5.3 Hz, 1H), 8.02(s, 1H), 7.95(t, *J* = 6.5 Hz, 2H), 7.85(t, *J* = 7.5 Hz, 1H), 7.53(d, *J* = 4.6 Hz, 1H), 4.78(d, *J* = 11.9 Hz, 1H), 4.45(d, *J* = 16.3 Hz, 2H), 4.06(d, *J* = 12.5 Hz, 1H), 3.69(bs, 2H), 3.34(t, *J* = 11.3 Hz, 1H), 3.01(d, *J* = 13.1 Hz, 1H), 2.20(d, *J* = 11.1 Hz, 2H), 2.12(br, 1H); MS (M + H): 432 (base peak).

The following examples can be prepared in a manner similar to that described above for the synthesis of Examples C1-C13.

Example D-14

5-[4-N-(2-hydroxy-2-(2-chlorophenyl)acetyl)piperidinyl]-4-(4-pyrimidinyl)-3-(4-chlorophenyl)pyrazole




1073

Example D-15


5- [4-*N*- (2-hydroxy-2- (3-chlorophenyl) acetyl) piperidyl] -4-
(4-pyrimidyl) -3- (4-chlorophenyl) pyrazole

5



Example D-16


10 5- [4-*N*- (1-hydroxy-1-cyclohexylacetyl) piperidyl] -4- (4-
pyrimidyl) -3- (4-chlorophenyl) pyrazole



15

Example D-17

5- [4-*N*- (2-hydroxy-1-cyclohexylacetyl) piperidyl] -4- (4-
pyrimidyl) -3- (4-chlorophenyl) pyrazole




20

1074


Example D-18

5- [4-*N*- (3-hydroxy-1-cyclohexylacetyl)piperidyl] -4- (4-
pyrimidyl) -3- (4-chlorophenyl)pyrazole




Example D-19

5- [4-*N*- (4-hydroxy-1-cyclohexylacetyl)piperidyl] -4- (4-
pyrimidyl) -3- (4-chlorophenyl)pyrazole



Example D-20


5- [4-*N*- (1-hydroxy-1-cyclopentylacetyl)piperidyl] -4- (4-
pyrimidyl) -3- (4-chlorophenyl)pyrazole



1075


Example D-21

5- [4-*N*- (2-hydroxy-1-cyclopentylacetyl)piperidyl] -4- (4-
pyrimidyl) -3- (4-chlorophenyl)pyrazole




Example D-22

5- [4-*N*- (3-hydroxy-1-cyclopentylacetyl)piperidyl] -4- (4-
pyrimidyl) -3- (4-chlorophenyl)pyrazole



Example D-23


5- [4-*N*- (3-hydroxypropionyl)piperidyl] -4- (4-pyrimidyl) -3-
(4-chlorophenyl)pyrazole



1076


Example D-24

5- [4-*N*- (2-hydroxy-3,3,3-trifluoropropionyl)piperidyl] -4-
(4-pyrimidyl) -3- (4-chlorophenyl)pyrazole




Example D-25

5- [4-*N*- (2-hydroxy-3-methylbutyryl)piperidyl] -4- (4-
pyrimidyl) -3- (4-chlorophenyl)pyrazole



Example D-26


5- [4-*N*- (2-hydroxyisocaproyl)piperidyl] -4- (4-pyrimidyl) -3-
(4-chlorophenyl)pyrazole



1077

Example D-27


5- [4-*N*- (2-hydroxy-2-cyclohexylacetyl)piperidyl] -4- (4-
pyrimidyl) -3- (4-chlorophenyl) pyrazole



Example D-28

10

5- [4-*N*- (2-hydroxy-2- (4-methoxyphenyl) acetyl)piperidyl] -4-
(4-pyrimidyl) -3- (4-chlorophenyl) pyrazole




15

Example D-29

5- [4-*N*- (2-hydroxy-2- (3-methoxyphenyl) acetyl)piperidyl] -4-
(4-pyrimidyl) -3- (4-chlorophenyl) pyrazole


20

1078



Example D-30

5 5 - [4-*N* - (2-hydroxy-2 - (4 -
trifluoromethylphenyl) acetyl) piperidyl] - 4 - (4-pyrimidyl) - 3 -
 (4-chlorophenyl) pyrazole




10

Example D-31

 5 - [4-*N* - (2-hydroxy-3-phenylpropionyl) piperidyl] - 4 - (4 -
pyrimidyl) - 3 - (4-chlorophenyl) pyrazole

15




1079

Example D-32


5- [4-*N*- (2-hydroxy-3- (4-hydroxyphenyl)propionyl)piperidyl] -
4- (4-pyrimidyl) -3- (4-chlorophenyl)pyrazole

5



Example D-33

10 5- [4-*N*- (2-hydroxy-3-imidazolpropionyl)piperidyl] -4- (4-
pyrimidyl) -3- (4-chlorophenyl)pyrazole



15

The synthesis of 2-substituted pyrimidinyl pyrazoles is shown in Scheme 2. Reaction of 2-methylmercapto-4-methyl pyrimidine 10 with *N*-Boc methyl ester of isonipecotic acid (1) under basic (base selected from
20 LiHMDS or LDA or *t*BuOK) conditions in an anhydrous solvent such as tetrahydrofuran or ether affords the desired ketone 11. Condensation of the ketone 11 with tosyl hydrazine under refluxing conditions in either toluene or


1080

benzene affords the hydrazone 12. The hydrazone 12 is deprotonated under basic (base selected from LiHMDS or LDA or tBuOK) conditions in an anhydrous solvent such as tetrahydrofuran or ether and the anion is reacted in situ
5 with a suitably substituted benzoyl chloride 5 to afford, after mild aqueous work up, the desired and fully protected pyrazole 13. Oxidation of the 2-mercaptomethyl group present in 13 with oxidants selected from but not limited to Oxone[®], H₂O₂ or mCPBA in solvents such as
10 dichloromethane, acetonitrile or tetrahydrofuran affords the 2-methane sulfonyl pyrazole 14. The 2-methanesulfone group in 14 is conveniently displaced with various amines, aryloxides or alkoxides in solvents such as tetrahydrofuran, dioxane, dimethylformamide or
15 acetonitrile at temperatures ranging from 20 °C to 200 °C. Under these reaction conditions the tosyl protecting group on the pyrazole is also simultaneously deprotected. Aqueous workup affords the desired tosyl deprotected, 2-alkoxy, or 2-aryloxy or 2-amino substituted pyrazoles 15.
20 The alkoxides or aryloxides are generated from their respective alcohols or phenols with suitable bases such as LiHMDS, NaH, LDA or tBuOK in solvents such as tetrahydrofuran, dioxane or dimethylformamide. Deprotection of the remaining N-Boc group in 15 is
25 accomplished with trifluoroacetic acid or hydrochloric acid in solvents such as dichloromethane or dioxane to afford the pyrazole 16. Treatment of the pyrazole 16 with an acid chloride 7 in the presence of base or with an acid 8 under standard peptide coupling conditions (EDC or DCC
30 or PyBrOP with an additive such as HOBT or HATU and base

1081

such as N-methylmorpholine or diisopropyl ethylamine) affords the desired final products 17.

Scheme D-2




1082

The following 2-substituted pyrimidine compounds can be prepared as set forth above, particularly in a manner similar to that outlined above in Scheme D-2.

5

Example D-34


5-[4-N-(2-hydroxyacetyl)piperidyl]-4-[4-(2-thiomethyl)pyrimidyl]-3-(4-chlorophenyl)pyrazole



10

Example D-35

15 5-[4-N-(2-hydroxyacetyl)piperidyl]-4-[4-(2-methanesulfonyl)pyrimidyl]-3-(4-chlorophenyl)pyrazole




20

Example D-36

5-[4-N-(2-hydroxyacetyl)piperidyl]-4-[4-(2-amino)pyrimidyl]-3-(4-chlorophenyl)pyrazole


1083



Example D-37

5


5-[4-N-(2-hydroxyacetyl)piperidyl]-4-[4-(2-methylamino)pyrimidyl]-3-(4-chlorophenyl)pyrazole



10

Example D-38

5-[4-N-(2-hydroxyacetyl)piperidyl]-4-[4-(2-isopropylamino)pyrimidyl]-3-(4-chlorophenyl)pyrazole




15

Example D-39

20 5-[4-N-(2-hydroxyacetyl)piperidyl]-4-[4-(2-S-methylbenzylamino)pyrimidyl]-3-(4-chlorophenyl)pyrazole


1084



Example D-40

5


5-[4-N-(2-hydroxyacetyl)piperidyl]-4-[4-(2-R-methylbenzylamino)pyrimidyl]-3-(4-chlorophenyl)pyrazole



10

Example D-41

5-[4-N-(2-hydroxyacetyl)piperidyl]-4-[4-(2-methoxy)pyrimidyl]-3-(4-chlorophenyl)pyrazole




15

Example D-42

1085

5- [4-*N*- (2-hydroxyacetyl)piperidyl] -4- [4- (p-fluorophenoxy)pyrimidyl] -3- (4-chlorophenyl)pyrazole




5

Example D-43

5- [4-*N*- (2-hydroxyacetyl)piperidyl] -4- [4- (p-fluoroanilino)pyrimidyl] -3- (4-chlorophenyl)pyrazole

10




In a manner similar to that outlined above in Scheme D-1, for the synthesis of the piperidine analogs 6, the aminocyclohexane analogs are prepared by substitution of 1 in Scheme D-1 with a suitably protected (Boc is shown) methyl or ethyl ester of cis-aminocyclohexane carboxylic acid 10 or trans-aminocyclohexane carboxylic acid 11 or trans-aminomethylcyclohexane carboxylic acid 12, which

1086

affords the cis-aminocyclohexane 13, or trans-aminocyclohexane 14 or the trans-aminomethylcyclohexane 15 respectively (Scheme 3). Suitable reductive alkylations on 13, 14 or 15 with 1-1.5 equivalents of aldehydes or ketones in the presence of a reducing agent like sodium cyanoborohydride or sodium triacetoxyborohydride in solvents such as methanol, ethanol, acetic acid, tetrahydrofuran or dichloromethane lead to the desired mono-alkylated derivatives 16, 17 or 18 respectively.

10




Scheme 3



The dimethyl derivatives 19, 20 or 21 can be prepared by heating a solution of the aminocyclohexanes 13, 14 or 15




1087

respectively in a mixture of formaldehyde and formic acid at temperatures ranging from 40 °C to 110 °C.



5

An additional group of compounds of interest includes
10 the following:



15

1088


Biological data for a number of compounds are shown in the following table. In vitro p38 alpha kinase inhibitory data are shown in the column identified as "p38 alpha IC_{50} (μM)". In vitro human whole blood assay data for measuring the ability of the compounds to inhibit TNF production in human whole blood stimulated with LPS are shown in the column identified as: "HWB IC_{50} (μM)". In vivo assessment of the ability of the compounds to inhibit LPS-stimulated TNF-release in the rat is shown in the column identified as: "ratLPS/%Inh@dose(mg/kg)" wherein the dose is in milligram per kilogram (mg/kg) administered by oral gavage, 4 hours before LPS challenge.

Example	p38 alpha IC_{50} (μM)	HWB IC_{50} (μM)	ratLPS/%Inh @1.0 (mg/kg)	ratLPS/%Inh @5.0 (mg/kg)	ratLPS/%Inh @20.0 (mg/kg)
D-1	0.17		83.0		
D-2	0.084	1.79	89.0	95.0	
D-3	0.095	0.46	69.0	88.0	91.0
D-4	0.91	1.55	42.3	83.0	99.0
D-5	0.14	4.09	65.0	78.5	83.0
D-6	0.083	1.33	82.0	96.0	100
D-7	0.44	>25.0		0	
D-8	0.18	1.3	65	85	
D-9	1.63	15.8	5	86	
D-10	3.95	14.8		80	
D-11	0.16	1.5	43	86	
D-12	0.82	7.06	71	91	
D-13	0.33	8.36	53	87	

1089

WHAT IS CLAIMED IS:

1. A compound of Formula IB:




wherein

- 5 R^1 is selected from hydrido, hydroxy, alkyl, cycloalkyl, alkenyl, cycloalkenyl, alkynyl, aryl, heterocyclyl, cycloalkylalkylene, cycloalkenylalkylene, heterocyclylalkylene, haloalkyl, haloalkenyl, haloalkynyl, hydroxyalkyl, hydroxyalkenyl, hydroxyalkynyl, aralkyl, aralkenyl, aralkynyl, arylheterocyclyl, carboxy, carboxyalkyl, alkoxyalkyl, alkenoxyalkyl, alkynoxyalkyl, aryloxyalkyl, alkoxyaryl, heterocycliloxyalkyl, alkoxyalkoxy, mercaptoalkyl, alkylthioalkylene, alkenylthioalkylene, alkylthioalkenylene, amino, aminoalkyl, alkylamino, alkenylamino, alkynylamino, arylamino, heterocyclylamino, alkylsulfinyl, alkenylsulfinyl, alkynylsulfinyl, arylsulfinyl, heterocyclylsulfinyl, alkylsulfonyl, alkenylsulfonyl, alkynylsulfonyl, arylsulfonyl, heterocyclylsulfonyl, alkylaminoalkylene, alkylsulfonylalkylene, acyl, acyloxycarbonyl, alkoxycarbonylalkylene, aryloxycarbonylalkylene, heterocycliloxycarbonylalkylene, alkoxycarbonylarylene, aryloxycarbonylarylene, heterocycliloxycarbonylarylene, alkylcarbonylalkylene, arylcarbonylalkylene, heterocyclylcarbonylalkylene, alkylcarbonylarylene, arylcarbonylarylene, heterocyclylcarbonylarylene, alkylcarbonyloxyalkylene, arylcarbonyloxyalkylene, heterocyclylcarbonyloxyalkylene, alkylcarbonyloxyarylene, heterocyclylcarbonyloxyarylene,

1090

30 arylcarbonyloxyarylene, and
heterocyclylcarbonyloxyarylene; or

R¹ has the formula



wherein:

35 i is an integer from 0 to 9;

R²⁵ is selected from hydrogen, alkyl, aralkyl,
heterocyclylalkyl, alkoxyalkylene, aryloxyalkylene,
aminoalkyl, alkylaminoalkyl, arylaminoalkyl,
alkylcarbonylalkylene, arylcarbonylalkylene, and
40 heterocyclylcarbonylaminoalkylene; and

R²⁶ is selected from hydrogen, alkyl, alkenyl,
alkynyl, cycloalkylalkylene, aralkyl,
alkoxycarbonylalkylene, and alkylaminoalkyl; and

R²⁷ is selected from alkyl, cycloalkyl, alkynyl,
45 aryl, heterocyclyl, aralkyl, cycloalkylalkylene,
cycloalkenylalkylene, cycloalkylarylene,
cycloalkylcycloalkyl, heterocyclylalkylene, alkylarylene,
alkylaralkyl, aralkylarylene, alkylheterocyclyl,
alkylheterocyclylalkylene, alkylheterocyclylarylene,
50 aralkylheterocyclyl, alkoxyalkylene, alkoxyarylene,
alkoxyaralkyl, alkoxyheterocyclyl, alkoxyalkoxyarylene,
aryloxyarylene, aralkoxyarylene,
alkoxyheterocyclylalkylene, aryloxyalkoxyarylene,
alkoxycarbonylalkylene, alkoxycarbonylheterocyclyl,
55 alkoxycarbonylheterocyclylcarbonylalkylene, aminoalkyl,
alkylaminoalkylene, arylaminocarbonylalkylene,
alkoxyarylaminocarbonylalkylene, aminocarbonylalkylene,
arylaminocarbonylalkylene, alkylaminocarbonylalkylene,
arylcarbonylalkylene, alkoxycarbonylarylene,
60 aryloxycarbonylarylene, alkylaryloxycarbonylarylene,
arylcarbonylarylene, alkylarylcarbonylarylene,
alkoxycarbonylheterocyclylarylene,

alkoxycarbonylalkoxylarylene,
heterocyclylcarbonylalkylarylene, alkylthioalkylene,
65 cycloalkylthioalkylene, alkylthioarylene,
aralkylthioarylene, heterocyclylthioarylene,
arylthioalkylarylene, arylsulfonylaminoalkylene,
alkylsulfonylarylene, alkylaminosulfonylarylene; wherein
said alkyl, cycloalkyl, aryl, heterocyclyl, aralkyl,
70 heterocyclylalkylene, alkylheterocyclylarylene,
alkoxyarylene, aryloxyarylene, arylaminocarbonylalkylene,
aryloxycarbonylarylene, arylcarbonylarylene,
alkylthioarylene, heterocyclylthioarylene,
arylthioalkylarylene, and alkylsulfonylarylene groups
75 may be optionally substituted with one or more radicals
independently selected from alkyl, halo, haloalkyl,
alkoxy, keto, amino, nitro, and cyano; or


R^{27} is $-\text{CHR}^{28}\text{R}^{29}$ wherein R^{28} is alkoxycarbonyl, and R^{29}
is selected from aralkyl, aralkoxyalkylene,
80 heterocyclylalkylene, alkylheterocyclylalkylene,
alkoxycarbonylalkylene, alkylthioalkylene, and
aralkylthioalkylene; wherein said aralkyl and
heterocyclyl groups may be optionally substituted with
one or more radicals independently selected from alkyl
85 and nitro; or

R^{26} and R^{27} together with the nitrogen atom to which
they are attached form a heterocycle, wherein said
heterocycle is optionally substituted with one or more
radicals independently selected from alkyl, aryl,
90 heterocyclyl, heterocyclylalkylene,
alkylheterocyclylalkylene, aryloxyalkylene,
alkoxyarylene, alkylaryloxyalkylene, alkylcarbonyl,
alkoxycarbonyl, aralkoxycarbonyl, alkylamino and
alkoxycarbonylamino; wherein said aryl,
95 heterocyclylalkylene and aryloxyalkylene radicals may be
optionally substituted with one or more radicals
independently selected from halogen, alkyl and alkoxy;
and


1092

R² is piperidinyl substituted with one or more
100 substituents selected from hydroxyalkyl, hydroxyalkenyl,
hydroxyalkynyl, alkoxyalkylene, alkoxyalkenylene,
alkoxyalkynylene, and hydroxyacyl, wherein said
hydroxyalkyl, hydroxyalkenyl, hydroxyalkynyl,
alkoxyalkylene, alkoxyalkenylene, alkoxyalkynylene, and
105 hydroxyacyl substitutents may be optionally substituted
with one or more substituents selected from cycloalkyl,
alkyl, aryl, arylalkyl, haloalkyl, and heteroarylalkyl,
wherein said cycloalkyl, alkyl, aryl, arylalkyl,
haloalkyl, and heteroarylalkyl substituents may be
110 optionally substituted with one or more substituents
selected from alkylene, alkynylene, hydroxy, halo,
haloalkyl, alkoxy, keto, amino, nitro, cyano,
alkylsulfonyl, alkylsulfinyl, alkylthio, alkoxyalkyl,
aryloxy, heterocyclyl, and heteroaralkoxy; or
115 R² is piperidinyl substituted with one or more
substituents selected from hydroxycycloalkyl and
alkoxycycloalkyl, and wherein said hydroxycycloalkyl and
alkoxycycloalkyl substitutents may be optionally
substituted with one or more substituents selected from
120 cycloalkyl, alkyl, aryl, arylalkyl, haloalkyl, and
heteroarylalkyl, wherein said cycloalkyl, alkyl, aryl,
arylalkyl, haloalkyl, and heteroarylalkyl substituents
may be optionally substituted with one or more
substituents selected from alkylene, alkynylene, hydroxy,
125 halo, haloalkyl, alkoxy, keto, amino, nitro, cyano,
alkylsulfonyl, alkylsulfinyl, alkylthio, alkoxyalkyl,
aryloxy, heterocyclyl, and heteroaralkoxy; and
R³ is selected from pyridinyl, pyrimidinyl,
quinolinyl, purinyl, maleimidyl, pyridonyl, thiazolyl,
130 thiazolylalkyl, thiazolylamino,

1093



wherein the R³ pyridinyl, pyrimidinyl, quinolinyl, purinyl, maleimidyl, pyridonyl, thiazolyl, thiazolylalkyl, thiazolylamino,



groups may be optionally substituted with one or more substituents independently selected from hydrogen, aryl, alkylamino, alkylthio, alkyloxy, aryloxy, arylamino, arylthio, aralkoxy, wherein said aryl, alkylamino, alkylthio, alkyloxy, aryloxy, arylamino, arylthio, aralkoxy substituents may be optionally substituted with one or more alkylene, alkenylene, hydroxy, halo, haloalkyl, alkoxy, keto, amino, nitro, cyano, alkylsulfonyl, alkylsulfinyl, alkylthio, alkoxyalkyl, aryloxy, heterocyclyl, and heteroaralkoxy; and

R⁴ is selected from hydrido, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, and heterocyclyl, wherein R⁴ is optionally substituted with one or more substituents independently selected from halo, haloalkyl, haloalkoxy, alkoxy, cyano, hydroxy, alkyl, alkenyl, and alkynyl, wherein said haloalkyl, haloalkoxy, alkoxy, cyano, hydroxy, alkyl, alkenyl, and alkynyl substituents may be optionally substituted with one or more alkylene, alkenylene, alkynylene, hydroxy, halo, haloalkyl, alkoxy, keto, amino, nitro, cyano, alkylsulfonyl, alkylsulfinyl, alkylthio, alkoxyalkyl, aryloxy, heterocyclyl, and heteroaralkoxy; or

a pharmaceutically-acceptable salt or tautomer

thereof.


2. A compound of Claim 1 wherein:

R^2 is piperidinyl substituted with one or more substituents selected from hydroxyalkyl, hydroxyalkenyl, hydroxyalkynyl, alkoxyalkylene, alkoxyalkenylene, alkoxyalkynylene, hydroxyalkylcarbonyl, hydroxyalkenylcarbonyl, and hydroxyalkynylcarbonyl, wherein said hydroxyalkyl, hydroxyalkenyl, hydroxyalkynyl, alkoxyalkylene, alkoxyalkenylene, alkoxyalkynylene, hydroxyalkylcarbonyl, hydroxyalkenylcarbonyl, and hydroxyalkynylcarbonyl substituents may be optionally substituted with one or more substituents selected from cycloalkyl, alkyl, aryl, arylalkyl, haloalkyl, and heteroarylalkyl, wherein said cycloalkyl, alkyl, aryl, arylalkyl, haloalkyl, and heteroarylalkyl substituents may be optionally substituted with one or more substituents selected from alkylene, alkynylene, hydroxy, halo, haloalkyl, alkoxy, keto, amino, nitro, cyano, alkylsulfonyl, alkylsulfinyl, alkylthio, alkoxyalkyl, aryloxy, heterocyclyl, and heteroaralkoxy; or


R^2 is piperidinyl substituted with one or more substituents selected from hydroxycycloalkyl, alkoxycycloalkyl, and hydroxycycloalkylcarbonyl, wherein said hydroxycycloalkyl, alkoxycycloalkyl, and hydroxycycloalkylcarbonyl substituents may be optionally substituted with one or more substituents selected from cycloalkyl, alkyl, aryl, arylalkyl, haloalkyl, and heteroarylalkyl, wherein said cycloalkyl, alkyl, aryl, arylalkyl, haloalkyl, and heteroarylalkyl substituents may be optionally substituted with one or more substituents selected from alkylene, alkynylene, hydroxy, halo, haloalkyl, alkoxy, keto, amino, nitro, cyano, alkylsulfonyl, alkylsulfinyl, alkylthio, alkoxyalkyl, aryloxy, heterocyclyl, and heteroaralkoxy.

1095



3. A compound of Claim 1 selected from compounds, their tautomers and their pharmaceutically acceptable salts, of the group consisting of:




5



1096




;




; and

1097



4. A compound of Claim 1 having Formula XB:



wherein

Z represents a carbon atom or a nitrogen atom;

R¹ is selected from hydrido, hydroxy, alkyl,
 5 cycloalkyl, alkenyl, cycloalkenyl, alkynyl, aryl,
 heterocyclyl, cycloalkylalkylene, cycloalkenylalkylene,
 heterocyclylalkylene, haloalkyl, haloalkenyl,
 haloalkynyl, hydroxyalkyl, hydroxyalkenyl,
 hydroxyalkynyl, aralkyl, aralkenyl, aralkynyl,
 10 arylheterocyclyl, carboxy, carboxyalkyl, alkoxyalkyl,

alkenoxyalkyl, alkynoxyalkyl, aryloxyalkyl, alkoxyaryl,
heterocyclyloxyalkyl, alkoxyalkoxy, mercaptoalkyl,
alkylthioalkylene, alkenylthioalkylene,
alkylthioalkenylene, amino, aminoalkyl, alkylamino,
15 alkenylamino, alkynylamino, arylamino, heterocyclylamino,
alkylsulfinyl, alkenylsulfinyl, alkynylsulfinyl,
arylsulfinyl, heterocyclylsulfinyl, alkylsulfonyl,
alkenylsulfonyl, alkynylsulfonyl, arylsulfonyl,
heterocyclylsulfonyl, alkylaminoalkylene,
20 alkylsulfonylalkylene, acyl, acyloxycarbonyl,
alkoxycarbonylalkylene, aryloxycarbonylalkylene,
heterocyclyloxycarbonylalkylene, alkoxycarbonylarylene,
aryloxycarbonylarylene, heterocyclyloxycarbonylarylene,
alkylcarbonylalkylene, arylcarbonylalkylene,
25 heterocyclylcarbonylalkylene, alkylcarbonylarylene,
arylcarbonylarylene, heterocyclylcarbonylarylene,
alkylcarbonyloxyalkylene, arylcarbonyloxyalkylene,
heterocyclylcarbonyloxyalkylene, alkylcarbonyloxyarylene,
arylcarbonyloxyarylene, and
30 heterocyclylcarbonyloxyarylene; and

R² is piperidinyl substituted with one or more
substituents selected from hydroxyalkyl, hydroxyalkenyl,
alkoxyalkylene, alkoxyalkenylene, hydroxyalkylcarbonyl,
and hydroxyalkenylcarbonyl, wherein said hydroxyalkyl,
35 hydroxyalkenyl, alkoxyalkylene, alkoxyalkenylene,
hydroxyalkylcarbonyl, and hydroxyalkenylcarbonyl
substituents may be optionally substituted with one or
more substituents selected from cycloalkyl, alkyl, aryl,
arylalkyl, haloalkyl, and heteroarylalkyl, wherein said
40 cycloalkyl, alkyl, aryl, arylalkyl, haloalkyl, and
heteroarylalkyl substituents may be optionally
substituted with one or more substituents selected from
alkylene, alkynylene, hydroxy, halo, haloalkyl, alkoxy,
keto, amino, nitro, cyano, alkylsulfonyl, alkylsulfinyl,
45 alkylthio, alkoxyalkyl, aryloxy, heterocyclyl, and
heteroaralkoxy; or

R² is piperidinyl substituted with one or more substituents selected from hydroxycycloalkyl and hydroxycycloalkylcarbonyl, wherein said hydroxycycloalkyl and hydroxycycloalkylcarbonyl substituents may be optionally substituted with one or more substituents selected from cycloalkyl, alkyl, aryl, arylalkyl, haloalkyl, and heteroarylalkyl, wherein said cycloalkyl, alkyl, aryl, arylalkyl, haloalkyl, and heteroarylalkyl substituents may be optionally substituted with one or more substituents selected from alkylene, alkynylene, hydroxy, halo, haloalkyl, alkoxy, keto, amino, nitro, cyano, alkylsulfonyl, alkylsulfinyl, alkylthio, alkoxyalkyl, aryloxy, heterocyclyl, and heteroaralkoxy; and

R⁴ is selected from cycloalkyl, cycloalkenyl, aryl, and heterocyclyl, wherein R⁴ is optionally substituted with one or more substituents independently selected from halo, haloalkyl, haloalkoxy, alkoxy, cyano, hydroxy, alkyl, alkenyl, and alkynyl, wherein said haloalkyl, haloalkoxy, alkoxy, hydroxy, alkyl, alkenyl, and alkynyl substituents may be optionally substituted with one or more alkylene, alkenylene, alkynylene, hydroxy, halo, haloalkyl, alkoxy, keto, amino, nitro, cyano, alkylsulfonyl, alkylsulfinyl, alkylthio, alkoxyalkyl, aryloxy, heterocyclyl, and heteroaralkoxy; and

R⁵ represents one or more substituents independently selected from hydrogen, aryl, alkylamino, alkylthio, alkyloxy, aryloxy, arylamino, arylthio, aralkoxy, wherein said aryl, alkylamino, alkylthio, alkyloxy, aryloxy, arylamino, arylthio, aralkoxy substituents may be optionally substituted with one or more alkylene, alkenylene, hydroxy, halo, haloalkyl, alkoxy, keto, amino, nitro, cyano, alkylsulfonyl, alkylsulfinyl, alkylthio, alkoxyalkyl, aryloxy, heterocyclyl, and heteroaralkoxy; or

a pharmaceutically-acceptable salt or tautomer

1100

thereof.

5. A compound of Claim 4 wherein R^2 is piperidinyl substituted with at least one substituent attached to the distal nitrogen heteroatom or to a carbon ring atom adjacent to the distal nitrogen heteroatom of the piperidine ring.

6. A compound of Claim 4 wherein Z represents a carbon atom.

7. A compound of Claim 4 wherein Z represents a nitrogen atom.

8. A compound of Claim 4 wherein R^1 is selected from hydrido, alkyl, hydroxyalkyl and alkynyl.

9. A compound of Claim 4 wherein R^1 is hydrido.

10. A compound of Claim 4 wherein R^2 is piperidinyl substituted with at least one substituent selected from lower hydroxyalkyl, lower hydroxyalkylcarbonyl and hydroxycycloalkylcarbonyl.

11. A compound of Claim 4 wherein R^4 is optionally substituted phenyl.


12. A compound of Claim 4 wherein R^4 is phenyl optionally substituted at a substitutable position with one or more radicals independently selected from chloro, fluoro, bromo and iodo.

13. A compound of Claim 4 wherein R^4 is phenyl optionally substituted at the meta or para position with one or more chloro radicals.

1101

14. A compound of Claim 4 wherein R⁵ is hydrido.

15. A compound of Claim 1 having Formula XX:



wherein:

Z represents a carbon atom or a nitrogen atom;

5 R⁴⁰⁰ is selected from hydroxyalkyl,

hydroxyalkylcarbonyl and alkoxyalkylene, wherein said hydroxyalkyl, hydroxyalkylcarbonyl and alkoxyalkylene may be optionally substituted with one or more substituents selected from cycloalkyl, alkyl, aryl, arylalkyl, haloalkyl, and heteroarylalkyl, wherein said cycloalkyl, alkyl, aryl, arylalkyl, haloalkyl, and heteroarylalkyl substituents may be optionally substituted with one or more substituents selected from alkylene, alkynylene, hydroxy, halo, haloalkyl, alkoxy, keto, amino, nitro, cyano, alkylsulfonyl, alkylsulfinyl, alkylthio, alkoxyalkyl, aryloxy, heterocyclyl, and heteroaralkoxy; or

20 R⁴⁰⁰ is hydroxycycloalkylcarbonyl that is optionally substituted with one or more substituents selected from cycloalkyl, alkyl, aryl, arylalkyl, haloalkyl, and

1102

heteroarylalkyl, wherein said cycloalkyl, alkyl, aryl, arylalkyl, haloalkyl, and heteroarylalkyl substituents may be optionally substituted with one or more substituents selected from alkylene, alkynylene, hydroxy, halo, haloalkyl, alkoxy, keto, amino, nitro, cyano, alkylsulfonyl, alkylsulfinyl, alkylthio, alkoxyalkyl, aryloxy, heterocyclyl, and heteroaralkoxy; and

R^{401a} and R^{401b} are independently selected from hydrogen, halo, haloalkyl, haloalkoxy, alkoxy, cyano, hydroxy, alkyl, alkenyl, and alkynyl, wherein said haloalkyl, haloalkoxy, alkoxy, hydroxy, alkyl, alkenyl, and alkynyl substituents may be optionally substituted with one or more alkylene, alkenylene, alkynylene, hydroxy, halo, haloalkyl, alkoxy, keto, amino, nitro, cyano, alkylsulfonyl, alkylsulfinyl, alkylthio, alkoxyalkyl, aryloxy, heterocyclyl, and heteroaralkoxy; and

R^{402} is selected from hydrogen, aryl, alkylamino, alkylthio, alkyloxy, aryloxy, arylamino, arylthio, aralkoxy, wherein said aryl, alkylamino, alkylthio, alkyloxy, aryloxy, arylamino, arylthio, aralkoxy substituents may be optionally substituted with one or more alkylene, alkenylene, hydroxy, halo, haloalkyl, alkoxy, keto, amino, nitro, cyano, alkylsulfonyl, alkylsulfinyl, alkylthio, alkoxyalkyl, aryloxy, heterocyclyl, and heteroaralkoxy; or

a pharmaceutically-acceptable salt or tautomer thereof.

16. A compound of Claim 15 wherein:

R^{400} is selected from lower hydroxyalkyl, lower hydroxyalkylcarbonyl and lower alkoxyalkylene, wherein said lower hydroxyalkyl, lower hydroxyalkylcarbonyl and lower alkoxyalkylene may be optionally substituted with one or more substituents selected from cycloalkyl, lower alkyl, phenyl, lower phenylalkyl, lower haloalkyl, and

1103

lower heteroarylalkyl, wherein said cycloalkyl, lower alkyl, phenyl, lower phenylalkyl, lower haloalkyl, and lower heteroarylalkyl substituents may be optionally substituted with one or more substituents selected from lower alkylene, lower alkynylene, hydroxy, halo, lower haloalkyl, lower alkoxy, keto, amino, nitro, cyano, lower alkylsulfonyl, lower alkylsulfinyl, lower alkylthio, lower alkoxyalkyl, phenyloxy, heterocyclyl, and lower heteroaralkoxy; or

R^{400} is hydroxycycloalkylcarbonyl that is optionally substituted with one or more substituents selected from cycloalkyl, lower alkyl, phenyl, lower phenylalkyl, lower haloalkyl, and lower heteroarylalkyl, wherein said cycloalkyl, lower alkyl, phenyl, lower phenylalkyl, lower haloalkyl, and lower heteroarylalkyl substituents may be optionally substituted with one or more substituents selected from lower alkylene, lower alkynylene, hydroxy, halo, lower haloalkyl, lower alkoxy, keto, amino, nitro, cyano, lower alkylsulfonyl, lower alkylsulfinyl, lower alkylthio, lower alkoxyalkyl, aryloxy, heterocyclyl, and lower heteroaralkoxy; and

R^{401a} and R^{401b} are independently selected from hydrogen, halo, lower haloalkyl, lower haloalkoxy, lower alkoxy, cyano, hydroxy, lower alkyl, lower alkenyl, and lower alkynyl, wherein said lower haloalkyl, lower haloalkoxy, lower alkoxy, cyano, hydroxy, lower alkyl, lower alkenyl, and lower alkynyl substituents may be optionally substituted with one or more lower alkylene, lower alkenylene, lower alkynylene, hydroxy, halo, lower haloalkyl, lower alkoxy, keto, amino, nitro, cyano, lower alkylsulfonyl, lower alkylsulfinyl, lower alkylthio, lower alkoxyalkyl, phenyloxy, heterocyclyl, and lower heteroaralkoxy; and

R^{402} is selected from hydrogen, phenyl, lower alkylamino, lower alkylthio, lower alkylloxy, phenyloxy, phenylamino, phenylthio, and phenylalkoxy, wherein said

1104

phenyl, lower alkylamino, lower alkylthio, lower
alkyloxy, phenyloxy, phenylamino, phenylthio, and
45 phenylalkoxy may be optionally substituted with one or
more lower alkylene, lower alkenylene, hydroxy, halo,
lower haloalkyl, lower alkoxy, keto, amino, nitro, cyano,
lower alkylsulfonyl, lower alkylsulfinyl, lower
alkylthio, lower alkoxyalkyl, phenyloxy, heterocyclyl,
50 and lower heteroaralkoxy; or
a pharmaceutically-acceptable salt or tautomer
thereof.

17. A compound of Claim 15 wherein Z represents a carbon atom.

18. A compound of Claim 15 wherein Z represents a nitrogen atom.

19. A compound of Claim 15 wherein R⁴⁰⁰ is optionally substituted hydroxyalkylcarbonyl.

20. A compound of Claim 15 wherein R⁴⁰⁰ is optionally substituted hydroxycycloalkylcarbonyl.

21. A compound of Claim 15 wherein R⁴⁰⁰ is optionally substituted alkoxyalkylene.

22. A compound of Claim 15 wherein R⁴⁰⁰ is optionally substituted hydroxyalkyl.

23. A compound of Claim 15 wherein R⁴⁰¹ represents one or more chloro, fluoro, bromo and iodo.

24. A compound of Claim 15 wherein R⁴⁰¹ is meta-chloro or para-chloro.

25. A compound of Claim 15 wherein R⁴⁰² is hydrido.

1105

26. A compound of Claim 15 wherein:

R⁴⁰⁰ is optionally substituted lower
hydroxyalkylcarbonyl;

R^{401a} is selected from chloro, fluoro, bromo and iodo;

5 and

R⁴⁰² is hydrido.

27. A compound of Claim 15 wherein:

R⁴⁰⁰ is selected from optionally substituted 2-
hydroxyacetyl, 2-hydroxy-propionyl, 2-hydroxy-2-
methylpropionyl, 2-hydroxy-2-phenylacetyl, 3-
5 hydroxypropionyl, 2-hydroxy-3-methylbutyryl, 2-
hydroxyisocaprotyl, 2-hydroxy-3-phenylpropionyl, and 2-
hydroxy-3-imidazolylpropionyl;

R^{401a} is selected from chloro, fluoro, bromo and iodo;
and

10 R⁴⁰² is hydrido.

28. A compound of Claim 27 wherein R^{401a} is meta-
chloro or para-chloro.

29. A compound of Claim 27 wherein R^{401a} is para-
chloro and R^{401b} is hydrogen.

30. A compound of Claim 15 wherein:

R⁴⁰⁰ is optionally substituted lower
hydroxycycloalkylcarbonyl;

R^{401a} is selected from chloro, fluoro, bromo and iodo;

5 and

R⁴⁰² is hydrido.

31. A compound of Claim 15 wherein:

R⁴⁰⁰ is selected from optionally substituted 1-
hydroxy-1-cyclohexylacetyl, 2-hydroxy-1-cyclohexylacetyl,
3-hydroxy-1-cyclohexylacetyl, 4-hydroxy-1-
5 cyclohexylacetyl, 1-hydroxy-1-cyclopentylacetyl, 2-

1106

hydroxy-1-cyclopentylacetyl, and 3-hydroxy-1-cyclopentylacetyl, 2-hydroxy-2-cyclohexylacetyl;

R^{401a} is selected from chloro, fluoro, bromo and iodo;
and

10 R^{402} is hydrido.

32. A compound of Claim 31 wherein R^{401a} is meta-chloro or para-chloro.

33. A compound of Claim 15 wherein:

R^{400} is optionally substituted lower hydroxyalkyl;

R^{401} is selected from chloro, fluoro, bromo and iodo;
and

5 R^{402} is hydrido.

34. A compound of Claim 15 wherein:

R^{400} is selected from optionally substituted hydroxymethyl, hydroxyethyl, hydroxypropyl and hydroxyisopropyl;

5 R^{401a} is selected from chloro, fluoro, bromo and iodo;
and

R^{402} is hydrido.

35. A compound of Claim 34 wherein R^{401a} is meta-chloro or para-chloro.

36. A compound of Claim 15 wherein:

R^{400} is optionally substituted lower alkoxyalkylene;

R^{401a} is selected from chloro, fluoro, bromo and iodo;
and

5 R^{402} is hydrido.

37. A compound of Claim 15 wherein:

R^{400} is selected from optionally substituted methoxymethylene, methoxyethylene, methoxypropylene, methoxyisopropylene, ethoxymethylene, ethoxyethylene,

1107


5 ethoxypropylene, and ethoxyisopropylene.

R^{401a} is selected from chloro, fluoro, bromo and iodo;
and

R^{402} is hydrido.

38. A compound of Claim 37 wherein R^{401a} is meta-chloro or para-chloro.

39. A compound of Formula IC:



5 wherein

R^1 is selected from hydrido, hydroxy, alkyl, cycloalkyl, alkenyl, cycloalkenyl, alkynyl, aryl, heterocyclyl, cycloalkylalkylene, cycloalkenylalkylene, heterocyclylalkylene, haloalkyl, haloalkenyl, haloalkynyl, hydroxyalkyl, hydroxyalkenyl, hydroxyalkynyl, aralkyl, aralkenyl, aralkynyl, arylheterocyclyl, carboxy, carboxyalkyl, alkoxyalkyl, alkenoxyalkyl, alkynoxyalkyl, aryloxyalkyl, alkoxyaryl, heterocyclyloxyalkyl, alkoxyalkoxy, mercaptoalkyl, alkylthioalkylene, alkenylthioalkylene, alkylthioalkenylene, amino, aminoalkyl, alkylamino, alkenylamino, alkynylamino, arylamino, heterocyclylamino, alkylsulfinyl, alkenylsulfinyl, alkynylsulfinyl, arylsulfinyl, heterocyclylsulfinyl, alkylsulfonyl, alkenylsulfonyl, alkynylsulfonyl, arylsulfonyl, heterocyclylsulfonyl, alkylaminoalkylene, alkylsulfonylalkylene, acyl, acyloxycarbonyl, alkoxycarbonylalkylene, aryloxycarbonylalkylene,

10


15

20

1108

heterocyclyloxycarbonylalkylene, alkoxycarbonylarylene,
 25 aryloxycarbonylarylene, heterocyclyloxycarbonylarylene,
 alkylcarbonylalkylene, arylcarbonylalkylene,
 heterocyclylcarbonylalkylene, alkylcarbonylarylene,
 arylcarbonylarylene, heterocyclylcarbonylarylene,
 alkylcarbonyloxyalkylene, arylcarbonyloxyalkylene,
 30 heterocyclylcarbonyloxyalkylene, alkylcarbonyloxyarylene,
 arylcarbonyloxyarylene, and
 heterocyclylcarbonyloxyarylene; or

R¹ has the formula



35 wherein:

i is an integer from 0 to 9;

R²⁵ is selected from hydrogen, alkyl, aralkyl,
 heterocyclylalkyl, alkoxyalkylene, aryloxyalkylene,
 aminoalkyl, alkylaminoalkyl, arylaminoalkyl,
 40 alkylcarbonylalkylene, arylcarbonylalkylene, and
 heterocyclylcarbonylaminoalkylene; and

R²⁶ is selected from hydrogen, alkyl, alkenyl,
 alkynyl, cycloalkylalkylene, aralkyl,
 alkoxycarbonylalkylene, and alkylaminoalkyl; and

45 R²⁷ is selected from alkyl, cycloalkyl, alkynyl,
 aryl, heterocyclyl, aralkyl, cycloalkylalkylene,
 cycloalkenylalkylene, cycloalkylarylene,
 cycloalkylcycloalkyl, heterocyclylalkylene, alkylarylene,
 alkylaralkyl, aralkylarylene, alkylheterocyclyl,
 50 alkylheterocyclylalkylene, alkylheterocyclylarylene,
 aralkylheterocyclyl, alkoxyalkylene, alkoxyarylene,
 alkoxyaralkyl, alkoxyheterocyclyl, alkoxyalkoxyarylene,
 aryloxyarylene, aralkoxyarylene,
 alkoxyheterocyclylalkylene, aryloxyalkoxyarylene,
 55 alkoxycarbonylalkylene, alkoxycarbonylheterocyclyl,
 alkoxycarbonylheterocyclylcarbonylalkylene, aminoalkyl,


alkylaminoalkylene, arylaminocarbonylalkylene,
alkoxyarylaminoalkylene, aminocarbonylalkylene,
arylaminocarbonylalkylene, alkylaminocarbonylalkylene,
60 arylcarbonylalkylene, alkoxycarbonylarylene,
aryloxycarbonylarylene, alkylaryloxycarbonylarylene,
arylcarbonylarylene, alkylarylcarbonylarylene,
alkoxycarbonylheterocyclylarylene,
alkoxycarbonylalkoxylarylene,
65 heterocyclylcarbonylalkylarylene, alkylthioalkylene,
cycloalkylthioalkylene, alkylthioarylene,
aralkylthioarylene, heterocyclylthioarylene,
arylthioalkylarylene, arylsulfonylaminoalkylene,
alkylsulfonylarylene, alkylaminosulfonylarylene; wherein
70 said alkyl, cycloalkyl, aryl, heterocyclyl, aralkyl,
heterocyclylalkylene, alkylheterocyclylarylene,
alkoxyarylene, aryloxyarylene, arylaminocarbonylalkylene,
aryloxycarbonylarylene, arylcarbonylarylene,
alkylthioarylene, heterocyclylthioarylene,
75 arylthioalkylarylene, and alkylsulfonylarylene groups
may be optionally substituted with one or more radicals
independently selected from alkyl, halo, haloalkyl,
alkoxy, keto, amino, nitro, and cyano; or
R²⁷ is -CHR²⁸R²⁹ wherein R²⁸ is alkoxycarbonyl, and R²⁹
80 is selected from aralkyl, aralkoxyalkylene,
heterocyclylalkylene, alkylheterocyclylalkylene,
alkoxycarbonylalkylene, alkylthioalkylene, and
aralkylthioalkylene; wherein said aralkyl and
heterocyclyl groups may be optionally substituted with
85 one or more radicals independently selected from alkyl
and nitro; or
R²⁶ and R²⁷ together with the nitrogen atom to which
they are attached form a heterocycle, wherein said
heterocycle is optionally substituted with one or more
90 radicals independently selected from alkyl, aryl,
heterocyclyl, heterocyclylalkylene,
alkylheterocyclylalkylene, aryloxyalkylene,

1110


alkoxyarylene, alkylaryloxyalkylene, alkylcarbonyl, alkoxy carbonyl, aralkoxy carbonyl, alkylamino and
 95 alkoxy carbonylamino; wherein said aryl, heterocyclylalkylene and aryloxyalkylene radicals may be optionally substituted with one or more radicals independently selected from halogen, alkyl and alkoxy; and

100 R^2 is cyclohexyl substituted with one or more substituents selected from optionally substituted hydroxyalkyl, alkylaminoalkylene and cycloalkylamino; and

R^3 is selected from pyridinyl, pyrimidinyl, quinolinyl, purinyl, maleimidyl, pyridonyl, thiazolyl, thiazolylalkyl, thiazolylamino,
 105



wherein the R^3 pyridinyl, pyrimidinyl, quinolinyl, purinyl, maleimidyl, pyridonyl, thiazolyl, thiazolylalkyl, thiazolylamino,
 110




groups may be optionally substituted with one or more substituents independently selected from hydrogen, aryl, alkylamino, alkylthio, alkyloxy, aryloxy, arylamino, arylthio, aralkoxy, wherein said aryl, alkylamino, alkylthio, alkyloxy, aryloxy, arylamino, arylthio, aralkoxy substituents may be optionally substituted with one or more alkylene, alkenylene, hydroxy, halo, haloalkyl, alkoxy, keto, amino, nitro, cyano, alkylsulfonyl, alkylsulfinyl, alkylthio, alkoxyalkyl, aryloxy, heterocyclyl, and heteroaralkoxy; and
 115
 120


1111

R⁴ is selected from hydrido, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, and heterocyclyl, wherein
125 R⁴ is optionally substituted with one or more substituents independently selected from halo, haloalkyl, haloalkoxy, alkoxy, cyano, hydroxy, alkyl, alkenyl, and alkynyl, wherein said haloalkyl, haloalkoxy, alkoxy, cyano, hydroxy, alkyl, alkenyl, and alkynyl substituents may be
130 optionally substituted with one or more alkylene, alkenylene, alkynylene, hydroxy, halo, haloalkyl, alkoxy, keto, amino, nitro, cyano, alkylsulfonyl, alkylsulfinyl, alkylthio, alkoxyalkyl, aryloxy, heterocyclyl, and heteroaralkoxy; or
135 a pharmaceutically-acceptable salt or tautomer thereof.


40. A compound of Claim 39 selected from compounds, their tautomers and their pharmaceutically acceptable salts, of the group consisting of :



1112



41. A compound of Claim 39 having Formula XC:



wherein

Z represents a carbon atom or a nitrogen atom;

- R¹ is selected from hydrido, hydroxy, alkyl,
 5 cycloalkyl, alkenyl, cycloalkenyl, alkynyl, aryl,
 heterocyclyl, cycloalkylalkylene, cycloalkenylalkylene,
 heterocyclylalkylene, haloalkyl, haloalkenyl,
 haloalkynyl, hydroxyalkyl, hydroxyalkenyl,
 hydroxyalkynyl, aralkyl, aralkenyl, aralkynyl,
 10 arylheterocyclyl, carboxy, carboxyalkyl, alkoxyalkyl,
 alkenoxyalkyl, alkynoxyalkyl, aryloxyalkyl, alkoxyaryl,
 heterocyclyloxyalkyl, alkoxyalkoxy, mercaptoalkyl,
 alkylthioalkylene, alkenylthioalkylene,
 alkylthioalkenylene, amino, aminoalkyl, alkylamino,
 15 alkenylamino, alkynylamino, arylamino, heterocyclylamino,

1113

alkylsulfinyl, alkenylsulfinyl, alkynylsulfinyl,
arylsulfinyl, heterocyclylsulfinyl, alkylsulfonyl,
alkenylsulfonyl, alkynylsulfonyl, arylsulfonyl,
heterocyclylsulfonyl, alkylaminoalkylene,
20 alkylsulfonylalkylene, acyl, acyloxycarbonyl,
alkoxycarbonylalkylene, aryloxycarbonylalkylene,
heterocyclylloxycarbonylalkylene, alkoxycarbonylarylene,
aryloxycarbonylarylene, heterocyclylloxycarbonylarylene,
alkylcarbonylalkylene, arylcarbonylalkylene,
25 heterocyclylcarbonylalkylene, alkylcarbonylarylene,
arylcarbonylarylene, heterocyclylcarbonylarylene,
alkylcarbonyloxyalkylene, arylcarbonyloxyalkylene,
heterocyclylcarbonyloxyalkylene, alkylcarbonyloxyarylene,
arylcarbonyloxyarylene, and
30 heterocyclylcarbonyloxyarylene; and

R² is cyclohexyl substituted with one or more
substituents selected from optionally substituted
hydroxyalkyl, alkylaminoalkylene and cycloalkylamino; and

R⁴ is selected from cycloalkyl, cycloalkenyl, aryl,
35 and heterocyclyl, wherein R⁴ is optionally substituted
with one or more substituents independently selected from
halo, haloalkyl, haloalkoxy, alkoxy, cyano, hydroxy,
alkyl, alkenyl, and alkynyl, wherein said haloalkyl,
haloalkoxy, alkoxy, hydroxy, alkyl, alkenyl, and alkynyl
40 substituents may be optionally substituted with one or
more alkylene, alkenylene, alkynylene, hydroxy, halo,
haloalkyl, alkoxy, keto, amino, nitro, cyano,
alkylsulfonyl, alkylsulfinyl, alkylthio, alkoxylalkyl,
aryloxy, heterocyclyl, and heteroaralkoxy; and

45 R⁵ represents one or more substituents independently
selected from hydrogen, aryl, alkylamino, alkylthio,
alkyloxy, aryloxy, arylamino, arylthio, aralkoxy, wherein
said aryl, alkylamino, alkylthio, alkyloxy, aryloxy,
arylamino, arylthio, aralkoxy substituents may be
50 optionally substituted with one or more alkylene,
alkenylene, hydroxy, halo, haloalkyl, alkoxy, keto,

1114

amino, nitro, cyano, alkylsulfonyl, alkylsulfinyl, alkylthio, alkoxyalkyl, aryloxy, heterocyclyl, and heteroaralkoxy; or

55 a pharmaceutically-acceptable salt or tautomer thereof.

42. A compound of Claim 41 wherein R² is cyclohexyl substituted with at least one substituent attached to the 4-position carbon ring atom of the cyclohexyl ring.

43. A compound of Claim 41 wherein Z represents a carbon atom.

44. A compound of Claim 41 wherein Z represents a nitrogen atom.

45. A compound of Claim 41 wherein R¹ is selected from hydrido, alkyl, hydroxyalkyl and alkynyl.

46. A compound of Claim 41 wherein R¹ is hydrido.

47. A compound of Claim 41 wherein R² is cyclohexyl substituted with one or more substituents selected from optionally substituted lower hydroxyalkyl, lower alkylaminoalkylene and cycloalkylamino.

48. A compound of Claim 41 wherein R⁴ is optionally substituted phenyl.

49. A compound of Claim 41 wherein R⁴ is phenyl optionally substituted at a substitutable position with one or more radicals independently selected from chloro, fluoro, bromo and iodo.


50. A compound of Claim 41 wherein R⁴ is phenyl optionally substituted at the meta or para position with

1115

one or more chloro radicals.

51. A compound of Claim 41 wherein R⁵ is hydrido.

52. A compound of Claim 41 having Formula XXIA:



wherein:

Z represents a carbon atom or a nitrogen atom;

R⁴⁰³ is selected from hydroxyalkyl,

5 alkylaminoalkylene and cycloalkylamino; and

R^{404a} and R^{404b} are independently selected from
hydrogen, halo, haloalkyl, haloalkoxy, alkoxy, cyano,
hydroxy, alkyl, alkenyl, and alkynyl, wherein said
haloalkyl, haloalkoxy, alkoxy, hydroxy, alkyl, alkenyl,
10 and alkynyl substituents may be optionally substituted
with one or more alkylene, alkenylene, alkynylene,
hydroxy, halo, haloalkyl, alkoxy, keto, amino, nitro,
cyano, alkylsulfonyl, alkylsulfinyl, alkylthio,
alkoxyalkyl, aryloxy, heterocyclyl, and heteroaralkoxy;
15 and

R⁴⁰⁵ is selected from hydrogen, aryl, alkylamino,
alkylthio, alkyloxy, aryloxy, arylamino, arylthio,
aralkoxy, wherein said aryl, alkylamino, alkylthio,
alkyloxy, aryloxy, arylamino, arylthio, aralkoxy

1116

- 20 substituents may be optionally substituted with one or more alkylene, alkenylene, hydroxy, halo, haloalkyl, alkoxy, keto, amino, nitro, cyano, alkylsulfonyl, alkylsulfinyl, alkylthio, alkoxyalkyl, aryloxy, heterocyclyl, and heteroaralkoxy; or
- 25 a pharmaceutically-acceptable salt or tautomer thereof.

53. A compound of Claim 52 wherein:

R^{403} is selected from lower hydroxyalkyl, lower alkylaminoalkylene and cycloalkylamino; and

- R^{404a} and R^{404b} are independently selected from hydrogen, halo, lower haloalkyl, lower haloalkoxy, lower alkoxy, cyano, hydroxy, lower alkyl, lower alkenyl, and lower alkynyl, wherein said lower haloalkyl, lower haloalkoxy, lower alkoxy, cyano, hydroxy, lower alkyl, lower alkenyl, and lower alkynyl substituents may be optionally substituted with one or more lower alkylene, lower alkenylene, lower alkynylene, hydroxy, halo, lower haloalkyl, lower alkoxy, keto, amino, nitro, cyano, lower alkylsulfonyl, lower alkylsulfinyl, lower alkylthio, lower alkoxyalkyl, phenyloxy, heterocyclyl, and lower heteroaralkoxy; and
- 10

- 15 R^{405} is selected from hydrogen, phenyl, lower alkylamino, lower alkylthio, lower alkyloxy, phenyloxy, phenylamino, phenylthio, and phenylalkoxy, wherein said phenyl, lower alkylamino, lower alkylthio, lower alkyloxy, phenyloxy, phenylamino, phenylthio, and phenylalkoxy may be optionally substituted with one or more lower alkylene, lower alkenylene, hydroxy, halo, lower haloalkyl, lower alkoxy, keto, amino, nitro, cyano, lower alkylsulfonyl, lower alkylsulfinyl, lower alkylthio, lower alkoxyalkyl, phenyloxy, heterocyclyl, and lower heteroaralkoxy; or
- 20
- 25

a pharmaceutically-acceptable salt or tautomer thereof.

1117

54. A compound of Claim 52 wherein Z represents a carbon atom.

55. A compound of Claim 52 wherein Z represents a nitrogen atom.

56. A compound of Claim 52 wherein R^{403} is optionally substituted hydroxyalkyl.

57. A compound of Claim 52 wherein R^{403} is optionally substituted alkylaminoalkylene.

58. A compound of Claim 57 wherein R^{403} is optionally substituted dialkylaminoalkylene.

59. A compound of Claim 52 wherein R^{403} is optionally substituted cycloalkylamino.

60. A compound of Claim 52 wherein R^{404a} is selected from chloro, fluoro, bromo and iodo.

61. A compound of Claim 52 wherein R^{404a} is meta-chloro or para-chloro.

62. A compound of Claim 52 wherein R^{405} is hydrido.

63. A compound of Claim 52 wherein:

R^{403} is optionally substituted lower hydroxyalkyl;

R^{404a} is selected from chloro, fluoro, bromo and iodo;

5 and

R^{405} is hydrido.

64. A compound of Claim 52 wherein:

R^{403} is selected from optionally substituted hydroxymethyl, hydroxyethyl, hydroxypropyl and hydroxybutyl;

1118

5 R^{404a} is selected from chloro, fluoro, bromo and iodo;
and
 R⁴⁰⁵ is hydrido.

65. A compound of Claim 64 wherein R^{404a} is meta-chloro or para-chloro.

66. A compound of Claim 52 wherein:
 R⁴⁰³ is optionally substituted lower
alkylaminoalkylene;
 R^{404a} is selected from chloro, fluoro, bromo and iodo;
5 and
 R⁴⁰⁵ is hydrido.

67. A compound of Claim 52 wherein:
 R⁴⁰³ is selected from optionally substituted
methylaminomethylene, methylaminoethylene,
methylaminopropylene, ethylaminomethylene,
5 ethylaminoethylene, ethylaminopropylene,
propylaminomethylene, propylaminoethylene,
propylaminopropylene, dimethylaminomethylene,
dimethylaminoethylene, dimethylaminopropylene,
diethylaminomethylene, diethylaminoethylene,
10 diethylaminopropylene, dipropylaminomethylene,
dipropylaminoethylene, and dipropylaminopropylene;
 R^{404a} is selected from chloro, fluoro, bromo and iodo;
and
 R⁴⁰⁵ is hydrido.

68. A compound of Claim 67 wherein R^{404a} is meta-chloro or para-chloro.

69. A compound of Claim 52 wherein:
 R⁴⁰³ is optionally substituted cycloalkylamino;
 R^{404a} is selected from chloro, fluoro, bromo and iodo;
and

1119

5 R^{405} is hydrido.

70. A compound of Claim 52 wherein:


R^{403} is selected from optionally substituted cyclopropyl, cyclobutyl, cyclopentyl and cyclohexyl;

R^{404a} is selected from chloro, fluoro, bromo and iodo;

5 and

R^{405} is hydrido.

71. A compound of Formula XXIB:



wherein:

Z represents a carbon atom or a nitrogen atom;

R^{403} is selected from alkylamino; and

5 R^{404a} and R^{404b} are independently selected from hydrogen, halo, haloalkyl, haloalkoxy, alkoxy, cyano, hydroxy, alkyl, alkenyl, and alkynyl, wherein said haloalkyl, haloalkoxy, alkoxy, hydroxy, alkyl, alkenyl, and alkynyl substituents may be optionally substituted
 10 with one or more alkylene, alkenylene, alkynylene, hydroxy, halo, haloalkyl, alkoxy, keto, amino, nitro,

1120

cyano, alkylsulfonyl, alkylsulfinyl, alkylthio, alkoxyalkyl, aryloxy, heterocyclyl, and heteroaralkoxy; and

- 15 R^{405} is selected from hydrogen, aryl, alkylamino, alkylthio, alkyloxy, aryloxy, arylamino, arylthio, aralkoxy, wherein said aryl, alkylamino, alkylthio, alkyloxy, aryloxy, arylamino, arylthio, aralkoxy substituents may be optionally substituted with one or
20 more alkylene, alkenylene, hydroxy, halo, haloalkyl, alkoxy, keto, amino, nitro, cyano, alkylsulfonyl, alkylsulfinyl, alkylthio, alkoxyalkyl, aryloxy, heterocyclyl, and heteroaralkoxy; or
 a pharmaceutically-acceptable salt or tautomer
25 thereof.

72. A compound of Claim 71 wherein:

R^{403} is selected from lower alkylamino; and

- R^{404a} and R^{404b} are independently selected from hydrogen, halo, lower haloalkyl, lower haloalkoxy, lower alkoxy, cyano, hydroxy, lower alkyl, lower alkenyl, and
5 lower alkynyl, wherein said lower haloalkyl, lower haloalkoxy, lower alkoxy, cyano, hydroxy, lower alkyl, lower alkenyl, and lower alkynyl substituents may be optionally substituted with one or more lower alkylene, lower alkenylene, lower alkynylene, hydroxy, halo, lower
10 haloalkyl, lower alkoxy, keto, amino, nitro, cyano, lower alkylsulfonyl, lower alkylsulfinyl, lower alkylthio, lower alkoxyalkyl, phenyloxy, heterocyclyl, and lower heteroaralkoxy; and

- R^{405} is selected from hydrogen, phenyl, lower
15 alkylamino, lower alkylthio, lower alkyloxy, phenyloxy, phenylamino, phenylthio, and phenylalkoxy, wherein said phenyl, lower alkylamino, lower alkylthio, lower alkyloxy, phenyloxy, phenylamino, phenylthio, and phenylalkoxy may be optionally substituted with one or
20 more lower alkylene, lower alkenylene, hydroxy, halo,

1121

lower haloalkyl, lower alkoxy, keto, amino, nitro, cyano, lower alkylsulfonyl, lower alkylsulfinyl, lower alkylthio, lower alkoxyalkyl, phenyloxy, heterocyclyl, and lower heteroaralkoxy; or

25 a pharmaceutically-acceptable salt or tautomer thereof.

73. A compound of Claim 71 wherein Z represents a carbon atom.

74. A compound of Claim 71 wherein Z represents a nitrogen atom.

75. A compound of Claim 71 wherein R^{403} is optionally substituted dialkylamino.

76. A compound of Claim 71 wherein R^{404a} is selected from chloro, fluoro, bromo and iodo.

77. A compound of Claim 71 wherein R^{404a} is meta-chloro or para-chloro.

78. A compound of Claim 71 wherein R^{405} is hydrido.

79. A compound of Claim 71 wherein:

R^{403} is optionally substituted lower alkylamino;

R^{404a} is selected from chloro, fluoro, bromo and iodo;

and

5 R^{405} is hydrido.

80. A compound of Claim 71 wherein:

R^{403} is selected from optionally substituted methylamino, ethylamino, n-propylamino, isopropylamino, n-butylamino, sec-butylamino, t-butylamino,

5 isobutylamino, dimethylamino, diethylamino, di-n-propylamino, di-isopropylamino, di-n-butylamino, di-sec-

1122

butylamino, di-t-butylamino, and di-isobutylamino;


R^{404a} is selected from chloro, fluoro, bromo and iodo;

and

10 R^{405} is hydrido.

81. A compound of Claim 80 wherein R^{404a} is meta-chloro or para-chloro.

82. A compound Formula XXII:



wherein:

Z represents a carbon atom or a nitrogen atom;

R^{406} is alkynyl; and

5 R^{407a} and R^{407b} are independently selected from hydrogen, halo, haloalkyl, haloalkoxy, alkoxy, cyano, hydroxy, alkyl, alkenyl, and alkynyl, wherein said haloalkyl, haloalkoxy, alkoxy, hydroxy, alkyl, alkenyl, and alkynyl substituents may be optionally substituted

10 with one or more alkylene, alkenylene, alkynylene, hydroxy, halo, haloalkyl, alkoxy, keto, amino, nitro, cyano, alkylsulfonyl, alkylsulfinyl, alkylthio, alkoxyalkyl, aryloxy, heterocyclyl, and heteroaralkoxy; and

15 R^{408} is selected from hydrogen, aryl, alkylamino, alkylthio, alkyloxy, aryloxy, arylamino, arylthio,

1123

aralkoxy, wherein said aryl, alkylamino, alkylthio, alkyloxy, aryloxy, arylamino, arylthio, aralkoxy substituents may be optionally substituted with one or
20 more alkylene, alkenylene, hydroxy, halo, haloalkyl, alkoxy, keto, amino, nitro, cyano, alkylsulfonyl, alkylsulfinyl, alkylthio, alkoxyalkyl, aryloxy, heterocyclyl, and heteroaralkoxy; or
a pharmaceutically-acceptable salt or tautomer
25 thereof.

83. A compound of Claim 82 wherein:

R⁴⁰⁶ is selected from lower alkynyl; and

R^{407a} and R^{407b} are independently selected from hydrogen, halo, lower haloalkyl, lower haloalkoxy, lower alkoxy, cyano, hydroxy, lower alkyl, lower alkenyl, and
5 lower alkynyl, wherein said lower haloalkyl, lower haloalkoxy, lower alkoxy, cyano, hydroxy, lower alkyl, lower alkenyl, and lower alkynyl substituents may be optionally substituted with one or more lower alkylene, lower alkenylene, lower alkynylene, hydroxy, halo, lower
10 haloalkyl, lower alkoxy, keto, amino, nitro, cyano, lower alkylsulfonyl, lower alkylsulfinyl, lower alkylthio, lower alkoxyalkyl, phenyloxy, heterocyclyl, and lower heteroaralkoxy; and

R⁴⁰⁸ is selected from hydrogen, phenyl, lower
15 alkylamino, lower alkylthio, lower alkyloxy, phenyloxy, phenylamino, phenylthio, and phenylalkoxy, wherein said phenyl, lower alkylamino, lower alkylthio, lower alkyloxy, phenyloxy, phenylamino, phenylthio, and phenylalkoxy may be optionally substituted with one or
20 more lower alkylene, lower alkenylene, hydroxy, halo, lower haloalkyl, lower alkoxy, keto, amino, nitro, cyano, lower alkylsulfonyl, lower alkylsulfinyl, lower alkylthio, lower alkoxyalkyl, phenyloxy, heterocyclyl, and lower heteroaralkoxy; or

25 a pharmaceutically-acceptable salt or tautomer

1124

thereof.

84. A compound of Claim 82 wherein Z represents a carbon atom.

85. A compound of Claim 82 wherein Z represents a nitrogen atom.

86. A compound of Claim 82 wherein R^{407a} is selected from chloro, fluoro, bromo and iodo.

87. A compound of Claim 82 wherein R^{407a} is meta-chloro or para-chloro.

88. A compound of Claim 82 wherein R⁴⁰⁸ is hydrido.

89. A compound of Claim 82 wherein:

R⁴⁰⁶ is optionally substituted lower alkynyl;

R^{407a} is selected from chloro, fluoro, bromo and iodo;

and

5 R⁴⁰⁸ is hydrido.

90. A compound of Claim 82 wherein:

R⁴⁰⁶ is selected from optionally substituted ethynyl, propynyl and butynyl;

R^{407a} is selected from chloro, fluoro, bromo and iodo;

5 and


R⁴⁰⁸ is hydrido.

91. A compound of Claim 82 wherein R⁴⁰⁶ is propargyl.

92. A compound of Claim 82 wherein R^{407a} is meta-chloro or para-chloro.

93. A compound of Formula IA

1125




wherein

R¹ is selected from hydrido, hydroxy, alkyl,
 5 cycloalkyl, alkenyl, cycloalkenyl, alkynyl, aryl,
 heterocyclyl, cycloalkylalkylene, cycloalkenylalkylene,
 heterocyclylalkylene, haloalkyl, haloalkenyl,
 haloalkynyl, hydroxyalkyl, hydroxyalkenyl,
 hydroxyalkynyl, aralkyl, aralkenyl, aralkynyl,
 10 arylheterocyclyl, carboxy, carboxyalkyl, alkoxyalkyl,
 alkenoxyalkyl, alkynoxyalkyl, aryloxyalkyl, alkoxyaryl,
 heterocycliloxyalkyl, alkoxyalkoxy, mercaptoalkyl,
 alkylthioalkylene, alkenylthioalkylene,
 alkylthioalkenylene, amino, aminoalkyl, alkylamino,
 15 alkenylamino, alkynylamino, arylamino, heterocyclylamino,
 alkylsulfinyl, alkenylsulfinyl, alkynylsulfinyl,
 arylsulfinyl, heterocyclylsulfinyl, alkylsulfonyl,
 alkenylsulfonyl, alkynylsulfonyl, arylsulfonyl,
 heterocyclylsulfonyl, alkylaminoalkylene,
 20 alkylsulfonylalkylene, acyl, acyloxy carbonyl,
 alkoxy carbonylalkylene, aryloxy carbonylalkylene,
 heterocycliloxy carbonylalkylene, alkoxy carbonylarylene,
 aryloxy carbonylarylene, heterocycliloxy carbonylarylene,
 alkylcarbonylalkylene, arylcarbonylalkylene,
 25 heterocyclylcarbonylalkylene, alkylcarbonylarylene,
 arylcarbonylarylene, heterocyclylcarbonylarylene,
 alkylcarbonyloxyalkylene, arylcarbonyloxyalkylene,
 heterocyclylcarbonyloxyalkylene, alkylcarbonyloxyarylene,
 arylcarbonyloxyarylene, and
 30 heterocyclylcarbonyloxyarylene; or

R¹ has the formula

1126



wherein:

i is an integer from 0 to 9;

35 R^{25} is selected from hydrogen, alkyl, aralkyl, heterocyclalkyl, alkoxyalkylene, aryloxyalkylene, aminoalkyl, alkylaminoalkyl, arylaminoalkyl, alkylcarbonylalkylene, arylcarbonylalkylene, and heterocyclalkylcarbonylaminoalkylene; and

40 R^{26} is selected from hydrogen, alkyl, alkenyl, alkynyl, cycloalkylalkylene, aralkyl, alkoxy carbonylalkylene, and alkylaminoalkyl; and

45 R^{27} is selected from alkyl, cycloalkyl, alkynyl, aryl, heterocycl, aralkyl, cycloalkylalkylene, cycloalkenylalkylene, cycloalkylarylene, cycloalkylcycloalkyl, heterocyclalkylene, alkylarylene, alkylaralkyl, aralkylarylene, alkylheterocycl, alkylheterocyclalkylene, alkylheterocyclarylene, aralkylheterocycl, alkoxyalkylene, alkoxyarylene, 50 alkoxyaralkyl, alkoxyheterocycl, alkoxyalkoxyarylene, aryloxyarylene, aralkoxyarylene, alkoxyheterocyclalkylene, aryloxyalkoxyarylene, alkoxy carbonylalkylene, alkoxy carbonyl heterocycl, alkoxy carbonyl heterocycl carbonylalkylene, aminoalkyl, 55 alkylaminoalkylene, arylaminocarbonylalkylene, alkoxyarylaminocarbonylalkylene, aminocarbonylalkylene, arylaminocarbonylalkylene, alkylaminocarbonylalkylene, arylcarbonylalkylene, alkoxy carbonylarylene, aryloxy carbonylarylene, alkylaryloxy carbonylarylene, 60 arylcarbonylarylene, alkylarylcarbonylarylene, alkoxy carbonyl heterocyclarylene, alkoxy carbonylalkoxyarylene, heterocycl carbonylalkylarylene, alkylthioalkylene, cycloalkylthioalkylene, alkylthioarylene,

65 aralkylthioarylene, heterocyclylthioarylene,
arylthioalkylarylene, arylsulfonylaminoalkylene,
alkylsulfonylarylene, and alkylaminosulfonylarylene;
wherein said alkyl, cycloalkyl, aryl, heterocyclyl,
aralkyl, heterocyclylalkylene, alkylheterocyclylarylene,
70 alkoxyarylene, aryloxyarylene, arylaminocarbonylalkylene,
aryloxycarbonylarylene, arylcarbonylarylene,
alkylthioarylene, heterocyclylthioarylene,
arylthioalkylarylene, and alkylsulfonylarylene groups
may be optionally substituted with one or more radicals
75 independently selected from alkyl, halo, haloalkyl,
alkoxy, keto, amino, nitro, and cyano; or

R^{27} is $-CHR^{28}R^{29}$ wherein R^{28} is alkoxycarbonyl, and R^{29}
is selected from aralkyl, aralkoxyalkylene,
heterocyclylalkylene, alkylheterocyclylalkylene,
80 alkoxycarbonylalkylene, alkylthioalkylene, and
aralkylthioalkylene; wherein said aralkyl and
heterocyclyl groups may be optionally substituted with
one or more radicals independently selected from alkyl
and nitro; or

85 R^{26} and R^{27} together with the nitrogen atom to which
they are attached form a heterocycle, wherein said
heterocycle is optionally substituted with one or more
radicals independently selected from alkyl, aryl,
heterocyclyl, heterocyclylalkylene,
90 alkylheterocyclylalkylene, aryloxyalkylene,
alkoxyarylene, alkylaryloxyalkylene, alkylcarbonyl,
alkoxycarbonyl, aralkoxycarbonyl, alkylamino and
alkoxycarbonylamino; wherein said aryl,
heterocyclylalkylene and aryloxyalkylene radicals may be
95 optionally substituted with one or more radicals
independently selected from halogen, alkyl and alkoxy;
and

R^2 is selected from mercapto,
aryl(hydroxyalkyl)amino, N-alkyl-N-alkynyl-amino,
100 aminocarbonylalkylene, alkylcarbonylaminoalkylene,

1128

aminoalkylcarbonylaminoalkylene,
 alkylaminoalkylcarbonylamino, aminoalkylthio,
 alkylaminocarbonylalkylthio,
 alkylaminoalkylaminocarbonylalkylthio, cyanoalkylthio,
 105 alkenylthio, alkynylthio, carboxyalkylthio,
 alkoxycarbonylalkylthio, alkylsulfinyl, alkylsulfonyl,
 alkoxyalkyl, alkoxyalkylthio, alkoxycarbonylalkylamino,
 alkoxycarbonylaminoalkylene, alkoxycarbonylaminoalkoxy,
 aralkylthio, heterocyclylalkylthio, aminoalkoxy,
 110 cyanoalkoxy, carboxyalkoxy, aryloxy, aralkoxy,
 alkenyloxy, alkynyloxy, and heterocyclylalkyloxy; or

R^2 is R^{200} -heterocyclyl- R^{201} , R^{200} -aryl- R^{201} , or R^{200} -
 cycloalkyl- R^{201} wherein:

R^{200} is selected from:

- 115 - $(CR^{202}R^{203})_y^-$;
 - $C(O)-$;
 - $C(O)-(CH_2)_y^-$;
 - $C(O)-O-(CH_2)_y^-$;
 - $(CH_2)_y-C(O)-$;
 120 - $O-(CH_2)_y-C(O)-$;
 - $NR^{202}-$;
 - $NR^{202}-(CH_2)_y^-$;
 - $(CH_2)_y-NR^{202}-$;
 - $(CH_2)_y-NR^{202}-(CH_2)_z^-$;
 125 - $(CH_2)_y-C(O)-NR^{202}-(CH_2)_z^-$;
 - $(CH_2)_y-NR^{202}-C(O)-(CH_2)_z^-$;
 - $(CH_2)_y-NR^{202}-C(O)-NR^{203}-(CH_2)_z^-$;
 - $S(O)_x-(CR^{202}R^{203})_y^-$;
 - $(CR^{202}R^{203})_y-S(O)_x-$;
 130 - $S(O)_x-(CR^{202}R^{203})_y-O-$;
 - $S(O)_x-(CR^{202}R^{203})_y-C(O)-$;
 - $O-(CH_2)_y^-$;
 - $(CH_2)_y-O-$;
 - $S-$; and
 135 - $O-$;
 or R^{200} represents a bond;

1129

R^{201} represents one or more radicals selected from the group consisting of hydroxy, hydroxyalkyl, cycloalkyl, hydroxyalkylcarbonyl, cycloalkylcarbonyl, arylcarbonyl, haloarylcarbonyl, alkoxyalkylene, alkoxyarylene, carboxyalkylcarbonyl, alkoxyalkylcarbonyl, heterocyclylalkylcarbonyl, alkylsulfonylalkylene, aminoalkyl, aralkylamino, alkylaminoalkylene, aminocarbonyl, alkylcarbonylamino, alkylcarbonylaminoalkylene, alkylaminoalkylcarbonyl, alkylaminoalkylcarbonylamino, aminoalkylcarbonylaminoalkyl, alkoxy carbonylamino, alkoxyalkylcarbonylamino, alkoxy carbonylaminoalkylene, alkylimidocarbonyl, amidino, alkylamidino, aralkylamidino, guanidino, guanidinoalkylene, and alkylsulfonylamino; and

R^{202} and R^{203} are independently selected from hydrido, alkyl, aryl and aralkyl; and


y and z are independently 0, 1, 2, 3, 4, 5 or 6 wherein y + z is less than or equal to 6; and

x is 0, 1 or 2; or

R^2 is $-NHCR^{204}R^{205}$ wherein R^{204} is alkylaminoalkylene, and R^{205} is aryl; or


R^2 is $-C(NR^{206})R^{207}$ wherein R^{206} is selected from hydrogen and hydroxy, and R^{207} is selected from alkyl, aryl and aralkyl; and

R^3 is selected from pyridinyl, pyrimidinyl, quinolinyl, purinyl, maleimidyl, pyridonyl, thiazolyl, thiazolylalkyl, thiazolylamino,



wherein the R^3 pyridinyl, pyrimidinyl, quinolinyl, purinyl, maleimidyl, pyridonyl, thiazolyl, thiazolylalkyl, thiazolylamino,

1130



170

groups may be optionally substituted with one or more radicals independently selected from halo, keto, alkyl, aralkyl, aralkenyl, arylheterocyclyl, carboxy, carboxyalkyl, alkoxy, aryloxy, alkylthio, arylthio, alkylsulfinyl, arylsulfinyl, alkylsulfonyl, arylsulfonyl, aralkoxy, heterocyclylalkoxy, amino, alkylamino, alkenylamino, alkynylamino, cycloalkylamino, cycloalkenylamino, arylamino, haloaryl amino, heterocyclylamino, aminocarbonyl, cyano, hydroxy, hydroxyalkyl, alkoxyalkylene, alkenoxyalkylene, aryloxyalkyl, alkoxyalkylamino, alkylaminoalkoxy, alkoxy carbonyl, aryloxy carbonyl, heterocyclyl oxy carbonyl, alkoxy carbonyl amino, alkoxyaryl amino, alkoxyaralkyl amino, aminosulfinyl, aminosulfonyl, alkylsulfonyl amino, alkylaminoalkyl amino, hydroxyalkyl amino, aralkyl amino, aryl(hydroxyalkyl) amino, alkylaminoalkyl aminoalkyl amino, alkylheterocyclyl amino, heterocyclylalkyl amino, alkylheterocyclylalkyl amino, aralkylheterocyclyl amino, heterocyclylheterocyclylalkyl amino, alkoxy carbonyl heterocyclyl amino, nitro, alkylaminocarbonyl, alkylcarbonyl amino, haloalkylsulfonyl, aminoalkyl, haloalkyl, alkylcarbonyl, hydrazinyl, alkylhydrazinyl, arylhydrazinyl, and -NR⁴⁴R⁴⁵ wherein R⁴⁴ is alkylcarbonyl or amino, and R⁴⁵ is alkyl or aralkyl; and


R⁴ is selected from hydrido, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, and heterocyclyl, wherein R⁴ is optionally substituted with one or more radicals independently selected from halo, alkyl, alkenyl, alkynyl, aryl, heterocyclyl, alkylthio, arylthio, alkylthioalkylene, arylthioalkylene, alkylsulfinyl,

200

1131

- alkylsulfinylalkylene, arylsulfinylalkylene,
 alkylsulfonyl, alkylsulfonylalkylene,
 205 arylsulfonylalkylene, alkoxy, aryloxy, aralkoxy,
 aminocarbonyl, alkylaminocarbonyl, arylaminocarbonyl,
 alkoxycarbonyl, aryloxycarbonyl, haloalkyl, amino, cyano,
 nitro, alkylamino, arylamino, alkylaminoalkylene,
 arylaminoalkylene, aminoalkylamino, and hydroxy;
 210 provided R^3 is not 2-pyridinyl when R^4 is a phenyl
 ring containing a 2-hydroxy substituent and when R^1 is
 hydrido; and
 further provided R^2 is selected from $-R^{200}-$
 heterocyclyl- R^{201} , $-R^{200}-$ aryl- R^{201} , or $-R^{200}-$ unsubstituted
 215 cycloalkyl- R^{201} when R^4 is hydrido; and
 further provided that R^4 is not methylsulfonylphenyl
 or aminosulfonylphenyl; and
 further provided that R^1 is not methylsulfonylphenyl;
 or
 220 a pharmaceutically-acceptable salt or tautomer
 thereof.

94. A compound of Formula IXA:



wherein

Z represents a carbon atom or a nitrogen atom; and
 5 R^1 is selected from hydrido, lower alkyl, lower

1132

hydroxyalkyl, lower alkynyl, lower aralkyl, lower aminoalkyl and lower alkylaminoalkyl; and

R^2 is lower hydroxyalkylamino; or

R^2 is R^{200} -heterocyclyl- R^{201} or R^{200} -cycloalkyl- R^{201}

10 wherein:

R^{200} is selected from:

- $(CR^{202}R^{203})_y-$;

- $NR^{202}-$;

- $NR^{202}-(CH_2)_y-$;

15 - $(CH_2)_y-NR^{202}-$;

- $O-(CH_2)_y-$;

- $(CH_2)_y-O-$;

-S-;

-O-;

20 or R^{200} represents a bond;

R^{201} represents one or more radicals selected from

the group consisting of hydroxy, lower hydroxyalkyl, lower cycloalkyl; lower hydroxyalkylcarbonyl, lower cycloalkylcarbonyl, arylcarbonyl, haloarylcarbonyl, lower

25 alkoxyalkylene, lower alkoxyarylene, lower

carboxyalkylcarbonyl, lower alkoxyalkylcarbonyl, lower heterocyclylalkylcarbonyl, lower alkylsulfonylalkylene, amino, lower aminoalkyl, lower aralkylamino, lower alkylaminoalkylene, aminocarbonyl, lower

30 alkylcarbonylamino, lower alkylcarbonylaminoalkylene,

lower alkylaminoalkylcarbonyl, lower

alkylaminoalkylcarbonylamino, lower

aminoalkylcarbonylaminoalkyl, lower alkoxycarbonylamino,

lower alkoxyalkylcarbonylamino, lower

35 alkoxycarbonylaminoalkylene, lower alkylimidocarbonyl,

amidino, lower alkylamidino, lower aralkylamidino,

guanidino, lower guanidinoalkylene, and lower

alkylsulfonylamino; and

R^{202} and R^{203} are independently selected from hydrido,

40 lower alkyl, aryl and lower aralkyl; and

y is 0, 1, 2 or 3; and

1133

R⁴ is selected from aryl selected from phenyl, biphenyl, naphthyl, wherein said aryl is optionally substituted at a substitutable position with one or more radicals independently selected from halo, lower alkyl, lower alkoxy, aryloxy, lower aralkoxy, lower haloalkyl, lower alkylthio, lower alkylamino, nitro, and hydroxy; and

R⁵ is selected from hydrido, halo, amino, cyano, aminocarbonyl, lower alkyl, lower alkoxy, hydroxy, lower aminoalkyl, lower aralkyl, lower aralkyloxy, lower aralkylamino, lower alkoxycarbonyl, lower alkylamino, lower hydroxyalkylamino, lower alkylcarbonyl, lower aralkenyl, lower arylheterocyclyl, carboxy, lower cycloalkylamino, lower hydroxycycloalkylamino, lower alkoxycarbonylamino, lower alkoxylaralkylamino, lower alkylaminoalkylamino, lower heterocyclylamino, lower heterocyclylalkylamino, lower aralkylheterocyclylamino, lower alkylaminocarbonyl, lower alkylcarbonyl, lower alkoxylaralkylamino, hydrazinyl, and lower alkylhydrazinyl, or -NR⁶²R⁶³ wherein R⁶² is lower alkylcarbonyl or amino, and R⁶³ is lower alkyl or lower phenylalkyl; or

a pharmaceutically-acceptable salt or tautomer thereof.

95. A compound of Claim 94 wherein R² is R²⁰⁰-heterocyclyl-R²⁰¹.

96. A compound of Claim 94 wherein R² is R²⁰⁰-cycloalkyl-R²⁰¹.

97. A compound of Claim 94 wherein:

R¹ is selected from hydrido, methyl, ethyl, hydroxyethyl and propargyl; and

R² is R²⁰⁰-piperidinyl-R²⁰¹, R²⁰⁰-piperazinyl-R²⁰¹, or R²⁰⁰-cyclohexyl-R²⁰¹ wherein:

R²⁰⁰ is selected from:

1134

- (CR²⁰²R²⁰³)_y-;

-NR²⁰²-;

-S-;

10 -O-;

or R²⁰⁰ represents a bond;

R²⁰¹ represents one or more radicals selected from the group consisting of hydroxy, hydroxymethyl, hydroxyethyl, hydroxypropyl, hydroxybutyl, (1-hydroxy-
15 1,1-dimethyl)ethyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, methoxymethylene, methoxyethylene, methoxypropylene, ethoxyethylene, ethoxypropylene, propoxyethylene, propoxypropylene, methoxyphenylene, ethoxyphenylene, propoxyphenylene, cyclopropylcarbonyl, cyclobutylcarbonyl, cyclopentylcarbonyl,
20 cyclohexylcarbonyl, benzoyl, chlorobenzoyl, fluorobenzoyl, hydroxymethylcarbonyl, hydroxyethylcarbonyl, hydroxypropylcarbonyl, carboxymethylcarbonyl, carboxyethylcarbonyl, carboxypropylcarbonyl, methoxymethylcarbonyl, methoxyethylcarbonyl, methoxypropylcarbonyl, ethoxymethylcarbonyl, ethoxyethylcarbonyl, ethoxypropylcarbonyl, propoxymethylcarbonyl, propoxyethylcarbonyl, propoxypropylcarbonyl,
25 methoxyphenylcarbonyl, ethoxyphenylcarbonyl, propoxyphenylcarbonyl, piperidinylmethylcarbonyl, piperazinylmethylcarbonyl, morpholinylcarbonyl, methylsulfonylmethylene, amino, aminomethyl, aminoethyl, aminopropyl, phenylamino, benzylamino, methylaminomethylene, ethylaminomethylene, methylaminoethylene, ethylaminoethylene, aminocarbonyl, methylcarbonylamino, ethylcarbonylamino, methylaminomethylcarbonyl, ethylaminomethylcarbonyl, methylcarbonylaminoethylene,
35 ethylcarbonylaminoethylene, aminomethylcarbonylaminoethylmethylene, methoxycarbonylamino, ethoxycarbonylamino,

40

methoxymethylcarbonylamino, methoxyethylcarbonylamino,
ethoxymethylcarbonylamino, ethoxyethylcarbonylamino,
45 methoxycarbonylaminomethylene,
ethoxycarbonylaminomethylene, methylimidocarbonyl,
ethylimidocarbonyl, amidino, methylamidino,
methylamidino, benzylamidino, guanidino,
guanidinomethylene, guanidinoethylene, and
50 methylsulfonylamino; and
R²⁰² and R²⁰³ are independently selected from hydrido,
methyl, ethyl, propyl, butyl, phenyl and benzyl; and
y is 0, 1 or 2; and
R⁴ is phenyl, wherein said phenyl is optionally
55 substituted with one or more radicals independently
selected from methylthio, fluoro, chloro, bromo, iodo,
methyl, ethyl, methoxy, ethoxy, phenoxy, benzyloxy,
trifluoromethyl, nitro, dimethylamino, and hydroxy; and
R⁵ is selected from hydrido, fluoro, chloro, bromo,
60 iodo, hydroxy, methyl, ethyl, propyl, benzyl,
fluorophenylethyl, fluorophenylethenyl,
fluorophenylpyrazolyl, cyano, carboxy, methoxy,
methoxycarbonyl, aminocarbonyl, acetyl, methylamino,
dimethylamino, 2-methylbutylamino, ethylamino,
65 dimethylaminoethylamino, hydroxyethylamino,
hydroxypropylamino, hydroxybutylamino,
hydroxycyclopropylamino, hydroxycyclobutylamino,
hydroxycyclopentylamino, hydroxycyclohexylamino,
imidazolylamino, morpholinylethylamino, (1-ethyl-2-
70 hydroxy)ethylamino, piperidinylamino,
pyridinylmethylamino, phenylmethylpiperidinylamino,
aminomethyl, cyclopropylamino, amino,
ethoxycarbonylamino, methoxyphenylmethylamino,
phenylmethylamino, fluorophenylmethylamino,
75 fluorophenylethylamino, methylaminoethylamino,
dimethylaminoethylamino, methylaminopropylamino,
dimethylaminopropylamino, methylaminobutylamino,
dimethylaminobutylamino, methylaminopentylamino,

1136

80 dimethylaminopentylamino, ethylaminoethylamino,
 diethylaminoethylamino, ethylaminopropylamino,
 diethylaminopropylamino, ethylaminobutylamino,
 diethylaminobutylamino, ethylaminopentylamino,
 methylaminocarbonyl, methylcarbonyl, ethylcarbonyl,
 hydrazinyl, and 1-methylhydrazinyl, or $-NR^{62}R^{63}$ wherein R^{62}
 85 is methylcarbonyl or amino, and R^{63} is methyl or benzyl;
 or


a pharmaceutically-acceptable salt or tautomer thereof.

98. A compound of Claim 97 wherein R^2 is R^{200} -piperidinyl- R^{201} .

99. A compound of Claim 97 wherein R^2 is R^{200} -pyrazinyl- R^{201} .

100. A compound of Claim 97 wherein R^2 is R^{200} -cyclohexyl- R^{201} .

101. A compound of Claim 94 having the Formula XA:



wherein:

Z represents a carbon atom or a nitrogen atom; and

R^1 is selected from hydrido, methyl, ethyl,

1137

hydroxyethyl and propargyl; and

R^2 is R^{200} -piperidinyl- R^{201} wherein:

R^{200} is selected from:

$-(CR^{202}R^{203})_y-$;

10 $-NR^{202}-$;

$-S-$;

$-O-$;

or R^{200} represents a bond;

R^{201} represents one or more radicals selected from

15 the group consisting of hydroxy, hydroxymethyl, hydroxyethyl, hydroxypropyl, hydroxybutyl, (1-hydroxy-1,1-dimethyl)ethyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, methoxymethylene, methoxyethylene, methoxypropylene, ethoxyethylene, ethoxypropylene,

20 propoxyethylene, propoxypropylene, methoxyphenylene, ethoxyphenylene, propoxyphenylene, cyclopropylcarbonyl, cyclobutylcarbonyl, cyclopentylcarbonyl, cyclohexylcarbonyl, benzoyl, chlorobenzoyl, fluorobenzoyl, hydroxymethylcarbonyl,

25 hydroxyethylcarbonyl, hydroxypropylcarbonyl, carboxymethylcarbonyl, carboxyethylcarbonyl, carboxypropylcarbonyl, methoxymethylcarbonyl, methoxyethylcarbonyl, methoxypropylcarbonyl, ethoxymethylcarbonyl, ethoxyethylcarbonyl,

30 ethoxypropylcarbonyl, propoxymethylcarbonyl, propoxyethylcarbonyl, propoxypropylcarbonyl, methoxyphenylcarbonyl, ethoxyphenylcarbonyl, propoxyphenylcarbonyl, piperidinylmethylcarbonyl, piperazinylmethylcarbonyl, morpholinylcarbonyl,

35 methylsulfonylmethylene, amino, aminomethyl, aminoethyl, aminopropyl, N-methylamino, N,N-dimethylamino, N-ethylamino, N,N-diethylamino, N-propylamino, N,N-dipropylamino, phenylamino, benzylamino, methylaminomethylene, ethylaminomethylene,

40 methylaminoethylene, ethylaminoethylene, aminocarbonyl, methylcarbonylamino, ethylcarbonylamino,

methylaminomethylcarbonyl, ethylaminomethylcarbonyl,
methylcarbonylaminomethylene,
ethylcarbonylaminomethylene,

45 aminomethylcarbonylaminocarbonylmethylene,
methoxycarbonylamino, ethoxycarbonylamino,
methoxymethylcarbonylamino, methoxyethylcarbonylamino,
ethoxymethylcarbonylamino, ethoxyethylcarbonylamino,
methoxycarbonylaminomethylene,

50 ethoxycarbonylaminomethylene, methylimidocarbonyl,
ethylimidocarbonyl, amidino, methylamidino,
methylamidino, benzylamidino, guanidino,
guanidinomethylene, guanidinoethylene, and
methylsulfonylamino; and

55 R^{202} and R^{203} are independently selected from hydrido,
methyl, ethyl, propyl, butyl, phenyl and benzyl; and
y is 0, 1 or 2; and

R^4 is phenyl, wherein said phenyl is optionally
substituted with one or more radicals independently
60 selected from fluoro, chloro, methyl, ethyl, methoxy and
ethoxy; and

R^5 is selected from hydrido, fluoro, chloro, bromo,
hydroxy, methyl, ethyl, propyl, benzyl, cyano, carboxy,
methoxy, methoxycarbonyl, aminocarbonyl, acetyl,
65 methylamino, dimethylamino, 2-methylbutylamino,
ethylamino, dimethylaminoethylamino, hydroxyethylamino,
hydroxypropylamino, hydroxybutylamino,
hydroxycyclopropylamino, hydroxycyclobutylamino,
hydroxycyclopentylamino, hydroxycyclohexylamino,
70 imidazolylamino, morpholinylethylamino, (1-ethyl-2-
hydroxy)ethylamino, piperidinylamino,
pyridinylmethylamino, phenylmethylpiperidinylamino,
aminomethyl, cyclopropylamino, amino,
ethoxycarbonylamino, methoxyphenylmethylamino,
75 phenylmethylamino, fluorophenylmethylamino,
fluorophenylethylamino, methylaminoethylamino,
dimethylaminoethylamino, methylaminopropylamino,

1139

dimethylaminopropylamino, methylaminobutylamino,
dimethylaminobutylamino, methylaminopentylamino,
80 dimethylaminopentylamino, ethylaminoethylamino,
diethylaminoethylamino, ethylaminopropylamino,
diethylaminopropylamino, ethylaminobutylamino,
diethylaminobutylamino, ethylaminopentylamino,
methylaminocarbonyl, methylcarbonyl, and ethylcarbonyl;
85 or

a pharmaceutically-acceptable salt or tautomer
thereof.

102. A compound of Claim 101 wherein:

R^1 is selected from hydrido, methyl, ethyl,
hydroxyethyl and propargyl; and

R^2 is R^{200} -piperidinyl- R^{201} wherein:

5 R^{200} is selected from:

methylene;

- NR^{202} -;

-S-;

-O-;

10 or R^{200} represents a bond;

R^{201} represents one or more radicals selected from
the group consisting of hydroxy, hydroxymethyl,
hydroxyethyl, hydroxypropyl, (1-hydroxy-1,1-
dimethyl)ethyl, methoxymethyl, methoxyethyl,
15 methoxypropyl, ethoxyethyl, ethoxypropyl, propoxyethyl,
propoxypropyl, methoxyphenyl, ethoxyphenyl,
propoxyphenyl, hydroxymethylcarbonyl,
hydroxyethylcarbonyl, carboxymethylcarbonyl,
carboxyethylcarbonyl, methoxymethylcarbonyl,
20 methoxyethylcarbonyl, methoxypropylcarbonyl,
ethoxymethylcarbonyl, ethoxyethylcarbonyl,
ethoxypropylcarbonyl, propoxymethylcarbonyl,
propoxyethylcarbonyl, propoxypropylcarbonyl,
methoxyphenylcarbonyl, ethoxyphenylcarbonyl,
25 propoxyphenylcarbonyl, methylsulfonylmethylene, amino,

1140

aminomethyl, aminoethyl, aminopropyl, N-benzylamino, methylaminomethylene, aminocarbonyl, methoxycarbonylamino, ethoxycarbonylamino, or methylsulfonylamino; and

30 R^{202} is selected from hydrido, methyl, ethyl, phenyl and benzyl; and

R^4 is phenyl, wherein said phenyl is optionally substituted with one or more radicals independently selected from fluoro, chloro, methyl, ethyl, methoxy and
35 ethoxy; and

R^5 is selected from hydrido, fluoro, chloro, bromo, hydroxy, methyl, ethyl, cyano, carboxy, methoxy, methoxycarbonyl, aminocarbonyl, acetyl, methylamino, dimethylamino, ethylamino, dimethylaminoethylamino,
40 hydroxyethylamino, hydroxypropylamino, hydroxybutylamino, hydroxycyclopropylamino, hydroxycyclobutylamino, hydroxycyclopentylamino, hydroxycyclohexylamino, (1-ethyl-2-hydroxy)ethylamino, aminomethyl, cyclopropylamino, amino, ethoxycarbonylamino,
45 methoxyphenylmethylamino, phenylmethylamino, fluorophenylmethylamino, fluorophenylethylamino, methylaminoethylamino, dimethylaminoethylamino, methylaminopropylamino, dimethylaminopropylamino, methylaminobutylamino, dimethylaminobutylamino,
50 methylaminopentylamino, dimethylaminopentylamino, ethylaminoethylamino, diethylaminoethylamino, ethylaminopropylamino, diethylaminopropylamino, ethylaminobutylamino, diethylaminobutylamino, ethylaminopentylamino, methylaminocarbonyl,
55 methylcarbonyl, and ethylcarbonyl; or

 a pharmaceutically-acceptable salt or tautomer thereof.

103. A compound of Claim 101 wherein:

R^1 is hydrido; and

R^2 is R^{200} -piperidinyl- R^{201} wherein:

1141

R²⁰⁰ is selected from:

5 methylene;

-NR²⁰²-;

-S-;

-O-;

or R²⁰⁰ represents a bond;

10 R²⁰¹ represents one or more radicals selected from
the group consisting of hydroxy, hydroxymethyl,
hydroxyethyl, hydroxypropyl, methoxymethyl, methoxyethyl,
methoxypropyl, ethoxyethyl, ethoxypropyl, propoxyethyl,
propoxypropyl, methoxyphenyl, ethoxyphenyl,
15 propoxyphenyl, hydroxymethylcarbonyl,
hydroxyethylcarbonyl, carboxymethylcarbonyl,
carboxyethylcarbonyl, methoxymethylcarbonyl,
methoxyethylcarbonyl, ethoxymethylcarbonyl,
ethoxyethylcarbonyl, methoxyphenylcarbonyl,
20 ethoxyphenylcarbonyl, amino, aminomethyl, aminoethyl,
aminopropyl, N-benzylamino, methylaminomethylene,
aminocarbonyl, methoxycarbonylamino, and
ethoxycarbonylamino; and

25 R²⁰² is selected from hydrido, methyl phenyl and
benzyl; and

R⁴ is phenyl, wherein said phenyl is optionally
substituted with one or more radicals independently
selected from fluoro, chloro, methyl, and methoxy; and

R⁵ is selected from hydrido, methylamino,
30 dimethylamino, 2-methylbutylamino, ethylamino,
dimethylaminoethylamino, hydroxypropylamino,
hydroxyethylamino, hydroxypropylamino, hydroxybutylamino,
hydroxycyclopropylamino, hydroxycyclobutylamino,
hydroxycyclopentylamino, hydroxycyclohexylamino, (1-
35 ethyl-2-hydroxy)ethylamino, aminomethyl,
cyclopropylamino, amino, dimethylaminoethylamino,
dimethylaminopropylamino, dimethylaminobutylamino,
dimethylaminopentylamino, diethylaminoethylamino,
diethylaminopropylamino, diethylaminobutylamino, and

1142

40 diethylaminopentylamino; or
a pharmaceutically-acceptable salt or tautomer thereof.

104. A compound of Claim 101 wherein:

R^1 is hydrido; and

R^2 is R^{200} -piperidinyl- R^{201} wherein:

R^{200} is selected from:

5 methylene;

- NR^{202} -;

-S-;

-O-;

or R^{200} represents a bond;

10 R^{201} represents one or more radicals selected from the group consisting of methoxyethyl, methylcarbonyl, hydroxymethylcarbonyl, methoxymethylcarbonyl, and amino; and


R^{202} is selected from hydrido and methyl; and

15 R^4 is phenyl, wherein said phenyl is optionally substituted with one or more radicals independently selected from fluoro, chloro, methyl, and methoxy; and

R^5 is selected from hydrido, hydroxypropylamino, hydroxycyclohexylamino, diethylaminoethylamino; or

20 a pharmaceutically-acceptable salt or tautomer thereof.

105. A compound of Claim 94 having the Formula XA:



(XA)

1143

wherein:

Z represents a carbon atom or a nitrogen atom; and

5 R^1 is selected from hydrido, methyl, ethyl, hydroxyethyl and propargyl; and

R^2 is R^{200} -piperazinyl- R^{201} wherein:

R^{200} is selected from:

- ($CR^{202}R^{203}$)_y-;

10 - NR^{202} -;

-S-;

-O-;

or R^{200} represents a bond;

15 R^{201} represents one or more radicals selected from the group consisting of hydroxy, hydroxymethyl, hydroxyethyl, hydroxypropyl, hydroxybutyl, (1-hydroxy-1,1-dimethyl)ethyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, methoxymethylene, methoxyethylene, methoxypropylene, ethoxyethylene, ethoxypropylene, propoxyethylene, propoxypropylene, methoxyphenylene, ethoxyphenylene, propoxyphenylene, cyclopropylcarbonyl, cyclobutylcarbonyl, cyclopentylcarbonyl, cyclohexylcarbonyl, benzoyl, chlorobenzoyl, fluorobenzoyl, hydroxymethylcarbonyl, hydroxyethylcarbonyl, hydroxypropylcarbonyl, carboxymethylcarbonyl, carboxyethylcarbonyl, carboxypropylcarbonyl, methoxymethylcarbonyl, methoxyethylcarbonyl, methoxypropylcarbonyl, ethoxymethylcarbonyl, ethoxyethylcarbonyl, ethoxypropylcarbonyl, propoxymethylcarbonyl, propoxyethylcarbonyl, propoxypropylcarbonyl, methoxyphenylcarbonyl, ethoxyphenylcarbonyl, propoxyphenylcarbonyl, piperidinylmethylcarbonyl, piperazinylmethylcarbonyl, morpholinylcarbonyl, methylsulfonylmethylene, amino, aminomethyl, aminoethyl, aminopropyl, phenylamino, benzylamino, methylaminomethylene, ethylaminomethylene, methylaminoethylene, ethylaminoethylene, aminocarbonyl,

20
25
30
35

1144

methylecarbonylamino, ethylecarbonylamino,
40 methyleaminomethylecarbonyl, ethyleaminomethylecarbonyl,
methylecarbonylaminomethylelene,
ethylecarbonylaminomethylelene,
aminomethylecarbonylamino carbonylmethylelene,
methoxycarbonylamino, ethoxycarbonylamino,
45 methoxymethylecarbonylamino, methoxyethylecarbonylamino,
ethoxymethylecarbonylamino, ethoxyethylecarbonylamino,
methoxycarbonylaminomethylelene,
ethoxycarbonylaminomethylelene, methylimidocarbonyl,
ethylimidocarbonyl, amidino, methyleamidino,
50 methyleamidino, benzyleamidino, guanidino,
guanidinomethylelene, guanidinoethylelene, and
methyleulfonylamino; and
R²⁰² and R²⁰³ are independently selected from hydrido,
methyle, ethyle, propyle, butyle, phenyle and benzyle; and
55 y is 0, 1 or 2; and
R⁴ is phenyle, wherein said phenyle is optionally
substituted with one or more radicals independently
selected from fluoro, chloro, methyle, ethyle, methoxy and
ethoxy; and
60 R⁵ is selected from hydrido, fluoro, chloro, bromo,
hydroxy, methyle, ethyle, propyle, benzyle, cyano, carboxy,
methoxy, methoxycarbonyl, aminocarbonyl, acetyl,
methyleamino, dimethyleamino, 2-methylebutyleamino,
ethyleamino, dimethyleaminoethyleamino, hydroxyethyleamino,
65 hydroxypropyleamino, hydroxybutyleamino,
hydroxycyclopropyleamino, hydroxycyclobutyleamino,
hydroxycyclopentyleamino, hydroxycyclohexyleamino,
imidazolyleamino, morpholinylethyleamino, (1-ethyle-2-
hydroxy)ethyleamino, piperidinyleamino,
70 pyridinylemethyleamino, phenylemethylepiperidinyleamino,
aminomethyle, cyclopropyleamino, amino,
ethoxycarbonylamino, methoxyphenylemethyleamino,
phenylemethyleamino, fluorophenylemethyleamino,
fluorophenylethyleamino, methyleaminoethyleamino,

1145

75 dimethylaminoethylamino, methylaminopropylamino,
dimethylaminopropylamino, methylaminobutylamino,
dimethylaminobutylamino, methylaminopentylamino,
dimethylaminopentylamino, ethylaminoethylamino,
diethylaminoethylamino, ethylaminopropylamino,
80 diethylaminopropylamino, ethylaminobutylamino,
diethylaminobutylamino, ethylaminopentylamino,
methylaminocarbonyl, methylcarbonyl, and ethylcarbonyl;
or

a pharmaceutically-acceptable salt or tautomer
85 thereof.

106. A compound of Claim 105 wherein:

R^1 is selected from hydrido, methyl, ethyl,
hydroxyethyl and propargyl; and

R^2 is R^{200} -piperazinyl- R^{201} wherein:

5 R^{200} is selected from:

$-(CR^{202}R^{203})_y-$;

$-NR^{202}-$;

$-S-$;

$-O-$;

10 or R^{200} represents a bond;


R^{201} represents one or more radicals selected from
the group consisting of hydroxy, hydroxymethyl,
hydroxyethyl, hydroxypropyl, (1-hydroxy-1,1-
dimethyl)ethyl, cyclopropyl, cyclobutyl, cyclopentyl,
15 cyclohexyl, methoxymethylene, methoxyethylene,
ethoxyethylene, methoxyphenylene, ethoxyphenylene,
cyclopropylcarbonyl, cyclobutylcarbonyl,
cyclopentylcarbonyl, cyclohexylcarbonyl, benzoyl,
chlorobenzoyl, fluorobenzoyl, hydroxymethylcarbonyl,
20 hydroxyethylcarbonyl, hydroxypropylcarbonyl,
carboxymethylcarbonyl, carboxyethylcarbonyl,
carboxypropylcarbonyl, methoxymethylcarbonyl,
methoxyethylcarbonyl, methoxypropylcarbonyl,
ethoxymethylcarbonyl, ethoxyethylcarbonyl,

- 25 ethoxypropylcarbonyl, propoxymethylcarbonyl,
propoxyethylcarbonyl, propoxypropylcarbonyl,
methoxyphenylcarbonyl, ethoxyphenylcarbonyl,
propoxyphenylcarbonyl, piperidinylmethylcarbonyl,
piperazinylmethylcarbonyl, morpholinylcarbonyl,
30 methylsulfonylmethylene, amino, aminomethyl, aminoethyl,
aminopropyl, phenylamino, benzylamino,
methylaminomethylene, ethylaminomethylene,
methylaminoethylene, ethylaminoethylene, aminocarbonyl,
methylcarbonylamino, ethylcarbonylamino,
35 methylaminomethylcarbonyl, ethylaminomethylcarbonyl,
methylcarbonylaminomethylene,
ethylcarbonylaminomethylene,
aminomethylcarbonylaminoethylmethylene,
methoxycarbonylamino, ethoxycarbonylamino,
40 methoxymethylcarbonylamino, methoxyethylcarbonylamino,
ethoxymethylcarbonylamino, ethoxyethylcarbonylamino,
methoxycarbonylaminomethylene,
ethoxycarbonylaminomethylene, and methylsulfonylamino;
and
45 R^{202} and R^{203} are independently selected from hydrido,
methyl, ethyl, phenyl and benzyl; and
y is 0, 1 or 2; and
 R^4 is phenyl, wherein said phenyl is optionally
substituted with one or more radicals independently
50 selected from fluoro, chloro, methyl, ethyl, methoxy and
ethoxy; and
 R^5 is selected from hydrido, fluoro, chloro, bromo,
hydroxy, methyl, ethyl, cyano, carboxy, methoxy,
methoxycarbonyl, aminocarbonyl, acetyl, methylamino,
55 dimethylamino, ethylamino, dimethylaminoethylamino,
hydroxyethylamino, hydroxypropylamino, hydroxybutylamino,
hydroxycyclopropylamino, hydroxycyclobutylamino,
hydroxycyclopentylamino, hydroxycyclohexylamino, (1-
ethyl-2-hydroxy)ethylamino, aminomethyl,
60 cyclopropylamino, amino, ethoxycarbonylamino,

1147

methoxyphenylmethylamino, phenylmethylamino,
 fluorophenylmethylamino, fluorophenylethylamino,
 methylaminoethylamino, dimethylaminoethylamino,
 methylaminopropylamino, dimethylaminopropylamino,
 65 methylaminobutylamino, dimethylaminobutylamino,
 methylaminopentylamino, dimethylaminopentylamino,
 ethylaminoethylamino, diethylaminoethylamino,
 ethylaminopropylamino, diethylaminopropylamino,
 ethylaminobutylamino, diethylaminobutylamino,
 70 ethylaminopentylamino, methylaminocarbonyl,
 methylcarbonyl, and ethylcarbonyl; or
 a pharmaceutically-acceptable salt or tautomer
 thereof.

107. A compound of Claim 94 having the Formula XA:



wherein:

Z represents a carbon atom or a nitrogen atom; and

5 R¹ is selected from hydrido, methyl, ethyl,
 hydroxyethyl and propargyl; and

R² is R²⁰⁰-cyclohexyl-R²⁰¹ wherein:

R²⁰⁰ is selected from:

-(CR²⁰²R²⁰³)_y-;

10 -NR²⁰²-;

-S-;

1148

-O-;

or R²⁰⁰ represents a bond;

R²⁰¹ represents one or more radicals selected from

- 15 the group consisting of hydroxy, hydroxymethyl,
hydroxyethyl, hydroxypropyl, hydroxybutyl, (1-hydroxy-
1,1-dimethyl)ethyl, cyclopropyl, cyclobutyl, cyclopentyl,
cyclohexyl, methoxymethylene, methoxyethylene,
methoxypropylene, ethoxyethylene, ethoxypropylene,
20 propoxyethylene, propoxypropylene, methoxyphenylene,
ethoxyphenylene, propoxyphenylene, cyclopropylcarbonyl,
cyclobutylcarbonyl, cyclopentylcarbonyl,
cyclohexylcarbonyl, benzoyl, chlorobenzoyl,
fluorobenzoyl, hydroxymethylcarbonyl,
25 hydroxyethylcarbonyl, hydroxypropylcarbonyl,
carboxymethylcarbonyl, carboxyethylcarbonyl,
carboxypropylcarbonyl, methoxymethylcarbonyl,
methoxyethylcarbonyl, methoxypropylcarbonyl,
ethoxymethylcarbonyl, ethoxyethylcarbonyl,
30 ethoxypropylcarbonyl, propoxymethylcarbonyl,
propoxyethylcarbonyl, propoxypropylcarbonyl,
methoxyphenylcarbonyl, ethoxyphenylcarbonyl,
propoxyphenylcarbonyl, piperidinylmethylcarbonyl,
piperazinylmethylcarbonyl, morpholinylcarbonyl,
35 methylsulfonylmethylene, amino, aminomethyl, aminoethyl,
aminopropyl, phenylamino, benzylamino,
methylaminomethylene, ethylaminomethylene,
methylaminoethylene, ethylaminoethylene, aminocarbonyl,
methylcarbonylamino, ethylcarbonylamino,
40 methylaminomethylcarbonyl, ethylaminomethylcarbonyl,
methylcarbonylaminomethylene,
ethylcarbonylaminomethylene,
aminomethylcarbonylaminoethylmethylene,
methoxycarbonylamino, ethoxycarbonylamino,
45 methoxymethylcarbonylamino, methoxyethylcarbonylamino,
ethoxymethylcarbonylamino, ethoxyethylcarbonylamino,
methoxycarbonylaminomethylene,

ethoxycarbonylaminomethylene, methylimidocarbonyl,
ethylimidocarbonyl, amidino, methylamidino,
50 methylamidino, benzylamidino, guanidino,
guanidinomethylene, guanidinoethylene, and
methylsulfonylamino; and
R²⁰² and R²⁰³ are independently selected from hydrido,
methyl, ethyl, propyl, butyl, phenyl and benzyl; and
55 y is 0, 1 or 2; and
R⁴ is phenyl, wherein said phenyl is optionally
substituted with one or more radicals independently
selected from fluoro, chloro, methyl, ethyl, methoxy and
ethoxy; and
60 R⁵ is selected from hydrido, fluoro, chloro, bromo,
hydroxy, methyl, ethyl, propyl, benzyl, cyano, carboxy,
methoxy, methoxycarbonyl, aminocarbonyl, acetyl,
methylamino, dimethylamino, 2-methylbutylamino,
ethylamino, dimethylaminoethylamino, hydroxyethylamino,
65 hydroxypropylamino, hydroxybutylamino,
hydroxycyclopropylamino, hydroxycyclobutylamino,
hydroxycyclopentylamino, hydroxycyclohexylamino,
imidazolylamino, morpholinylethylamino, (1-ethyl-2-
hydroxy)ethylamino, piperidinylamino,
70 pyridinylmethylamino, phenylmethylpiperidinylamino,
aminomethyl, cyclopropylamino, amino,
ethoxycarbonylamino, methoxyphenylmethylamino,
phenylmethylamino, fluorophenylmethylamino,
fluorophenylethylamino, methylaminoethylamino,
75 dimethylaminoethylamino, methylaminopropylamino,
dimethylaminopropylamino, methylaminobutylamino,
dimethylaminobutylamino, methylaminopentylamino,
dimethylaminopentylamino, ethylaminoethylamino,
diethylaminoethylamino, ethylaminopropylamino,
80 diethylaminopropylamino, ethylaminobutylamino,
diethylaminobutylamino, ethylaminopentylamino,
methylaminocarbonyl, methylcarbonyl, and ethylcarbonyl;
or

1150

a pharmaceutically-acceptable salt or tautomer
85 thereof.

108. A compound of Claim 107 wherein:

R^1 is selected from hydrido, methyl, ethyl,
hydroxyethyl and propargyl; and

R^2 is R^{200} -cyclohexyl- R^{201} wherein:

5 R^{200} is selected from:

- $(CR^{202}R^{203})_y-$;

- $NR^{202}-$;

-S-;

-O-;

10 or R^{200} represents a bond;

R^{201} represents one or more radicals selected from
the group consisting of hydroxy, hydroxymethyl,
hydroxyethyl, hydroxypropyl, (1-hydroxy-1,1-
dimethyl)ethyl, cyclopropyl, cyclobutyl, cyclopentyl,
15 cyclohexyl, methoxymethylene, methoxyethylene,
methoxypropylene, ethoxyethylene, ethoxypropylene,
propoxyethylene, propoxypropylene, methoxyphenylene,
ethoxyphenylene, propoxyphenylene, cyclopropylcarbonyl,
cyclobutylcarbonyl, cyclopentylcarbonyl,
20 cyclohexylcarbonyl, benzoyl, chlorobenzoyl,
fluorobenzoyl, hydroxymethylcarbonyl,
hydroxyethylcarbonyl, hydroxypropylcarbonyl,
carboxymethylcarbonyl, carboxyethylcarbonyl,
carboxypropylcarbonyl, methoxymethylcarbonyl,
25 methoxyethylcarbonyl, methoxypropylcarbonyl,
ethoxymethylcarbonyl, ethoxyethylcarbonyl,
ethoxypropylcarbonyl, propoxymethylcarbonyl,
propoxyethylcarbonyl, propoxypropylcarbonyl,
methoxyphenylcarbonyl, ethoxyphenylcarbonyl,
30 propoxyphenylcarbonyl, piperidinylmethylcarbonyl,
piperazinylmethylcarbonyl, morpholinylcarbonyl,
methylsulfonylmethylene, amino, aminomethyl, aminoethyl,
aminopropyl, phenylamino, benzylamino,

1151

methylaminomethylene, ethylaminomethylene,
35 methylaminoethylene, ethylaminoethylene, aminocarbonyl,
methylcarbonylamino, ethylcarbonylamino,
methylaminomethylcarbonyl, ethylaminomethylcarbonyl,
methylcarbonylaminomethylene,
ethylcarbonylaminomethylene,
40 aminomethylcarbonylaminoethylmethylene,
methoxycarbonylamino, ethoxycarbonylamino,
methoxymethylcarbonylamino, methoxyethylcarbonylamino,
ethoxymethylcarbonylamino, ethoxyethylcarbonylamino,
methoxycarbonylaminomethylene, and
45 ethoxycarbonylaminomethylene; and

R^{202} and R^{203} are independently selected from hydrido,
methyl, ethyl, phenyl and benzyl; and

y is 0, 1 or 2; and

R^4 is phenyl, wherein said phenyl is optionally
50 substituted with one or more radicals independently
selected from fluoro, chloro, methyl, ethyl, methoxy and
ethoxy; and

R^5 is selected from hydrido, fluoro, chloro, bromo,
hydroxy, methyl, ethyl, cyano, carboxy, methoxy,
55 methoxycarbonyl, aminocarbonyl, acetyl, methylamino,
dimethylamino, ethylamino, dimethylaminoethylamino,
hydroxyethylamino, hydroxypropylamino, hydroxybutylamino,
hydroxycyclopropylamino, hydroxycyclobutylamino,
hydroxycyclopentylamino, hydroxycyclohexylamino, (1-
60 ethyl-2-hydroxy)ethylamino, aminomethyl,
cyclopropylamino, amino, ethoxycarbonylamino,
methoxyphenylmethylamino, phenylmethylamino,
fluorophenylmethylamino, fluorophenylethylamino,
methylaminoethylamino, dimethylaminoethylamino,
65 methylaminopropylamino, dimethylaminopropylamino,
methylaminobutylamino, dimethylaminobutylamino,
methylaminopentylamino, dimethylaminopentylamino,
ethylaminoethylamino, diethylaminoethylamino,
ethylaminopropylamino, diethylaminopropylamino,

1152

70 ethylaminobutylamino, diethylaminobutylamino,
ethylaminopentylamino, methylaminocarbonyl,
methylcarbonyl, and ethylcarbonyl; or
a pharmaceutically-acceptable salt or tautomer
thereof.

109. A compound of Claim 107 wherein:

R¹ is hydrido; and

R² is R²⁰⁰-cyclohexyl-R²⁰¹ wherein:

R²⁰⁰ is selected from:

5 methylene;

-NR²⁰²-;

-S-;

-O-;

or R²⁰⁰ represents a bond;

10 R²⁰¹ represents one or more radicals selected from
the group consisting of amino, aminomethyl, aminoethyl,
aminopropyl, phenylamino, benzylamino,
methylaminomethylene, ethylaminomethylene,
methylaminoethylene, ethylaminoethylene, aminocarbonyl,
15 methylcarbonylamino, ethylcarbonylamino,
methylaminomethylcarbonyl, ethylaminomethylcarbonyl,
methylcarbonylaminomethylene,
ethylcarbonylaminomethylene,
aminomethylcarbonylaminocarbonylmethylene,
20 methoxycarbonylamino, ethoxycarbonylamino,
methoxymethylcarbonylamino, methoxyethylcarbonylamino,
ethoxymethylcarbonylamino, ethoxyethylcarbonylamino,
methoxycarbonylaminomethylene, and
ethoxycarbonylaminomethylene; and

25 R²⁰² is selected from hydrido, methyl, phenyl and
benzyl; and

R⁴ is phenyl, wherein said phenyl is optionally
substituted with one or more radicals independently
selected from fluoro, chloro, methyl, and methoxy; and

30 R⁵ is selected from hydrido, methylamino,

1153

dimethylamino, 2-methylbutylamino, ethylamino,
dimethylaminoethylamino, hydroxypropylamino,
hydroxyethylamino, hydroxypropylamino, hydroxybutylamino,
hydroxycyclopropylamino, hydroxycyclobutylamino,
35 hydroxycyclopentylamino, hydroxycyclohexylamino, (1-
ethyl-2-hydroxy)ethylamino, aminomethyl,
cyclopropylamino, amino, dimethylaminoethylamino,
dimethylaminopropylamino, dimethylaminobutylamino,
dimethylaminopentylamino, diethylaminoethylamino,
40 diethylaminopropylamino, diethylaminobutylamino, and
diethylaminopentylamino; or
a pharmaceutically-acceptable salt or tautomer
thereof.

110. A compound of Claim 94 wherein R² comprises a
substituted piperidinyl or piperazinyl moiety with at
least one substituent attached to the distal nitrogen
heteroatom or to a carbon ring atom adjacent to the
5 distal nitrogen heteroatom of the piperidine or
piperazine ring.

111. A compound Claim 94 wherein R² comprises a
substituted piperidinyl moiety with at least one
substituent attached to the distal nitrogen heteroatom or
to a carbon ring atom adjacent to the distal nitrogen
5 heteroatom of the piperidine ring.

112. A compound of Claim 94 wherein R² comprises a
substituted piperazinyl moiety with at least one
substituent attached to the distal nitrogen heteroatom or
to a carbon ring atom adjacent to the distal nitrogen
5 heteroatom of the piperazine ring.

113. A compound of Claim 94 wherein Z represents a
carbon atom.

1154

114. A compound of Claim 94 wherein Z represents a nitrogen atom.

115. A compound of Claim 94 wherein R¹ is hydrido.

116. A compound of Claim 94 wherein R²⁰⁰ represents a bond.

117. A compound of Claim 94 wherein R²⁰¹ represents one or more radicals selected from the group consisting of lower hydroxyalkyl, lower hydroxyalkylcarbonyl, and lower alkylaminoalkylene.

118. A compound of Claim 94 wherein R²⁰¹ represents one or more radicals selected from the group consisting of hydroxymethyl, hydroxyethyl, hydroxypropyl, hydroxybutyl, (1-hydroxy-1,1-dimethyl)ethyl, hydroxymethylcarbonyl, hydroxyethylcarbonyl, hydroxypropylcarbonyl, methylaminomethylene, ethylaminomethylene, methylaminoethylene, and ethylaminoethylene.

119. A compound of Claim 94 wherein R⁴ is optionally substituted phenyl.

120. A compound of Claim 94 wherein R⁴ is phenyl optionally substituted at a substitutable position with one or more radicals independently selected from chloro, fluoro, bromo and iodo.

121. A compound of Claim 94 wherein R⁴ is phenyl optionally substituted at the meta or para position with one or more chloro radicals.

122. A compound of Claim 94 wherein R⁵ is hydrido.

1155

123. A compound of Claim 94 wherein:

R¹ is hydrido;

R²⁰⁰ represents a bond;

5 R²⁰¹ represents one or more radicals selected from
the group consisting of lower hydroxyalkyl, lower
hydroxyalkylcarbonyl, and lower alkylaminoalkylene.

R⁴ is phenyl optionally substituted at a
substitutable position with one or more radicals
independently selected from halo; and

10 R⁵ is hydrido.

124. A compound of Claim 94 wherein:

R¹ is hydrido;

R²⁰⁰ represents a bond;



5 R²⁰¹ represents one or more radicals selected from
the group consisting of hydroxymethyl, hydroxyethyl,
hydroxypropyl, hydroxybutyl, (1-hydroxy-1,1-
dimethyl)ethyl, hydroxymethylcarbonyl,
hydroxyethylcarbonyl, hydroxypropylcarbonyl,
methylaminomethylene, ethylaminomethylene,
10 methylaminoethylene, and ethylaminoethylene;

R⁴ is phenyl optionally substituted at a
substitutable position with one or more radicals
independently selected from chloro, fluoro, bromo and
iodo; and


15 R⁵ is hydrido.

125. A compound selected from compounds, their
tautomers and their pharmaceutically acceptable salts, of
the group consisting of:





1156





5



1157





1158




10

;




;


1159




;



;




; and



HCl
HCl
H₂O

126. A compound of Formula IA




wherein

- 5 R^1 is selected from hydrido, hydroxy, alkyl, cycloalkyl, alkenyl, cycloalkenyl, alkynyl, aryl, heterocyclyl, cycloalkylalkylene, cycloalkenylalkylene, heterocyclylalkylene, haloalkyl, haloalkenyl, haloalkynyl, hydroxyalkyl, hydroxyalkenyl, hydroxyalkynyl, aralkyl, aralkenyl, aralkynyl, arylheterocyclyl, carboxy, carboxyalkyl, alkoxyalkyl, alkenoxyalkyl, alkynoxyalkyl, aryloxyalkyl, alkoxyaryl, heterocycliloxyalkyl, alkoxyalkoxy, mercaptoalkyl, alkylthioalkylene, alkenylthioalkylene, alkylthioalkenylene, amino, aminoalkyl, alkylamino, alkenylamino, alkynylamino, arylamino, heterocyclylamino, alkylsulfinyl, alkenylsulfinyl, alkynylsulfinyl, arylsulfinyl, heterocyclylsulfinyl, alkylsulfonyl, alkenylsulfonyl, alkynylsulfonyl, arylsulfonyl, heterocyclylsulfonyl, alkylaminoalkylene, alkylsulfonylalkylene, acyl, acyloxycarbonyl, alkoxycarbonylalkylene, aryloxycarbonylalkylene, heterocycliloxy carbonylalkylene, alkoxycarbonylarylene, aryloxycarbonylarylene, heterocycliloxy carbonylarylene, alkylcarbonylalkylene, arylcarbonylalkylene, heterocyclylcarbonylalkylene, alkylcarbonylarylene, arylcarbonylarylene, heterocyclylcarbonylarylene, alkylcarbonyloxyalkylene, arylcarbonyloxyalkylene, heterocyclylcarbonyloxyalkylene, alkylcarbonyloxyarylene,

1161

- 30 arylcarbonyloxyarylene, and
heterocyclylcarbonyloxyarylene; or

R¹ has the formula



wherein:

- 35 i is an integer from 0 to 9;
R²⁵ is selected from hydrogen, alkyl, aralkyl,
heterocyclylalkyl, alkoxyalkylene, aryloxyalkylene,
aminoalkyl, alkylaminoalkyl, arylaminoalkyl,
alkylcarbonylalkylene, arylcarbonylalkylene, and
40 heterocyclylcarbonylaminoalkylene; and
R²⁶ is selected from hydrogen, alkyl, alkenyl,
alkynyl, cycloalkylalkylene, aralkyl,
alkoxycarbonylalkylene, and alkylaminoalkyl; and
R²⁷ is selected from alkyl, cycloalkyl, alkynyl,
45 aryl, heterocyclyl, aralkyl, cycloalkylalkylene,
cycloalkenylalkylene, cycloalkylarylene,
cycloalkylcycloalkyl, heterocyclylalkylene, alkylarylene,
alkylaralkyl, aralkylarylene, alkylheterocyclyl,
alkylheterocyclylalkylene, alkylheterocyclylarylene,
50 aralkylheterocyclyl, alkoxyalkylene, alkoxyarylene,
alkoxyaralkyl, alkoxyheterocyclyl, alkoxyalkoxyarylene,
aryloxyarylene, aralkoxyarylene,
alkoxyheterocyclylalkylene, aryloxyalkoxyarylene,
alkoxycarbonylalkylene, alkoxycarbonylheterocyclyl,
55 alkoxycarbonylheterocyclylcarbonylalkylene, aminoalkyl,
alkylaminoalkylene, arylaminocarbonylalkylene,
alkoxyarylaminocarbonylalkylene, aminocarbonylalkylene,
arylaminocarbonylalkylene, alkylaminocarbonylalkylene,
arylcarbonylalkylene, alkoxycarbonylarylene,
60 aryloxycarbonylarylene, alkylaryloxycarbonylarylene,
arylcarbonylarylene, alkylarylcarbonylarylene,
alkoxycarbonylheterocyclylarylene,

alkoxycarbonylalkoxylarylene,
heterocyclylcarbonylalkylarylene, alkylthioalkylene,
65 cycloalkylthioalkylene, alkylthioarylene,
aralkylthioarylene, heterocyclylthioarylene,
arylthioalkylarylene, arylsulfonylaminoalkylene,
alkylsulfonylarylene, alkylaminosulfonylarylene; wherein
said alkyl, cycloalkyl, aryl, heterocyclyl, aralkyl,
70 heterocyclylalkylene, alkylheterocyclylarylene,
alkoxyarylene, aryloxyarylene, arylaminocarbonylalkylene,
aryloxy carbonylarylene, arylcarbonylarylene,
alkylthioarylene, heterocyclylthioarylene,
arylthioalkylarylene, and alkylsulfonylarylene groups
75 may be optionally substituted with one or more radicals
independently selected from alkyl, halo, haloalkyl,
alkoxy, keto, amino, nitro, and cyano; or

R^{27} is $-\text{CHR}^{28}\text{R}^{29}$ wherein R^{28} is alkoxycarbonyl, and R^{29}
is selected from aralkyl, aralkoxyalkylene,
80 heterocyclylalkylene, alkylheterocyclylalkylene,
alkoxycarbonylalkylene, alkylthioalkylene, and
aralkylthioalkylene; wherein said aralkyl and
heterocyclyl groups may be optionally substituted with
one or more radicals independently selected from alkyl
85 and nitro; or

R^{26} and R^{27} together with the nitrogen atom to which
they are attached form a heterocycle, wherein said
heterocycle is optionally substituted with one or more
radicals independently selected from alkyl, aryl,
90 heterocyclyl, heterocyclylalkylene,
alkylheterocyclylalkylene, aryloxyalkylene,
alkoxyarylene, alkylaryloxyalkylene, alkylcarbonyl,
alkoxycarbonyl, aralkoxycarbonyl, alkylamino and
alkoxycarbonylamino; wherein said aryl,
95 heterocyclylalkylene and aryloxyalkylene radicals may be
optionally substituted with one or more radicals
independently selected from halogen, alkyl and alkoxy;
and

1163

R^2 is R^{200} -cycloalkyl- R^{201} wherein:

100 R^{200} is selected from:

- $(CR^{202}R^{203})_y-$;

- $C(O)-$;

- $C(O)-(CH_2)_y-$;

- $C(O)-O-(CH_2)_y-$;

105 - $(CH_2)_y-C(O)-$;

- $O-(CH_2)_y-C(O)-$;

- $NR^{202}-$;

- $NR^{202}-(CH_2)_y-$;

- $(CH_2)_y-NR^{202}-$;

110 - $(CH_2)_y-NR^{202}-(CH_2)_z-$;

- $(CH_2)_y-C(O)-NR^{202}-(CH_2)_z-$;

- $(CH_2)_y-NR^{202}-C(O)-(CH_2)_z-$;

- $(CH_2)_y-NR^{202}-C(O)-NR^{203}-(CH_2)_z-$;

- $S(O)_x-(CR^{202}R^{203})_y-$;

115 - $(CR^{202}R^{203})_y-S(O)_x-$;

- $S(O)_x-(CR^{202}R^{203})_y-O-$;

- $S(O)_x-(CR^{202}R^{203})_y-C(O)-$;

- $O-(CH_2)_y-$;

- $(CH_2)_y-O-$;

120 - $S-$; and

- $O-$;

R^{201} represents one or more radicals selected from the group consisting of hydrido, halogen, hydroxy,

carboxy, keto, alkyl, hydroxyalkyl, haloalkyl,

125 cycloalkyl, alkenyl, alkynyl, aryl, heterocyclyl,

aralkyl, heterocyclylalkylene, alkylcarbonyl,

hydroxyalkylcarbonyl, cycloalkylcarbonyl, arylcarbonyl,

haloarylcarbonyl, alkoxy, alkoxyalkylene, alkoxyarylene,

alkoxycarbonyl, carboxyalkylcarbonyl,

130 alkoxyalkylcarbonyl, heterocyclylalkylcarbonyl,

alkylsulfonyl, alkylsulfonylalkylene, amino, aminoalkyl,

alkylamino, aralkylamino, alkylaminoalkylene,

aminocarbonyl, alkylcarbonylamino,

alkylcarbonylaminoalkylene, alkylaminoalkylcarbonyl,

1164


135 alkylaminoalkylcarbonylamino,
 aminoalkylcarbonylaminoalkyl, alkoxy carbonylamino,
 alkoxyalkylcarbonylamino, alkoxy carbonylaminoalkylene,
 alkylimidocarbonyl, amidino, alkylamidino,
 aralkylamidino, guanidino, guanidinoalkylene, and
 140 alkylsulfonylamino; and

R^{202} and R^{203} are independently selected from hydrido,
 alkyl, aryl and aralkyl; and

y and z are independently 0, 1, 2, 3, 4, 5 or 6
 wherein y + z is less than or equal to 6; and


145 x is 0, 1 or 2; and

R^3 is selected from pyridinyl, pyrimidinyl,
 quinolinyl, purinyl, maleimidyl, pyridonyl, thiazolyl,
 thiazolylalkyl, thiazolylamino,



150

wherein the R^3 pyridinyl, pyrimidinyl, quinolinyl,
 purinyl, maleimidyl, pyridonyl, thiazolyl,
 thiazolylalkyl, thiazolylamino,



155

groups may be optionally substituted with one or more
 radicals independently selected from halo, keto, alkyl,
 aralkyl, aralkenyl, arylheterocyclyl, carboxy,
 carboxyalkyl, alkoxy, aryloxy, alkylthio, arylthio,
 160 alkylsulfinyl, arylsulfinyl, alkylsulfonyl, arylsulfonyl,
 aralkoxy, heterocyclylalkoxy, amino, alkylamino,
 alkenylamino, alkynylamino, cycloalkylamino,
 cycloalkenylamino, arylamino, haloaryl amino,
 heterocyclylamino, aminocarbonyl, cyano, hydroxy,

1165

165 hydroxyalkyl, alkoxyalkylene, alkenoxyalkylene,
aryloxyalkyl, alkoxyalkylamino, alkylaminoalkoxy,
alkoxycarbonyl, aryloxycarbonyl, heterocyclyloxycarbonyl,
alkoxycarbonylamino, alkoxyarylamino, alkoxyaralkylamino,
aminosulfinyl, aminosulfonyl, alkylsulfonylamino,
170 alkylaminoalkylamino, hydroxyalkylamino, aralkylamino,
aryl(hydroxyalkyl)amino, alkylaminoalkylaminoalkylamino,
alkylheterocyclylamino, heterocyclylalkylamino,
alkylheterocyclylalkylamino, aralkylheterocyclylamino,
heterocyclylheterocyclylalkylamino,
175 alkoxycarbonylheterocyclylamino, nitro,
alkylaminocarbonyl, alkylcarbonylamino,
haloalkylsulfonyl, aminoalkyl, haloalkyl, alkylcarbonyl,
hydrazinyl, alkylhydrazinyl, arylhydrazinyl, and $-NR^{44}R^{45}$
wherein R^{44} is alkylcarbonyl or amino, and R^{45} is alkyl or
180 aralkyl; and

R^4 is selected from hydrido, alkyl, alkenyl, alkynyl,
cycloalkyl, cycloalkenyl, aryl, and heterocyclyl, wherein
 R^4 is optionally substituted with one or more radicals
independently selected from halo, alkyl, alkenyl,
185 alkynyl, aryl, heterocyclyl, alkylthio, arylthio,
alkylthioalkylene, arylthioalkylene, alkylsulfinyl,
alkylsulfinylalkylene, arylsulfinylalkylene,
alkylsulfonyl, alkylsulfonylalkylene,
arylsulfonylalkylene, alkoxy, aryloxy, aralkoxy,
190 aminocarbonyl, alkylaminocarbonyl, arylaminocarbonyl,
alkoxycarbonyl, aryloxycarbonyl, haloalkyl, amino, cyano,
nitro, alkylamino, arylamino, alkylaminoalkylene,
arylaminoalkylene, aminoalkylamino, and hydroxy;

provided R^3 is not 2-pyridinyl when R^4 is a phenyl
195 ring containing a 2-hydroxy substituent and when R^1 is
hydrido; and


further provided that R^4 is not methylsulfonylphenyl
or aminosulfonylphenyl; and

further provided that R^1 is not methylsulfonylphenyl;
200 or

1166

a pharmaceutically-acceptable salt or tautomer thereof.

127. A compound of Formula IA




wherein

- 5 R^1 is selected from hydrido, hydroxy, alkyl, cycloalkyl, alkenyl, cycloalkenyl, alkynyl, aryl, heterocyclyl, cycloalkylalkylene, cycloalkenylalkylene, heterocyclylalkylene, haloalkyl, haloalkenyl, haloalkynyl, hydroxyalkyl, hydroxyalkenyl, hydroxyalkynyl, aralkyl, aralkenyl, aralkynyl, arylheterocyclyl, carboxy, carboxyalkyl, alkoxyalkyl, alkenoxyalkyl, alkynoxyalkyl, aryloxyalkyl, alkoxyaryl, heterocycliloxyalkyl, alkoxyalkoxy, mercaptoalkyl, alkylthioalkylene, alkenylthioalkylene, alkylthioalkenylene, amino, aminoalkyl, alkylamino, alkenylamino, alkynylamino, arylamino, heterocyclylamino, alkylsulfinyl, alkenylsulfinyl, alkynylsulfinyl, arylsulfinyl, heterocyclylsulfinyl, alkylsulfonyl, alkenylsulfonyl, alkynylsulfonyl, arylsulfonyl, heterocyclylsulfonyl, alkylaminoalkylene, alkylsulfonylalkylene, acyl, acyloxycarbonyl, alkoxycarbonylalkylene, aryloxycarbonylalkylene, heterocycliloxy carbonylalkylene, alkoxycarbonylarylene, aryloxycarbonylarylene, heterocycliloxy carbonylarylene, alkylcarbonylalkylene, arylcarbonylalkylene, heterocyclylcarbonylalkylene, alkylcarbonylarylene, arylcarbonylarylene, heterocyclylcarbonylarylene,
- 10
- 15
- 20
- 25

1167

alkylcarbonyloxyalkylene, arylcarbonyloxyalkylene,
 heterocyclylcarbonyloxyalkylene, alkylcarbonyloxyarylene,
 30 arylcarbonyloxyarylene, and
 heterocyclylcarbonyloxyarylene; or

R¹ has the formula



wherein:

35 i is an integer from 0 to 9;

R²⁵ is selected from hydrogen, alkyl, aralkyl,
 heterocyclylalkyl, alkoxyalkylene, aryloxyalkylene,
 aminoalkyl, alkylaminoalkyl, arylaminoalkyl,
 alkylcarbonylalkylene, arylcarbonylalkylene, and
 40 heterocyclylcarbonylaminoalkylene; and

R²⁶ is selected from hydrogen, alkyl, alkenyl,
 alkynyl, cycloalkylalkylene, aralkyl,
 alkoxycarbonylalkylene, and alkylaminoalkyl; and

R²⁷ is selected from alkyl, cycloalkyl, alkynyl,
 45 aryl, heterocyclyl, aralkyl, cycloalkylalkylene,
 cycloalkenylalkylene, cycloalkylarylene,
 cycloalkylcycloalkyl, heterocyclylalkylene, alkylarylene,
 alkylaralkyl, aralkylarylene, alkylheterocyclyl,
 alkylheterocyclylalkylene, alkylheterocyclylarylene,
 50 aralkylheterocyclyl, alkoxyalkylene, alkoxyarylene,
 alkoxyaralkyl, alkoxyheterocyclyl, alkoxyalkoxyarylene,
 aryloxyarylene, aralkoxyarylene,
 alkoxyheterocyclylalkylene, aryloxyalkoxyarylene,
 alkoxycarbonylalkylene, alkoxycarbonylheterocyclyl,
 55 alkoxycarbonylheterocyclylcarbonylalkylene, aminoalkyl,
 alkylaminoalkylene, arylaminocarbonylalkylene,
 alkoxyarylaminocarbonylalkylene, aminocarbonylalkylene,
 arylaminocarbonylalkylene, alkylaminocarbonylalkylene,
 arylcarbonylalkylene, alkoxycarbonylarylene,
 60 aryloxycarbonylarylene, alkylaryloxycarbonylarylene,

arylcarbonylarylene, alkylarylcarbonylarylene,
alkoxycarbonylheterocyclylarylene,
alkoxycarbonylalkoxylarylene,
heterocyclylcarbonylalkylarylene, alkylthioalkylene,
65 cycloalkylthioalkylene, alkylthioarylene,
aralkylthioarylene, heterocyclylthioarylene,
arylthioalkylarylene, arylsulfonylaminoalkylene,
alkylsulfonylarylene, alkylaminosulfonylarylene; wherein
said alkyl, cycloalkyl, aryl, heterocyclyl, aralkyl,
70 heterocyclylalkylene, alkylheterocyclylarylene,
alkoxyarylene, aryloxyarylene, arylaminocarbonylalkylene,
aryloxycarbonylarylene, arylcarbonylarylene,
alkylthioarylene, heterocyclylthioarylene,
arylthioalkylarylene, and alkylsulfonylarylene groups
75 may be optionally substituted with one or more radicals
independently selected from alkyl, halo, haloalkyl,
alkoxy, keto, amino, nitro, and cyano; or

R^{27} is $-\text{CHR}^{28}\text{R}^{29}$ wherein R^{28} is alkoxycarbonyl, and R^{29}
is selected from aralkyl, aralkoxyalkylene,
80 heterocyclylalkylene, alkylheterocyclylalkylene,
alkoxycarbonylalkylene, alkylthioalkylene, and
aralkylthioalkylene; wherein said aralkyl and
heterocyclyl groups may be optionally substituted with
one or more radicals independently selected from alkyl
85 and nitro; or

R^{26} and R^{27} together with the nitrogen atom to which
they are attached form a heterocycle, wherein said
heterocycle is optionally substituted with one or more
radicals independently selected from alkyl, aryl,
90 heterocyclyl, heterocyclylalkylene,
alkylheterocyclylalkylene, aryloxyalkylene,
alkoxyarylene, alkylaryloxyalkylene, alkylcarbonyl,
alkoxycarbonyl, aralkoxycarbonyl, alkylamino and
alkoxycarbonylamino; wherein said aryl,
95 heterocyclylalkylene and aryloxyalkylene radicals may be
optionally substituted with one or more radicals

1169

independently selected from halogen, alkyl and alkoxy;
and

R^2 is R^{200} -aryl- R^{201} wherein:

100 R^{200} is selected from:

- $(CR^{202}R^{203})_y-$;

- $C(O)-$;

- $C(O)-(CH_2)_y-$;

- $C(O)-O-(CH_2)_y-$;

105 - $(CH_2)_y-C(O)-$;

- $O-(CH_2)_y-C(O)-$;

- $NR^{202}-$;

- $NR^{202}-(CH_2)_y-$;

- $(CH_2)_y-NR^{300}-$;

110 - $(CH_2)_y-NR^{202}-(CH_2)_{z1}-$;

- $(CH_2)_y-C(O)-NR^{202}-(CH_2)_z-$;

- $(CH_2)_y-NR^{202}-C(O)-(CH_2)_z-$;

- $(CH_2)_y-NR^{202}-C(O)-NR^{203}-(CH_2)_z-$;

- $S(O)_x-(CR^{202}R^{203})_y-$;

115 - $(CR^{202}R^{203})_y-S(O)_x-$;

- $S(O)_x-(CR^{202}R^{203})_y-O-$;

- $S(O)_x-(CR^{202}R^{203})_y-C(O)-$;

- $O-(CH_2)_y-$;

- $(CH_2)_y-O-$; and

120 - $O-$;

R^{201} represents one or more radicals selected from
the group consisting of hydrido, halogen, hydroxy,

carboxy, keto, alkyl, hydroxyalkyl, haloalkyl,

cycloalkyl, alkenyl, alkynyl, aryl, heterocyclyl,

125 aralkyl, heterocyclylalkylene, alkylcarbonyl,

hydroxyalkylcarbonyl, cycloalkylcarbonyl, arylcarbonyl,

haloarylcarbonyl, alkoxy, alkoxyalkylene, alkoxyarylene,

alkoxycarbonyl, carboxyalkylcarbonyl,

alkoxyalkylcarbonyl, heterocyclylalkylcarbonyl,

130 alkylsulfonyl, alkylsulfonylalkylene, amino, aminoalkyl,

alkylamino, aralkylamino, alkylaminoalkylene,

aminocarbonyl, alkylcarbonylamino,

1170

alkylcarbonylaminoalkylene, alkylaminoalkylcarbonyl,
 alkylaminoalkylcarbonylamino,
 135 aminoalkylcarbonylaminoalkyl, alkoxycarbonylamino,
 alkoxyalkylcarbonylamino, alkoxycarbonylaminoalkylene,
 alkylimidocarbonyl, amidino, alkylamidino,
 aralkylamidino, guanidino, guanidinoalkylene, and
 alkylsulfonylamino; and

140 R^{202} and R^{203} are independently selected from hydrido,
 alkyl, aryl and aralkyl; and


R^{300} is selected from alkyl, aryl and aralkyl; and

y and z are independently 0, 1, 2, 3, 4, 5 or 6
 wherein y + z; and y1 is 1, 2, 3, 4, 5 or 6; wherein y +


145 z and y1 + z are less than or equal to 6; and

x is 0, 1 or 2; and

R^3 is selected from pyridinyl, pyrimidinyl,
 quinolinyl, purinyl, maleimidyl, pyridonyl, thiazolyl,
 thiazolylalkyl, thiazolylamino,



wherein the R^3 pyridinyl, pyrimidinyl, quinolinyl,
 purinyl, maleimidyl, pyridonyl, thiazolyl,
 thiazolylalkyl, thiazolylamino,



groups may be optionally substituted with one or more
 radicals independently selected from halo, keto, alkyl,
 aralkyl, aralkenyl, arylheterocyclyl, carboxy,
 160 carboxyalkyl, alkoxy, aryloxy, alkylthio, arylthio,
 alkylsulfinyl, arylsulfinyl, alkylsulfonyl, arylsulfonyl,
 aralkoxy, heterocyclylalkoxy, amino, alkylamino,

1171

alkenylamino, alkynylamino, cycloalkylamino,
cycloalkenylamino, arylamino, haloarylamino,
165 heterocyclylamino, aminocarbonyl, cyano, hydroxy,
hydroxyalkyl, alkoxyalkylene, alkenoxyalkylene,
aryloxyalkyl, alkoxyalkylamino, alkylaminoalkoxy,
alkoxycarbonyl, aryloxycarbonyl, heterocycliloxy carbonyl,
alkoxycarbonylamino, alkoxyarylamino, alkoxyaralkylamino,
170 aminosulfinyl, aminosulfonyl, alkylsulfonylamino,
alkylaminoalkylamino, hydroxyalkylamino, aralkylamino,
aryl(hydroxyalkyl)amino, alkylaminoalkylaminoalkylamino,
alkylheterocyclylamino, heterocyclylalkylamino,
alkylheterocyclylalkylamino, aralkylheterocyclylamino,
175 heterocyclylheterocyclylalkylamino,
alkoxycarbonylheterocyclylamino, nitro,
alkylaminocarbonyl, alkylcarbonylamino,
haloalkylsulfonyl, aminoalkyl, haloalkyl, alkylcarbonyl,
hydrazinyl, alkylhydrazinyl, arylhydrazinyl, and $-NR^{44}R^{45}$
180 wherein R^{44} is alkylcarbonyl or amino, and R^{45} is alkyl or
aralkyl; and

R^4 is selected from hydrido, alkyl, alkenyl, alkynyl,
cycloalkyl, cycloalkenyl, aryl, and heterocyclyl, wherein
 R^4 is optionally substituted with one or more radicals
185 independently selected from halo, alkyl, alkenyl,
alkynyl, aryl, heterocyclyl, alkylthio, arylthio,
alkylthioalkylene, arylthioalkylene, alkylsulfinyl,
alkylsulfinylalkylene, arylsulfinylalkylene,
alkylsulfonyl, alkylsulfonylalkylene,
190 arylsulfonylalkylene, alkoxy, aryloxy, aralkoxy,
aminocarbonyl, alkylaminocarbonyl, arylaminocarbonyl,
alkoxycarbonyl, aryloxycarbonyl, haloalkyl, amino, cyano,
nitro, alkylamino, arylamino, alkylaminoalkylene,
arylaminoalkylene, aminoalkylamino, and hydroxy;
195 provided R^3 is not 2-pyridinyl when R^4 is a phenyl
ring containing a 2-hydroxy substituent and when R^1 is
hydrido; and

further provided that R^4 is not methylsulfonylphenyl

1172


or aminosulfonylphenyl; and

200 further provided that R¹ is not methylsulfonylphenyl;

or

a pharmaceutically-acceptable salt or tautomer thereof.

128. A compound of Formula IA



wherein

5 R¹ is selected from hydrido, hydroxy, alkyl, cycloalkyl, alkenyl, cycloalkenyl, alkynyl, aryl, heterocyclyl, cycloalkylalkylene, cycloalkenylalkylene, heterocyclalkylene, haloalkyl, haloalkenyl, haloalkynyl, hydroxyalkyl, hydroxyalkenyl, hydroxyalkynyl, aralkyl, aralkenyl, aralkynyl, arylheterocyclyl, carboxy, carboxyalkyl, alkoxyalkyl, alkenoxyalkyl, alkynoxyalkyl, aryloxyalkyl, alkoxyaryl, heterocyclloxyalkyl, alkoxyalkoxy, mercaptoalkyl, alkylthioalkylene, alkenylthioalkylene, alkylthioalkenylene, amino, aminoalkyl, alkylamino, alkenylamino, alkynylamino, arylamino, heterocycllamino, alkylsulfinyl, alkenylsulfinyl, alkynylsulfinyl, arylsulfinyl, heterocycllsulfinyl, alkylsulfonyl, alkenylsulfonyl, alkynylsulfonyl, arylsulfonyl, heterocycllsulfonyl, alkylaminoalkylene, alkylsulfonylalkylene, acyl, acyloxycarbonyl, alkoxycarbonylalkylene, aryloxycarbonylalkylene, heterocyclloxyoxycarbonylalkylene, alkoxyoxycarbonylarylene, aryloxycarbonylarylene, heterocyclloxyoxycarbonylarylene,

10


15

20

1173

- 25 alkylcarbonylalkylene, arylcarbonylalkylene,
 heterocyclylcarbonylalkylene, alkylcarbonylarylene,
 arylcarbonylarylene, heterocyclylcarbonylarylene,
 alkylcarbonyloxyalkylene, arylcarbonyloxyalkylene,
 heterocyclylcarbonyloxyalkylene, alkylcarbonyloxyarylene,
 30 arylcarbonyloxyarylene, and
 heterocyclylcarbonyloxyarylene; or

R¹ has the formula



wherein:

- 35 i is an integer from 0 to 9;
 R²⁵ is selected from hydrogen, alkyl, aralkyl,
 heterocyclylalkyl, alkoxyalkylene, aryloxyalkylene,
 aminoalkyl, alkylaminoalkyl, arylaminoalkyl,
 alkylcarbonylalkylene, arylcarbonylalkylene, and
 40 heterocyclylcarbonylaminoalkylene; and
 R²⁶ is selected from hydrogen, alkyl, alkenyl,
 alkynyl, cycloalkylalkylene, aralkyl,
 alkoxyalkylene, and alkylaminoalkyl; and
 R²⁷ is selected from alkyl, cycloalkyl, alkynyl,
 45 aryl, heterocyclyl, aralkyl, cycloalkylalkylene,
 cycloalkenylalkylene, cycloalkylarylene,
 cycloalkylcycloalkyl, heterocyclylalkylene, alkylarylene,
 alkylaralkyl, aralkylarylene, alkylheterocyclyl,
 alkylheterocyclylalkylene, alkylheterocyclylarylene,
 50 aralkylheterocyclyl, alkoxyalkylene, alkoxyarylene,
 alkoxyaralkyl, alkoxyheterocyclyl, alkoxyalkoxyarylene,
 aryloxyarylene, aralkoxyarylene,
 alkoxyheterocyclylalkylene, aryloxyalkoxyarylene,
 alkoxyalkoxyalkylene, alkoxyalkoxyheterocyclyl,
 55 alkoxyalkoxyheterocyclylalkylene, aminoalkyl,
 alkylaminoalkylene, arylaminocarbonylalkylene,
 alkoxyarylaminocarbonylalkylene, aminocarbonylalkylene,

arylaminoacetylalkylene, alkylaminoacetylalkylene,
arylacetylalkylene, alkoxyacetylarylene,
60 aryloxyacetylarylene, alkylaryloxyacetylarylene,
arylacetylarylene, alkylarylacetylarylene,
alkoxyacetylheterocyclylarylene,
alkoxyacetylalkoxyarylene,
heterocyclylacetylalkylarylene, alkylthioalkylene,
65 cycloalkylthioalkylene, alkylthioarylene,
aralkylthioarylene, heterocyclylthioarylene,
arylthioalkylarylene, arylsulfonylaminoalkylene,
alkylsulfonylarylene, alkylaminosulfonylarylene; wherein
said alkyl, cycloalkyl, aryl, heterocyclyl, aralkyl,
70 heterocyclylalkylene, alkylheterocyclylarylene,
alkoxyarylene, aryloxyarylene, arylaminoacetylalkylene,
aryloxyacetylarylene, arylacetylarylene,
alkylthioarylene, heterocyclylthioarylene,
arylthioalkylarylene, and alkylsulfonylarylene groups
75 may be optionally substituted with one or more radicals
independently selected from alkyl, halo, haloalkyl,
alkoxy, keto, amino, nitro, and cyano; or

R^{27} is $-CHR^{28}R^{29}$ wherein R^{28} is alkoxyacetyl, and R^{29}
is selected from aralkyl, aralkoxyalkylene,
80 heterocyclylalkylene, alkylheterocyclylalkylene,
alkoxyacetylalkylene, alkylthioalkylene, and
aralkylthioalkylene; wherein said aralkyl and
heterocyclyl groups may be optionally substituted with
one or more radicals independently selected from alkyl
85 and nitro; or

R^{26} and R^{27} together with the nitrogen atom to which
they are attached form a heterocycle, wherein said
heterocycle is optionally substituted with one or more
radicals independently selected from alkyl, aryl,
90 heterocyclyl, heterocyclylalkylene,
alkylheterocyclylalkylene, aryloxyalkylene,
alkoxyarylene, alkylaryloxyalkylene, alkylacetyl,
alkoxyacetyl, aralkoxyacetyl, alkylamino and

1175

alkoxycarbonylamino; wherein said aryl,
 95 heterocyclylalkylene and aryloxyalkylene radicals may be
 optionally substituted with one or more radicals
 independently selected from halogen, alkyl and alkoxy;
 and

R^2 is R^{200} -heterocyclyl- R^{201} wherein:

100 R^{200} is selected from:

- $(CR^{301}R^{302})_y-$;

- $C(O)-(CH_2)_{y1}-$;

- $C(O)-O-(CH_2)_y-$;

- $(CH_2)_y-C(O)-$;

105 - $O-(CH_2)_y-C(O)-$;

- $NR^{303}-$;

- $NR^{303}-(CH_2)_y-$;

- $(CH_2)_{y1}-NR^{202}-$;

- $(CH_2)_y-NR^{202}-(CH_2)_{z1}-$;

110 - $(CH_2)_y-C(O)-NR^{202}-(CH_2)_z-$;

- $(CH_2)_y-NR^{202}-C(O)-(CH_2)_z-$;

- $(CH_2)_y-NR^{202}-C(O)-NR^{203}-(CH_2)_z-$;

- $S(O)_x-(CR^{202}R^{203})_y-$;

- $(CR^{202}R^{203})_y-S(O)_x-$;

115 - $S(O)_x-(CR^{202}R^{203})_y-O-$;

- $S(O)_x-(CR^{202}R^{203})_y-C(O)-$;

- $O-(CH_2)_y-$; and

- $(CH_2)_y-O-$;

R^{201} represents one or more radicals selected from
 120 the group consisting of hydrido, halogen, hydroxy,
 carboxy, keto, alkyl, hydroxyalkyl, haloalkyl,
 cycloalkyl, alkenyl, alkynyl, aryl, heterocyclyl,
 aralkyl, heterocyclylalkylene, alkylcarbonyl,
 hydroxyalkylcarbonyl, cycloalkylcarbonyl, arylcarbonyl,
 125 haloarylcarbonyl, alkoxy, alkoxyalkylene, alkoxyarylene,
 alkoxycarbonyl, carboxyalkylcarbonyl,
 alkoxyalkylcarbonyl, heterocyclylalkylcarbonyl,
 alkylsulfonyl, alkylsulfonylalkylene, amino, aminoalkyl,
 alkylamino, aralkylamino, alkylaminoalkylene,

1176

- 130 aminocarbonyl, alkylcarbonylamino,
alkylcarbonylaminoalkylene, alkylaminoalkylcarbonyl,
alkylaminoalkylcarbonylamino,
aminoalkylcarbonylaminoalkyl, alkoxycarbonylamino,
alkoxyalkylcarbonylamino, alkoxycarbonylaminoalkylene,
135 alkylimidocarbonyl, amidino, alkylamidino,
aralkylamidino, guanidino, guanidinoalkylene, and
alkylsulfonylamino; and

R^{202} and R^{203} are independently selected from hydrido,
alkyl, aryl and aralkyl; and


- 140 R^{301} and R^{302} are independently selected from aryl and
aralkyl; and

R^{303} is selected from alkyl, aryl and aralkyl; and


y and z are independently 0, 1, 2, 3, 4, 5 or 6; and
yl is 1, 2, 3, 4, 5 or 6; wherein y + z and yl + z are
145 less than or equal to 6; and

x is 0, 1 or 2; wherein either x or y is other than
0 when R^{200} is $-S(O)_x-(CR^{202}R^{203})_y-$; and

- R^3 is selected from pyridinyl, pyrimidinyl,
quinolinyl, purinyl, maleimidyl, pyridonyl, thiazolyl,
150 thiazolylalkyl, thiazolylamino,



- wherein the R^3 pyridinyl, pyrimidinyl, quinolinyl,
purinyl, maleimidyl, pyridonyl, thiazolyl,
155 thiazolylalkyl, thiazolylamino,



groups may be optionally substituted with one or more
radicals independently selected from halo, keto, alkyl,

1177

- 160 aralkyl, aralkenyl, arylheterocyclyl, carboxy, carboxyalkyl, alkoxy, aryloxy, alkylthio, arylthio, alkylsulfinyl, arylsulfinyl, alkylsulfonyl, arylsulfonyl, aralkoxy, heterocyclylalkoxy, amino, alkylamino, alkenylamino, alkynylamino, cycloalkylamino,
- 165 cycloalkenylamino, arylamino, haloaryl amino, heterocyclylamino, aminocarbonyl, cyano, hydroxy, hydroxyalkyl, alkoxyalkylene, alkenoxyalkylene, aryloxyalkyl, alkoxyalkylamino, alkylaminoalkoxy, alkoxycarbonyl, aryloxycarbonyl, heterocyclylalkoxycarbonyl,
- 170 alkoxycarbonylamino, alkoxyaryl amino, alkoxyaralkylamino, aminosulfinyl, aminosulfonyl, alkylsulfonylamino, alkylaminoalkylamino, hydroxyalkylamino, aralkylamino, aryl(hydroxyalkyl)amino, alkylaminoalkylaminoalkylamino, alkylheterocyclylamino, heterocyclylalkylamino,
- 175 alkylheterocyclylalkylamino, aralkylheterocyclylamino, heterocyclylheterocyclylalkylamino, alkoxycarbonylheterocyclylamino, nitro, alkylaminocarbonyl, alkylcarbonylamino, haloalkylsulfonyl, aminoalkyl, haloalkyl, alkylcarbonyl,
- 180 hydrazinyl, alkylhydrazinyl, arylhydrazinyl, and $-NR^{44}R^{45}$ wherein R^{44} is alkylcarbonyl or amino, and R^{45} is alkyl or aralkyl; and
- R^4 is selected from hydrido, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, and heterocyclyl, wherein
- 185 R^4 is optionally substituted with one or more radicals independently selected from halo, alkyl, alkenyl, alkynyl, aryl, heterocyclyl, alkylthio, arylthio, alkylthioalkylene, arylthioalkylene, alkylsulfinyl, alkylsulfinylalkylene, arylsulfinylalkylene,
- 190 alkylsulfonyl, alkylsulfonylalkylene, arylsulfonylalkylene, alkoxy, aryloxy, aralkoxy, aminocarbonyl, alkylaminocarbonyl, arylaminocarbonyl, alkoxycarbonyl, aryloxycarbonyl, haloalkyl, amino, cyano, nitro, alkylamino, arylamino, alkylaminoalkylene,
- 195 arylaminoalkylene, aminoalkylamino, and hydroxy;

1178

provided R^3 is not 2-pyridinyl when R^4 is a phenyl ring containing a 2-hydroxy substituent and when R^1 is hydrido; and


200 further provided R^2 is selected from aryl, heterocyclyl, unsubstituted cycloalkyl and cycloalkenyl when R^4 is hydrido; and

further provided that R^4 is not methylsulfonylphenyl or aminosulfonylphenyl; and

205 further provided that R^1 is not methylsulfonylphenyl; or

a pharmaceutically-acceptable salt or tautomer thereof.

129. A compound of Formula IA



wherein


5 R^1 is selected from hydrido, hydroxy, alkyl, cycloalkyl, alkenyl, cycloalkenyl, alkynyl, aryl, heterocyclyl, cycloalkylalkylene, cycloalkenylalkylene, heterocyclylalkylene, haloalkyl, haloalkenyl, haloalkynyl, hydroxyalkyl, hydroxyalkenyl, hydroxyalkynyl, aralkyl, aralkenyl, aralkynyl, arylheterocyclyl, carboxy, carboxyalkyl, alkoxyalkyl, alkenoxyalkyl, alkynoxyalkyl, aryloxyalkyl, alkoxyaryl, heterocycliloxyalkyl, alkoxyalkoxy, mercaptoalkyl, alkylthioalkylene, alkenylthioalkylene, alkylthioalkenylene, amino, aminoalkyl, alkylamino, alkenylamino, alkynylamino, arylamino, heterocyclylamino, alkylsulfinyl, alkenylsulfinyl, alkynylsulfinyl,

10

15

arylsulfinyl, heterocyclylsulfinyl, alkylsulfonyl,
 alkenylsulfonyl, alkynylsulfonyl, arylsulfonyl,
 20 heterocyclylsulfonyl, alkylaminoalkylene,
 alkylsulfonylalkylene, acyl, acyloxy carbonyl,
 alkoxycarbonylalkylene, aryloxy carbonylalkylene,
 heterocyclyloxy carbonylalkylene, alkoxycarbonylarylene,
 aryloxy carbonylarylene, heterocyclyloxy carbonylarylene,
 25 alkylcarbonylalkylene, arylcarbonylalkylene,
 heterocyclylcarbonylalkylene, alkylcarbonylarylene,
 arylcarbonylarylene, heterocyclylcarbonylarylene,
 alkylcarbonyloxyalkylene, arylcarbonyloxyalkylene,
 heterocyclylcarbonyloxyalkylene, alkylcarbonyloxyarylene,
 30 arylcarbonyloxyarylene, and
 heterocyclylcarbonyloxyarylene; or

R¹ has the formula



wherein:

35 i is an integer from 0 to 9;

R²⁵ is selected from hydrogen, alkyl, aralkyl,
 heterocyclylalkyl, alkoxyalkylene, aryloxyalkylene,
 aminoalkyl, alkylaminoalkyl, arylaminoalkyl,
 alkylcarbonylalkylene, arylcarbonylalkylene, and
 40 heterocyclylcarbonylaminoalkylene; and

R²⁶ is selected from hydrogen, alkyl, alkenyl,
 alkynyl, cycloalkylalkylene, aralkyl,
 alkoxycarbonylalkylene, and alkylaminoalkyl; and

R²⁷ is selected from alkyl, cycloalkyl, alkynyl,
 45 aryl, heterocyclyl, aralkyl, cycloalkylalkylene,
 cycloalkenylalkylene, cycloalkylarylene,
 cycloalkylcycloalkyl, heterocyclylalkylene, alkylarylene,
 alkylaralkyl, aralkylarylene, alkylheterocyclyl,
 alkylheterocyclylalkylene, alkylheterocyclylarylene,
 50 aralkylheterocyclyl, alkoxyalkylene, alkoxyarylene,

alkoxyaralkyl, alkoxyheterocyclyl, alkoxyalkoxyarylene,
 aryloxyarylene, aralkoxyarylene,
 alkoxyheterocyclylalkylene, aryloxyalkoxyarylene,
 alkoxycarbonylalkylene, alkoxycarbonylheterocyclyl,
 55 alkoxycarbonylheterocyclylcarbonylalkylene, aminoalkyl,
 alkylaminoalkylene, arylaminocarbonylalkylene,
 alkoxyarylaminoalkylene, aminocarbonylalkylene,
 arylaminocarbonylalkylene, alkylaminocarbonylalkylene,
 arylcarbonylalkylene, alkoxycarbonylarylene,
 60 aryloxycarbonylarylene, alkylaryloxycarbonylarylene,
 arylcarbonylarylene, alkylarylcarbonylarylene,
 alkoxycarbonylheterocyclylarylene,
 alkoxycarbonylalkoxyarylene,
 heterocyclylcarbonylalkylarylene, alkylthioalkylene,
 65 cycloalkylthioalkylene, alkylthioarylene,
 aralkylthioarylene, heterocyclylthioarylene,
 arylthioalkylarylene, arylsulfonylaminoalkylene,
 alkylsulfonylarylene, alkylaminosulfonylarylene; wherein
 said alkyl, cycloalkyl, aryl, heterocyclyl, aralkyl,
 70 heterocyclylalkylene, alkylheterocyclylarylene,
 alkoxyarylene, aryloxyarylene, arylaminocarbonylalkylene,
 aryloxycarbonylarylene, arylcarbonylarylene,
 alkylthioarylene, heterocyclylthioarylene,
 arylthioalkylarylene, and alkylsulfonylarylene groups
 75 may be optionally substituted with one or more radicals
 independently selected from alkyl, halo, haloalkyl,
 alkoxy, keto, amino, nitro, and cyano; or
 R^{27} is $-CHR^{28}R^{29}$ wherein R^{28} is alkoxycarbonyl, and R^{29}
 is selected from aralkyl, aralkoxyalkylene,
 80 heterocyclylalkylene, alkylheterocyclylalkylene,
 alkoxycarbonylalkylene, alkylthioalkylene, and
 aralkylthioalkylene; wherein said aralkyl and
 heterocyclyl groups may be optionally substituted with
 one or more radicals independently selected from alkyl
 85 and nitro; or

R^{26} and R^{27} together with the nitrogen atom to which

1181

they are attached form a heterocycle, wherein said heterocycle is optionally substituted with one or more radicals independently selected from alkyl, aryl,

90 heterocyclyl, heterocyclylalkylene, alkylheterocyclylalkylene, aryloxyalkylene, alkoxyarylene, alkylaryloxyalkylene, alkylcarbonyl, alkoxycarbonyl, aralkoxycarbonyl, alkylamino and alkoxycarbonylamino; wherein said aryl,
95 heterocyclylalkylene and aryloxyalkylene radicals may be optionally substituted with one or more radicals independently selected from halogen, alkyl and alkoxy; and

R^2 is selected from hydrido, halogen, mercapto,
100 alkyl, alkenyl, alkynyl, aryl, heterocyclyl, haloalkyl, hydroxyalkyl, aralkyl, alkylheterocyclyl, heterocyclylalkyl, heterocyclylheterocyclyl, heterocyclylalkylheterocyclyl, alkylamino, alkenylamino, alkynylamino, arylamino, aryl(hydroxyalkyl)amino,
105 heterocyclylamino, heterocyclylalkylamino, aralkylamino, N-alkyl-N-alkynyl-amino, aminoalkyl, aminoaryl, aminoalkylamino, aminocarbonylalkylene, arylaminoalkylene, alkylaminoalkylene, arylaminoarylene, alkylaminoarylene, alkylaminoalkylamino,
110 alkylcarbonylaminoalkylene, aminoalkylcarbonylaminoalkylene, alkylaminoalkylcarbonylamino, cycloalkyl, cycloalkenyl, aminoalkylthio, alkylaminocarbonylalkylthio, alkylaminoalkylaminocarbonylalkylthio, alkoxy,
115 heterocyclyoxy, alkylthio, cyanoalkylthio, alkenylthio, alkynylthio, carboxyalkylthio, arylthio, heterocyclylthio, alkoxycarbonylalkylthio, alkylsulfinyl, alkylsulfonyl, carboxy, carboxyalkyl, alkoxyalkyl, alkoxyalkylthio, carboxycycloalkyl, carboxycycloalkenyl,
120 carboxyalkylamino, alkoxycarbonyl, heterocyclylcarbonyl, alkoxycarbonylalkyl, alkoxycarbonylalkylamino, alkoxycarbonylheterocyclyl,

alkoxycarbonylheterocyclylcarbonyl, alkoxyalkylamino,
 alkoxycarbonylaminoalkylene, alkoxycarbonylaminoalkoxy,
 125 alkoxycarbonylaminoalkylamino, heterocyclylsulfonyl,
 aralkythio, heterocyclylalkylthio, aminoalkoxy,
 cyanoalkoxy, carboxyalkoxy, aryloxy, aralkoxy,
 alkenyloxy, alkynyloxy, and heterocyclylalkyloxy; wherein
 the aryl, heterocyclyl, heterocyclylalkyl, cycloalkyl and
 130 cycloalkenyl groups may be optionally substituted with
 one or more radicals independently selected from halo,
 keto, amino, alkyl, alkenyl, alkynyl, aryl, heterocyclyl,
 aralkyl, heterocyclylalkyl, epoxyalkyl,
 amino(hydroxyalkyl) carboxy, alkoxy, aryloxy, aralkoxy,
 135 haloalkyl, alkylamino, alkynylamino,
 alkylaminoalkylamino, heterocyclylalkylamino,
 alkylcarbonyl, alkoxycarbonyl, alkylsulfonyl,
 arylsulfonyl, and aralkylsulfonyl; or

R^2 is R^{200} -heterocyclyl- R^{201} , R^{200} -aryl- R^{201} , or R^{200} -
 140 cycloalkyl- R^{201} wherein:

R^{200} is selected from:

- $(CR^{202}R^{203})_y-$;
- $C(O)-$;
- $C(O)-(CH_2)_y-$;
- 145 - $C(O)-O-(CH_2)_y-$;
- $(CH_2)_y-C(O)-$;
- $O-(CH_2)_y-C(O)-$;
- $NR^{202}-$;
- $NR^{202}-(CH_2)_y-$;
- 150 - $(CH_2)_y-NR^{202}-$;
- $(CH_2)_y-NR^{202}-(CH_2)_z-$;
- $(CH_2)_y-C(O)-NR^{202}-(CH_2)_z-$;
- $(CH_2)_y-NR^{202}-C(O)-(CH_2)_z-$;
- $(CH_2)_y-NR^{202}-C(O)-NR^{203}-(CH_2)_z-$;
- 155 - $S(O)_x-(CR^{202}R^{203})_y-$;
- $(CR^{202}R^{203})_y-S(O)_x-$;
- $S(O)_x-(CR^{202}R^{203})_y-O-$;
- $S(O)_x-(CR^{202}R^{203})_y-C(O)-$;

-O-(CH₂)_y-;

160 - (CH₂)_y-O-;

-S-;

-O-;

or R²⁰⁰ represents a bond;

R²⁰¹ represents one or more radicals selected from
 165 the group consisting of hydrido, halogen, hydroxy,
 carboxy, keto, alkyl, hydroxyalkyl, haloalkyl,
 cycloalkyl, alkenyl, alkynyl, aryl, heterocyclyl,
 aralkyl, heterocyclylalkylene, alkylcarbonyl,
 hydroxyalkylcarbonyl, cycloalkylcarbonyl, arylcarbonyl,
 170 haloarylcarbonyl, alkoxy, alkoxyalkylene, alkoxyarylene,
 alkoxycarbonyl, carboxyalkylcarbonyl,
 alkoxyalkylcarbonyl, heterocyclylalkylcarbonyl,
 alkylsulfonyl, alkylsulfonylalkylene, amino, aminoalkyl,
 alkylamino, aralkylamino, alkylaminoalkylene,
 175 aminocarbonyl, alkylcarbonylamino,
 alkylcarbonylaminoalkylene, alkylaminoalkylcarbonyl,
 alkylaminoalkylcarbonylamino,
 aminoalkylcarbonylaminoalkyl, alkoxycarbonylamino,
 alkoxyalkylcarbonylamino, alkoxycarbonylaminoalkylene,
 180 alkylimidocarbonyl, amidino, alkylamidino,
 aralkylamidino, guanidino, guanidinoalkylene, and
 alkylsulfonylamino; and

R²⁰² and R²⁰³ are independently selected from hydrido,
 alkyl, aryl and aralkyl; and

185 y and z are independently 0, 1, 2, 3, 4, 5 or 6
 wherein y + z is less than or equal to 6; and


x is 0, 1 or 2; or

R² is -NHCR²⁰⁴R²⁰⁵ wherein R²⁰⁴ is alkylaminoalkylene,
 and R²⁰⁵ is aryl; or

190 R² is -C(NR²⁰⁶)R²⁰⁷ wherein R²⁰⁶ is selected from
 hydrogen and hydroxy, and R²⁰⁷ is selected from alkyl,
 aryl and aralkyl; or

R² has the formula:

1184



195 wherein:

j is an integer from 0 to 8; and

m is 0 or 1; and

200 R³⁰ and R³¹ are independently selected from hydrogen, alkyl, aryl, heterocyclyl, aralkyl, heterocyclalkylene, aminoalkyl, alkylaminoalkyl, aminocarbonylalkyl, alkoxyalkyl, and alkylcarbonyloxyalkyl; and


205 R³² is selected from hydrogen, alkyl, aralkyl, heterocyclalkyl, alkoxyalkylene, aryloxyalkylene, aminoalkyl, alkylaminoalkyl, arylaminoalkyl, alkylcarbonylalkylene, arylcarbonylalkylene, and heterocyclcarbonylaminoalkylene;

210 R³³ is selected from hydrogen, alkyl, -C(O)R³⁵, -C(O)OR³⁵, -SO₂R³⁶, -C(O)NR³⁷R³⁸, and -SO₂NR³⁹R⁴⁰, wherein R³⁵, R³⁶, R³⁷, R³⁸, R³⁹ and R⁴⁰ are independently selected from hydrocarbon, heterosubstituted hydrocarbon and heterocyclyl; and

R³⁴ is selected from hydrogen, alkyl, aminocarbonyl, alkylaminocarbonyl, and arylaminocarbonyl; or


215 R² is -CR⁴¹R⁴² wherein R⁴¹ is aryl, and R⁴² is hydroxy; and

R³ is selected from maleimidyl, pyridonyl, thiazolyl, thiazolylalkyl, thiazolylamino,



220 wherein the R³ maleimidyl, pyridonyl, thiazolyl, thiazolylalkyl, thiazolylamino,

1185




groups may be optionally substituted with one or more
 225 radicals independently selected from halo, keto, alkyl,
 aralkyl, aralkenyl, arylheterocyclyl, carboxy,
 carboxyalkyl, alkoxy, aryloxy, alkylthio, arylthio,
 alkylsulfinyl, arylsulfinyl, alkylsulfonyl, arylsulfonyl,
 aralkoxy, heterocyclylalkoxy, amino, alkylamino,
 230 alkenylamino, alkynylamino, cycloalkylamino,
 cycloalkenylamino, arylamino, haloarylamino,
 heterocyclylamino, aminocarbonyl, cyano, hydroxy,
 hydroxyalkyl, alkoxyalkylene, alkenoxyalkylene,
 aryloxyalkyl, alkoxyalkylamino, alkylaminoalkoxy,
 235 alkoxycarbonyl, aryloxycarbonyl, heterocyclylloxycarbonyl,
 alkoxycarbonylamino, alkoxyarylamino, alkoxyaralkylamino,
 aminosulfinyl, aminosulfonyl, alkylsulfonylamino,
 alkylaminoalkylamino, hydroxyalkylamino, aralkylamino,
 aryl(hydroxyalkyl)amino, alkylaminoalkylaminoalkylamino,
 240 alkylheterocyclylamino, heterocyclylalkylamino,
 alkylheterocyclylalkylamino, aralkylheterocyclylamino,
 heterocyclylheterocyclylalkylamino,
 alkoxycarbonylheterocyclylamino, nitro,
 alkylaminocarbonyl, alkylcarbonylamino,
 245 haloalkylsulfonyl, aminoalkyl, haloalkyl, alkylcarbonyl,
 hydrazinyl, alkylhydrazinyl, arylhydrazinyl, and -NR⁴⁴R⁴⁵
 wherein R⁴⁴ is alkylcarbonyl or amino, and R⁴⁵ is alkyl or
 aralkyl; and

R⁴ is selected from hydrido, alkyl, alkenyl, alkynyl,
 250 cycloalkyl, cycloalkenyl, aryl, and heterocyclyl, wherein
 R⁴ is optionally substituted with one or more radicals
 independently selected from halo, alkyl, alkenyl,
 alkynyl, aryl, heterocyclyl, alkylthio, arylthio,
 alkylthioalkylene, arylthioalkylene, alkylsulfinyl,

1186

- 255 alkylsulfinylalkylene, arylsulfinylalkylene,
 alkylsulfonyl, alkylsulfonylalkylene,
 arylsulfonylalkylene, alkoxy, aryloxy, aralkoxy,
 aminocarbonyl, alkylaminocarbonyl, arylaminocarbonyl,
 alkoxycarbonyl, aryloxycarbonyl, haloalkyl, amino, cyano,
 260 nitro, alkylamino, arylamino, alkylaminoalkylene,
 arylaminoalkylene, aminoalkylamino, and hydroxy;
 provided R^3 is not




(IV)

(V)

- 265 wherein R^{43} is selected from hydrogen, alkyl,
 aminoalkyl, alkoxyalkyl, alkenoxyalkyl, and aryloxyalkyl;
 and
 further provided R^2 is selected from aryl,
 heterocyclyl, unsubstituted cycloalkyl and cycloalkenyl
 270 when R^4 is hydrido; and
 further provided that R^4 is not methylsulfonylphenyl
 or aminosulfonylphenyl; and
 further provided that R^1 is not methylsulfonylphenyl;
 or
 275 a pharmaceutically-acceptable salt or tautomer
 thereof.

130. A compound of Formula IA

1187




wherein

- 5 R^1 is selected from hydrido, hydroxy, alkyl, cycloalkyl, alkenyl, cycloalkenyl, alkynyl, aryl, heterocyclyl, cycloalkylalkylene, cycloalkenylalkylene, heterocyclylalkylene, haloalkyl, haloalkenyl, haloalkynyl, hydroxyalkyl, hydroxyalkenyl, hydroxyalkynyl, aralkyl, aralkenyl, aralkynyl, arylheterocyclyl, carboxy, carboxyalkyl, alkoxyalkyl, alkenoxyalkyl, alkynoxyalkyl, aryloxyalkyl, alkoxyaryl, heterocycliloxyalkyl, alkoxyalkoxy, mercaptoalkyl, alkylthioalkylene, alkenylthioalkylene, alkylthioalkenylene, amino, aminoalkyl, alkylamino, alkenylamino, alkynylamino, arylamino, heterocyclylamino, alkylsulfinyl, alkenylsulfinyl, alkynylsulfinyl, arylsulfinyl, heterocyclylsulfinyl, alkylsulfonyl, alkenylsulfonyl, alkynylsulfonyl, arylsulfonyl, heterocyclylsulfonyl, alkylaminoalkylene, alkylsulfonylalkylene, acyl, acyloxycarbonyl, alkoxycarbonylalkylene, aryloxycarbonylalkylene, heterocycliloxycarbonylalkylene, alkoxycarbonylarylene, aryloxycarbonylarylene, heterocycliloxycarbonylarylene, alkylcarbonylalkylene, arylcarbonylalkylene, heterocyclylcarbonylalkylene, alkylcarbonylarylene, arylcarbonylarylene, heterocyclylcarbonylarylene, alkylcarbonyloxyalkylene, arylcarbonyloxyalkylene, heterocyclylcarbonyloxyalkylene, alkylcarbonyloxyarylene, arylcarbonyloxyarylene, and heterocyclylcarbonyloxyarylene; or

R^1 has the formula

1188



wherein:

```
35         i is an integer from 0 to 9;
```

R²⁵ is selected from hydrogen, alkyl, aralkyl, heterocyclylalkyl, alkoxyalkylene, aryloxyalkylene, aminoalkyl, alkylaminoalkyl, arylaminoalkyl, alkylcarbonylalkylene, arylcarbonylalkylene, and
40 heterocyclylcarbonylaminoalkylene; and

R²⁶ is selected from hydrogen, alkyl, alkenyl, alkynyl, cycloalkylalkylene, aralkyl, alkoxy carbonylalkylene, and alkylaminoalkyl; and

R²⁷ is selected from alkyl, cycloalkyl, alkynyl, aryl, heterocyclyl, aralkyl, cycloalkylalkylene, cycloalkenylalkylene, cycloalkylarylene, cycloalkylcycloalkyl, heterocyclylalkylene, alkylarylene, alkylaralkyl, aralkylarylene, alkylheterocyclyl, alkylheterocyclylalkylene, alkylheterocyclylarylene, aralkylheterocyclyl, alkoxyalkylene, alkoxyarylene, alkoxyaralkyl, alkoxyheterocyclyl, alkoxyalkoxyarylene, aryloxyarylene, aralkoxyarylene, alkoxyheterocyclylalkylene, aryloxyalkoxyarylene, alkoxy-carbonylalkylene, alkoxy-carbonyl-heterocyclyl, alkoxy-carbonyl-heterocyclyl-carbonylalkylene, aminoalkyl, alkylaminoalkylene, arylaminocarbonylalkylene, alkoxyarylaminocarbonylalkylene, aminocarbonylalkylene, arylaminocarbonylalkylene, alkylaminocarbonylalkylene, arylcarbonylalkylene, alkoxy-carbonylarylene, aryloxy-carbonylarylene, alkylaryloxy-carbonylarylene, arylcarbonylarylene, alkylarylcarbonylarylene, alkoxy-carbonyl-heterocyclylarylene, alkoxy-carbonylalkoxyarylene, heterocyclylcarbonylalkylarylene, alkylthioalkylene, cycloalkylthioalkylene, alkylthioarylene,

aralkylthioarylene, heterocyclylthioarylene,
arylthioalkylarylene, arylsulfonylaminoalkylene,
alkylsulfonylarylene, alkylaminosulfonylarylene; wherein
said alkyl, cycloalkyl, aryl, heterocyclyl, aralkyl,
70 heterocyclylalkylene, alkylheterocyclylarylene,
alkoxyarylene, aryloxyarylene, arylaminocarbonylalkylene,
aryloxycarbonylarylene, arylcarbonylarylene,
alkylthioarylene, heterocyclylthioarylene,
arylthioalkylarylene, and alkylsulfonylarylene groups
75 may be optionally substituted with one or more radicals
independently selected from alkyl, halo, haloalkyl,
alkoxy, keto, amino, nitro, and cyano; or

R^{27} is $-CHR^{28}R^{29}$ wherein R^{28} is alkoxycarbonyl, and R^{29}
is selected from aralkyl, aralkoxyalkylene,
80 heterocyclylalkylene, alkylheterocyclylalkylene,
alkoxycarbonylalkylene, alkylthioalkylene, and
aralkylthioalkylene; wherein said aralkyl and
heterocyclyl groups may be optionally substituted with
one or more radicals independently selected from alkyl
85 and nitro; or

R^{26} and R^{27} together with the nitrogen atom to which
they are attached form a heterocycle, wherein said
heterocycle is optionally substituted with one or more
radicals independently selected from alkyl, aryl,
90 heterocyclyl, heterocyclylalkylene,
alkylheterocyclylalkylene, aryloxyalkylene,
alkoxyarylene, alkylaryloxyalkylene, alkylcarbonyl,
alkoxycarbonyl, aralkoxycarbonyl, alkylamino and
alkoxycarbonylamino; wherein said aryl,
95 heterocyclylalkylene and aryloxyalkylene radicals may be
optionally substituted with one or more radicals
independently selected from halogen, alkyl and alkoxy;
and

R^2 is selected from hydrido, halogen, mercapto,
100 alkyl, alkenyl, alkynyl, aryl, heterocyclyl, haloalkyl,
hydroxyalkyl, aralkyl, alkylheterocyclyl,

heterocyclylalkyl, heterocyclylheterocyclyl,
heterocyclylalkylheterocyclyl, alkylamino, alkenylamino,
alkynylamino, arylamino, aryl(hydroxyalkyl)amino,
105 heterocyclylamino, heterocyclylalkylamino, aralkylamino,
N-alkyl-N-alkynyl-amino, aminoalkyl, aminoaryl,
aminoalkylamino, aminocarbonylalkylene,
arylaminoalkylene, alkylaminoalkylene, arylaminoarylene,
alkylaminoarylene, alkylaminoalkylamino,
110 alkylcarbonylaminoalkylene,
aminoalkylcarbonylaminoalkylene,
alkylaminoalkylcarbonylamino, cycloalkyl, cycloalkenyl,
aminoalkylthio, alkylaminocarbonylalkylthio,
alkylaminoalkylaminocarbonylalkylthio, alkoxy,
115 heterocyclylloxy, alkylthio, cyanoalkylthio, alkenylthio,
alkynylthio, carboxyalkylthio, arylthio,
heterocyclylthio, alkoxycarbonylalkylthio, alkylsulfinyl,
alkylsulfonyl, carboxy, carboxyalkyl, alkoxyalkyl,
alkoxyalkylthio, carboxycycloalkyl, carboxycycloalkenyl,
120 carboxyalkylamino, alkoxycarbonyl, heterocyclylcarbonyl,
alkoxycarbonylalkyl, alkoxycarbonylalkylamino,
alkoxycarbonylheterocyclyl,
alkoxycarbonylheterocyclylcarbonyl, alkoxyalkylamino,
alkoxycarbonylaminoalkylene, alkoxycarbonylaminoalkoxy,
125 alkoxycarbonylaminoalkylamino, heterocyclylsulfonyl,
aralkylthio, heterocyclylalkylthio, aminoalkoxy,
cyanoalkoxy, carboxyalkoxy, aryloxy, aralkoxy,
alkenyloxy, alkynyloxy, and heterocyclylalkyloxy; wherein
the aryl, heterocyclyl, heterocyclylalkyl, cycloalkyl and
130 cycloalkenyl groups may be optionally substituted with
one or more radicals independently selected from halo,
keto, amino, alkyl, alkenyl, alkynyl, aryl, heterocyclyl,
aralkyl, heterocyclylalkyl, epoxyalkyl,
amino(hydroxyalkyl) carboxy, alkoxy, aryloxy, aralkoxy,
135 haloalkyl, alkylamino, alkynylamino,
alkylaminoalkylamino, heterocyclylalkylamino,
alkylcarbonyl, alkoxycarbonyl, alkylsulfonyl,

1191

arylsulfonyl, and aralkylsulfonyl; or

R^2 is R^{200} -heterocyclyl- R^{201} , R^{200} -aryl- R^{201} , or R^{200} -
 140 cycloalkyl- R^{201} wherein:

R^{200} is selected from:

- $(CR^{202}R^{203})_y-$;
- $C(O)-$;
- $C(O)-(CH_2)_y-$;
- 145 - $C(O)-O-(CH_2)_y-$;
- $(CH_2)_y-C(O)-$;
- $O-(CH_2)_y-C(O)-$;
- $NR^{202}-$;
- $NR^{202}-(CH_2)_y-$;
- 150 - $(CH_2)_y-NR^{202}-$;
- $(CH_2)_y-NR^{202}-(CH_2)_z-$;
- $(CH_2)_y-C(O)-NR^{202}-(CH_2)_z-$;
- $(CH_2)_y-NR^{202}-C(O)-(CH_2)_z-$;
- $(CH_2)_y-NR^{202}-C(O)-NR^{203}-(CH_2)_z-$;
- 155 - $S(O)_x-(CR^{202}R^{203})_y-$;
- $(CR^{202}R^{203})_y-S(O)_x-$;
- $S(O)_x-(CR^{202}R^{203})_y-O-$;
- $S(O)_x-(CR^{202}R^{203})_y-C(O)-$;
- $O-(CH_2)_y-$;
- 160 - $(CH_2)_y-O-$;
- $S-$; and
- $O-$;

or R^{200} represents a bond;

R^{201} represents one or more radicals selected from
 165 the group consisting of hydrido, halogen, hydroxy,
 carboxy, keto, alkyl, hydroxyalkyl, haloalkyl,
 cycloalkyl, alkenyl, alkynyl, aryl, heterocyclyl,
 aralkyl, heterocyclylalkylene, alkylcarbonyl,
 hydroxyalkylcarbonyl, cycloalkylcarbonyl, arylcarbonyl,
 170 haloarylcarbonyl, alkoxy, alkoxyalkylene, alkoxyarylene,
 alkoxycarbonyl, carboxyalkylcarbonyl,
 alkoxyalkylcarbonyl, heterocyclylalkylcarbonyl,
 alkylsulfonyl, alkylsulfonylalkylene, amino, aminoalkyl,

1192

alkylamino, aralkylamino, alkylaminoalkylene,
 175 aminocarbonyl, alkylcarbonylamino,
 alkylcarbonylaminoalkylene, alkylaminoalkylcarbonyl,
 alkylaminoalkylcarbonylamino,
 aminoalkylcarbonylaminoalkyl, alkoxycarbonylamino,
 alkoxylalkylcarbonylamino, alkoxycarbonylaminoalkylene,
 180 alkylimidocarbonyl, amidino, alkylamidino,
 aralkylamidino, guanidino, guanidinoalkylene, and
 alkylsulfonylamino; and

R^{202} and R^{203} are independently selected from hydrido,
 alkyl, aryl and aralkyl; and


185 y and z are independently 0, 1, 2, 3, 4, 5 or 6
 wherein y + z is less than or equal to 6; and

x is 0, 1 or 2; or

R^2 is $-NHCR^{204}R^{205}$ wherein R^{204} is alkylaminoalkylene,
 and R^{205} is aryl; or

190 R^2 is $-C(NR^{206})R^{207}$ wherein R^{206} is selected from
 hydrogen and hydroxy, and R^{207} is selected from alkyl,
 aryl and aralkyl; or

R^2 has the formula:



195 wherein:

j is an integer from 0 to 8; and

m is 0 or 1; and

R^{30} and R^{31} are independently selected from hydrogen,
 alkyl, aryl, heterocyclyl, aralkyl, heterocyclylalkylene,
 200 aminoalkyl, alkylaminoalkyl, aminocarbonylalkyl,
 alkoxylalkyl, and alkylcarbonyloxyalkyl; and

R^{32} is selected from hydrogen, alkyl, aralkyl,
 heterocyclylalkyl, alkoxylalkylene, aryloxyalkylene,
 aminoalkyl, alkylaminoalkyl, arylaminoalkyl,
 205 alkylcarbonylalkylene, arylcarbonylalkylene, and

1193

heterocyclylcarbonylaminoalkylene;


R^{33} is selected from hydrogen, alkyl, $-C(O)R^{35}$,
 $-C(O)OR^{35}$, $-SO_2R^{36}$, $-C(O)NR^{37}R^{38}$, and $-SO_2NR^{39}R^{40}$,
 wherein

210 R^{35} , R^{36} , R^{37} , R^{38} , R^{39} and R^{40} are independently
 selected from hydrocarbon, heterosubstituted hydrocarbon
 and heterocyclyl; and

R^{34} is selected from hydrogen, alkyl, aminocarbonyl,
 alkylaminocarbonyl, and arylaminocarbonyl; or

215 R^2 is $-CR^{41}R^{42}$ wherein R^{41} is aryl, and R^{42} is hydroxy;
 and

R^3 is selected from pyridinyl, pyrimidinyl,
 quinolinyl, purinyl, maleimidyl, pyridonyl, thiazolyl,
 thiazolylalkyl, thiazolylamino,




220

wherein the R^3 pyridinyl, pyrimidinyl, quinolinyl,
 purinyl groups are substituted with one or more radicals
 independently selected from keto, haloarylamino,
 225 alkoxyalkylene, alkenoxyalkylene, aryloxyalkyl,
 alkoxyalkylamino, alkylaminoalkoxy, alkoxyarylamino,
 alkylsulfonylamino, aryl(hydroxyalkyl)amino,
 alkylaminoalkylaminoalkylamino, alkylheterocyclylamino,
 alkylheterocyclylalkylamino,
 230 heterocyclylheterocyclylalkylamino,
 alkoxycarbonylheterocyclylamino and haloalkylsulfonyl;
 and

wherein the R^3 maleimidyl, pyridonyl, thiazolyl,
 thiazolylalkyl, thiazolylamino,

1194



235


groups may be optionally substituted with one or more radicals independently selected from halo, keto, alkyl, aralkyl, aralkenyl, arylheterocyclyl, carboxy, carboxyalkyl, alkoxy, aryloxy, alkylthio, arylthio, alkylsulfinyl, arylsulfinyl, alkylsulfonyl, arylsulfonyl, aralkoxy, heterocyclylalkoxy, amino, alkylamino, alkenylamino, alkynylamino, cycloalkylamino, cycloalkenylamino, arylamino, haloaryl amino, heterocyclylamino, aminocarbonyl, cyano, hydroxy, hydroxyalkyl, alkoxyalkylene, alkenoxyalkylene, aryloxyalkyl, alkoxyalkylamino, alkylaminoalkoxy, alkoxycarbonyl, aryloxy carbonyl, heterocyclyl oxycarbonyl, alkoxycarbonylamino, alkoxyaryl amino, alkoxyaralkyl amino, aminosulfinyl, aminosulfonyl, alkylsulfonylamino, alkylaminoalkylamino, hydroxyalkylamino, aralkylamino, aryl(hydroxyalkyl)amino, alkylaminoalkylaminoalkylamino, alkylheterocyclylamino, heterocyclylalkylamino, alkylheterocyclylalkylamino, aralkylheterocyclylamino, heterocyclylheterocyclylalkylamino, alkoxycarbonyl heterocyclylamino, nitro, alkylaminocarbonyl, alkylcarbonylamino, haloalkylsulfonyl, aminoalkyl, haloalkyl, alkylcarbonyl, hydrazinyl, alkylhydrazinyl, arylhydrazinyl, and -NR⁴⁴R⁴⁵ wherein R⁴⁴ is alkylcarbonyl or amino, and R⁴⁵ is alkyl or aralkyl; and

R⁴ is selected from hydrido, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, and heterocyclyl, wherein R⁴ is optionally substituted with one or more radicals independently selected from halo, alkyl, alkenyl, alkynyl, aryl, heterocyclyl, alkylthio, arylthio, alkylthioalkylene, arylthioalkylene, alkylsulfinyl,

265

1195


alkylsulfinylalkylene, arylsulfinylalkylene,
 alkylsulfonyl, alkylsulfonylalkylene,
 270 arylsulfonylalkylene, alkoxy, aryloxy, aralkoxy,
 aminocarbonyl, alkylaminocarbonyl, arylaminocarbonyl,
 alkoxycarbonyl, aryloxycarbonyl, haloalkyl, amino, cyano,
 nitro, alkylamino, arylamino, alkylaminoalkylene,
 arylaminoalkylene, aminoalkylamino, and hydroxy;
 275 provided R^3 is not 2-pyridinyl when R^4 is a phenyl
 ring containing a 2-hydroxy substituent and when R^1 is
 hydrido; and
 provided R^3 is not



280 (IV) (V)
 wherein R^{43} is selected from hydrogen, alkyl,
 aminoalkyl, alkoxyalkyl, alkenoxyalkyl, and aryloxyalkyl;
 and
 further provided R^2 is selected from aryl,
 285 heterocyclyl, unsubstituted cycloalkyl and cycloalkenyl
 when R^4 is hydrido; and
 further provided that R^4 is not methylsulfonylphenyl
 or aminosulfonylphenyl; and
 further provided that R^1 is not methylsulfonylphenyl;
 290 or
 a pharmaceutically-acceptable salt or tautomer
 thereof.

131. A compound of Formula IA

1196



wherein

- 5 R^1 is selected from hydroxy and alkoxyaryl; and
 R^2 is selected from hydrido, halogen, mercapto,
 alkyl, alkenyl, alkynyl, aryl, heterocyclyl, haloalkyl,
 hydroxyalkyl, aralkyl, alkylheterocyclyl,
 heterocyclylalkyl, heterocyclylheterocyclyl,
 10 heterocyclylalkylheterocyclyl, alkylamino, alkenylamino,
 alkynylamino, arylamino, aryl(hydroxyalkyl)amino,
 heterocyclylamino, heterocyclylalkylamino, aralkylamino,
 N-alkyl-N-alkynyl-amino, aminoalkyl, aminoaryl,
 aminoalkylamino, aminocarbonylalkylene,
 15 arylaminoalkylene, alkylaminoalkylene, arylaminoarylene,
 alkylaminoarylene, alkylaminoalkylamino,
 alkylcarbonylaminoalkylene,
 aminoalkylcarbonylaminoalkylene,
 alkylaminoalkylcarbonylamino, cycloalkyl, cycloalkenyl,
 20 aminoalkylthio, alkylaminocarbonylalkylthio,
 alkylaminoalkylaminocarbonylalkylthio, alkoxy,
 heterocyclyoxy, alkylthio, cyanoalkylthio, alkenylthio,
 alkynylthio, carboxyalkylthio, arylthio,
 heterocyclylthio, alkoxycarbonylalkylthio, alkylsulfinyl,
 25 alkylsulfonyl, carboxy, carboxyalkyl, alkoxyalkyl,
 alkoxyalkylthio, carboxycycloalkyl, carboxycycloalkenyl,
 carboxyalkylamino, alkoxycarbonyl, heterocyclylcarbonyl,
 alkoxycarbonylalkyl, alkoxycarbonylalkylamino,
 alkoxycarbonylheterocyclyl,
 30 alkoxycarbonylheterocyclylcarbonyl, alkoxyalkylamino,
 alkoxycarbonylaminoalkylene, alkoxycarbonylaminoalkoxy,
 alkoxycarbonylaminoalkylamino, heterocyclylsulfonyl,

1197

aralkythio, heterocyclylalkylthio, aminoalkoxy,
 cyanoalkoxy, carboxyalkoxy, aryloxy, aralkoxy,
 35 alkenyloxy, alkynyloxy, and heterocyclylalkyloxy; wherein
 the aryl, heterocyclyl, heterocyclylalkyl, cycloalkyl and
 cycloalkenyl groups may be optionally substituted with
 one or more radicals independently selected from halo,
 keto, amino, alkyl, alkenyl, alkynyl, aryl, heterocyclyl,
 40 aralkyl, heterocyclylalkyl, epoxyalkyl,
 amino(hydroxyalkyl) carboxy, alkoxy, aryloxy, aralkoxy,
 haloalkyl, alkylamino, alkynylamino,
 alkylaminoalkylamino, heterocyclylalkylamino,
 alkylcarbonyl, alkoxycarbonyl, alkylsulfonyl,
 45 arylsulfonyl, and aralkylsulfonyl; or

R^2 is R^{200} -heterocyclyl- R^{201} , R^{200} -aryl- R^{201} , or R^{200} -
 cycloalkyl- R^{201} wherein:

R^{200} is selected from:

- $(CR^{202}R^{203})_y-$;
- 50 - $C(O)-$;
- $C(O)-(CH_2)_y-$;
- $C(O)-O-(CH_2)_y-$;
- $(CH_2)_y-C(O)-$;
- $O-(CH_2)_y-C(O)-$;
- 55 - $NR^{202}-$;
- $NR^{202}-(CH_2)_y-$;
- $(CH_2)_y-NR^{202}-$;
- $(CH_2)_y-NR^{202}-(CH_2)_z-$;
- $(CH_2)_y-C(O)-NR^{202}-(CH_2)_z-$;
- 60 - $(CH_2)_y-NR^{202}-C(O)-(CH_2)_z-$;
- $(CH_2)_y-NR^{202}-C(O)-NR^{203}-(CH_2)_z-$;
- $S(O)_x-(CR^{202}R^{203})_y-$;
- $(CR^{202}R^{203})_y-S(O)_x-$;
- $S(O)_x-(CR^{202}R^{203})_y-O-$;
- 65 - $S(O)_x-(CR^{202}R^{203})_y-C(O)-$;
- $O-(CH_2)_y-$;
- $(CH_2)_y-O-$;
- $S-$; and

1198

-O-;

70 or R²⁰⁰ represents a bond;

R²⁰¹ represents one or more radicals selected from the group consisting of hydrido, halogen, hydroxy, carboxy, keto, alkyl, hydroxyalkyl, haloalkyl, cycloalkyl, alkenyl, alkynyl, aryl, heterocyclyl, aralkyl, heterocyclylalkylene, alkylcarbonyl, hydroxyalkylcarbonyl, cycloalkylcarbonyl, arylcarbonyl, haloarylcarbonyl, alkoxy, alkoxyalkylene, alkoxyarylene, alkoxycarbonyl, carboxyalkylcarbonyl, alkoxyalkylcarbonyl, heterocyclylalkylcarbonyl, alkylsulfonyl, alkylsulfonylalkylene, amino, aminoalkyl, alkylamino, aralkylamino, alkylaminoalkylene, aminocarbonyl, alkylcarbonylamino, alkylcarbonylaminoalkylene, alkylaminoalkylcarbonyl, alkylaminoalkylcarbonylamino, aminoalkylcarbonylaminoalkyl, alkoxycarbonylamino, alkoxyalkylcarbonylamino, alkoxycarbonylaminoalkylene, alkylimidocarbonyl, amidino, alkylamidino, aralkylamidino, guanidino, guanidinoalkylene, and alkylsulfonylamino; and

90 R²⁰² and R²⁰³ are independently selected from hydrido, alkyl, aryl and aralkyl; and


y and z are independently 0, 1, 2, 3, 4, 5 or 6 wherein y + z is less than or equal to 6; and

x is 0, 1 or 2; or

95 R² is -NHCR²⁰⁴R²⁰⁵ wherein R²⁰⁴ is alkylaminoalkylene, and R²⁰⁵ is aryl; or

R² is -C(NR²⁰⁶)R²⁰⁷ wherein R²⁰⁶ is selected from hydrogen and hydroxy, and R²⁰⁷ is selected from alkyl, aryl and aralkyl; or

100 R² has the formula:



1199

wherein:

j is an integer from 0 to 8; and

m is 0 or 1; and

105 R^{30} and R^{31} are independently selected from hydrogen, alkyl, aryl, heterocyclyl, aralkyl, heterocyclylalkylene, aminoalkyl, alkylaminoalkyl, aminocarbonylalkyl, alkoxyalkyl, and alkylcarbonyloxyalkyl; and

110 R^{32} is selected from hydrogen, alkyl, aralkyl, heterocyclylalkyl, alkoxyalkylene, aryloxyalkylene, aminoalkyl, alkylaminoalkyl, arylaminoalkyl, alkylcarbonylalkylene, arylcarbonylalkylene, and heterocyclylcarbonylaminoalkylene;


115 R^{33} is selected from hydrogen, alkyl, $-C(O)R^{35}$, $-C(O)OR^{35}$, $-SO_2R^{36}$, $-C(O)NR^{37}R^{38}$, and $-SO_2NR^{39}R^{40}$, wherein

R^{35} , R^{36} , R^{37} , R^{38} , R^{39} and R^{40} are independently selected from hydrocarbon, heterosubstituted hydrocarbon and heterocyclyl; and

120 R^{34} is selected from hydrogen, alkyl, aminocarbonyl, alkylaminocarbonyl, and arylaminocarbonyl; or


R^2 is $-CR^{41}R^{42}$ wherein R^{41} is aryl, and R^{42} is hydroxy; and

125 R^3 is selected from pyridinyl, pyrimidinyl, quinolinyl, purinyl, maleimidyl, pyridonyl, thiazolyl, thiazolylalkyl, thiazolylamino,



130 wherein the R^3 pyridinyl, pyrimidinyl, quinolinyl, purinyl, maleimidyl, pyridonyl, thiazolyl, thiazolylalkyl, thiazolylamino,

1200



groups may be optionally substituted with one or more
 135 radicals independently selected from halo, keto, alkyl,
 aralkyl, aralkenyl, arylheterocyclyl, carboxy,
 carboxyalkyl, alkoxy, aryloxy, alkylthio, arylthio,
 alkylsulfinyl, arylsulfinyl, alkylsulfonyl, arylsulfonyl,
 aralkoxy, heterocyclylalkoxy, amino, alkylamino,
 140 alkenylamino, alkynylamino, cycloalkylamino,
 cycloalkenylamino, arylamino, haloarylamino,
 heterocyclylamino, aminocarbonyl, cyano, hydroxy,
 hydroxyalkyl, alkoxyalkylene, alkenoxyalkylene,
 aryloxyalkyl, alkoxyalkylamino, alkylaminoalkoxy,
 145 alkoxycarbonyl, aryloxy carbonyl, heterocyclylalkoxycarbonyl,
 alkoxycarbonylamino, alkoxyarylamino, alkoxyaralkylamino,
 aminosulfinyl, aminosulfonyl, alkylsulfonylamino,
 alkylaminoalkylamino, hydroxyalkylamino, aralkylamino,
 aryl(hydroxyalkyl)amino, alkylaminoalkylaminoalkylamino,
 150 alkylheterocyclylamino, heterocyclylalkylamino,
 alkylheterocyclylalkylamino, aralkylheterocyclylamino,
 heterocyclylheterocyclylalkylamino,
 alkoxycarbonylheterocyclylamino, nitro,
 alkylaminocarbonyl, alkylcarbonylamino,
 155 haloalkylsulfonyl, aminoalkyl, haloalkyl, alkylcarbonyl,
 hydrazinyl, alkylhydrazinyl, arylhydrazinyl, and $-NR^{44}R^{45}$
 wherein R^{44} is alkylcarbonyl or amino, and R^{45} is alkyl or
 aralkyl; and

R^4 is selected from hydrido, alkyl, alkenyl, alkynyl,
 160 cycloalkyl, cycloalkenyl, aryl, and heterocyclyl, wherein
 R^4 is optionally substituted with one or more radicals
 independently selected from halo, alkyl, alkenyl,
 alkynyl, aryl, heterocyclyl, alkylthio, arylthio,
 alkylthioalkylene, arylthioalkylene, alkylsulfinyl,

1201

- 165 alkylsulfinylalkylene, arylsulfinylalkylene,
alkylsulfonyl, alkylsulfonylalkylene,
arylsulfonylalkylene, alkoxy, aryloxy, aralkoxy,
aminocarbonyl, alkylaminocarbonyl, arylaminocarbonyl,
alkoxycarbonyl, aryloxycarbonyl, haloalkyl, amino, cyano,
170 nitro, alkylamino, arylamino, alkylaminoalkylene,
arylaminoalkylene, aminoalkylamino, and hydroxy;
provided R^3 is not 2-pyridinyl when R^4 is a phenyl
ring containing a 2-hydroxy substituent and when R^1 is
hydrido; and
175 further provided R^2 is selected from aryl,
heterocyclyl, unsubstituted cycloalkyl and cycloalkenyl
when R^4 is hydrido; and
further provided that R^4 is not methylsulfonylphenyl
or aminosulfonylphenyl; or
180 a pharmaceutically-acceptable salt or tautomer
thereof.

132. A pharmaceutical composition comprising a
therapeutically-effective amount of a compound, said
compound selected from the compounds of any one of Claims
1, 39, 71, 82 and 94, or a pharmaceutically acceptable
5 salt thereof.

133. A method of treating a TNF mediated disorder,
said method comprising treating the subject having or
susceptible to such disorder with a therapeutically-
effective amount of a compound, said compound selected
from the compounds of any one of Claims 1, 39, 71, 82 and
5 94, or a pharmaceutically acceptable salt thereof.

134. A method of treating a p38 kinase mediated
disorder, said method comprising treating the subject
having or susceptible to such disorder with a
therapeutically-effective amount of a compound, said
compound selected from the compounds of any one of Claims

1202

5 1, 39, 71, 82 and 94, or a pharmaceutically acceptable salt thereof.

135. The method of Claim 134 wherein the p38 kinase mediated disorder is selected from the group of disorders consisting of bone resorption, graft vs. host reaction, atherosclerosis, arthritis, osteoarthritis, rheumatoid
5 arthritis, gout, psoriasis, topical inflammatory disease state, adult respiratory distress syndrome, asthma, chronic pulmonary inflammatory disease, cardiac reperfusion injury, renal reperfusion injury, thrombus, glomerulonephritis, Crohn's disease, ulcerative colitis,
10 inflammatory bowel disease and cachexia.

136. The method of Claim 134 wherein the p38 kinase mediated disorder is inflammation.

137. The method of Claim 134 wherein the p38 kinase mediated disorder is arthritis.


138. The method of Claim 134 wherein the p38 kinase mediated disorder is asthma.

139. A method of treating inflammation, said method comprising treating the subject having or susceptible to inflammation with a therapeutically-effective amount of a compound, said compound selected from the compounds of
5 any one of Claims 1, 39, 71, 82 and 94, or a pharmaceutically acceptable salt thereof.

140. A method of treating arthritis, said method comprising treating the subject having or susceptible to arthritis with a therapeutically-effective amount of a compound, said compound selected from the compounds of
any one of Claims 1, 39, 71, 82 and 94, or a
5 pharmaceutically acceptable salt thereof.

1203

141. A method of preparing pyrazoles of Formula IA




wherein

R¹ is selected from hydrido, hydroxy, alkyl,
 5 cycloalkyl, alkenyl, cycloalkenyl, alkynyl, aryl,
 heterocyclyl, cycloalkylalkylene, cycloalkenylalkylene,
 heterocyclylalkylene, haloalkyl, haloalkenyl,
 haloalkynyl, hydroxyalkyl, hydroxyalkenyl,
 hydroxyalkynyl, aralkyl, aralkenyl, aralkynyl,
 10 arylheterocyclyl, carboxy, carboxyalkyl, alkoxyalkyl,
 alkenoxyalkyl, alkynoxyalkyl, aryloxyalkyl, alkoxyaryl,
 heterocycliloxyalkyl, alkoxyalkoxy, mercaptoalkyl,
 alkylthioalkylene, alkenylthioalkylene,
 alkylthioalkenylene, amino, aminoalkyl, alkylamino,
 15 alkenylamino, alkynylamino, arylamino, heterocyclylamino,
 alkylsulfinyl, alkenylsulfinyl, alkynylsulfinyl,
 arylsulfinyl, heterocyclylsulfinyl, alkylsulfonyl,
 alkenylsulfonyl, alkynylsulfonyl, arylsulfonyl,
 heterocyclylsulfonyl, alkylaminoalkylene,
 20 alkylsulfonylalkylene, acyl, acyloxycarbonyl,
 alkoxycarbonylalkylene, aryloxycarbonylalkylene,
 heterocycliloxyalkylene, alkoxycarbonylarylene,
 aryloxycarbonylarylene, heterocycliloxyalkylene,
 alkylcarbonylalkylene, arylcarbonylalkylene,
 25 heterocyclylcarbonylalkylene, alkylcarbonylarylene,
 arylcarbonylarylene, heterocyclylcarbonylarylene,
 alkylcarbonyloxyalkylene, arylcarbonyloxyalkylene,
 heterocyclylcarbonyloxyalkylene, alkylcarbonyloxyarylene,
 arylcarbonyloxyarylene, and
 30 heterocyclylcarbonyloxyarylene; or

1204

R¹ has the formula



wherein:

i is an integer from 0 to 9;

35 R²⁵ is selected from hydrogen, alkyl, aralkyl, heterocyclalkyl, alkoxyalkylene, aryloxyalkylene, aminoalkyl, alkylaminoalkyl, arylaminoalkyl, alkylcarbonylalkylene, arylcarbonylalkylene, and heterocyclcarbonylaminoalkylene; and

40 R²⁶ is selected from hydrogen, alkyl, alkenyl, alkynyl, cycloalkylalkylene, aralkyl, alkoxyalkylene, and alkylaminoalkyl; and

R²⁷ is selected from alkyl, cycloalkyl, alkynyl, aryl, heterocycl, aralkyl, cycloalkylalkylene, cycloalkenylalkylene, cycloalkylarylene, cycloalkylcycloalkyl, heterocyclalkylene, alkylarylene, alkylaralkyl, aralkylarylene, alkylheterocycl, alkylheterocyclalkylene, alkylheterocyclarylene, aralkylheterocycl, alkoxyalkylene, alkoxyarylene, alkoxyaralkyl, alkoxyheterocycl, alkoxyalkoxyarylene, aryloxyarylene, aralkoxyarylene, alkoxyheterocyclalkylene, aryloxyalkoxyarylene, alkoxyalkoxyalkylene, alkoxyalkoxyheterocycl, alkoxyalkoxyheterocyclcarbonylalkylene, aminoalkyl, alkylaminoalkylene, arylaminocarbonylalkylene, alkoxyarylaminocarbonylalkylene, aminocarbonylalkylene, arylaminocarbonylalkylene, alkylaminocarbonylalkylene, arylcarbonylalkylene, alkoxyalkoxyarylene, aryloxyalkoxyarylene, alkylaryloxyalkoxyarylene, arylcarbonylarylene, alkylarylcarbonylarylene, alkoxyalkoxyheterocyclarylene, alkoxyalkoxyalkoxyarylene, heterocyclcarbonylalkylarylene, alkylthioalkylene,

50

55

60

1205

cycloalkylthioalkylene, alkylthioarylene,
65 aralkylthioarylene, heterocyclylthioarylene,
arylthioalkylarylene, arylsulfonylaminoalkylene,
alkylsulfonylarylene, and alkylaminosulfonylarylene;
wherein said alkyl, cycloalkyl, aryl, heterocyclyl,
aralkyl, heterocyclylalkylene, alkylheterocyclylarylene,
70 alkoxyarylene, aryloxyarylene, arylaminocarbonylalkylene,
aryloxycarbonylarylene, arylcarbonylarylene,
alkylthioarylene, heterocyclylthioarylene,
arylthioalkylarylene, and alkylsulfonylarylene groups
may be optionally substituted with one or more radicals
75 independently selected from alkyl, halo, haloalkyl,
alkoxy, keto, amino, nitro, and cyano; or

R^{27} is $-CHR^{28}R^{29}$ wherein R^{28} is alkoxycarbonyl, and R^{29}
is selected from aralkyl, aralkoxyalkylene,
heterocyclylalkylene, alkylheterocyclylalkylene,
80 alkoxyalkylene, alkylthioalkylene, and
aralkylthioalkylene; wherein said aralkyl and
heterocyclyl groups may be optionally substituted with
one or more radicals independently selected from alkyl
and nitro; or

85 R^{26} and R^{27} together with the nitrogen atom to which
they are attached form a heterocycle, wherein said
heterocycle is optionally substituted with one or more
radicals independently selected from alkyl, aryl,
heterocyclyl, heterocyclylalkylene,
90 alkylheterocyclylalkylene, aryloxyalkylene,
alkoxyarylene, alkylaryloxyalkylene, alkylcarbonyl,
alkoxycarbonyl, aralkoxycarbonyl, alkylamino and
alkoxycarbonylamino; wherein said aryl,
heterocyclylalkylene and aryloxyalkylene radicals may be
95 optionally substituted with one or more radicals
independently selected from halogen, alkyl and alkoxy;
and

R^2 is selected from mercapto,
aryl(hydroxyalkyl)amino, N-alkyl-N-alkynyl-amino,

1206

100 aminocarbonylalkylene, alkylcarbonylaminoalkylene,
 aminoalkylcarbonylaminoalkylene,
 alkylaminoalkylcarbonylamino, aminoalkylthio,
 alkylaminocarbonylalkylthio,
 alkylaminoalkylaminocarbonylalkylthio, cyanoalkylthio,
 105 alkenylthio, alkynylthio, carboxyalkylthio,
 alkoxycarbonylalkylthio, alkylsulfinyl, alkylsulfonyl,
 alkoxyalkyl, alkoxyalkylthio, alkoxycarbonylalkylamino,
 alkoxycarbonylaminoalkylene, alkoxycarbonylaminoalkoxy,
 aralkylthio, heterocyclylalkylthio, aminoalkoxy,
 110 cyanoalkoxy, carboxyalkoxy, aryloxy, aralkoxy,
 alkenyloxy, alkynyloxy, and heterocyclylalkyloxy; or

R^2 is R^{200} -heterocyclyl- R^{201} , R^{200} -aryl- R^{201} , or R^{200} -
 cycloalkyl- R^{201} wherein:

R^{200} is selected from:

- 115 - $(CR^{202}R^{203})_y-$;
 -C(O)-;
 -C(O)-(CH₂)_y-;
 -C(O)-O-(CH₂)_y-;
 - (CH₂)_y-C(O)-;
 120 -O-(CH₂)_y-C(O)-;
 -NR²⁰²-;
 -NR²⁰²-(CH₂)_y-;
 - (CH₂)_y-NR²⁰²-;
 - (CH₂)_y-NR²⁰²-(CH₂)_z-;
 125 - (CH₂)_y-C(O)-NR²⁰²-(CH₂)_z-;
 - (CH₂)_y-NR²⁰²-C(O)-(CH₂)_z-;
 - (CH₂)_y-NR²⁰²-C(O)-NR²⁰³-(CH₂)_z-;
 -S(O)_x-(CR²⁰²R²⁰³)_y-;
 - (CR²⁰²R²⁰³)_y-S(O)_x-;
 130 -S(O)_x-(CR²⁰²R²⁰³)_y-O-;
 -S(O)_x-(CR²⁰²R²⁰³)_y-C(O)-;
 -O-(CH₂)_y-;
 - (CH₂)_y-O-;
 -S-; and
 135 -O-;

1207

or R^{200} represents a bond;

R^{201} represents one or more radicals selected from the group consisting of hydroxy, hydroxyalkyl, cycloalkyl, hydroxyalkylcarbonyl, cycloalkylcarbonyl, arylcarbonyl, haloarylcarbonyl, alkoxyalkylene, alkoxyarylene, carboxyalkylcarbonyl, alkoxyalkylcarbonyl, heterocyclylalkylcarbonyl, alkylsulfonylalkylene, aminoalkyl, aralkylamino, alkylaminoalkylene, aminocarbonyl, alkylcarbonylamino, alkylcarbonylaminoalkylene, alkylaminoalkylcarbonyl, alkylaminoalkylcarbonylamino, aminoalkylcarbonylaminoalkyl, alkoxycarbonylamino, alkoxyalkylcarbonylamino, alkoxycarbonylaminoalkylene, alkylimidocarbonyl, amidino, alkylamidino, aralkylamidino, guanidino, guanidinoalkylene, and alkylsulfonylamino; and

R^{202} and R^{203} are independently selected from hydrido, alkyl, aryl and aralkyl; and


y and z are independently 0, 1, 2, 3, 4, 5 or 6 wherein y + z is less than or equal to 6; and

x is 0, 1 or 2; or

R^2 is $-NHCR^{204}R^{205}$ wherein R^{204} is alkylaminoalkylene, and R^{205} is aryl; or

R^2 is $-C(NR^{206})R^{207}$ wherein R^{206} is selected from hydrogen and hydroxy, and R^{207} is selected from alkyl, aryl and aralkyl; and


R^3 is selected from pyridinyl, pyrimidinyl, quinolinyl, purinyl, maleimidyl, pyridonyl, thiazolyl, thiazolylalkyl, thiazolylamino,



wherein the R^3 pyridinyl, pyrimidinyl, quinolinyl, purinyl, maleimidyl, pyridonyl, thiazolyl,

1208

thiazolylalkyl, thiazolylamino,



170

groups may be optionally substituted with one or more radicals independently selected from halo, keto, alkyl, aralkyl, aralkenyl, arylheterocyclyl, carboxy, carboxyalkyl, alkoxy, aryloxy, alkylthio, arylthio, alkylsulfinyl, arylsulfinyl, alkylsulfonyl, arylsulfonyl, aralkoxy, heterocyclylalkoxy, amino, alkylamino, alkenylamino, alkynylamino, cycloalkylamino, cycloalkenylamino, arylamino, haloaryl amino, heterocyclylamino, aminocarbonyl, cyano, hydroxy, hydroxyalkyl, alkoxyalkylene, alkenoxyalkylene, aryloxyalkyl, alkoxyalkylamino, alkylaminoalkoxy, alkoxy carbonyl, aryloxy carbonyl, heterocyclyl oxy carbonyl, alkoxy carbonyl amino, alkoxy aryl amino, alkoxy aralkyl amino, aminosulfinyl, aminosulfonyl, alkylsulfonyl amino, alkylaminoalkyl amino, hydroxyalkyl amino, aralkyl amino, aryl(hydroxyalkyl) amino, alkylaminoalkyl aminoalkyl amino, alkylheterocyclyl amino, heterocyclylalkyl amino, alkylheterocyclylalkyl amino, aralkylheterocyclyl amino, heterocyclylheterocyclylalkyl amino, alkoxy carbonyl heterocyclyl amino, nitro, alkylaminocarbonyl, alkylcarbonyl amino, haloalkylsulfonyl, aminoalkyl, haloalkyl, alkylcarbonyl, hydrazinyl, alkylhydrazinyl, arylhydrazinyl, and $-NR^{44}R^{45}$ wherein R^{44} is alkylcarbonyl or amino, and R^{45} is alkyl or aralkyl; and

R^4 is selected from hydrido, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, and heterocyclyl, wherein R^4 is optionally substituted with one or more radicals independently selected from halo, alkyl, alkenyl, alkynyl, aryl, heterocyclyl, alkylthio, arylthio,

200

1209

alkylthioalkylene, arylthioalkylene, alkylsulfinyl,
alkylsulfinylalkylene, arylsulfinylalkylene,
alkylsulfonyl, alkylsulfonylalkylene,
205 arylsulfonylalkylene, alkoxy, aryloxy, aralkoxy,
aminocarbonyl, alkylaminocarbonyl, arylaminocarbonyl,
alkoxycarbonyl, aryloxycarbonyl, haloalkyl, amino, cyano,
nitro, alkylamino, arylamino, alkylaminoalkylene,
arylaminoalkylene, aminoalkylamino, and hydroxy; or
210 a pharmaceutically-acceptable salt or tautomer
thereof,


said method comprising the steps of treating a
substituted ketone with an acyl hydrazide to give the
pyrazole.

142. The process of Claim 141 wherein the process is
carried out in an acidic solvent.

143. The process of Claim 141 wherein the acidic
solvent is acetic acid.

144. The process of Claim 141 wherein the acidic
solvent is an organic solvent containing an acid.


145. The compound:



or a tautomer or pharmaceutically acceptable salt thereof.

1210


146. A compound of Claim 71 that is:



5

or a tautomer or pharmaceutically acceptable salt thereof.

147. A compound of Claim 39 that is:




10

or a tautomer or pharmaceutically acceptable salt thereof.

148. The compound:


1211



15

or a tautomer or pharmaceutically acceptable salt thereof.

149. A compound of Claim 1 that is:




20

or a tautomer or pharmaceutically acceptable salt thereof.

25

150. The compound:


1212



or a tautomer or pharmaceutically acceptable salt thereof.

30


151. A compound of Claim 1 that is:



1213

or a tautomer or pharmaceutically acceptable salt thereof.


35 152. A compound of Claim 1 that is:



or a tautomer or pharmaceutically acceptable salt thereof.

40

153. A compound of Claim 1 that is:




1214

or a tautomer or pharmaceutically acceptable salt thereof.

45


154. A compound of Claim 39 that is:



or a tautomer or pharmaceutically acceptable salt thereof.

50

155. A compound of Claim 1 that is:




or a tautomer or pharmaceutically acceptable salt thereof.

55

156. A compound of Claim 82 that is:


1215



or a tautomer or pharmaceutically acceptable salt thereof.

60

157. A compound of Claim 42 that is:




or a tautomer or pharmaceutically acceptable salt thereof.

65

158. A compound of Claim 71 that is:


1216



or a tautomer or pharmaceutically acceptable salt thereof.

70

159. A compound of Claim 71 that is:



or a tautomer or pharmaceutically acceptable salt thereof.

75

160. A compound of Claim 70 wherein R^{404a} is meta-chloro or para-chloro.

INTERNATIONAL SEARCH REPORT

International application No

PCT/US 99/26007

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 C07D401/04 A61K31/415 A61K31/47 A61K31/445 A61K31/44
A61K31/50 A61K31/505 A61K31/52 C07D405/14 C07D401/14
C07D409/14 C07D403/04 C07D487/04 C07D473/00 C07D413/14

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C07D A61K A61P

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 96 03385 A (SEARLE & CO ;LEE LEN F (US); PENNING THOMAS D (US); KRAMER STEVEN) 8 February 1996 (1996-02-08) cited in the application abstract; claims 1,8-10; examples 1-15 page 9 -page 73	1,39,71, 82,93, 94,101, 126-140
A	EP 0 846 687 A (LILLY CO ELI) 10 June 1998 (1998-06-10) abstract; examples page 21; table 1A page 23 -page 25; table 2A	1,39,71, 82,93, 94,101

-/--

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents :

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

- "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- "&" document member of the same patent family

Date of the actual completion of the international search

6 April 2000

Date of mailing of the international search report

18/04/2000

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3018

Authorized officer

Paisdor, B

INTERNATIONAL SEARCH REPORT

International application No

PCT/US 99/26007

A. CLASSIFICATION OF SUBJECT MATTERIPC 7 C07D417/14 C07D471/04 A61P29/00 //(C07D487/04,293:00,
231:00),(C07D471/04,221:00,209:00)

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	EP 0 846 686 A (PFIZER LTD ;PFIZER (US)) 10 June 1998 (1998-06-10) abstract; claims 1,15 page 19; example A24	1,39,71, 82,93, 94,101
A	WO 94 19350 A (OKU TERUO ;KAWAI YOSHIO (JP); TANAKA HIROKAZU (JP); FUJISAWA PHARM) 1 September 1994 (1994-09-01) page 53; example 8	1,39,71, 82,93, 94,101
A	EP 0 531 901 A (FUJISAWA PHARMACEUTICAL CO) 17 March 1993 (1993-03-17) abstract pages 49 - 51, preparations page 52; example 1	1,39,71, 82,93, 94,101
	-/-	



Further documents are listed in the continuation of box C.



Patent family members are listed in annex.

*** Special categories of cited documents :**

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

- "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- "&" document member of the same patent family

Date of the actual completion of the international search

6 April 2000

Date of mailing of the international search report

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Paidsor, B

INTERNATIONAL SEARCH REPORT

International application No

PCT/US 99/26007

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	DD 295 374 A (STERLING DRUG INC) 31 October 1991 (1991-10-31) page 7 -page 8; claims; examples ---	1,39,71, 82,93, 94,101
A	WO 95 31451 A (SMITHKLINE BEECHAM CORP ;ADAMS JERRY LEROY (US); GALLAGHER TIMOTHY) 23 November 1995 (1995-11-23) page 1 -page 3; claim 1 page 16 -page 19; examples ---	1,39,71, 82,93, 94,101, 126-140
P,X	WO 98 52937 A (ANANTANARAYAN ASHOK ;STEALEY MICHAEL A (US); CLARE MICHAEL (US); G) 26 November 1998 (1998-11-26) abstract; claims page 35 -page 49; examples ---	1-160
P,X	WO 98 52940 A (ANANTANARAYAN ASHOK ;CRICH JOYCE ZUOWU (US); SELNESS SHAUN RAJ (US) 26 November 1998 (1998-11-26) abstract; claims ---	1-160
P,X	WO 98 52941 A (SEARLE & CO ;HANSON GUNNAR J (US); LIAO SHUYUAN (US)) 26 November 1998 (1998-11-26) abstract; claim 1 page 21 -page 24; examples 1,2 ---	1-160

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US 99/26007

Box I Observations where certain claims were found unsearchable (Continuation of Item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.: 133-140
because they relate to subject matter not required to be searched by this Authority, namely:
Remark: Although claims 133-140
are directed to a method of treatment of the human/animal
body, the search has been carried out and based on the alleged
effects of the compound/composition.
2. ☐ Claims Nos.:
because they relate to parts of the International Application that do not comply with the prescribed requirements to such
an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of Item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all
searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment
of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report
covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is
restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No.

PCT/US 99/26007

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9603385 A	08-02-1996	US 5486534 A	23-01-1996
		AU 3126795 A	22-02-1996
		CA 2195123 A	08-02-1996
		EP 0772597 A	14-05-1997
		JP 10503201 T	24-03-1998
		US 5580985 A	03-12-1996
		US 5756530 A	26-05-1998
		US 6028072 A	22-02-2000
EP 0846687 A	10-06-1998	AU 5365598 A	29-06-1998
		WO 9824437 A	11-06-1998
		US 5972972 A	26-10-1999
EP 0846686 A	10-06-1998	CA 2223237 A	30-05-1998
		JP 10182614 A	07-07-1998
WO 9419350 A	01-09-1994	AU 681625 B	04-09-1997
		AU 6010894 A	14-09-1994
		CA 2156919 A	01-09-1994
		CN 1120840 A, B	17-04-1996
		EP 0686156 A	13-12-1995
		HU 70832 A	28-11-1995
		IL 108562 A	10-06-1997
		JP 8507056 T	30-07-1996
		MX 9401408 A	31-08-1994
		US 5670503 A	23-09-1997
		ZA 9400787 A	08-09-1994
EP 0531901 A	17-03-1993	AU 2280592 A	11-03-1993
		CA 2077732 A	10-03-1993
		CN 1070404 A	31-03-1993
		HU 65204 A	02-05-1994
		JP 7252256 A	03-10-1995
		JP 2057962 C	10-06-1996
		JP 6287188 A	11-10-1994
		JP 7088386 B	27-09-1995
		MX 9205145 A	01-04-1993
		US 5478827 A	26-12-1995
		US 5624931 A	29-04-1997
		US 5356897 A	18-10-1994
		ZA 9206417 A	15-03-1993
		CN 1075965 A	08-09-1993
DD 295374 A	31-10-1991	NONE	
WO 9531451 A	23-11-1995	US 5559137 A	24-09-1996
		EP 0871622 A	21-10-1998
		JP 10500413 T	13-01-1998
		US 5998425 A	07-12-1999
WO 9852937 A	26-11-1998	AU 7698198 A	11-12-1998
		EP 0983260 A	08-03-2000
		NO 995635 A	17-11-1999
		US 5932576 A	03-08-1999
WO 9852940 A	26-11-1998	AU 7588398 A	11-12-1998
		NO 995695 A	21-01-2000

Information on patent family members

PCT/US 99/26007

Form PCT/ISA/210 (patent family annex) (July 1992)